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ABSTRACT 
Administration of (±)3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy') to rats 
produces an acute release of cerebral 5-hydroxytryptamine (5-HT) and dopamine, an 
acute hyperthermic response, and long-term selective neurotoxic depletion of regional 
brain 5-HT. In the studies reported in this thesis, administration of a single dose of 
MDMA (12.5 mg/kg i.p.) to Dark Agouti rats produced a 20 - 40 % depletion of 
regional brain 5-HT and 5-illAA content one week later. The functional consequences 
of this loss were investigated by assessing the effects on anxiety-related behaviour and 
thermoregulation. The acute hyperthermic respons~ was investigated by administering 
compounds affecting serotonergic or dopaminergic function. In contrast to rats, MDMA 
induces a selective long-term dopaminergic depletion in mouse brain. The mechanisms 
involved in this depletion were investigated using putative neuroprotective compounds. 
MDMA pretreatment markedly reduced "anxiety", 80 days post-treatment, as measured 
in the elevated plus-maze and open-field. Changes did not become apparent until over 
two months after MDMA administration, indicating that the changes are not solely due 
to the cerebral 5-HT loss (evident one week post-treatment), but that adaptive changes 
also occur. 
When rats given a single dose ofMDMA (12.5 mglkg.) 5-6 weeks earlier were exposed 
to high ambient temperature (30 ± 0.5 °C) for I h, they displayed a faster rise in rectal 
temperature, and sustained hyperthermia when returned to a normal temperature 
environment (20 ± 2 °C). These data demonstrate that a long-term defect in 
thermoregulation is produced by a modest MDMA-induced loss of cerebral 5-HT. 
Investigation of the acute MDMA-induced hyperthermia revealed that 5-HT antagonists 
and uptake inhibitors had little effect on the hyperthermia, even though fluoxetine 
almost completely abolished MDMA-induced release of hippocampal 5-HT. The 
dopamine Dl antagonist, SCH 23390, dose-dependently attenuated the hyperthermia, 
indicating that 5-HT is probably not directly involved in the response, but that dopamine 
plays a role via an action at Dl receptors. 
The selective neuronal nitric oxide synthase (nNDS) inhibitors, AR-R17477AR and S-
methyithiocitrulline, protected against MDMA-induced dopaminergic depletion in mice, 
indicating the involvement of nNDS in the neurotoxic pathway. The free radical 
scavenger, a-phenyl-N-tert-butyl nitrone, was not protective, although there is evidence 
of MDMA-induced free radical generation. Since neither of the N-methyl-D-aspartate 
antagonists, AR-R15896AR and MK-801, were neuroprotective, free radicals are 
probably not being formed as a result of increased glutamatergic activity at NMDA 
receptors, but rather auto-oxidation ofMDMA metabolites. 
In conclusion, the studies demonstrated that administration of a single dose of MDMA, 
producing a 20 - 40 % regional brain depletion of 5-HT in rats, induced long-term 
functional deficits. These findings have important clinical implications, since a similar 
loss of cerebral 5-HT has also been reported to occur in the brains of human recreational 
users ofMDMA. 
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1 GENERAL INTRODUCTION 
1.1 ORIGINS AND RECREATIONAL USE OF MDMA 
1.1.1 History of MDMA 
3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy') is a ring-substituted 
amphetamine derivative (see Figure 1.1), which is structurally related to both 
amphetamine and the hallucinogenic compound, 3,4,5-trimethoxyphenethylamine 
(mescaline). MDMA has often been reported to have been originally synthesised for use 
as an appetite suppressant (see Christophersen, 2000; Dowling et aI., 1987; Green et aI., 
1995; Henry, 1992; Henry et al., 1992; Rattray, 1991; Steele et aI., 1994). However, 
according to Cohen (1998), "MDMA was actually patented in Germany in the 1900s as 
a precursor agent - or intermediate structural compound - possessing properties deemed 
to contain primary constituents for therapeutically active compounds", and was never 
intended for use as an anorectic drug. In the 1970s, MDMA was reported to have been 
used in psychotherapy, where it was seen to increase patient self-esteem and facilitate 
therapeutic communication. In such settings, MDMA was orally administered at a dose 
of 75 - 175 mg and was reported to have some acute sympathomimetic side effects, 
such as increased heart rate and blood pressure, and transient anxiety (see Greer & 
Strassman, 1985; Grinspoon & Bakalar, 1986). 
Whatever its ongms MDMA has, in more recent years, gained popularity as a 
recreational drug (see Christophersen, 2000; Green et aI., 1995; Hegadoren et aI., 1999; 
Morgan, 2000; Parrott & Lasky, 1998; PefOutka, 1997; Randall, 1992; Rattray, 1991; 
Solowij et al., 1992; Steele et aI., 1994). In 1985, the U.S. Drug Enforcement 
Administration (DEA) classified MDMA as a Schedule 1 drug due to its high abuse 
potential, lack of clinical application, lack of accepted safety for use under medical 
supervision (see www.usdoj.gov/dea), and evidence that the related compound, 3,4-
methylenedioxyamphetamine (MDA) , induced serotonergic nerve terminal degeneration 
in rat brain (Ricaurte et al., 1985). In the u.K., possession of MDMA is also illegal, 
being controlled as a Class A drug under the Misuse of Drugs Act (1971) (see 
www.drugscope.org.uk). 
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1.1.2 Recreational use of MDMA 
MDMA first gained popularity as a recreational drug in the early 1980s, especially 
among college students (see Peroutka, 1987), usually being taken at "rave" or "techno" 
parties, particularly in large dance clubs, although there is a reported increase of use in 
smaller party environments (www.usdoj.gov/dea). MDMA usually produces a relaxed, 
euphoric state, including emotional openness, empathy, reduction of negative thoughts 
and a decrease in inhibitions (see Davison & Parrott, 1997; Green et ai., 1995; 
Hegadoren et at., 1999; Henry, 1992; Liechti & Vollenweider, 2000; Morgan, 2000; 
Parrott & Stuart, 1997; Peroutka et ai., 1988; dancesafe.org; www.drugscope.org.uk; 
www.erowid.org; www.thesite.org; www.usdoj.gov/dea). One of the major acute 
physiological effects of MDMA use is an increase in body temperature, which is 
potentially extremely dangerous when taking the drug in a hot, crowded environment, 
and can result in heatstroke. Therefore, users are recommended to take regular breaks 
from dancing and to sip approximately one pint of non-alcoholic fluid over the course 
of each hour. "Rave" venues often have "chill out" rooms, which enable individuals to 
take breaks from dancing in a less crowded, relaxed atmosphere (see Henry, 1992; 
www.dancesafe.org; www.drugscope.org.uk; www.thesite.org). 
1.2 EFFECTS OF MDMA IN EXPERIMENTAL ANIMALS 
1.2.1 Acute etTects 
The acute effects which follow MDMA administration to rats include: (1 ) a 
hyperthermic response, (2) a release of 5-hydroxytryptamine (5-HT; serotonin), (3) 
alterations in 5-HT synthesis, (4) a release of dopamine, (5) free radical production (6) 
neuroendocrine changes, (7) cardiovascular responses, and (8) behavioural responses. 
Acute 5-HT and dopamine release and behavioural responses have also been 
demonstrated in mice. 
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1.2.1.1 Acute hyperthermia and thermoregulatory responses 
(1) Hyperthermia under 'normal' ambient temperature conditions 
Under 'normal' ambient temperature (Ta) conditions (20 - 22 °C), MDMA 
administration to rats tends to result in a marked hyperthermic response of 
approximately + 1 - 2°C, which peaks at about 40 - 60 min post-injection (see Broening 
et aI., 1995; Dafiers, 1994; 1995; Malberg et a!., 1996; O'Shea et aI., 1998; Shankaran 
& Gudelsky, 1999). Similar responses are observed following administration of MDMA 
(see Johnson et aI., 2000; Miller & O'Callaghan, 1994; 1995; O'Callaghan & Miller, 
1994), methamphetamine (see Albers & Sonsalla, 1995; Ali & Itzhak, 1998; 
O'Callaghan & Miller, 1994), or MDA (see Miller & O'Callaghan, 1994; O'Callaghan 
& Miller, 1994) to mice, in addition to administration of methamphetamine (see Green 
et aI., 1992; Metzger et aI., 2000), or MDEA (see Colado et aI., 1999d) to rats. 
While the majority of studies demonstrate an acute hyperthermic response to MDMA 
administration under 'normal' Ta conditions, an acute decrease in temperature has also 
been reported. For example, Malberg & Seiden (1998) administered MDMA (20 or 40 
mg/kg s.c.) to male Holtzman rats and demonstrated a hypothermic response at a Ta of 
20 - 22°C, no change from control animals at a T a of 24 - 26°C, and a hyperthermic 
response at a Ta of28 - 30°C. Thus relatively small changes in Ta were demonstrated to 
produce marked changes in the temperature response to MDMA administration 
(Malberg & Seiden, 1998). O'Shea et al. (2001) administered MDMA (10, 20 or 30 
mg/kg i.p.) to male Swiss-Webster mice, three times at 3 h intervals, and observed a 
hypothermic response following the first injection at doses of 10 and 20 mg/kg, while 
hyperthermia was observed following the first injection at a dose of 30 mg/kg, and 
following the second injection at a dose of 20 mg/kg. 
(2) Involvement of ambient temperature in the hyperthermic response 
A number of authors have further demonstrated the importance of ambient temperature 
in the changes in body temperature (Broening et al., 1995; Dafters, 1994; 1995; Dafters 
& Lynch, 1998; Farfel & Seiden, 1995a; Gordon et aI., 1991), and thermoregulatory 
responses (Gordon et aI., 1991) induced by MDMA. For example, Dafters (1994) 
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administered MDMA (2.5, 5 or 7.5 mgfkg s.c.) to male Wistar rats and measured 
temperature for the following 10 h. The first experiment comprised animals being 
housed under T a conditions of either 11 or 24°C for a total of 48 h, commencing 24 h 
before drug administration. At a T a of 11 °e, a dose-dependent hypothermic response 
was observed; a maximal decrease in temperature of approximately -1°C was seen in 
animals administered 7.S mg/kg MDMA. At a Ta of 24 °e, a dose-dependent 
hyperthermic response was seen; administration of 7.5 mgfkg MDMA resulted in an 
increase in temperature of approximately + 1. 75 °e. During the second experiment, rats 
were administered MDMA (2.5, 5 or 7.5 mgfkg s.c.) under Ta conditions of 24°C, 30 
min before half of each treatment group were transferred to a "cool" room (T a = 11°C) 
for 90 min. Hyperthermia was significantly attenuated in animals exposed to the cool 
environment; maximal hyperthermic responses were approximately half the value of 
those seen in animals kept at 24 °e. Thus, dose-related changes in body temperature 
induced by MDMA appear to be dependent on Ta (Dafters, 1994). 
Dafters & Lynch (1998) investigated the effects of more subtle changes in Ta (a 
reduction of 5 °C below the temperature of the animal holding room, from 22°C to 17 
°C) on MDMA-induced changes in body temperature ("thermogenic response"). 
Animals which were administered MDMA (10 or 15 mglkg s.c.) at a Ta of 17°C were 
placed in a temperature-controlled test room for a total of 4 h (1 h prior to drug 
treatment and 3 h post-treatment). This resulted in a hypothermic response, where body 
temperature decreased by approximately -2°C. At 22 °e, however, an increase in body 
temperature of approximately + 1 °e was observed. The authors suggested that such a 
high degree of sensitivity to T a indicated that MDMA has some effect on the 
thermoregulatory set-point mechanism, which they believed was compatible with the 
fact that MDMA administration results in an acute release of serotonin and subsequent 
stimulation of central serotonergic pathways, and that serotonergic pathways are 
involved in thermoregulation (Dafters & Lynch, 1998). 
Gordon et al. (1991) administered MDMA (30 mg/kg s.c.) to male Long-Evans rats and 
investigated the effects on their thermoregulatory systems, by monitoring metabolic rate 
(MR), evaporative water loss (EWL) and rectal temperature, under three T a conditions 
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(10, 20 and 30°C). MR was significantly increased, compared to control animals, under 
Ta conditions of 20 and 30°C and was unchanged at 10 DC. "MDMA-treated rats 
demonstrated an increasing EWL with increasing Ta; EWL values in MDMA-treated 
rats were approximately 275 % above control values, at a Ta of 30°C. Rectal 
temperature increased with increasing Ta: (1) hypothermia (-2°C) occurred at 10°C, (2) 
at 20 °c there was no difference between MDMA- and saline-treated animals, and (3) at 
30°C, hyperthermia was seen (+2 DC). The authors thus demonstrated that MDMA 
administration had profound effects on the thermoregulatory system of the rat, 
involving increases in MR, EWL and rectal temperature, and that such effects were 
apparently dependent on Ta (Gordon et a/., 1991). 
(3) Pharmacological inhibition of the hyperthermic response 
Prevention of the MDMA-induced acute hyperthermic response in both rats and mice 
provides neuroprotection against toxicological damage (see Chapters 6 and 7). Chapter 
6 of this thesis reports an investigation of the acute hyperthermic response following 
MDMA administration to Dark Agouti (DA) rats, which involved the administration of 
a series of drugs which alter either 5-HT or dopamine function. Chapter 7 reports an 
investigation of the mechanisms of MDMA-induced neurotoxicity in mice, and 
demonstrates that PBN, for example, provided neuroprotection against MDMA-induced 
dopamine loss only where the hyperthermic response was blocked. 
1.2.1.2 Acute release and depletion of 5-BT 
MDMA administration to rats has been demonstrated to induce an acute release of 5-HT 
both in vivo (Gough et ai., 1991; Gudelsky & Nash, 1996; Meehan et ai., 2001b; 
Nixdorf et ai., 2001; Sabol & Seiden, 1998; Shankaran & Gudelsky, 1999; Yamamoto 
et a/., 1995) and in vitro (see Berger et ai., 1992; Crespi et a/., 1997; Johnson et aI., 
1986; Koch & Galloway, 1997; O'Loinsigh et aI., 2001; Schmidt, 1987a; 1987b; 
Schmidt et aI., 1987). In addition, a number of studies have been reported where 5-HT 
concentrations have been measured in brain tissue during the first few hours after drug 
administration, in both rats (see Aguirre et aI., 1995; Colado & Green, 1994; Gough et 
aI., 1991; Logan etal., 1988; McKenna et aI., 1990; Schmidt, 1987a; 1987b; Schmidt & 
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Kehne, 1990; Schmidt et aI., 1986; 1987; 1990c; Stone et aI., 1987a; 1987b) and mice 
(see Logan etal., 1988; O'Shea et ai., 2001; Stoneetal., 1987a). 
(1) In vivo 5-HT release 
Gudelsky & Nash (1996) demonstrated a dose-related increase in extracellular 5-HT 
concentrations in the striatum and medial prefrontal cortex, following peripheral 
administration of MDMA (2.5, 10 or 20 mglkg i.p.). Striatal 5-HT release was 
significantly attenuated by pretreatment with the serotonin uptake inhibitor, fluoxetine, 
indicating that MDMA-induced 5-HT release involves a carrier-mediated mechanism. 
Co-administration of 5-hydroxytryptophan (5-HTP; 5-HT precursor) and carbidopa 
(DOP A decarboxylase inhibitor) produced a significant increase in striatal extracellular 
5-HT, a response which was enhanced ten-fold by administration of MDMA. The 
authors suggested that these data indicated a possible action of MDMA on synaptic 
vesicles, since 5-HTP treatment would enhance 5-HT synthesis, while MDMA 
treatment led to disruption of storage mechanism and activation of the 5-HT transporter, 
thus leading to the pronounced increase in extracellular 5-HT (Gudelsky & Nash, 1996). 
Sabol & Seiden (1998) investigated the effects of pretreatment with reserpine, which 
depletes vesicular dopamine stores, on MDMA-induced striatal 5-HT release. MDMA 
administration (10 mg/kg i.p.) resulted in an acute, massive release of 5-HT 
(approximately 30 times above baseline values) within 30 min. Reserpine pretreatment 
(10 mg/kg i.p., 18 h prior to MDMA injection) resulted in a significant attenuation of 5-
HT release, however reserpine was also demonstrated to induce a marked hypothermic 
response. Thus the reserpine-treated animals were warmed to maintain a normal body 
temperature (37.9 DC), which resulted in a peak 5-HT release which was intermediate 
between that induced by MDMA alone and MDMA + reserpine. The authors suggested 
that, since maintenance of normal body temperature did not fully reinstate MDMA-
induced 5-HT release, the depletion of vesicular stores rather than attenuation of 
hyperthermia was primarily responsible for the inhibitory effects of reserpine (Sabol & 
Seiden, 1998). 
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Shankaran & Gudelsky (1999) demonstrated an acute, significant increase in striatal 
extracellular 5-HT concentrations following administration of MDMA (7.5 mglkg i.p.) 
to male SD rats. This response was markedly attenuated in rats which had previously 
been subjected to a neurotoxic dose regimen ofMDMA (10 mg/kg i.p., four times at 2 h 
intervals). The authors suggested that this attenuation could be due to the loss of 5-HT 
nerve terminals induced by the neurotoxic treatment regimen, and indicated functional 
deficits in serotonergic neurotransmission (Shankaran & Gudelsky, 1999). 
(2) In vitro 5-HT release and uptake 
In vitro 5-HT release and uptake have been demonstrated using rat brain slices and 
synaptosomes. For example, Koch & Galloway (1997) demonstrated that incubation of 
MDMA (0.3 - 3 /lMol) with rat striatal slices resulted in a dose-dependent increase in 
extracellular 5-HT, which was completely prevented by pretreatment with either 
fluoxetine (3 /lMol) or the 5-HT2 receptor antagonist, ketanserin (1 /JMol). The 
inhibitory effects of fluoxetine indicated that 'MDMA increases extracellular 5-HT 
levels via a 5-HT transporter-sensitive mechanism. The authors suggested that the 
effects of ketanserin may be due to the drug binding non-specifically to the 5-HT 
transporter, or that 5-HT may regulate the activity of the transporter via an action at the 
5-HT2 receptor (Koch & Galloway, 1997). Crespi et al. (1997) reported that MDMA 
and p-chloroamphetamine (PCA) demonstrated equipotent inhibition of CH]5-HT 
uptake in rat hippocampal synaptosomes, while PCA was the most potent inducer of 
eH]5-HT release, followed by MDMA, fenfluramine and amphetamine (in descending 
order of potency). Removal of calcium from the incubation medium had no effect on 
inhibition of uptake, but did result in significant attenuation of MDMA-induced eH]5-
HT release. Thus em5-HT release was shown to be calcium-dependent, while uptake 
inhibition appeared to be calcium-independent. 
(3) 5-HT depletion in regional brain tissue 
An acute depletion of 5-HT in the striatum, frontal cortex, hippocampus and 
hypothalamus has been demonstrated during the first 3 - 4 h after MDMA 
administration to rats, accompanied by depletion of 5-hydroxyindoleacetic acid (5-
illAA) (see Aguirre et aI., 1995; Colada & Green, 1994; Logan et aI., 1988; Schmidt, 
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1987a; 1987b; Schmidt & Kehne, 1990; Schmidt et al., 1986; Stone et al., 1987a; 
1987b). Cortical/hippocampal and striatal 5-HT depletion has also been observed in 
mice (see Logan et aI., 1988; O'Shea et al., 2001; Stone et al., 1987a) following 
MDMA administration. 
Colado & Green (1994) administered MDMA (20 mglkg i.p.) to male Hooded Lister 
(HL) rats and measured hippocampal and cortical concentrations of 5-HT and 5-IDAA 4 
h later. 5-HT was depleted by approximately 80 % in both the hippocampus and cortex, 
while 5-HIAA was depleted by approximately 60 %. O'Shea et al. (2001) administered 
MDMA to mice (10, 20 or 30 mg/kg i.p., three times at 3 h intervals) and, 3 h after the 
last injection, demonstrated an acute depletion of 5-HT and 5-HIAA in the hippocampus 
and cortex, and a decrease in striatal 5-IDAA levels. Stone et al. (1987a) demonstrated 
the differences in MDMA-induced effects on serotonergic activity between rats and 
mice: 3 h post-injection (rats: 10 mg/kg s.c.; mice: 15 mg/kg s.c.) an approximately 55 
% depletion of striatal 5-HT was observed in rats, and an approximately 35 % depletion 
in mice. At this time-point, an approximately 30 % depletion of 5-HlAA was observed 
in both species, which, by 6 h, was further diminished in rats but returning towards 
control values in mice (Stone et al., 1987a). Administration of the 5-HT uptake 
inhibitor, MDL 27,777 to rats 1 or 2 h after MDMA has been shown to prevent any 
further decline in hippocampal 5-HT levels, these returning to control values within 6 h 
after MDMA administration. These data indicate a role for the 5-HT transporter in 
mediation ofMDMA-induced 5-HT release (see Schmidt & Kehne, 1990). 
1.2.1.3 Alterations in 5-HT synthesis 
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme required for 5-HT synthesis, 
which has been shown to decrease in activity in response to MDMA administration (see 
Che et al., 1995; Johnson et ai., 1992; Schmidt & Taylor, 1988; Stone et al., 1987a; 
1987b; 1988). For example, Stone et al. (1987b) demonstrated that IPH activity had 
started to decline in the neostriatum, frontal cortex, hippocampus and hypothalamus 
within 15 min after MDMA administration (10 mg/kg s.c.) to male SD rats. This 
decrease in activity was seen to precede depletion of 5-HI and 5-IDAA. Depletion of 
central dopamine content (through treatment with a-methyl-p-tyrosine (AMPI) or 
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reserpine), or selective destruction of nigrostriatal dopamine projections (through 
administration of 6-hydroxydopamine; 6-0H-DA) has been shown to provide partial 
blockade of MDMA-induced reductions of TPH activity in rats. Thus dopamine appears 
to be involved in the acute serotonergic effects of MDMA, catecholamine depletion 
apparently having a protective effect (Stone et al., 1988). 
1.2.1.4 Acute release and depletion of dopamine 
Acute dopamine release has also been demonstrated, both in vivo (see Colada et ai., 
1999a; Gudelsky et al., 1994; Koch & Galloway, 1997; Nash & Brodkin, 1991; Nixdorf 
et al., 2001; Sabol & Seiden, 1998; Shankaran & Gudelsky, 1998; 1999; Yamamoto & 
Spanos, 1988) and in vitro (see Crespi et aI., 1997; Johnson et aI., 1986; O'Loinsigh et 
aI., 2001; Schmidt, 1987b), following MDMA administration to rats. Striatal 
concentrations of dopamine and its metabolites have also been measured within the first 
few hours after MDMA administration (see Colado & Green 1994; Gough et aI., 1991; 
Logan et al., 1988; O'Shea et al., 2001; Schmidt et al., 1991; Yamamoto & Spanos, 
1988). 
(1) In vivo dopamine release 
Yamamoto & Spanos (1988) placed in vivo voltammetry electrodes in the anterodorsal 
caudate and nucleus accumbens to enable measurement of dopamine release in awake-
behaving rats, following peripheral administration of MDMA (2.5, 5 or 10 mg/kg i.p.). 
MDMA produced a dose-dependent release of dopamine in both brain areas, being 
significantly greater in the caudate compared to the nucleus accumbens at the highest 
dose of MDMA, but of similar magnitude at the two lower doses. The peak release 
occurred within 120 min after drug administration and returned towards baseline values 
within 180 min. Colado et al. (1997a) administered MDMA (15 mg/kg i.p.) to male DA 
rats and, using in vivo microdialysis, demonstrated a rapid, significant increase in 
extracellular dopamine concentrations in the striatum, while sustained depletion of 3,4-
dihydroxyphenylacetic acid (OOP AC) and homovanillic acid (RV A) were observed. 
The involvement of 5-HT in MDMA-induced acute dopamine depletion has been shown 
by the fact that fluoxetine pretreatment produces significant attenuation of the response 
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(Koch & Galloway, 1997), as does pretreatment with the 5-HT 2AJ2C receptor antagonist, 
ritanserin (Yamamoto et al., 1995). Gudelsky et al. (1994) reported significant 
potentiation of MDMA-induced striatal dopamine release by pretreatment with either 
the 5-HT2 receptor agonist, (±)-2,5-dimethoxy-4-iodoamphetamine (DOl), or the non-
selective 5-HT agonist, 5-methoxy-N,N-dimethyltryptamine (5-MeODMT). These data 
indicated that stimulation of 5-HT 2 receptors enhanced dopaminergic activity. 
Shankaran & Gudelsky (1999) demonstrated that, although MDMA-induced striatal 5-
HT release was inhibited by pretreatment with a neurotoxic dose regimen of MDMA, 
the significant release of dopamine was unaltered. These data indicated that the 
pretreatment schedule produced selective neurotoxic damage to serotonergic nerve 
terminals, leaving dopaminergic neurones unaffected. 
Yamamoto et al. (1995) reported that MDMA administration results in a decrease in 
extracellular concentrations of y-aminobutyric acid (GABA) in the substantia nigra, 
which is prevented by ritanserin infusion (10 JlMol). The authors suggested that 
MDMA-induced striatal dopamine release could be modulated through an interaction 
between 5-HT and GABA. Shankaran & Gudelsky (1998) demonstrated prevention of 
an MDMA-induced increase in extracellular dopamine concentrations in the 
hippocampus by pretreatment with either the noradrenaline uptake inhibitor, 
desipramine, or N-(2-chloroethyl)-N-ethyl-2-bromo benzylamine (DSP 4), a compound 
which is believed to selectively deplete brain noradrenaline. However, neither 
pretreatment affected MDMA-induced dopamine release within the striatum. These data 
indicated that MDMA-induced increases in hippocampal extracellular dopamine could 
occur as a result of dopamine release from noradrenergic nerve terminals, since MDMA 
taken up into noradrenergic nerve terminals might increase efflux of cytosolic dopamine 
via the noradrenergic transporter. Thus desipramine could prevent MDMA uptake into 
the noradrenergic nerve terminal, or prevent dopamine efllux from the terminal 
(Shankaran & Gudelsky, 1998). 
Nash & Brodkin (1991) demonstrated that central administration of MDMA (10 IiMol 
infusion via a microdialysis probe implanted in the striatum) resulted in a pronounced 
increase in extracellular dopamine concentrations, which was significantly attenuated by 
34 
Chapter 1 General Introduction 
peripheral administration of the selective dopamine uptake inhibitor,. 1-[2-bis (4-
fluorophenyl) methoxy]ethyl]-4-3-phenylpropyl]piperazine (GBR 12909). Dopamine 
release was also prevented by mazindol, which inhibits uptake of dopamine, 
noradrenaline and, to a lesser extent, 5-HT. These results indicated that MDMA releases 
dopamine via an interaction with the dopamine transporter. 
(2) In vitro dopamine release 
Johnson et al. (1986) demonstrated an acute release of eH]dopamine in vitro, following 
incubation of rat caudate nucleus slices with MDMA (10 IlMol), although this response 
was significantly smaller than the response to MDA administration. Koch & Galloway 
(1997) demonstrated that incubation of rat striatal slices with MDMA resulted in a dose-
dependent release of dopamine, which was completely prevented by pretreatment with 
GBR 12909, but unaffected by pretreatment with fluoxetine. These data indicated that 
the dopamine transporter is involved in the mediation of the effects of MDMA, and that 
intact neurones are likely to be required for 5-HT -facilitated dopamine release, since 
fluoxetine did not affect in vitro dopamine release, but did attenuate in vivo release 
(Koch & Galloway, 1997). 
Crespi et al. (1997) demonstrated acute eH]dopamine release in striatal synaptosomes, 
following incubation with amphetamine, PCA, MDMA and fenfluramine (in descending 
order of potency). This response was demonstrated to be calcium-dependent, since 
removal of calcium from the superfusion buffer significantly attenuated eH]dopamine 
release. O'Loinsigh et al. (2001) demonstrated [3H]dopamine release in striatal 
synaptosomes as induced by MDMA and its analogues: MDA, MDMA, MDEA and 
MDBA (in descending order of potency). 
(3) Striatal dopamine depletion 
Logan et al. (1988) measured striatal monoamine concentrations at various time-points 
following MDMA administration, and reported a rise in dopamine and fall in DOP AC 
levels, 3 h post-injection in both rats and mice. Yamamoto & Spanos (1988) reported 
similar results, demonstrating a rise in dopamine levels and fall in nop AC levels in 
both the caudate and the nucleus accumbens, which corresponded to the observed 
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release of dopamine as measured via in vivo voltammetry. Schmidt et al. (1991) co-
administered MDMA and the 5-HT2 antagonist, a-phenyl-l-(2-phenylethyl)-4-
piperidinemethanol (MDL 11,939) and measured striatal concentrations of dopamine, 
nop AC and HV A 3 h later. MDL 11,939 completely blocked MDMA-induced 
increases in striatal dopamine and significantly potentiated MDMA-induced decreases 
in DOP AC. While MDMA alone had no effect on striatal HV A concentration, MDL 
11,939 + MDMA treatment produced marked depletion of HV A 3 h after MDMA 
administration. These data indicated a critical role for the 5-HT 2 receptor in the 
neurochemical effects ofMDMA. 
0' Shea et al. (2001) demonstrated a significant depletion of striatal dopamine in mice, 3 
h after the last of three MDMA injections (30 mglkg i.p.), while striatal DOPAC 
concentration was dose-dependently depleted (10, 20 or 30 mglkg i.p., three times at 3 h 
intervals). Pretreatment with GBR 12909 (30 mg/kg i.p., 30 min prior to each 30 mg/kg 
MDMA injection) further enhanced MDMA-induced striatal dopamine loss, had no 
effect on MDMA-induced DOP AC loss, and enhanced striatal BV A concentrations. 
Fluoxetine pretreatment had no effect on MDMA-induced changes in dopamine. The 
potentiation of MDMA-induced dopamine loss by GBR 12909 raised the question as to 
whether this response does in fact involve the dopamine uptake carrier (O'Shea et a!., 
2001). 
1.2.1.5 Free radical production 
MDMA administration leads to the production of free radicals, such as hydroxyl 
radicals (Off) and peroxynitrite radicals (ONOO) The formation of free radicals and 
the potential involvement of nitric oxide in MDMA-induced neurotoxicity are discussed 
in Chapter 7. Briefly, Colado et al. (1997a) demonstrated the production of free radicals 
through the use of in vivo microdialysis in the hippocampus of male DA rats. An in vivo 
system can be used to measure the production of Off, whereby salicylic acid is perfused 
through the microdialysis probe and, when Off reacts with the salicylate, 2,3- and 2,5-
dihydroxybenzoic acid (2,3-DHBA and 2,5-DHBA) are generated. Thus by measuring 
the production of 2,3-DHBA and 2,5-DHBA, OH- generation can be assessed. MDMA 
(15 mg/kg i.p.) was shown to produce a sustained (50 %) rise in the dialysate 
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concentration of 2,3-DHBA, a response which was prevented by administration of the 
spin trap reagent, PBN (120 mg/kg i.p., 10 min prior to and 2 h after MDMA). These 
data thus demonstrated the production of free radicals following MDMA treatment, and 
that the protective action of PBN is likely to involve a free radical scavenging 
mechanism. 
1.2.1.6 Acute behavioural effects 
(1) Serotonin behavioural syndrome and locomotor activity 
The "serotonin behavioural syndrome" was first reported in rats by Grahame-Smith 
(1971) within 30 min after administration of the monoamine oxidase (MAO) inhibitor, 
tranylcypromine (TCP). Hyperactivity was accompanied by head-weaving, piloerection, 
forepaw treading, proptosis, penile erection, ejaculation, salivation and defecation. The 
time of onset of hyperactivity was decreased with increasing dose of L-tryptophan, 
which was administered 30 min after TCP. Administration of MDMA to rats (and 
mice, see Miller & O'Callaghan, 1995) results in an acute, dose-dependent, 
hyperlocomotor response (Callaway et aI., 1990~ Colado et aI., 1993; Dafters, 1994; De 
Souza et aI., 1997; Kehne et al., 1996a~ Marston et al., 1999; McCreary et aI., 1999~ 
McNamara et aI., 1995~ O'Loinsigh et aI., 2001; Slikker Jr. et aI., 1989~ Spanos & 
Yamamoto, 1989), which commences within 30 min after drug injection (Spanos & 
Yamamoto, 1989). In addition, serotonin syndrome behaviour is observed, which 
comprises: forepaw treading, head-weaving, low body posture, piloerection and 
salivation (Colado et al., 1993; De Souza et aI., 1997; Marston et aI., 1999; Shankaran 
& Gudelsky, 1999~ Slikker Jr. et al., 1989~ Spanos & Yamamoto, 1989). 
Slikker Jr. et al. (1989) administered MDMA (5 or 10 mglkg p.o.) to male SD rats, once 
per day on four consecutive days, and assessed spontaneous behaviour for 60 min 
commencing 10 min after each dose. Locomotor activity and serotonin syndrome 
behaviours were monitored and scored during 20, 15 s observation periods. On the first 
day, the serotonin motor syndrome score was significantly higher in MDMA-treated 
animals compared to controls, however on the other three test days, serotonin syndrome 
scores decreased on each successive day and were no different from control values. 
Overall locomotor activity was also greater in MDMA-treated animals on the first test 
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day, although this did not reach statistical significance. There were no significant 
differences between MDMA-treated and control animals on any of the subsequent test 
days. The authors suggested that the decrease in serotonin motor syndrome scores on 
the later test days were likely to be due to MDMA-induced serotonergic deficits 
(Slikker Jr., 1989). Callaway et al. (1990) demonstrated a dose-related effect of 
MDMA on locomotor activity, the greatest locomotor scores being obtained after 
administration of the highest two doses (3 and 10 mglkg s.c., 10 min prior to testing). 
Control and MDMA-treated animals administered the lower doses of drug (0.3 and 1 
mglkg s. c.) demonstrated a decrease in activity over time, while animals administered 
the highest two doses of MDMA demonstrated an increase in activity which peaked 30 
min after drug administration and was still markedly greater than the lower dose and 
control groups at the end of the test. Fluoxetine pretreatment prevented the MDMA-
induced increase in locomotor activity, indicating that 5-HT release plays an important 
role in the behavioural effects ofMDMA. 
MDMA-induced locomotor responses have been shown to be, at least partially, 
mediated by the 5-HT IB receptor. For example, McCreary et al. (1999) demonstrated 
MDMA-induced hyperactivity in rats in an open-field/activity meter apparatus, which 
was blocked by pretreatment with the 5-HTlBIlD receptor antagonist, 2'-methyl-4'-(5-
methyl-[ 1 ,2,4 ]oxadiazol-3-yl)-biphenyl-4-carboxylic acid [4-methoxy-3-( 4-methyl-
piperazin-l-yl)-phenyl]-amide (GR 127935), while the 5-HT1A antagonist, N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide (W A Y 
100,635) had no effect. Scearce-Levie et al. (1999) administered MDMA (3.3, 10 or 30 
mg/kg i.p.) to wild-type and 5-HT1B-knockout mice, 10 min prior to analysis of 
locomotor behaviour in an open field arena. The lowest dose had no effect on locomotor 
activity in either group, whereas 10 mglkg and 30 mg/kg doses resulted in two-fold and 
four-fold increases in locomotor activity, respectively, in wild-type mice. Only the 
highest dose produced an increase in locomotor activity in the knockout mice, although 
this response was delayed - the wild-type mice demonstrated significantly greater 
locomotor activity during the period 0 - 30 min, while there was no difference between 
groups during the period 60 - 90 min. The alterations in MDMA-induced locomotor 
behaviour were confirmed to be due to the absence of the 5-HT IB receptor, since 
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administration of the 5-HT1BllD antagonist, GR 127935, blocked MDMA-induced 
locomotor stimulation in a similar manner to that observed in the knockout mice. The 5-
HT 2A receptor also appears to be involved in expression of the MDMA-induced 
locomotor response. Kehne et al. (1996a) demonstrated a reduction of the response by 
pretreatment with the 5-HT 2A receptor antagonist, R-( + )-a-(2,3-dimethoxyphenyl)-1-[2-
(4-fluorophenylethyl)]-4-piperidinemethanol (MDL 100,907), while MDMA-induced 
increases in rearing behaviour were unaffected. This reduction was greater in the latter 
portion of the test (30 - 60 min) than the earlier portion (0 - 30 min). 
(2) Anxiety-related behaviours 
The anxiety-related responses which occur following acute MDMA administration are 
discussed in Chapter 4. In particular, Lin et al. (1999) reported dose-dependent effects, 
as measured on the elevated plus-maze 30 min after MDMA administration to mice; 
anxiogenic effects were observed at lower doses and anxiolytic effects at higher doses, 
shown by changes in the percentage (%) number of open arm entries and time spent on 
the open arms. In rats, Morley & McGregor (2000) demonstrated a dose-related 
decrease in the time spent on the open arms and the total number of arm entries, 
indicating an anxiogenic effect at these doses (1.25 - 5 mg/kg). Maldonado & Navarro 
(2001) conducted a study on social interaction behaviours between male mice, 30 min 
after MDMA injection (1, 8 or 15 mglkg i.p.). MDMA-treated animals performed 
significantly less grooming, digging, social investigation (sniffing, grooming, crawling 
over or under paired animal), threat (sideways or upright offensive) and attack (charge, 
lunge, chase) behaviours compared to control animals. Non-social exploration (rearing, 
exploring), defence/submission (upright defensive, upright submissive), exploration 
from a distance (stretched attend posture) and avoidance/flee (retreat, flinch, startle) 
behaviours were all increased in MDMA-treated mice. These behavioural changes are 
indicative of anxiogenic-like activity in :MDMA-treated mice (Maldonado & Navarro, 
2001). 
1.2.2 Long-term effects 
The long-term effects which follow MDMA administration to rats include: (1) a 
depletion of regional brain 5-HT, (2) neuronal damage and a reduction of 5-HT uptake 
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sites, (3) alterations in 5-HT receptor density, (4) behavioural changes. 5-HT depletion 
has also been demonstrated in guinea-pigs, and both loss of 5-HT content and 
serotonergic neuronal damage have been reported in non-human primates, whereas 
MDMA administration to mice results in long-term depletion of brain dopamine. 
1.2.2.1 
(1) 
Long-term 5-HT depletion and neuronal damage in rats 
Effects of preventing MDMA-induced acute hyperthermia 
Prevention of the MDMA-induced hyperthermic response tends to provide protection 
against loss of 5-HT and its metabolite (see Chapter 7) and a number of compounds 
which were previously shown to be neuroprotective have later been demonstrated to 
induce hypothermia or, at least, prevent hyperthermia. For example, Farfel & Seiden 
(1995a) demonstrated that the NMDA antagonist, dizocilpine (MK-801), protected 
against MDMA-induced depletions of 5-HT and 5-HIAA measured three days post-
treatment. However, co-administration of MK-801 and MDMA was also demonstrated 
to produce a hypothermic response. When the temperatures of MK-80 1 + MDMA 
animals were kept elevated, the neuroprotective effects of MK-801 were completely 
reversed. Similar effects were seen when the competitive NMDA receptor antagonist, 
cis-4-(phosphonomethyl)-2-piperidine carboxylic acid (CGS 19755) was co-
administered with MDMA - both a hypothermic response and some degree of protection 
against serotonergic depletion were observed. However, pretreatment with the a-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist, 2,3-
dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX), did not modify the 
MDMA-induced hyperthermic response, and did not protect against 5-HT and 5-HIAA 
depletion (Farfel & Seiden, 1995a). 
Malberg et al. (1996) investigated the effects of three pretreatment compounds on 
MDMA-induced hyperthermia and serotonergic neurotoxicity in male Holtzman rats: 
(1) ketanserin, (2) the competitive tyrosine hydroxylase inhibitor, AMPT, and (3) 
fluoxetine. Pretreatment with either ketanserin (6 mglkg i.p.) or AMPT (75 mg/kg i.p.) 
resulted in a hypothermic response to MDMA (40 mglkg s.c.) and, two weeks later, 
prevented MDMA-induced reductions in brain 5-HT and 5-HIAA concentrations. In 
order to prevent the hypothermic response to ketanserinIMDMA and AMPT/MDMA, 
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another group of animals were warmed (via a heating lamp positioned above their cage) 
to maintain core temperatures of 38.5 - 39.5 °C. This procedure abolished the 
neuroprotective effects of ketanserin and AMPT; 5-HT and 5-HIAA concentrations 
being similar to those seen in MDMA-treated animals. Fluoxetine pretreatment (10 
mg/kg i.p.) did not significantly modify the MDMA-induced hyperthermic response, but 
did protect against 5-HT and 5-lllAA depletion. Thus, these results indicated that 
prevention of MDMA-induced hyperthermia, by ketanserin and AMPT, provided 
neuroprotection against loss of 5-HT and S-HIAA. The neuroprotective effects of 
fluoxetine (which was without effect on MDMA-induced hyperthermia) indicated that 
protection was afforded by some mechanism other than temperature modification. The 
authors suggested that selective blockade of the serotonin transporter by fluoxetine 
might prevent the uptake of MDMA or putative neurotoxins into the nerve terminal, 
thus providing a protective mechanism against MDMA-induced neurotoxicity (Malberg 
et at., 1996). 
Malberg & Seiden (1998) demonstrated the apparent importance ofTa in depletion of5-
HT and 5-HIAA, as measured two weeks after MDMA administration (20 or 40 mg/kg 
s.c.). No significant depletions were observed in any of the brain regions examined, 
where MDMA had been administered at a T a of 20, 22 or 24°C. However, under T a 
conditions of 26, 28 or 30°C, significant depletions of both 5-HT and S-HIAA were 
observed in the hippocampus, striatum, frontal cortex and somatosensory cortex. 
Significant negative correlations between core temperature and serotonergic depletion 
were observed. Thus small changes in T a were shown to produce marked changes in the 
degree of serotonergic neurotoxicity. 
(2) 5-HT depletion in rats and guinea-pigs 
Administration of single or multiple doses of MDMA to rats results in long-term 
depletions of 5-HT and 5-HIAA (see Aguirre et a/., 1998; Battaglia et aI., 1987; Colado 
et aI., 1993; 1999a; Commins et a!., 1987; Farfel & Seiden, 1995a; Gudelsky, 1996; 
Malberg et al., 1996; Nash & Yamamoto, 1992; Q'Loinsigh et al., 2001; O'Shea et a/., 
1998; Sanchez et a!., 2001; Scanzello et al., 1993; Schmidt, 1987a; 1987b; Shankaran & 
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Gudelsky, 1998~ 1999) and significant reductions in TPH activity (see Schmidt et aI., 
1990c; Stone et aI., 1987a; 1987b; 1988; Yeh, 1999). 
Following the initial decrease in 5-HT content, as 5-HT is released, concentrations 
return towards pretreatment levels within 24 h. Schmidt (1987a) administered a single 
dose of MDMA (10 mglkg s.c.) to male SD rats and monitored the time course of 
cortical 5-HT depletion, showing two clearly distinguishable phases of the response. 5-
HT was significantly depleted within 3 h of drug treatment, being only 16 % of control 
values at between 3 h and 6 h post-drug administration. Between 6 hand 24 h, however, 
a sharp recovery was observed~ 5-HT concentration had returned to control values one 
day after MDMA injection. The second phase of depletion was apparent one week post-
treatment, as 5-HT levels gradually declined during the period between one and seven 
days, being reduced to 74 % of control values one week after drug administration. 
Battaglia et al. (1988a) demonstrated dose-dependent reductions in frontal cortex 
concentrations of 5-HT and 5-HIAA in male SO rats during the sub-acute phase, 18 h 
after multiple doses of MDMA (5, 10 or 20 mglkg s.c. twice per day for four 
consecutive days). Following the highest dose, 5-HT and 5-IDAA were reduced by 
approximately 85 % and 60 %, respectively. Similar reductions were observed 
following four 20 mglkg doses administered to guinea-pigs. In addition, the loss of 5-
HT and 5-illAA content were shown to be dependent upon the number of doses of 
MDMA (lOmg /kg) administered - 5-HT was reduced by approximately 10 %, 20 %,40 
% and 80 % following one, two, four or eight doses, respectively (Battaglia et aI., 
1988a). Similar results were reported by Stone et al. (1986) 18 h after MDMA 
administration (10 mglkg s.c., five times at 6 h intervals), in addition to significant 
reductions in TPH activity. 
Following the acute/sub-acute depletion of 5-HT, long-term depletion occurs, is 
apparent within four days after drug administration and persists for many weeks. 
O'Shea et al. (1998) conducted a comprehensive study on MDMA-induced long-term 
serotonergic depletion, assessing the extent of neurotoxicity produced by: (1) single 
doses of MDMA (4, 10 and 15 mglkg i.p.), (2) multiple low doses (4 mglkg) 
administered once or twice daily for four consecutive days, and (3) multiple low doses 
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(4 mg/kg) administered twice weekly for eight consecutive weeks. Single doses 
produced dose-dependent decreases in hippocampal, cortical and striatal 5-HT and 5-
IDAA measures one week post-treatment, the lowest dose (4 mg/kg) only having a 
significant depleting effect on cortical 5-IDAA. Administration of 4 mg/kg MDMA 
daily for four days had no effect on regional brain concentrations of 5-HT or 5-HIAA, 
while twice daily administration resulted in significant depletions in all brain areas 
examined (e.g. 40% cortical loss of 5-HT). Twice weekly administration of low dose 
MDMA had no effect on regional brain concentrations of 5-HT or 5-HIAA. The authors 
suggested that, since MDMA-induced damage is likely to involve free radicals, the 
absence of serotonergic depletion following chronic, low dose MDMA could be due to 
the recovery of endogenous free radical scavenging systems between each 
administration. In addition, the data indicated that high or frequent doses of MDMA 
produced neurotoxic damage and could have significant implications for the recreational 
use ofMDMA (O'Shea et ai., 1998). 
Colado et ai. (1993) reported significant depletion of both 5-HT and 5-HlAA in the 
cortex and hippocampus four days after a single dose of MDMA (20 mg/kg i.p.). 
Administration of the GABAmimetic compound, clomethiazole (100 mg/kg i.p., 20 min 
after MDMA injection), significantly attenuated or prevented 5-HT and 5-HIAA loss in 
both brain regions. Administration of clomethiazole (50 mg/kg i.p.) pre- and post-
MDMA injection afforded complete protection against MDMA-induced loss of 5-HT 
and 5-HIAA in both brain regions, whereas MK.-801 treatment (I mg/kg i.p., 5 min 
before and 55 min after 'MDMA) only prevented 5-HT and 5-HIAA loss in the 
hippocampus. Since MK.-801 is a non-competitive N-methyl-D-aspartate (NMDA) 
receptor antagonist, these data could indicate that MDMA-induced neurotoxicity 
involved excitotoxic damage (Colado et ai., 1993). This study was further extended 
(Colado & Green, 1994) to investigate the effects of another GAB A-potentiating 
compound, pentobarbitone, and two drugs which inhibit dopamine release in the 
striatum (y-butyrolactone; GBL) and nucleus accumbens (ondansetron), on long-term 5-
HT depletion. Both pentobarbitone and GBL provided substantial protection against 
MDMA-induced 5-HT and 5-HIAA depletion in the hippocampus and cortex, with the 
exception of loss of cortical 5-HIAA which was not prevented by pentobarbitone. These 
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data thus indicated that MDMA-induced neurotoxicity might also involve striatal 
dopamine release, since GBL provided protection against MDMA-induced serotonergic 
depletion. None of the pretreatment compounds had any effect on the acute release of 5-
HT induced by MDMA (4 h post-injection), thus it appears that their neuroprotective 
actions do not involve prevention of 5-HT release (Colado & Green, 1994). 
The protective effects of cIomethiazole were later demonstrated to partially involve 
prevention of the :MDMA-induced hyperthermia, and partly some other unknown 
mechanism. Colado et al. (1998) demonstrated complete protection against MDMA-
induced reductions in hippocampal, cortical and striatal 5-HT and 5-HIAA, by 
administration of clomethiazole measured seven days post-treatment. However, the 
acute hyperthermic response to MDMA administration was completely prevented by 
clomethiazole treatment, thus a second experiment was performed where the animals 
were warmed via a homeothermic blanket, to maintain their body temperature at similar 
values to those observed in animals administered :MDMA alone. The clomethiazole-
induced prevention of hyperthermia was blocked and the neuroprotective effects of 
cIomethiazole were diminished, but not prevented. Thus the authors suggested that 
some additional mechanism(s) were involved in the neuroprotective effects of 
clomethiazole (Colado et al, 1998). Such mechanisms have been shown not to include 
free radical scavenging, as clomethiazole was shown only to prevent free radical 
production (as indicated by MDMA-induced increases in 2,3-DHBA generation from 
salicylic acid) where the acute hyperthermic response was prevented. When 
clomethiazole + MDMA animals were warmed to maintain body temperature similar to 
that of :MDMA-treated animals, inhibition of MDMA-induced increases in 2,3-DHBA 
generation were prevented. Furthermore, the protection against long-term 5-HT 
depletion was still afforded by clomethiazole, even when free radical production was 
not inhibited (Colado et aI., 1999b). 
Seven days after a single dose ofMDMA (10 mglkg Lp.) was administered to male DA 
rats, cortical and hippocampal 5-HT concentrations were both reduced by 40 %. The 
depletion of both 5-HT and 5-HIAA was significantly attenuated by pretreatment with 
the spin trap reagent, Cl-phenyl-N-tert-butyl nitrone (PBN; 150 mglkg i.p., 10 min prior 
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to and 2 h after MDMA), 5-HT depletion being only 16 % and 13 % in the cortex and 
hippocampus, respectively in the PBN + MDMA treatment group (Colado & Green, 
1995). Similar results were reported by Yeh (1999), where PBN attenuated both 
MDMA-induced 5-HT and 5-IllAA depletion, and MDMA-induced decreases in 
CH]paroxetine binding. However, PBN was also demonstrated to prevent the MDMA-
induced hyperthermic response, which may have contributed to the protective effect of 
PBN (Colado & Green, 1995; Yeh, 1999). While the protective effects of PBN could 
involve attenuation of the acute hyperthermic response, the involvement of free radicals 
in MDMA-induced neurotoxicity has been illustrated by the protective effects of the 
anti-oxidants, ascorbate and cysteine. Gudelsky (1996) administered MDMA (20 mg/kg 
s.c.) to male SD rats, which resulted in significant reductions of striatal 5-HT one week 
later. However, in animals which were administered sodium ascorbate (250 mglkg i.p.) 
or cysteine (500 mg/kg i.p.) 30 min prior to and 5 h after MDMA, significant 
attenuation of MDMA-induced 5-HT loss was observed. Thus these data are indicative 
of the involvement of oxidative damage in MDMA-induced serotonergic depletion. 
Schmidt et al. (1990a; 1990b; 1991) demonstrated the protective effects of 5-HT2 
receptor antagonists on MDMA-induced serotonergic depletion. Both MDL 11,939 and 
ritanserin significantly attenuated MDMA-induced 5-HT depletion, measured one week 
post-treatment (Schmidt et aI., 1990a; 1990b). However, partial attenuation of the acute 
hyperthermic response was also observed following MDL 11,939 administration which 
could account for its protective effects. MDL 11,939 was also shown to block MDMA-
mediated stimulation of dopamine synthesis and was thus believed to prevent the 
maintenance of MDMA-induced, carrier-mediated dopamine release, indicating that 
such dopamine release is required for MDMA-induced serotonergic neurotoxicity 
(Schmidt et al., 1990b). This suggestion is also consistent with the observations that 
antagonism of MDMA-induced neurotoxicity can be achieved by: (1) prior depletion of 
monoamine vesicular stores via reserpine administration, (2) by depletion of newly 
synthesised neurotransmitter via decarboxylase inhibition, (3) by inhibition of dopamine 
synthesis by AMPT (Schmidt et al., 1990c), or (4) by administration of the S-HT2 
antagonist, MDL 100,907, which inhibits MDMA-induced dopamine release (Schmidt 
et aI., 1992). 
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The mechanisms involved in the protective effects of fluoxetine have recently been 
investigated. Sanchez et al. (2001) administered MDMA (15 mg/kg i.p.) to male DA 
rats and measured regional brain concentrations of 5-HT and 5-HIAA and 
eH]paroxetine binding of uptake sites one week later. Fluoxetine was administered 
either: (1) 10 mg/kg i.p., 5 min prior to and 55 min after MDMA administration, or (2) 
10 mglkg i.p., twice, 1 h apart, two, four and seven days prior to MDMA. Acute 
fluoxetine treatment completely prevented MDMA-induced decreases in 5-HT and 5-
HIAA content, and significantly attenuated the decrease in uptake sites. Complete 
neuroprotection was also observed when fluoxetine was administered two or four days 
prior to MDMA, and significant protection was seen when fluoxetine was administered 
seven days prior to MDMA. Acutely, a peak cortical concentration of fluoxetine was 
recorded 30 min post-administration, which declined rapidly within 24 h, to reach a 
low, steady concentration four to seven days post-treatment. Concentrations of the main 
metabolite of fluoxetine, norfluoxetine, reached a peak 48 h after fluoxetine 
administration, and then declined gradually over the following five days. Thus 
fluoxetine produces a long-lasting neuroprotection against MDMA-induced 
serotonergic damage, which is likely to be related to the sustained presence of 
fluoxetine and norfluoxetine in the brain, both of which are still detectable seven days 
after fluoxetine administration. Both compounds are selective blockers of the 5-HT 
transporter, inhibiting 5-HT uptake, and are believed to disrupt the entry of MDMA (or 
a neurotoxic metabolite) into the presynaptic nerve terminal (Sanchez et ai., 2001). 
While 5-HT depletion appears to be potentiated by the production of an acute 
hyperthermia, it is not essential for serotonergic neurotoxicity. For example, Farfel & 
Seiden (1995a) demonstrated that administration ofMDMA (40 mg/kg s.c.) to male SD 
rats under T a conditions of 20 - 22°C, resulted in an acute hypothermic response (a 
decrease in body temperature of approximately 1°C) 30 min after injection. Three days 
later, hippocampal and striatal 5-HT concentrations were decreased by 37 % and 42 %, 
respectively, similar reductions to those observed in animals where an acute 
hyperthermic response was produced. 
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(3) Central administration of MDMA to rats 
Serotonergic neurotoxicity has been demonstrated not to occur following central 
administration of MDMA. For example, Paris & Cunningham (1991) infused MDMA 
(25 Ilgllll) directly into the median- and dorsal- raphe nuclei. Two weeks post-
administration, there were no differences in striatal or hippocampal concentrations of 5-
HT, dopamine, noradrenaline, or their metabolites. Immunocytochemical analysis also 
demonstrated no loss of 5-HT cell bodies or non-specific damage, and there were no 
structural abnormalities (such as inclusion bodies) in the raphe nuclei. Thus 
intracerebral MDMA injection appears to have no effect on 5-HT neurones, and could 
indicate that systemic administration and the production of a neurotoxic metabolite are 
required for neuronal damage. 
More recently, Esteban et al. (2001) reported that systemic MDMA treatment (15 
mglkg i.p.) resulted in a rapid increase in MDMA concentrations in the hippocampal 
dialysate (peak concentration of approximately 4.35 IlMol, 30 - 60 min post-
administration). Central drug administration (100, 200 or 400 IlMol perfused through 
the dialysis probe) produced a dose-dependent increase in the concentration of 5-HT in 
the hippocampal dialysate, reaching a peak 30 - 60 min post-administration. However, 
hippocampal 5-HT and 5-HlAA content were no different from control values, when 
measured seven days later. In addition, central drug administration did not produce an 
acute hyperthermic response, thus a second group of rats were warmed via a 
homeothermic blanket to maintain rectal temperature near to that of systemically-treated 
animals. Seven days later, there was still no evidence of serotonergic depletion. These 
results were in contrast to those observed following hippocampal perfusion of 5,7-DHT, 
where a pronounced decrease in 5-HT and 5-HlAA was observed in the ipsilateral 
hippocampus one week later. Striatal perfusion of MDMA resulted in a rapid increase in 
extracellular striatal dopamine concentrations, but neither dopamine nor 5-HT 
concentrations in the striatum were diminished when analysed seven days later. These 
data further indicated that serotonergic neurotoxicity, following systemic MDMA 
administration, is likely to be caused by peripherally-formed metabolites. 
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(4)' t HJparoxetine binding 
An indication of serotonergic neuronal damage can be demonstrated by [3H]paroxetine 
binding to the presynaptic 5-HT transporter - binding is reduced following MDMA 
administration (see Aguirre et at., 1995; Battaglia et al., 1987; 1988a; 1991; Broening et 
al., 1995; Colado & Green, 1995; Colado et al., 1995; Hewitt & Green, 1994; 
Obradovic et at., 1998; O'Loinsigh et al., 2001; O'Shea et al., 1998; Scanzello et al., 
1993). For example, seven days after administration of a single dose of MDMA (30 
mglkg i.p.), a 35 % reduction in eH]paroxetine binding was observed in the frontal 
cortex, while multiple doses ofMDMA (30 mg/kg i.p., twice daily for four consecutive 
days) resulted in an approximately 45 % reduction (Aguirre et at., 1995). However, 
dopaminergic and noradrenergic neurones, as investigated by eH]mazindol binding to 
dopamine and noradrenaline uptake sites, are unaffected by MDMA administration to 
the rat (see Battaglia et al., 1987; 1991). 
Battaglia et al. (1987) demonstrated significant reductions in CH]paroxetine binding in 
the cortex, hippocampus, striatum, hypothalamus and midbrain, two weeks after 
administration of MDMA (20 mg/kg s.c., twice daily for four consecutive days), while 
the density of dopamine and noradrenaline uptake sites were unaffected, with the single 
exception of dopamine uptake sites in the midbrain. In the same study, significant loss 
of 5-HT content was shown in the cortex and hypothalamus, while smaller effects were 
seen in the striatum and hippocampus, thus being in contrast to the significant reduction 
of eH]paroxetine binding in all brain regions examined. These results indicate that 
using loss of 5-HT content as a measure of neurodegeneration could underestimate the 
full magnitude of MDMA-induced neurotoxicity (Battaglia et at., 1987). Colado & 
Green (1995) reported a complete inhibition of MDMA-induced reductions in 
eH]paroxetine binding in the cortex, following a single dose ofMDMA (10 mg/kg i.p., 
seven days earlier), by administration of the spin trap reagent, PBN (150 mg/kg i.p., 10 
min prior to and 2 h after MDMA). Since eH]paroxetine binding provides a measure of 
neuronal degeneration, protection by PBN indicates protection against MDMA-induced 
neurodegeneration and indicates that free radical production is likely to be involved in 
the neurodegenerative process (Colado & Green, 1995). 
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(5) Histological analysis 
Silver-staining of rat striatal slices (13 - 16 h after the last of four 80 mg/kg doses of 
MDMA) demonstrated the presence of argyrophilic deposits in MDMA-treated rats, 
which were absent in control animals. Primary somatosensory cortex slices contained 
shrunken, argyrophilic neuronal cell bodies and what appeared to be fragmented 
dendrites and degenerating axon terminals (Commins et at., 1987). However, the 
staining method used (Fink-Heimer) does not enable identification of the specific 
neurotransmitter contained in the damaged nerve terminals, therefore it was not possible 
to determine whether serotonergic or dopaminergic neurones were affected (see 
Commins et al., 1987; Molliver et al., 1990; O'Hearn et at., 1988). O'Hearn et at. 
(1988) administered MDMA (20 mglkg s.c., eight times at 4 h intervals) to male SD rats 
and performed immunocytochemical analysis of regional brain sections two weeks later. 
Gross changes, indicated by reduced intensity of staining in MDMA-treated brain slices, 
were reflective of a marked reduction in serotonergic axonal density and were 
particularly apparent in the neocortex, striatum and thalamus, with smaller reductions 
occurring in the hippocampus, septum and amygdala. The terminal portions ofaxons 
were shown to be selectively vulnerable to MDMA-induced damage, as indicated by the 
reduced density of fine, arborised 5-HT axons, while smooth, straight preterminal 
fibres, fibres of passage and raphe cell bodies were spared. Morphological evidence of 
damage to axon terminals is consistent with the observed reductions in 5-HT uptake 
sites (see Molliver et al., 1990; O'Hearn et al., 1988). 
The time course of lesion and recovery has been shown to be region-specific - for 
example, two weeks after drug administration, neurodegenerative processes in the 
dorsal caudate region are only just fully expressed, while a maximal and persistent 
deficit in 5-HT innervation is apparent in the cortex, and some regeneration is beginning 
to occur in the substantia nigra. Furthermore, brain regions containing 5-HT axonal 
pathways or perikarya are little affected by MDMA, the predominant effects being 
mediated on axons and terminals (Battaglia et al., 1991). Such data are consistent with 
the lack of 5-HT depletion in the dorsal raphe region of the brain stem (see Aguirre et 
al., 1995), which includes serotonergic cell bodies. 
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(6) Measurement of anterograde axonal transport 
Measurement of anterograde axonal transport provides an additional method for 
assessment of serotonergic neurotoxicity, enabling study of ascending 5-HT axonal 
projections by tracing the transport of radioactive material. Rats were administered 
MDMA (20 mg/kg i.p., four times at 2 h intervals), three weeks prior to injection of 
eH]proline into the rostral raphe nuclei. Two days after injection of the labelled amino 
acid, regional brain radioactivity levels were measured. MDMA treatment resulted in 
significant decreases in anterograde axonal transport of labelled material, which 
paralleled (but were less severe than) decreases in 5-HT and 5-HlAA content. In 
addition, the effects of MDMA were similar to those observed following administration 
of5,7-DHT, a well-documented serotonergic neurotoxin (Callahan et aI., 2001). 
(7) Glial fibrillary acidic protein 
Astrocyte hypertrophy can occur as a result of neuronal injury and can lead to the 
enhanced expression of glial fibrillary acidic protein (GFAP). This marker of neuronal 
damage has been used in assessment of MDMA-induced toxicity, and its use in mice is 
discussed in Chapter 7. Briefly, striatal GFAP expression has been shown to increase 
significantly within 72 h of administration of MDMA, MDA and methamphetamine to 
mice, corresponding to the decrease in striatal dopamine content (see Miller & 
O'Callaghan, 1994). 
1.2.2.2 Alterations in 5-HT receptor density 
Aguirre et al. (1995) measured in vitro binding ofeH]8-0H-DPAT in rat brain cortical 
and dorsal raphe nucleus homogenates, in order to assess the effects of MDMA 
administration on 5-HT1A receptor density. Both a single dose (30 mg/kg i.p.) and 
multiple doses (30 mg/kg i.p., twice daily for four consecutive days) of MDMA 
resulted in a significant increase in eH]8-0H-DPAT binding in the frontal cortex, 
indicating an increase in 5-HT lA postsynaptic receptors in this brain region. However, a 
single dose had no effect on eH]8-0H-DPAT binding in the dorsal raphe region, while 
multiple doses resulted in a significant decrease in binding, indicating a reduction of 5-
HT lA inhibitory auto receptors in this region (Aguirre et aI., 1995). [3H]8-0H-DPAT 
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binding in the hypothalamus has also been shown to be significantly enhanced seven 
days after either single or multiple doses of MDMA, indicating up-regulation of the 5-
HTIA receptor in this brain region (Aguirre et a!., 1998). MDMA itself was shown to 
have negligible in vitro affinity for brain 5-HT IA receptors, but increased the density of 
this receptor subtype in the frontal cortex and reduced receptor density in the dorsal 
raphe region. A decrease in eH]paroxetine binding in the frontal cortex correlated with 
the increase in 5-HT IA receptors, which could indicate adaptive changes to compensate 
for the loss of serotonergic nerve terminals (Aguirre et aI., 1995). Pretreatment with 
fluoxetine, haloperidol or ketanserin prevented MDMA-induced increases in eH]8-0H-
DPAT binding in the frontal cortex (Aguirre et ai., 1998). 
While 5-HT IA receptors appear to be up-regulated following MDMA administration, a 
transient down-regulation of 5-HT 2 receptors has been reported. Scheffel et ai. (1992) 
performed in vivo and in vitro labelling of 5-HT 2 and 5-HT Ie receptors in rat brain using 
the radio ligand N I-methyl-2-[125J]lysergic acid diethylamide ([125I]MIL). In vivo 
[125J]MIL binding was unaffected by acute :MDMA administration (20 mg/kg s.c.), 
whereas chronic administration (20 mg/kg s.c., twice daily for four days) resulted in 
significant decreases in binding (a 55 - 80 % decrease in specific binding was observed 
24 h post-treatment). However, seven days and 21 days after cessation of treatment, 
there were no differences between MDMA-treated and control groups with respect to 
specific binding of [125I]MIL. Autoradiographic studies confirmed reductions in 
([125J]MIL binding in the claustrum, frontal cortex, parietal cortex and striatum, while 
no effects of MDMA were observed in the choroid plexus, thus 5-HT Ie receptors 
appeared unaffected by :MDMA treatment. 
1.2.2.3 Recovery of 5-HT content, [3H] paroxetine-Iabelled uptake sites, 
axonal morphology and synaptosomal eH]5-HT uptake in rats 
The extent of recovery of 5-HT content, uptake sites, synaptosomal CH] uptake and 
axonal morphology in rats (see Lew et ai., 1996; Sabol et a!., 1996; Scanzello et a!., 
1993) have been investigated up to one year after :MDMA administration. For example, 
Scanzello et ai. (1993) reported that the earliest recovery of 5-HT content was observed 
in the hypothalamus, eight weeks after MDMA administration (10 mglkg i.p., four 
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times at 2 h intervals), while hippocampal and striatal levels had recovered by 16 weeks. 
All brain regions examined showed complete recovery of 5-HT within one year of drug 
treatment, and similar patterns were observed in the recovery of 5-HIAA content. 
CH]paroxetine binding values in the cortex and striatum had returned to control levels 
within 32 weeks, while hippocampal binding was still 29 % below control values at 52 
weeks post-treatment. However, with regard to morphological changes, only one of 
three animals demonstrated recovery 52 weeks post-treatment~ the other two animals 
still showed marked reductions in axon density. 
Sabol et al. (1996) demonstrated that MDMA administration (20 mg/kg s.c., twice daily 
for four consecutive days) resulted in a significant decrease in synaptosomal CH]5-HT 
uptake two and eight weeks after treatment, but there was no difference between 
MDMA- and saline-pretreated animals at any of the later time-points. In contrast to the 
results of Scanzello et a!. (1993), significant depletion of 5-HT was still apparent in 
both the frontal-parietal- and occipital-temporal- cortex one year post-treatment, while 
some hyperinnervation was observed in the hypothalamus at 52 weeks, compared to 
control animals. Thus these data showed that MDMA-induced 5-HT depletion and rate 
of recovery are region-dependent (Sabol et ai., 1996). In an accompanying study, Lew 
et a!. (1996) reported that 5-HT uptake site density in the frontal-parietal cortex (as 
measured by 125I_RTI_55 binding) was reduced by 75 % two weeks post-drug 
administration. Partial recovery was observed at 16 weeks (53 % below control values), 
but the uptake site density at 52 weeks was still 40 % below control values. The density 
of hippocampal sites was significantly reduced two weeks post-treatment (66 % below 
control values), partial recovery being apparent by 16 weeks, and full recovery by 52 
weeks post-treatment. 
1.2.2.4 
(1) 
Long-term 5-BT depletion and neuronal damage in non-human 
primates 
5-HT depletion and neuronal damage 
Serotonergic depletion and neuronal damage has also been demonstrated in non-human 
primates (see Fischer et a!., 1995; Hatzidimitriou et a!., 1999; Insel et a!., 1989; 
Ricaurte & McCann, 1992; Ricaurte et a!., 1988a; 1988b~ 1992; Scheffel et a!., 1998; 
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Slikker Jr. et aI., 1988; 1989; Wilson et aI., 1989), the effects being more proneunced 
than those .observed in rodents. For example, administratien .of MDMA te rats and 
squirrel monkeys (twice daily, for four censecutive days), illustrated the significantly 
greater sensitivity .of monkeys to the 5-HT depleting effects of MDMA. The dose-
response curve was censiderably steeper in monkeys and the maximal effect was greater 
in the monkey than the rat (Ricaurte & McCann, 1992; Ricaurte et aI., 1988b). 
The degree of 5-HT depletion is dependent upon the route of administratien - .oral 
administration results in lower levels of depletion than subcutaneous injection (see 
Ricaurte et aI., 1988c). Since human recreational users of MDMA tend to ingest single 
doses several days or weeks apart, a single dose of MDMA (5 mg/kg p.o.) was 
administered to squirrel menkeys and 5-HT levels measured two weeks later. While 
multiple doses resulted in significant losses in all brain areas examined, a single dose 
only produced significant depletion of 5-HT in the thalamus (20 %) and hypothalamus 
(16 %) (Ricaurte et al., 1988c). However, since a single 5 mglkg oral dose is equivalent 
to a 1.4 mg/kg dose in a 70 kg human, based on interspecies dose scaling (see McCann 
& Ricaurte, 2001), and is thus within the same range as a recreatienal dose (100 - 150 
mg tablet), these data indicate a risk .of serotonergic damage in humans even after a 
single dose (see Ricaurte et aI., 1988c). 
In addition to reductions in 5-HT content, reduced cerebrospinal fluid (CSF) 
concentrations of 5-lllAA have also been demonstrated following MDMA 
administration to squirrel- (Ricaurte et al., 1988a) and Rhesus- menkeys (Insel et ai., 
1989). These data suggested that measurement .of CSF 5-lllAA could be used to detect 
serotonergic damage in living primates, and provided a potential basis for evaluating the 
effects of recreational MDMA use in humans (Ricaurte et aI., 1988a). Abnormal brain 
5-HT innervation patterns have still been shown seven years after MDMA 
administration te squirrel monkeys (5 mg/kg s.c., twice daily for four days). 
Hatzidimitriou et al. (1999) reperted that 5-HT axen density remained decreased 
(approximately 50 - 65 % of control values), in all neocortical regions examined, seven 
years post-treatment. The caudate and putamen demenstrated partial recovery, while the 
globus pallidus showed some evidence ofhyperinnervatien. 
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(2) In vivo detection of MDMA-induced neurotoxicity 
Scheffel et al. (1998) investigated the effects chronic MDMA treatment (5 mglkg s.c. 
twice daily for four consecutive days) in the baboon, using positron emission 
tomography (PET) and a selective 5-HT transporter radioligand, e IC](+)McN5652. 
Significant reductions in regional radioactivity were apparent in the hypothalamus and 
# ".. ....... ., 
frontal cortex of MDMA-treated animals 13 days post-treatment, and decreases in 
[11C](+)McN5652 accumulation occurred in all regions examined during the first 40 
days post-treatment. Nine months after MDMA administration, significant recovery of 
[llC](+)McN5652 binding was observed in the midbrain and hypothalamus, while 
persistent reduction were seen in all cortical regions. At 13 months, [IIC](+)McN5652 
concentrations were approximately 35 % greater than control levels in the pons, 
midbrain and hypothalamus, whereas tracer concentrations remained diminished in all 
cortical areas. Thus a time-dependent redistribution of 5-HT transporter sites was 
demonstrated in the baboon brain, which is likely to reflect the differential recovery of 
5-HT axon projections. In addition, the study demonstrated a potential method for 
performing a similar study in human recreational users ofMDMA. 
1.2.2.5 Long-term dopamine depletion in mice 
While 5-HT is selectively depleted following MDMA administration to rats, guinea-
pigs and non-human primates, dopamine is selectively lost in mice (see Chapter 7). For 
example, Battaglia et al. (1988a) clearly demonstrated the lack of serotonergic 
neurotoxicity in mice, as administration ofMDMA (20 mg/kg s.c. twice per day for four 
consecutive days) resulted in significant loss of 5-HT and 5-HlAA content and 5-HT 
uptake sites in the frontal cortex of both rats and guinea-pigs, whereas none of these 
parameters were altered in the mouse. Logan et al. (1988) demonstrated an initial 
decline in mouse cortexlhippocampus 5-HT concentrations (three days post-treatment), 
which had returned to control values within two weeks of drug administration. Striatal 
dopamine and DOP AC concentrations, however, were depleted by approximately 50 %, 
three days post-treatment, and demonstrated no recovery within two weeks of drug 
administration. 
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However, while long-term depletion of dopamine has not been shown in rats following 
MDMA administration, an acute release of dopamine has been reported (see above), 
thus dopamine could be involved in the production of MDMA-induced serotonergic 
neurotoxicity. Colado et al. (1999a) demonstrated that administration of the dopamine 
precursor, L-DOPA (25 mg/kg i.p., 2 h after "MDMA administration), prolonged the 
MDMA-induced hyperthermic response and increased the acute release of striatal 
dopamine. However, L-DOPA had no effect on either the acute production of free 
radicals, or the 5-HT depletion measured seven days post-drug administration, thus it 
appears that acute dopaminergic effects are not involved in long-term neurotoxicity in 
rats. 
1.2.2.6 Long-term behavioural changes 
Shankaran & Gudelsky (1999) reported a significant reduction in MDMA-induced 
serotonin syndrome behaviours in rats which had previously been treated with a 
neurotoxic dose regimen (10 mglkg i.p., four times at 2 h intervals), compared to rats 
administered a single dose ofMDMA (7.5 mglkg i.p.). The authors suggested that these 
data reflected long-term functional consequences of MDMA administration, and were 
indicative of 5-HT depletion resulting from the multiple dose regimen. Spanos & 
Yamamoto (1989) showed that chronic administration of"MDMA (2, 5 or 7.5 mg/kg 
i.p., on alternate days, up to a total of 12 doses) had no long-term effects on locomotor 
activity, when assessed 48 h after the last dose. However, the intensity of all serotonin 
syndrome behaviours increased in a dose-dependent manner following chronic drug 
administration. 
McNamara et al. (1995) measured locomotor activity in an open field arena on each day 
ofMDMA administration (5, 10 or 20 mg/kg i.p., twice daily for four consecutive days) 
and on the four days following the treatment period. While total locomotor activity was 
significantly higher in MDMA-treated rats (administered 10 or 20 mg/kg) compared to 
control animals during the drug treatment period, activity had returned to 
baseline/control values within 48 h after the last drug administration. Thus, using this 
treatment regimen, the MDMA-induced increase in locomotor activity was dose- and 
time-dependent and returned to normal following cessation of drug treatment. In 
55 
Chapter 1 General Introduction 
contrast, Wallace et aJ. (2001) reported reductions in locomotor activity, one week after 
multiple doses of MDMA (10 mglkg i.p., four times at 2 h intervals). Spontaneous 
locomotor activity was measured during diurnal and nocturnal cycles for seven 
consecutive days, and MDMA-treated animals demonstrated significant reductions in 
activity, compared to control animals, during both cycles. There was no difference in 
the activity of either treatment group between diurnal and nocturnal values. Such 
alterations were accompanied by significant reductions in striatal 5-HT levels and, while 
any connection between the two findings was not established, persistent behavioural 
modifications had been demonstrated following a monoamine-depleting dose of 
MDMA. 
1.3 EFFECTS OF MDMA IN HUMANS 
It is always difficult to make direct comparisons between results obtained in animal 
studies and those performed in humans, particularly based upon differing metabolic 
rates and weight:volume ratios of different species; small mammals tend to eliminate 
drugs at a faster rate than large mammals. However, interspecies scaling enables 
prediction of drug elimination in different species, based upon the underlying 
anatomical, physiological and biochemical similarities between most land mammals, 
and may be calculated by: Y = a Wb, where Y = the physiological variable of interest 
(e.g. heart rate), W = body weight, and log a is the y-intercept and b is the slope 
obtained from the plot oflog Y versus log W (see Mordenti, 1986). 
Thus, in order to achieve a similar effect to that seen in humans, smaller animals require 
higher doses of drug: ~uman = Danima\ (WhumanIWanimal)0.7, where D = dose of drug (mg) 
and W = body weight (kg). So, for example, if a single neurotoxic dose of MDMA 
administered to a 1 kg monkey were 5 mg/kg, the equivalent dose in a 70 kg human 
would be: 
5 (70/1)°·7 = 97.8 mg.;.. 70 kg = 1.4 mg/kg (McCann & Ricaurte, 2001). 
The dose of MDMA (12.5 mglkg) used in the majority of experiments in rats reported 
in this thesis would therefore be equivalent to: 
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12.5 (7010.25)°·7 =.645.5 mg -;- 70 kg = 9.2 mg/kg. 
If a typical MDMA tablet contains 80 mg to 150 mg of MDMA (see Henry, 1992; 
Schifano, 1991; dancesafe.org; www.drugscope.org.uk; www.erowid.org; 
www.thesite.org), then 645.5 mg is the equivalent of four to eight tablets. Peroutka 
(1987) reported that the amount of drug taken in a single dose ranged from 60 - 250 mg 
(1 - 4 mg per kg body weight), while Bolla et al. (1998) stated that, in a sample of 30 
MDMA users, an average monthly does was 441 mg (range: 55 - 4000) were ingested 
per month. Therefore, while 645.5 mg would seem to be a high dose for a single use, it 
could be ingested by a regular user of MDMA over a period of one to two months. In 
addition, a 10 mg/kg dose of MDMA administered to male DA rats resulted in a plasma 
MDMA concentration of 6.3 nMoVml, 45 min post-injection (Colado et al., 1995). This 
value is within the same range as has been reported in humans following MDMA 
ingestion; for example, ingestion of a 150 mg tablet resulted in a plasma concentration 
of5.2 nMoVml (Dowling eta!., 1987). 
1.3.1 Acute effects 
1.3.1.1 Acute physiological effects 
The acute adverse physiological effects which occur during the peak period after 
MDMA ingestion by humans include: elevated blood pressure and heart rate, nausea, 
chills, diaphoresis, tremor, trismus, bruxism, hyperreflexia, urinary urgency, muscle 
aches or tension, hot and cold flashes, nystagmus and insomnia (see McCann et al., 
1996). One of the major symptoms of MDMA-induced toxicity is hyperthermia, where 
body temperatures of over 43°C have been documented and may lead to other 
toxicological problems during the first few hours following MDMA ingestion, such as: 
rhabdomyolysis, disseminated intravascular coagulation (DIC) and acute renal failure. 
I 
Other physiological symptoms which have been reported during the first few hours 
following ingestion of MDMA, include: tachycardia, coagulopathy, thrombocytopenia, 
delayed leukocytosis, acidosis, hypo glycaemia, pulmonary congestion, oedema and 
hepatitis (see Barrett & Taylor, 1993; Brown & Osterloh, 1987; Chadwick et aI., 1991; 
Dowling et al., 1987; Green et aI., 1995; Henry et aI., 1992; McCann et aI., 1996; 
Milroy et a!., 1996; Screaton et al., 1992; Simpson & Rumack, 1981). 
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1.3.1.2 Acute psychological etTects 
The acute psychological effects which occur during the peak period following MDMA 
ingestion by humans include euphoria and reduction of negative thoughts. However, 
adverse effects may also be experienced, such as depression, irritability, panic attacks, 
visual hallucinations and paranoid delusions (see Brown & Osterloh, 1987; Creighton et 
al., 1991; Davison & Parrott, 1997; McCann et al., 1996; Whitaker-Azmitia & Aronson, 
1989; www.erowid.org). 
1.3.2 Long-term etTects 
1.3.2.1 Long-term biochemical etTects 
The longer-term biochemical effects of MDMA use by humans, include: (1) depletion 
of brain 5-HT and 5-IDAA, (2) reduced density of brain 5-HT transporter sites and 
receptors, (3) altered central 5-HT function, and (4) alterations in cerebral metabolites 
(see Chang et ai., 1999; Gerra et ai., 2000; Kish et al., 2000; McCann et ai., 1994; 
1998; Price et ai., 1989; Reneman et at., 2000a; 2000b; Semple et al., 1999). 
(1) Depletion of brain 5-HT and 5-HIAA 
Kish et ai. (2000) reported severe depletion (50 - 80 %) of striatal 5-HT and 5-HIAA in 
the brain of a 26-year old male, as measured 21 h post-mortem. The subject had taken 
MDMA regularly for nine years and his use had increased during the three years prior to 
his death. During this period, he ingested MDMA tablets four or five nights per week, 
including six to eight tablets taken within a three-day weekend "binge". Post-mortem 
examination revealed a blood MDMA concentration of 4.4 Ilg/ml, while concentration 
in the occipital cortex was approximately 1 Ilg/g tissue. The subject had also taken 
cocaine and heroin during the last few months before his death, which might have 
confounded the reported data. However, the authors stated that neither of these drugs 
had previously been demonstrated to alter striatal serotonin concentration, therefore 
they believed that the results seen were most likely to be due to chronic use of MDMA 
(Kish et al., 2000). 
58 
Chapter 1 Genera/Introduction 
(2) Reduced density of brain 5-HT transporter sites and 5-HT receptors 
McCann et al. (1998) and Ricaurte et al. (2000) employed PET with [IlC]McN-5652, in 
order to assess the extent of brain 5-HT transporter binding in recreational users of 
MDMA. Experimental subjects had used MDMA on at least 25 occasions, while control 
subjects had no previous experience with MDMA. The results indicated a lower density 
of brain 5-HT transporter sites in MDMA users, which positively correlated with the 
extent of previous MDMA ingestion (McCann et aI., 1998; Ricaurte et aI., 2000). 
Semple et al. (1999) performed a similar study to McCann et al. (1998), whereby single 
photon emission computed tomography (SPECT) was used with the iodine-123-labelled 
serotonin transporter ligand, 213-carbomethoxy-313-( 4-iodophenyl)tropane ([ 123I]13_CIT). 
The results indicated a reduction in [123I]13_CIT binding in the MDMA user group, and 
there was a correlation between the regional uptake of the radioligand and duration of 
abstinence. The authors suggested that the latter finding might be explained by a 
reversible down-regulation or occupation of the serotonin transporter (Semple et aI., 
1999). 
(3) Alterations in central 5-HT function 
Measurement of the concentration of 5-HIAA in cerebrospinal fluid (CSF) enables an 
indirect evaluation of central serotonergic function, and has been demonstrated to 
provide an indication of :MDMA-induced neurotoxicity in non-human primates 
(Ricaurte et aI., 1988a). Thirty recreational users ofMDMA (on at least 25 occasions) 
were demonstrated to have significantly lower levels of CSF 5-HIAA compared to 
control subjects (10.3 ± 3.1 ng/ml and 15.2 ± 7.9 mg/ml, respectively). There was a 
negative correlation between CSF 5-IDAA and the number of MDMA exposures, 
although this was not statistically significant, and there were no significant correlations 
between CSF 5-IDAA and the duration ofMDMA use, the frequency of use, or the time 
elapsed since the last exposure to :MDMA (McCann et aI., 1994). 
(4) Alterations in cerebral metabolites 
Chang et al. (1999) employed proton magnetic resonance spectroscopy eH MRS) to 
measure brain concentrations of N-acetylaspartate (NA), a neuronal marker, and myo-
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inositol (MI), a tentative glial marker, in order to determine whether MDMA use was 
associated with changes in neurones and glial cells. Concentrations of creatine (CR), 
choline compounds (CHO), and glutamate/glutamine (GLX) were also assessed, in 
addition to metabolite ratios, using CR as internal standard. Initial magnetic resonance 
imaging (MRI) scans demonstrated no significant brain atrophy or white matter lesions 
in either MDMA users or control subjects. IH MRS demonstrated that, in MDMA users, 
both MI and MIlCR were elevated in the parietal white matter, and CHO/CR was 
elevated in the occipital grey matter. The duration of MDMA use was correlated to the 
concentration of MI in parietal white matter and frontal cortex. NA, CR and CHO 
concentrations were similar in all brain regions examined between MDMA users and 
control subjects. The elevation of MI concentration indicated increased glial content in 
the brains of recreational users of MDMA, while the normal NA and GLX 
concentrations indicated a lack of persistent neuronal damage or ischaemic lesions. The 
latter could be due to minimal 5-HT neurotoxicity following recreational doses of 
MDMA (1.5 - 3 mglkg) , or the occurrence of neuronal recovery (Chang et al., 1999). 
1.3.2.2 Long-term psychological effects 
Longer-term psychological effects resulting from recreational use ofMDMA, which can 
persist after cessation of drug use (see Bolla et aI., 1998; Creighton et aI., 1991; 
McCann & Ricaurte, 1991; 1992; McCann et aI., 1994; 1996; 1999; McGuire, 2000), 
include: (1) visual hallucinations and paranoid delusions, which can form part of the 
peak effects of the drug, but can sometimes persist for days or weeks, (2) anxiety, 
depression and panic disorder, (3) cognitive impairment, and (4) alterations in 
behaviour (see Bhattachary & Powell, 2001; Bolla et aI., 1998; Creighton et aI., 1991; 
McCann & Ricaurte, 1991; 1992; McCann et aI., 1994; 1996; 1999; McGuire & Fahy, 
1991; McGuire et al., 1994; McGuire, 2000; Morgan, 1999; 2000; Parrott & Lasky, 
1998; Schifano, 1991; dancesafe.org; www.drugscope.org.uk; www.erowid.org; 
www.thesite.org; www.usdoj.gov/dea). 
Alterations in behaviour or personality traits 
McCann et al. (1994) examined personality traits in a group of recreational MDMA 
users (see above), and demonstrated that MDMA users showed lower impulsivity and 
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hostility and greater harm avoidance compared to control subjects. The greatest 
differences in personality were seen in female MDMA users, who also had the greatest 
decrement in CSF 5-HIAA. The authors suggested that the nature and regional 
distribution of MDMA-induced serotonergic deficits might differ from those in patients 
exhibiting increased impulsivity and aggression (such as individuals with personality 
disorders, violent offenders or suicidal individuals). In addition, individuals with an 
inherited MAO-A deficiency, and thus a likely increase in brain serotonin, have been 
demonstrated to have increased levels of impulsive, aggressive behaviour (see Brunner 
et aI., 1993). Taken together, these data indicate that such personality characteristics are 
modulated by serotonin (McCann et aI., 1994). 
McCann et al. (1999) compared m-CPP-induced changes in behaviour between MDMA 
users and control subjects, using a series of behavioural assessment scales. In each case, 
MDMA users demonstrated higher positive scores ("happy", "energetic", "content" and 
"elated") and lower negative scores ("sad", "tired" and "worried"). MDMA users also 
demonstrated greater positive- and fewer negative- mood responses to m-CPP treatment 
compared to control subjects. In addition, m-CPP treatment can induce panic attacks 
and, in this study, eight control subjects (32 %) experienced a panic attack compared to 
one MDMA user (4 %). Thus these data indicated altered behavioural responses to m-
CPP in recreational users of MDMA, although the authors did note that underlying 
personality differences in individuals who take MDMA, such as sensation-seeking, 
could be involved. The authors also suggested that the lowered sensitivity of MDMA 
users to m-CPP-induced anxiety indicated downregulation of postsynaptic 5-HT 2C 
receptors, which are thought to mediate these effects ofm-CPP (McCann et al., 1999). 
1.4 MECHANISMS OF ACTION OF MDMA 
MDMA induces the acute release of serotonin and dopamine and its administration 
results in the long-term depletion of serotonin, in rats, guinea-pigs and non-human 
primates, and long-term dopamine depletion in mice (see section 1.2). Based on their 
results obtained in rat hippocampal slices, where MDMA administration resulted in 
significant eH]5-HT effiux, Johnson et al. (1986) hypothesised that MDMA-induced 
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eH]5-HT release could occur via one of three mechanisms: (1) MDMA has a direct 
postsynaptic receptor-mediated excitatory action, leading to stimulus-coupled 5-HT 
release at the nerve terminal, (2) MDMA acts indirectly, displacing presynaptic 5-HT 
stores, by entering the nerve terminal through the 5-HT uptake mechanism, or (3) 
MDMA acts as a competitive uptake inhibitor, resulting in increased extracellular 
eH]5-HT concentrations following spontaneous release (see Johnson et aI., 1986; 
Rudnick & Wall, 1992). 
The affinity of MDMA for a range of brain recognition sites has been demonstrated 
using in vitro radioligand binding assays (e.g. CH]paroxetine, CH]mazindol and 
eH]SCH 23390 binding), MDMA being the most potent at 5-HT uptake sites, with 
affinity constants in the high nanomolar to low micromolar range. The rank order of 
affinities at different recognition sites (in descending order of potency) was: 5-HT 
uptake sites > uradrenoceptors = 5-HT 2 receptors = Ml muscarinic receptors = HI 
histamine receptors> noradrenaline uptake sites = M2 muscarinic receptors = UI-
adrenoceptors = ~-adrenoceptors :?: dopamine uptake sites = 5-HT1 receptors » D2 
dopamine receptors> Dl dopamine receptors (Battaglia et ai., 1988b). 
The fact that in vitro eH]5-HT release from rat brain slices is calcium-independent 
indicates that MDMA is unlikely to act via a postsynaptic receptor mechanism (see 
Johnson et aI., 1986). In addition, the likely involvement of the serotonin transporter in 
MDMA-induced 5-HT release has been demonstrated by the fact that serotonin uptake 
inhibitors, such as citalopram (see Schmidt et aI., 1987) or fluoxetine (see Berger et ai., 
1992; Gudelsky & Nash, 1996; Mechan et ai., 2001b; Shankaran et ai., 1999a), prevent 
in vivo and in vitro 5-HT release and long-term depletion. For example, Gudelsky & 
Nash (1996) demonstrated that MDMA-induced increases in extracellular 5-HT 
concentrations in the striatum were significantly attenuated by fluoxetine pretreatment. 
The fact that MDMA-induced striatal dopamine release was also attenuated by 
fluoxetine, indicates that the 5-HT release which results from MDMA administration 
serves to facilitate dopamine release. The involvement of the serotonin transporter in 
MDMA-induced 5-HT release has also been demonstrated in rat brain synaptosomes 
(see Crespi et ai., 1997; Fleckenstein et aI., 1999; 2000). For example, Crespi et al. 
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(1997) showed that MDMA produced potent inhibition of eH]5-HT uptake, and high 
potency for inducing eH]S-HT release, in rat hippocampal synaptosomes. Inhibition of 
eH]dopamine uptake and induction of eH]dopamine release were also demonstrated in 
striatal synaptosomes, although MDMA was significantly less potent than amphetamine 
and PCA in this regard. MDMA-induced inhibition of eH]5-HT uptake was calcium-
independent, while release was, at least partially, inhibited by the removal of calcium 
ions (Ca2+), indicating calcium-dependence of this mechanism. 
Purified platelet plasma membrane vesicles contain the serotonin transporter responsible 
for 5-HT uptake into presynaptic nerve endings (see Rudnick, 1977), and can therefore 
be used as a model for investigating the interaction of MDMA with the transporter 
mechanism. Rudnick & Wall (1992) demonstrated that MDMA produced potent 
inhibition of the transport of 5-HT into plasma membrane vesicles derived from human 
platelets. The inhibitory effect of MDMA was suggested to represent competition for 
the transport site, or could indicate alterations in the ionic gradients involved in 5-HT 
uptake through permeabilisation of the membrane, for example. However, MDMA was 
demonstrated to interact directly with the uptake site, due to its ability to displace 
imipramine, and MDMA-induced 5-HT efflux was shown to require sodium ions (Na +) 
on both sides of the membrane. MDMA was also seen to inhibit the ability of 
chromaffin granule membrane vesicles to accumulate eHJ5-HT and, in addition to a 
direct effect on the vesicular amine transporter, MDMA was demonstrated to dissipate 
the transmembrane pH difference (ApH). The accumulation of 5-HT is driven and 
maintained by ApH, thus any changes in ApH will decrease 5-HT accumulation and 
increase efilux. The effects of MDMA on ApH demonstrate that it is permeant and that 
it can readily diffuse across membranes (see Rudnick & Wall, 1992; 1993). As MDMA 
cycles between the cytoplasm and extracellular environment, Na + and chloride (Cn ions 
enter the cell, potassium ions (K+) leave and hydrogen ions (Ir) remain within the cell, 
as the protonated form tends to be transported inwards and the neutral form diffuses 
outwards (Rudnick, 1997; Figure 1.2). The net results of altered ion gradients and 
increased 5-HT -transporter binding sites, induced by MDMA influx, are 5-HT efflux 
(Rudnick & Wall, 1992; Rudnick, 1997) and increased intracellular acidity, which may 
contribute to neurotoxicity (Rudnick, 1997). 
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~IDMA-induced neurotoxicity is likely to involve oxidative stress within the nerve 
terminal, which could lead to irreversible terminal degeneration (see Rattray, 1991; 
Figure 1.3). There are a number of possible mechanisms by which toxicity could occur, 
including: 
(1) Metabolism to a quinoid (see Hiramatsu et aI., 1990), which can enter the nerve 
terminal and combine with sulphydryl groups within the active site ofTPH. 
(2) Redox cycling of MDMA metabolites could generate free radicals, which could 
lead to inactivation of TPH and damage to protein and lipid components of the nerve 
terminal (see Rattray, 1991). 
(3) Binding of MDMA to the 5-HT transporter or a 5-HT receptor could lead to 
inactivation of TPH, via increasing intracellular Ca2+ concentrations for example (see 
Azmitia et al., 1990). Elevated Ca2+ levels could, in turn, lead to protein kinase C 
(PKC)-mediated actions, such as proteolysis, and to osmotic stress. 
(4) MDMA may inhibit MAO, resulting in oxidation of 5-HT or dopamine to a 
known neurotoxin, such as 5,7-dihydroxytryptamine (5,7-DHT). 
Free radical (hydroxyl radical; OIf') generation by MDMA has been demonstrated in 
vivo by quantification of the formation of 2,3-DHBA from salicylic acid (see section 
1.2; Colado et aI., 1997a; Shankaran et aI., 1999a; 1999b; 2001). Shankaran et at. 
(1999a) demonstrated that MDMA-induced production of OH- was completely blocked 
by pretreatment with fluoxetine. This attenuation could be due to fluoxetine preventing 
the entry of reactive substances, which can generate free radicals, into the nerve 
terminal. Shankaran et al. (1999b) similarly demonstrated that MDMA-induced OH-
production was significantly attenuated by pretreatment with a dopamine uptake 
inhibitor, mazindol. In addition, mazindol pretreatment prevented MDMA-induced 
striatal 5-HT depletion, measured seven days post-drug administration. These data 
indicated that MDMA-induced serotonergic depletion might be due to oxidative stress 
caused by dopamine-dependent OH- generation, resulting in cytotoxicity. 
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Figure 1.2 
Generalln~oduction 
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MDMA + 
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MDMA 
Postulated mechanism for the interaction of MDMA with the 
serotonin transporter (SERT) (after Rudnick, 1997). 
MDMA is transported into cells, in a similar manner to 5-HT, with sodium (Na+) and 
chloride (Cn ions in exchange for potassium ions (Ky. Intracellular deprotonation of 
MDMA enables outward diffusion of the neutral form, which is then reprotonated and 
becomes a substrate for SERT. This cycle may result in disruption of ionic gradients 
(Na+, cr and Ky, causing intracellular acidification. 
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Postulated mechanisms of MDMA-induced toxicity (after Rattray, 
1991). 
MDMA could induce toxicity by: (1) metabolism to a quinoid, (2) generation of free 
radicals, (3) production of a 5-HT derived toxin, or (4) increasing intracellular calcium 
ion concentration. Neurotoxicity is likely to involve oxidative stress within the nerve 
terminal, which could lead to irreversible terminal degeneration. 
Ca2+: calcium ions; PKC: protein kinase C; Ins?: inositol triphosphate; DAG: 
diacylglycerol; TPH: tryptophan hydroxylase. 
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1.5 METABOLISM OF MDMA 
1.5.1 MDMA metabolism in the rat 
Metabolism of MDMA in the rat has been investigated using IOn trap mass 
spectrometry, and metabolites have been shown to be present in brain, blood, liver, 
urine and faeces homogenates. The metabolic pathways which are probably involved 
include: N-demethylation, O-dealkylation, deamination and conjugation (0-
methylation, O-glucoronidation, and/or O-sulfation), and result in the formation of 14 in 
vivo metabolites (Figure 1.4; Lim & Foltz, 1988; 1991a; 1991b). Initially, MDMA is 
metabolised to: (1) 3,4-methylenedioxyamphetamine (MDA) by N-demethylation, (2) 
3,4-dihydroxymethamphetamine (DHMA; N-methyl-cx-methyldopamine, N-Me-cx-
MeDA) by demethylenation, and (3) 2-hydroxy-4,5(methylenedioxy)methamphetamine 
(6-HO-MDMA) by ring hydroxylation (see Figure 1.4; Lim & Foltz, 1988; 1991a; 
1991b; Tucker et al., 1994). 
1.5.2 Pharmacokinetics of MDMA in humans 
De La Torre et al. (2000) reported the possibility of saturable kinetics of MDMA in 
human recreational users. With increasing dose of MDMA (50 - 150 mg), the rise in 
MDMA concentrations was seen not to follow the same proportionality, which could 
indicate non-linearity. Thus MDMA metabolism may become saturated at higher doses. 
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Figure 1.4 Postulated pathways of MDMA metabolism (after Hiramatsu et ai., 
1990; Lim & Foltz, 1988; Lim & Foltz, 1991; Tucker et al., 1994; 
Zhao et ai., 1992). 
Structures in brackets are postulated intermediate compounds in the formation of 4-
hydroxy-3 -methoxyamphetamine and 5, 6-dihydroxy-l ,2-dimethylindole. 
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1.6 THE NEUROCHEMISTRY OF SEROTONIN 
Serotonin IS synthesised from the aromatic amino acid, L-tryptophan, which IS 
hydroxylated to 5-hydroxy-L-trytophan (5-HTP) by tryptophan hydroxylase (TPH). 5-
HTP is a short-lived intermediate product, being decarboxylated almost immediately by 
the non-specific enzyme, L-aromatic acid decarboxylase, in the cytoplasm to form 5-HT 
(see Figure l.5). TPH is a specific enzyme found only in serotonin-synthesising cells 
and forms the rate-limiting step of serotonin synthesis. L-tryptophan is transported in 
plasma either in solution or bound to plasma proteins and is actively taken up into 5-HT 
nerve endings via an amino acid carrier mechanism. The amount of free L-tryptophan 
available in the presynaptic nerve terminal thus determines TPH activity and, 
ultimately, the rate of serotonin synthesis. Serotonin accumulates within storage 
granules, thought to be bound in a complex with proteins, divalent ions and adenosine 
triphosphate (ATP), and is released into the synaptic cleft following depolarisation of 
the axon terminal. Once released, uptake carriers present on the presynaptic nerve 
terminal remove serotonin from the synaptic cleft, transporting it back into the 
presynaptic neurone. Any serotonin which is not bound in storage vesicles, either before 
release or after reuptake, is metabolised to an aldehyde intermediate by monoamine 
oxidase (MAO), then oxidised to 5-IDAA by aldehyde dehydrogenase (see Figure 1.5; 
Fuller, 1985; Kruk & Pycock, 1991; Rang et ai., 1995). 
There are currently 14 known mammalian 5-HT receptor subtypes (see Figure 1.6) 
which are, with the exception of the 5-HT3 receptor (a ligand-gated ion channel), seven 
putative transmembrane spanning, G-protein coupled metabotropic receptors. Receptor 
localisation, agonists and antagonists for each SUbtype are displayed in Table 1.1. The 
behavioural and physiological responses mediated by serotonin include: temperature 
regulation, feeding behaviour, sexual behaviour, sleep and wakefulness, responding to 
painful stimuli, neuroendocrine responses, escape and stress, aggression, depression and 
anxiety (see Barnes & Sharp, 1999; Lucki, 1998; Roth et al., 1998; Uphouse, 1997). 
69 
Chapter 1 General Introduction 
COOH 
L-tryptophan ~?H2CH ~N)~ 
H 
1 Tryptophan hydroxylase (TPH) 
COOH 
HO I 
5 -hydroxy-L-tryptophan 
(5-HTP) 
HO 
5 -hydroxytryptamine 
(5-HT; serotonin) 
5 -hydroxyindoleacetic 
acid (5-HlAA) 
HO 
HO 
?H2CH 
~ 
1 L-aromatic acid decarboxylase 
1 Monoamine oxidase (MAO) 
1 Aldehyde dehydrogenase 
Figure 1.5 Synthesis and metabolism of 5-HT (see Fuller, 1985; Kruk & 
Pycock, 1991; Rang et al., 1995). 
L-tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan 
hydroxylase (TPH). 5-HTP is then decarboxylated to 5-hydroxytrytamine (5-HT) by L-
aromatic acid decarboxylase. 5-HT is metabolised to 5-hydroxyindoleacetic acid (5-
HIAA), via an aldehyde intermediate, by monoamine oxidase (MAO) and aldehyde 
dehydrogenase. 
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Figure 1.6 
General Introduction 
5-HT1B 
5-HT1A 
5-htSA 
5-HT7 
5-HT3 
Dendrogram showing 5-HT receptor protein sequences (after Barnes 
& Sharp, 1999; Hoyer et aI., 1994). 
Evolutionary relationship between human 5-HT receptor protein sequences (except 5-
htsA and 5-htsB which are murine in origin). 5-HT receptors cluster into subgroups 
according to amino acid sequence similarity. 
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Receptor 
subtype 
5-HTIA 
5-HT1B 
: 5-HTlD 
5-hhE 
5-ht lF 
5-HT2A 
5-HT2B 
5-HT2c 
Location 
Neuronal, mainly 
CNS 
CNS and some 
peripheral nerves 
MainlyCNS 
OnlyCNS 
Mainly CNS 
Vascular smooth 
muscle, platelets, 
lung, CNS, OI tract 
Mainly peripheral 
CNS - high density 
in choroid plexus 
Location within eNS 
Dorsal raphe nucleus, hippocampus, 
cortex 
Substantia nigra, basal ganglia, 
subiculum 
Substantia nigra, basal ganglia, 
superior colliculus 
Cortex, caudate putamen, claustrum 
Cortex, hippocampus, claustrum, 
caudate nucleus 
Claustrum, olfactory tubercle, cortex, 
hippocampus, caudate nucleus, 
nucleus accumbens 
Choroid plexus, cortex, globus 
pallidus, substantia nigra, caudate 
nucleus, nucleus accumbens, 
hinnocamnus amvl!dala 
Response Agonists 
Neuronal hyperpolarisation, 8-0H-DPAT, 
hypotension buspirone, 
5-CT 
Inhibition of CP 93,129,5-
neurotransmitter release CT 
Inhibition of Sumatriptan, 
neurotransmitter release L 694247, 5-
CT 
Inhibition of adenylyl 5-HT 
cyclase 
Inhibition of adenylyl 5-HT; 
cyclase sumatriptan 
Vasoconstriction, platelet a-methyl-5-
aggregation, HT, DOl 
bronchoconstriction 
Rat stomach fundic muscle a-methyl-5-
contraction HT,DOI 
t Phosphoinositide turnover a-methyl-5-
HT, DOl 
Antagonists 
WAY 100635, WAY 
100 135, [methiothepin 
(non-selective) ) 
SDZ 21009, 
[methiothepin (non-
selective)) 
OR 127935, 
[ metergoline, 
methiothepin (non-
selective) ) 
None [methiothepin-
weak] 
None [methiothepin-
weak) 
Ketanserin, cinanserin, 
ritanserin, MDL 
100,907, pirenpirone 
SB 200646, SB 242084 
Mesulergine 
Continued overleaf 
Q {l 
& 
100..0 
~ 
~ 
fa. 
i 
~ 
t 
r") 
~. 
~ 
;:: 
-.l 
w 
Receptor 
subtype 
5-HT3 
5-HT4 
5-ht5A and 
5-ht5B 
5-ht6 
5-HT7 
Table 1.1 
Location Location within eNS Response Agonists Antagonists 
Peripheral and Dorsal vagal nerve, solitary tract Depolarisation 2-methyl-5-HT, m- Ondansetron, 
central neurones nerve, trigeminal nerve, area chlorophenyl- tropisetron, 
postrema, spinal cord, hippocampus, biguanide granisetron 
amygdala 
GI tract, CNS, Colliculus, hippocampus, Activation of ACh release in Metoclopramide, GR 113808, SB 
heart, urinary nigrostriatal and mesolimbic systems gut, tachycardia, t cAMP in renzapride 204070, 
bladder CNS neurones tropisetron (weak) 
CNS Not known 5-HT, 5-CT, LSD Metbiothepin 
CNS Activation of adenylyl 5-HT Methiothepin 
cyclase 
(HEK 293 cells) 
CNS Activation of adenylyl 5-HT Metbiothepin 
cyclase 
(HeLa cells and COS cells) 
Operational characteristics of mammalian 5-HT receptors (after Barnes & Sharp, 1999; Hoyer et a1., 1994; Roth et 
a1., 1998; Uphouse, 1997). 
CNS: central nervous system; GI tract: gastrointestinal tract; ACh: acetylcholine; cAMP. cyclic adenosine monophosphate; 8-0H-DPAT: 8-hydroxy-
2-(di-n-propylamino )tetralin; 5-CT: 5-carboxamidotryptamine; WAY 100635: N-[2-[ 4-(2-methoxyphenyl)-I-piperazinyl]ethyl]-N-(2-pyridinyl) 
cyclohexane carboxamide; WAY 100135: N-tert-butyl-3-[4-(2-methoxyphenyl) piperazin-I-yl]-2-phenylpropanamide; CP 93,129: 3-(1,2,5,6-
tetrahydropyrid-4-yl)p}Tfolo[3 ,2-b ]pyrid-5-one; SDZ 21009: 4(3 -terbutylamino-2-hydroxypropoxy )indol-2-carbonic ac!d-isopropylester; L 
694247: 2-[5-[3-(4-methylsulphonylarnino)benzyl-1 2,4-oxadiazol-5-yl]-IH-indol-3-yl] ethanamine; GR 127935: 2' -methyl-4' -(5-methyl-
[l,2,4]oxadiazol-3-yl)-biphenyl-4-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-I-yl)-phenyl]-amide; DOl: (±)-2,5-dimethoxy-4-
iodoamphetamine; MDL 100,907: R -( + )-a-(2,3 -dimethoxyphenyl)-1-[2-( 4-fluorophenylethyl) ]-4-piperidinemethanol; SB 200646: N -(l-methyl-5-
indolyl)-N'-(3-pyridyl) urea; SB 242084: 6-chloro-5-methyl-methyl-I-[2-(-methylpyridyl-3-oxy)-pyrid-5-yl carbamoyl]indoline; GR 113808: 1-[2-
(methylsulphonylarnino )ethyl]4-piperidinyl]methyl-I-methyl-indole-3 carboxylate; SB 204070: 8-arnino-7 -chloro-(N-butyl-4-piperidyl)methylbenzo-
1,4-dioxan-5-carboxylate; LSD: lysergic acid diethylamide; HEK 293: human embryonic kidney 293 cells; HeLa: human epithelial cells (cervical 
cancer); COS: transformed monkey kidney fibroblast cells. 
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Chapter 1 General Introduction 
1.7 THE NEUROCHEMISTRY OF DOPAMINE 
Dopamine is synthesised from the amino acid, L-tyrosine, which is hydroxylated to 3,4-
dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH), this 
forming the rate-limiting step. TH is a relatively selective enzyme, being found only in 
catecholamine-containing cells (likely to be free in the cytosol). L-DOP A is 
decarboxylated by L-aromatic acid decarboxylase (DOPA decarboxylase), in the 
cytoplasm, to form dopamine (see Figure 1.7). Under normal conditions TH is 
completely saturated with L-tyrosine, therefore increased circulating L-tyrosine levels 
do not increase the rate of dopamine synthesis. TH activity is inhibited by the presence 
of high intraneuronal dopamine concentrations (end-product inhibition), leading to a 
decrease in further dopamine synthesis. L-DOPA is actively taken up into dopamine 
neurones, where it is converted to dopamine by DOPA decarboxylase. Dopamine 
accumulates in storage granules, as a complex with chromogranins, divalent metal ions 
and ATP. Dopamine is released into the synaptic cleft, via calcium-dependent 
exocytosis, following depolarisation of the axon terminal. Dopamine reuptake occurs 
following its release into the synaptic cleft, via a high-affinity, energy-dependent, active 
transport system. Following reuptake, any dopamine which is not bound in storage 
vesicles is metabolised by MAO and catechol-O-methyl transferase (COMT) to form 
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HV A; 3-methoxy-4-
hydroxyphenylacetic acid) (see Figure 1.7; Kruk & Pycock, 1991; Rang et aI., 1995). 
There are currently two main classes of dopamine receptors: "D1-like", comprising DJ 
and Ds receptor subtypes, and "D2-like", comprising D2, D3 and D4 receptor subtypes. 
Receptor localisation, agonists and antagonists for each receptor subtype are displayed 
in Table 1.2 (see Kruk & Pycock, 1991; Rang el ai., 1995; Strange, 2000). Dopamine is 
involved in the mediation of motor control, mood and emotion and neuroendocrine 
function (see Rang et aI., 1995). 
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L-tyrosine 
3,4-diydroxyphenylalanine 
(L-DOPA) 
Dopamine 
3,4-dihydroxyphenyl-
acetic acid (DOP AC) 
Homovanillic acid 
(HVA) 
General Introduction 
COOH 
0-?H,CH 
HO~ ~ 
! Tyrosine hydroxylase (TH) 
COOH 
H0JCrI I ~ r~CH 
HO .0 N~ 
! DOPA decarboxylase 
HO~ ~ CH,CH,NH, 
HO 
I Monoamine oxidase (MAO) and 
+ aldehyde dehydrogenase 
COOH 
H0JCrI I C~ 
.0 
HO 
I Catechol-O-methyltransferase 
+ (COMT) 
COOH 
CH30JCrI I CH2 
HO .0 
Figure 1.7 Synthesis and metabolism of dopamine (see Kruk & Pycock, 1991; 
Rang et al., 1995). 
L-tyrosine is hydroxylated to 3,4-dihydroxyphenyla1anine (L-DOPA) by tyrosine 
hydroxylase (TH). L-DOPA is then decarboxylated to dopamine by DOPA 
decarboxylase. Dopamine is metabolised to 3,4-dihydroxyphenylacetic acid (DOPAC) 
by monoamine oxidase (MAO), then DOPAC is further metabolised to form 
homovanillic acid (HV A) by the action of catechol-O-methyltransferase (COMT). 
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Receptor 
subwe 
DI- DI 
like 
D5 
D2- D2 
like 
D3 
D4 
Table 1.2 
Location within eNS Response Agonists Antagonists 
Caudate putamen, nucleus 
SKF 38393 and dihydrexidine accumbens, olfactory SCH 23390 and SKF 83566 (selective tubercle, hypothalamus, t adenylyl cyclase, (selective agonists), dopamine antagonists) phenothiazines and thalamus, frontal cortex t phospholipase C (low potency), apomorphine butyrophenones (low potency), clozapine 
Hippocampus, thalamus, and bromocriptine (partial (medium potency) 
striatum and cortex (all agonists) 
low densities) 
Caudate putamen, nucleus 
accumbens, olfactory 
tubercle, [cortex (low Sulpiride and nemonapride (selective density)] Quinpirole and N-0437 antagonists), phenothiazines and 
Nucleus accumbens ..,l.. adenylyl cyclase, (selective agonists), spiperone (high potency, non-selective), 
olfactory tubercle, [cortex t K+ channel, dopamine, apomorphine and butyrophenones (high potency, D2-(low density)] ..,l..Ca2+ channel bromocriptine (high potency) selective), clozapine (high potency, D4-
Frontal cortex, midbrain, selective) 
amygdala, hippocampus, 
hypothalamus, medulla 
(all low densities) 
Operational characteristics of mammalian dopamine receptors (see Kruk & Pycock, 1991; Rang et aI., 1995; Strange, 
2000). 
Low potency: activity in the micromolar range; high potency: activity in the nanomolar range; Phenothiazines: chlorpromazine, 
thioridazine, fluphenazine (no selectivity between DI and D2 receptors); Butyrophenones: haloperidol, spiroperidol (some selectivity for 
D2 receptors). 
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1.8 AIMS OF THE INVESTIGATION 
The initial aims of this study were to investigate the longer-term functional 
consequences of MDMA administration in rats and to study the long-term neurotoxic 
effects in mice. There is now some reported evidence of long-term serotonergic deficits 
in humans (Kish et aI., 2000; McCann et al., 1998, Semple et aI., 1999), in addition to 
evidence of lower impulsivity (McCann et al., 1994) and altered behavioural responses 
to m-CPP (McCann et aI., 1999). Such data prompted the question as to whether 
MDMA administration has long-term functional consequences on behaviour in animals. 
Thus the behavioural effects of a single neurotoxic dose ofMDMA (12.5 mg/kg i.p.), 
administered to Dark Agouti rats, were investigated at three time-points up to 80 days 
post-treatment using three models of anxiety-related and locomotor behaviour (elevated 
plus-maze, open field and automated activity meter). 
Several studies have indicated a long-term effect of MDMA administration on 
thermoregulatory responses (Dafters & Lynch, 1998; Shankaran & Gudelsky, 1999) and 
5-HT receptor activity (Aguirre et ai., 1998; McNamara et ai., 1995). The reported 
findings were further investigated by assessing: (1) the effects of three doses of 
MDMA, two or three weeks apart, on MDMA-induced acute hyperthermia, (2) the 
effects of a single dose of MDMA, five or six weeks earlier, on thermoregulatory 
responses under high (30 ± 0.5 °C) or low (10 ± 0.5 °C) ambient temperature 
conditions, and (3) the effects of a single dose of MDMA, three or four weeks earlier, 
on the hypothermic response to 8-0H-DPAT. The results obtained gave rise to an 
investigation of the mechanisms involved in the acute hyperthermic response. A series 
of drugs which affect serotonergic or dopaminergic function were administered in an 
attempt to determine which receptor subtype(s) might be involved in mediation of this 
response. 
Finally, while MDMA administration to rats, guinea-pigs and non-human primates has 
been demonstrated to result in long-term serotonergic neurodegeneration, mice exhibit 
long-term depletion of dopamine and its metabolites (see Logan et aI., 1988; Stone et 
aI., 1987). Thus, a series of putative neuroprotective compounds were administered 
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prior to MDMA in an attempt to elucidate the mechanisms involved in its neurotoxic 
actions in this species. 
All behavioural and thermoregulation experiments were conducted in Dark Agouti rats, 
which were chosen because a single dose of MDMA (10 - 15 mglkg i.p.) produces a 
definable, reproducible, neurotoxic degeneration of 5-HT nerve endings in the brain, 
demonstrated by a 30 - 60 % reduction in regional 5-HT and 5-HIAA concentrations 
measured seven days post-injection (Colado et al. 1995; O'Shea et at. 1998). This is in 
contrast to other rat strains where several doses, or a single higher dose, of MDMA are 
required to produce significant damage to brain 5-HT nerve endings. 
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2 GENERAL MATERIALS AND METHODS 
Details of specific methods used in this thesis are described in individual chapters. 
General materials and methods, relating to several chapters, are reported below. 
2.1 ANIMALS 
(1) De Montfort University 
Adult male Dark Agouti (DA) rats, weighing 175 - 200 g at the start of each 
experiment, and adult male "Swiss" -type Albino (NIH/S) mice, weighing 25 - 30 g at 
the start of each experiment, were obtained from Harlan UK Ltd. (Bicester, Oxon.). Rats 
were housed in groups of three or four and mice in groups of between five and seven, in 
an ambient temperature of 20 ± 2 °C and a 12 h light/dark cycle (lights on: 07:30 h). 
Food (B & K Universal Ltd., Aldbrough, Hull) and water were provided ad libitum. 
(2) University of Leicester 
Adult male DA and Sprague-Dawley (SD) rats, weighing 200 - 260 g at the start of 
each experiment (Harlan UK Ltd.) were housed in groups of two or three, in an ambient 
temperature of 21 ± 2 °C and a 12 h light/dark cycle (lights on: 07:00 h). Food (Special 
Diet Services, Witham, Essex) and water were freely provided. 
(3) Universidad Complutense 
Adult male DA rats, weighing 150 - 175 g at the start of each experiment, and adult 
male Swiss-Webster mice (CFWl), weighing 30 - 35 g at the start of each experiment, 
were obtained from Interfauna (Barcelona, Spain). Rats were housed in groups of five 
and mice in groups of ten, in an ambient temperature of 21 ± 2 °C and a 12 h light/dark 
cycle (lights on: 07:00 h). Food and water were freely provided. 
All experiments were performed according to guidelines set by De Montfort University, 
the University of Leicester and Universidad Complutense concerning the use of 
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experimental animals and under appropriate project and personal licence authority 
granted under the United Kingdom Animals (Scientific Procedures) Act, 1986. 
2.2 DRUGS 
Drugs were obtained from the following sources: 
• Diazepam, (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOl), 1-[2-bis (4-
fluorophenyl) methoxy ]ethyl]-4-3 -phenylpropyl]piperazine dihydrochloride (GBR 
12909), 8-hydroxy-2-( di-n-propylamino )tetralin hydrobromide (8-0H-DP AT), (±) 
3,4-methylenedioxymethamphetamine hydrochloride (MDMA), 7-nitroindazole (7-
NI) and a-phenyl-N-tert-butyl nitrone (PBN) (Sigma-Aldrich Company Ltd., Poole, 
Dorset). MDMA was also obtained from Dr P Guiry (University College, Dublin) 
and NIDA (Research Triangle Park, North Carolina, USA). 
• 1-(3-chlorophenyl)piperazine (m-CPP), a-phenyl-l-(2-phenylethyl)-4-
piperidinemethanol (MDL 11,939), (5R, lOS)-(+)-5-methyl-l0, 11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,1O-imine (dizocilpine; (+)-MK 801 maleate) and R-(+)-
7-chloro-8-hydroxy-3-methyl-l-phenyl-2,3,4,5-tetrahydro-lH-3-benzapine (SCH 
23390) (Tocris Cookson Ltd., Avonmouth, Bristol). 
• S-methyl-L-thiocitrulline (S-MTC) (Calbiochem, San Diego, California, USA). 
• S-(+)-a-phenyl-2-pyridine ethanamide dihydrochloride (AR-R15896AR) and N-(4-
(2-«3-chlorophenylmethyl) amino)-ethyl)phenyl) 2-thiophene carboxamidine (AR-
R17477 AR) (gifts from AstraZeneca, R&D Wilmington, Delaware). Clomethiazole 
edisilate, (S( -) )-remoxipride hydrochloride and (cis )-zimeldine (gifts from 
AstraZeneca, R&D Sodertalje, Sweden). 
• Ritanserin (gift from Janssen Research Foundation, Janssen Pharmaceutica N.Y., 
Beerse, Belgium). 
• Methysergide hydrogen maleate (gift from Novartis International AG, Basel, 
Switzerland). 
• R-( + )-a-(2,3-dimethoxyphenyl)-I-[2-( 4-tluorophenylethyl)]-4-piperidinemethanol 
(MDL 100,907) and 6-chloro-5-methyl-methyl-l-[2-( -methylpyridyl-3-oxy)-pyrid-
5-yl carbamoyl]indoline (SB 242084) (gifts from Dr G Kennett, Vernalis Ltd., 
Wokingham). 
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All drugs were dissolved in normal saline (0.9 % w/v), unless otherwise specified, and 
injected intraperitoneally in volumes of 1 ml/kg for rats and 10mllkg for mice, unless 
otherwise stated. Doses given were calculated as the base weight, unless otherwise 
specified. 
2.3 CHEMICALS 
Chemicals were obtained from the following sources: 
2.3.1 Vehicles for injection 
• Sodium chloride (Fisher Scientific UK, Loughborough, Leicestershire) was 
dissolved in deionised water (USF Elga Ltd., High Wycombe, Buckinghamshire), at 
a concentration of 0.9 % w/v. 
• Tween 20 (BDH Laboratory Supplies, Poole, Dorset). 
• Glacial acetic acid (Fisher). 
• Dimethylsulphoxide (DMSO) (Fisher). 
• Citric acid (Sigma). 
• B-cyclodextrin (Sigma). 
• Polyethylene glycol (pEG) (Fisons, Ipswich, Suffolk). 
2.3.2 Chemicals for h.p.l.c. 
• Components of the mobile phase utilised for high performance liquid 
chromatography (h.p.1.c.) were specified for h.p.1.c. with electrochemical detection 
where possible, and included potassium dihydrogen orthophosphate (KH2P04), 1-
octane sulphonic acid sodium salt (OSA), diaminoethanetetra acetic acid disodium 
salt (EDT A), methanol and orthophosphoric acid (Fisher). 
• Standards used for h.p.I.c. were dissolved in a 0.2 M perchloric acid solution 
containing 0.1 % w/v L-cysteine, 0.1 % w/v sodium metabisulphite and 0.01 % w/v 
EDTA (Fisher). 
• Standards used were: 5-hydroxytryptamine creatinine sulphate complex (5-HT), 5-
hydroxyindole-3-acetic acid (5-IDAA), 3-hydroxytyramine (dopamine), 3,4-
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dihydroxyphenylacetic acid (DOPAC) and 4-hydroxy-3-methoxy-phenylacetic acid 
(homovanillic acid, HV A) (Sigma). 
2.3.3 General chemicals 
• Cider vinegar, used for cleaning of behavioural testing apparatus (Tesco, Cheshunt, 
Hertfordshire ). 
2.4 GENERAL EQIDPMENT 
• Tissue dissection equipment (Richardsons of Leicester Ltd., Leicester). 
• AGl04 analytical balance (Mettler-Toledo Ltd., Beaumont Leys, Leicester). 
• POL YTRON PT 3100 homogeniser (Kinematica, Luzern, Switzerland). 
• MSE Soniprep 150 ultrasonic disintegrator (Sanyo Gallenkamp Pic., Loughborough, 
Leicestershire) . 
• Hettich Mikro RapidIK centrifuge (Sartorius Ltd., Epsom, Surrey). 
• Millipore solvent filtration system, with Durapore 45 Ilm membrane filters 
(Millipore (UK) Ltd, Watford, Hertfordshire). 
• Vacuum pump (KNF Neuberger, Freiburg, Germany). 
• Sonicating water bath (Ultrawave Ltd., Cardiff). 
• RE357 Microprocessor pH meter (EDT Instruments Ltd., Dover, Kent) 
• Accumet gel-filled pH electrode (Fisher). 
• SMll magnetic stirrer (Stuart Scientific, Bibby Sterilin Ltd., Stone, Staffordshire). 
• Variable volume pipettors, 20 - 200 Ill, 200 - 1000 III and 1000 - 5000 III (Fisher). 
2.5 STATISTICS 
Statistical analysis was performed using GraphPad Prism (San Diego, California, USA) 
and BMDP/386 Dynamic (BMDP Statistical Solutions Ltd., Cork, Eire). All data is 
presented as mean ± s.e.m. 
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2.6 BEBA VIOURAL TESTING 
2.6.1 Elevated plus-maze apparatus and behavioural assessment 
The elevated plus-maze (Figure 2.1; on loan from Professor C. Marsden, School of 
Biomedical Sciences, University of Nottingham) was constructed from black plastic and 
positioned 50 cm above the floor. The maze consisted of two open arms (each 16 x 46 
cm), two closed arms (each 16 x 46 cm, with side and end walls of height 10 cm) and a 
central square (16 x 16 cm). Each arm was divided, by a white line, into two zones; 
Zone 1 being that closest to the central square and Zone 2 being that closest to the distal 
end of the arm. The apparatus was situated in a darkened room, illuminated by a single 
60 W white light bulb positioned approximately 50 cm above the central square. 
Experiments were recorded by a video camera suspended approximately 100 cm above 
the centre of the plus-maze. A weak cider vinegar solution (10 %) was used to clean the 
apparatus prior to the introduction of each animal. 
Rats were tested on the maze in randomised order. Each rat was placed in the centre of 
the plus-maze facing one of the open arms and observed for 10 min by an experimenter 
seated approximately 1 m from the apparatus for behavioural scoring purposes. Arm 
entries were counted as four paw entries into either closed or open arms, while the time 
spent in different arms was calculated by subsequent analysis of video-recordings. Total 
arm entry data enabled calculation of the percentage (%) number of open arm entries 
and the % time spent on open arms. A number of simple behaviours were also noted, 
including: rearing (sitting on the hind paws only, apart from whilst grooming), head 
dips (lowering the head, either over the edge of an open arm or over the surrounding 
wall of a closed arm), stretched attend postures (SAP; full body stretch, usually with 
hindpaws in the central zone and forepaws in an open arm zone), directed sniffing 
(sniffing of the base or surrounding wall of the maze), non-directed sniffing (sniffing 
the air, often whilst rearing with forepaws positioned on the top edge of the surrounding 
wall), grooming and defecation. 
84 
Chapter 2 
Open arm 
Figure 2.1 
Closed arm 
~ ~ 
16 cm 
22cm 
24cm 
Plan diagram of the elevated plus-maze. 
General Materials and Methods 
The plus-maze was constructed from black plastic and was elevated 50 cm above the 
floor. All arms were 16 cm wide and 46 cm long and each was divided into two 
sections: Zone 1 (proximal to the centre) and Zone 2 (distal from the centre). The closed 
arms had 10 cm high walls. 
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2.6.2 Open-field apparatus and behavioural assessment 
The open-field (Figure 2.2; School of Psychology, University of Leicester) was 
constructed from a white painted board, with three concentric circles (15.5 cm, 45.5 cm 
and 81. 5 cm in diameter) delineated in black and a sheet metal surrounding wall of 
height 50 cm. Zone 2, surrounding the innermost circle, was further divided into six 
areas while Zone 1, the outermost circle, was subdivided into twelve marked areas. The 
apparatus was situated in a darkened room and was illuminated by a single 60 W white 
or red light bulb positioned approximately 65 cm above the centre of the arena. 
Experiments were recorded by a video camera, suspended approximately 150 cm above 
the open-field arena. A weak cider vinegar solution (10 %) was used to clean the 
apparatus prior to the introduction of each animal. Rats were tested in the open-field on 
three consecutive days. The first two days were performed under white-light 
illumination, in order to test any effects of habituation, whilst the third day was 
performed under red-light illumination, which, it was hoped, would be a less anxiogenic 
environment. On each day, each rat was placed in Zone 1 of the open field arena and 
observed for 5 min by an experimenter seated approximately 1 m from the apparatus for 
behavioural scoring purposes. Locomotor behaviour was recorded by noting the total 
number of crossings within each zone with all four paws. The behaviours observed 
were: freezing (no movement within any particular section), rearing, grooming and 
defecation. 
2.6.3 Automated activity meter apparatus and behavioural assessment 
The automated activity meter (Figure 2.3; Benwick AMI051 Activity Monitor, Linton 
Instrumentation, Diss, Norfolk) was a metal framework (dimensions 55.5 em x 33.5 em 
x 17 5 cm) inside which a test cage was placed containing a single animal. The unit was 
enclosed in a wooden box, without any illumination. The apparatus used an array of 44 
infrared beams, including a lower and upper set, enabling monitoring of horizontal and 
rearing activity. Data (numbers of lower and upper level beam breaks) was 
electronically logged at 5 min intervals for a total of 1 h. Four animals were tested at 
any particular time, in four separate activity monitor boxes. In each case, a rat was 
placed in a test cage immediately prior to the cage being placed in the activity monitor 
framework and the data logger switched on. 
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15.5 em 
45.5 em 
81.5 em 
Figure 2.2 Plan diagram of the open-field arena. 
The open-field comprised a white painted board, with three concentric circles delineated 
in black: Centre, 15.5 cm; Zone 2, 45.5 cm; Zone 1, 8l.5 cm diameter. Zone 2 was 
divided into 6 sections and Zone I was divided into 12 sections. A 50 cm high sheet 
metal wall surrounded the outennost circle. 
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Pattern of infrared beams 33 .5 em 24.5 em 
55.5 em 
45 .5 em 
Figure 2.3 Plan diagram of the automated activity meter. 
The automated activity meter comprised a metal framework, which was 55 .5 cm long, 
33 .5 em wide and 17.5 em high (Benwick AMI051 Activity Monitor) . A test cage 
containing a single arumal was placed inside the framework and the array of infrared 
beams enabled monitoring of total and vertical (rearing) activity. 
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2.6.4 Video-monitoring equipment 
• Black and white CCD pinhole board camera, 60 degrees field of view (Map lin 
Electronics PIc., Barnsley, South Yorkshire). 
• 14" combined TV/video (Goodmans TVC141, Comet, HUll). 
2.7 TEMPERA TURE MEASUREMENT 
Temperature measurement was performed using an MC 8700 thermometer, with digital 
readout (EXACON AfS, Roskilde, Denmark). A lubricated H-RB3 rectal temperature 
probe was used for measurements in rats (EXACON AfS) and an H-SFI probe 
(Cranbrook Electronics, Ascot, Berkshire) or a digital thermometer (GH Zeal Ltd., 
Merton, London) for measurements in mice. Each animal was lightly restrained by hand 
for 10 - 20 s, whilst the probe was inserted approximately 2 cm (mice) or 2.5 cm (rats) 
into its rectum and a steady reading was obtained. 
2.8 BRAIN DISSECTION AND TISSUE PROCESSING 
Rats and mice were sacrificed by cervical dislocation and decapitation, the brains 
rapidly removed and the cortex, hippocampus, striatum and hypothalamus dissected out 
on ice. Tissue was wrapped in labelled aluminium foil pieces and stored on ice until 
transferred to a -80°C freezer prior to further processing. Prior to biochemical analysis, 
tissue was weighed and placed in plastic tubes containing 0.2 M perchloric acid solution 
(see section 2.3). The size of tube and volume of perchioric acid solution were varied 
depending on the size of the tissue: (1) for rat cortical and hippocampal tissue 13 ml 
polycarbonate tubes were used, containing 2 ml and 1 ml of liquid, respectively; (2) for 
rat striatal and hypothalamic tissue 6 ml polycarbonate tubes were used, containing 1 ml 
and 500 ~l of liquid, respectively; (3) for mouse cortical tissue 6 ml polycarbonate 
tubes, containing 2 ml of liquid; and (4) for mouse hippocampal, striatal and 
hypothalamic tissue 1.5 ml microcentrifuge tubes were used, containing 300 ~I, 500 ~I 
and 250 ~l of liquid, respectively. All rat brain tissue samples and mouse cortical tissue 
samples were subsequently homogenised (POLYTRON PT 3100) at 20,000 r.p.m. for 
25 - 30 s. All remaining mouse brain tissue samples were homogenised by ultrasonic 
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disintegration (MSE Soniprep 150) at a rate of 23 kHz and an amplitude of 14 - 18 
microns for 15- 20 s. All tissue homogenates were then centrifuged at 12 000 r.p.m. for 
20 min at 4°C, the supernatants decanted and stored at -80°C, until analysed by h.p.1.c. 
with electrochemical detection (see section 2.9.6). 
2.9 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
2.9.1 Apparatus 
The apparatus used for the biochemical analysis of regional brain amine concentrations 
included: 
• An LKB 2150 HPLC pump (Amersham Pharmacia Biotech Limited, Little 
Chalfont, Buckinghamshire), a 7125-081 manual injector with a 50 III loop 
(Rheodyne L.P., California, USA) and a Hamilton syringe for sample injection. 
• A Shimadzu Liquid Chromatograph LC-9A pump (Shimadzu UK, Milton Keynes) 
and an automatic Jasco Intelligent Sampler 851-AS with a 100 III injection loop 
programmed to deliver 50 III samples (Jasco UK Ltd., Great Dunmow, Essex), and 
a Phenomenex Degassex DG-440 in-line degasser (Phenomenex, Macclesfield, 
Cheshire). 
• A CI8 Microsorb stainless steel reversed-phase column (150 x 4.6 mm), with an 
octadecyldimethylsilane monolayer bonded phase of particle size 5 11m and pore 
size 100 A (Anachem Ltd., Luton, Bedfordshire). 
• A CI8 Lichrospher RP-Select B stainless steel reversed-phase column (150 x 4.6 
mm), with a particle size of 5 11m (phenomenex). 
• An LC-4C amperometric detector (Bioanalytical Systems Inc. (BAS), Congleton, 
Cheshire), comprising a dual glassy carbon working electrode with an applied 
potential of 800 m V, versus a silver/silver chloride gel reference electrode. 
• An SP4400 ChromJet integrator (ThermoQuest UK, Wythenshawe, Manchester). 
• Nelson Analytical 900 Series Interface and 2600 Chromatography software, 
Version 5.1.5 (PE Nelson Systems Inc., LAB WORKS , Baton Rouge, Louisiana, 
USA). 
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2.9.2 Amperometric detector calibration 
Each standard was injected, in triplicate, on to the h.p.I.c. column over a range of 
applied potential of the working electrode, to ascertain the voltage at which optimum 
oxidation of each compound occurred (5-HT and 5-HIAA: 400 - 800 mY; dopamine: 
400 - 950 mY; DOPAC: 400 - 900 mY; HVA: 600 mV - 1 V). Voltage was then 
plotted against peak height (Figure 2.4) and values within the plateau of each resulting 
curve were deemed optimum for future h.p.l.c. analysis, 800 mV being chosen. 
2.9.3 Standard calibration curves 
Each standard was injected, in triplicate, on to the h.p.l.c. column over a range of 
concentrations in order to ascertain suitable values for calculation of tissue levels of 
monoamines and their metabolites (5-HT and 5-HIAA: 5 - 40 nglml; dopamine: 50 -
400 nglml; DOP AC and HV A: 10 - 80 nglml). Concentration was then plotted against 
peak height (Figure 2.5) and demonstrated linear relationships in each case, enabling the 
choice of suitable concentrations for future h.p.l.e. analysis (see section 2.9.5). 
2.9.4 Mobile phase 
The mobile phase consisted of KH2P04 (0.05 M), OSA (0.25 mM), EDT A (0.1 mM) 
and methanol (13 %) and was adjusted to pH 3.0 with orthophosphorie acid. The 
solution was vacuum-filtered and degassed via sonication and was subsequently 
pumped at a rate of 1.25 mllmin. 
2.9.5 Standards 
Hp.1.c. standards were initially dissolved at concentrations of 1 mg/ml in 0.2 M 
perchioric acid solution (see section 2.3). Following the development of calibration 
curves, the final concentrations of each standard injected on to the column were as 
follows: 5-HT and 5-HIAA: 25 ng/ml; dopamine: 250 nglml; OOP AC and HV A: 50 
nglml. 
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2.9.6 Measurement of 5-HT, dopamine and their metabolites in regional 
brain tissue 
Following dissection and processing of regional brain tissue (see section 2.8), samples 
were analysed by h.p.l.c. with electrochemical detection. The mobile phase flow rate 
was set at 1.25 rnlImin, the working electrode potential was 800 mV with a filter rate of 
0.10 Hz and the detector range was set at 10 nA. In each experiment, the relevant 
standard solutions were injected on to the h.p.I.c. column at regular intervals, 
interspersed between injections of tissue sample supernatants. The integrator or 
computerised data collection system calculated peak height data, which thus enabled 
determination of levels of 5-HT, 5-HIAA, dopamine, DOPAC and HV A in tissue 
samples by comparing the peak heights of known standard solutions with those of 
samples: 
1. 
2. 
[[std] (ng/ml~ x ts PH = [ts] (nglml) l stdPH J 
[ts] = [ts] (nglg tissue) 
ts W (g) 
(where [ ] = concentration; std = standard; ts = tissue; PH = peak height; W = weight). 
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3 BEHA VIOURAL TESTING I: 
A comparison between Dark Agouti and Sprague-Dawley 
rats in experimental models of anxiety 
3.1 INTRODUCTION 
3.1.1 Animal models of anxiety 
Anxiety cannot directly be measured in animals; rather behavioural models measure 
adaptive responses to specific stimuli (see Handley et aI., 1993). However, a variety of 
animal models of "anxiety" have been developed and are broadly grouped, according to 
the behaviours under investigation, into conditioned and unconditioned tests. 
3.1.1.1 Conditioned tests 
Conditioned "anxiety" tests include fear-potentiated startle and conflict tests, such as the 
Geller-Seifter and Vogel tests, and tend to require subject training followed by the 
presentation of some form of aversive stimulus (see Rodgers, 1997; Rodgers & Dalvi, 
1997). 
(1) Fear-potentiated startle 
Startle reflexes are often characterised by a whole body jump in the rat (see Richardson, 
2000) and may be investigated in the following manner: Brown et al. (1951) used a rat 
"stabilimeter", consisting of modified postage scales. A platform and confinement box 
were attached to the scales and, when rats were placed inside the box, any sharp sound 
induced a startle reaction which resulted in downward movement of the platform, 
deflection being measured via an ink polygraph. The conditioned stimulus (CS) 
consisted of a paired buzzer and light, the unconditioned stimulus (UCS) consisted of an 
electric shock (60 cycles, 70 - 80 V) applied via the grid forming the base of the 
confinement box, and the startle stimulus comprised the firing of a toy pistol. A four 
day training period was undertaken whereby, on each day, rats were trained through 
paired presentation of the CS and either the ues (seven out of ten trials) or startle 
stimulus (three out of ten trials) - the es was presented for 5 s and the DeS or startle 
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stimulus was presented for the final 2 s of the test period. Subjects demonstrated a 
significant increase in magnitude of startle response with each successive training day, 
indicating acquisition of a conditioned fear reaction. Subsequently, during three 
successive days of extinction trials, rats were presented with two paired presentations of 
the es and ues, followed by 12 presentations of the es alone. The startle stimulus was 
presented 3 s after the onset of the es in each trial (that is, at the same time at which the 
ues would usually be presented). Subjects demonstrated a progressive decline in startle 
response magnitude with each successive non-reinforced trial (that is, presentation of 
the CS without the shock UeS) on each day, yet their startle responses had 
spontaneously recovered 24 h later. The authors concluded that rats trained to respond 
to a paired presentation of a neutral and a noxious stimulus demonstrated acquisition of 
emotional responses of "fear" or "anxiety" (conditioned fear reaction). Furthermore, 
presence of conditioned fear served to increase the intensity of response to the startle 
stimulus (Brown et al., 1951), thus termed "fear-potentiated startle" (see Richardson, 
2000). 
(2) Punished responding 
Punished responding (conflict) paradigms include the Geller-Seifter and Vogel tests. 
"Punishment is defined as the presentation of a noxious stimulus and results in the 
suppression of behaviour. This suppressive effect of punishment is seen clearly in 
conflict situations where the organism is encouraged to respond and then is punished for 
doing so" (Tye et al., 1977). The Geller-Seifter test examines the conditioning of 
punishment discrimination and "conflict" behaviour, whereby rats are rewarded with 
food while simultaneously being punished by an electric shock (see Geller et a!., 1962). 
Geller et a!. (1962) deprived rats of food, being reduced to 60 % of their original body 
weight, prior to testing. Subjects learned to press a lever in order to receive a liquid food 
reward delivered, on average, once during each 2 min period (variable interval; VI). 
Subsequently, an auditory stimulus (3 min tone) was presented at 15 min intervals 
during a 75 min test period. Each auditory cue denoted a change from the 2 min VI to a 
continuous reinforcement schedule (crt), where all presses of the lever resulted in 
delivery of food. After approximately seven such training periods, punishment was 
administered in the form of an electric shock of varying intensity, delivered via the grid 
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floor of the test box each time the lever was pressed during the presentation of the 
auditory stimulus (Geller et aI., 1962). Thus the animals experienced a "contlict" 
between seeking the food reward and receiving an electric shock, resulting in 
punishment discrimination behaviour whereby the animal "chooses" whether to receive 
the shock in order to obtain food. Lever-press responding is subsequently reduced with 
increasing intensity of electric shock. 
This test can be used 10 the investigation of putative anxiolytic compounds. For 
example, Geller et al. (1962) administered chlordiazepoxide or chlorpromazine at 
several different doses and tested their effects on the lever-press responding of subjects 
administered high or low intensity shocks. Chlorpromazine treatment (1 mg/kg) resulted 
in a reduced number of shocks accepted at a low shock intensity and had no effect on 
responding at a high shock intensity, while chlordiazepoxide treatment (10 mg/kg) 
significantly attenuated punished discrimination at a high shock intensity (that is, the 
rats accepted more shocks in order to receive the reward) and had no significant effect 
at a low shock intensity. This study highlighted some of the differences between 
different classes of compounds, or those with differing mechanisms of action, as the 
anti-anxiety effect of chlordiazepoxide in the punishment discrimination paradigm was 
reported to be similar to the effects of meprobamate, phenobarbital and pentobarbital 
("central nervous system depressants"), while the effect of chlorpromazine was reported 
to be similar to the effects of the phenothiazines, promazine and trifluoperazine (Geller 
et aI., 1962). 
Kennett et al. (2000) employed a reinforcement schedule of ten 3 min tests which 
alternated between VI components, where one reinforcement was presented every 1 0 -
50 s, and fixed ratio (FR) components, comprising one reinforcement for every five 
lever presses. The FR component was accompanied by a light cue and reinforcement 
was paired with an electric foot shock (15 ms pulse at 200 ms intervals for 1 s), thus 
forming a punished responding trial. Punished responding was markedly increased by 
the benzodiazepine, chlordiazepoxide, whereas the novel 5-HT 2C receptor agonist, Ro 
60 0175, significantly reduced both punished and unpunished responding. The authors 
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concluded that Ro 60 0175 was neither anxiolytic nor anxiogenic at the doses tested, but 
was markedly sedative (Kennett et al., 2000). 
The Vogel conflict test involves a similar principle to the Geller-Seifter test, where 
thirsty animals seeking a water reward are punished with an electric shock (see Vogel et 
al., 1971). Vogel et al. (1971) deprived rats of water for 48 h prior to testing them in an 
apparatus consisting of two connected compartments with a stainless steel grid floor. 
The larger compartment comprised a clear Plexiglas box (38 x 38 cm) with an opening 
into a smaller compartment which comprised a black Plexiglas box (10 x 10.5 cm). A 
water bottle drinking tube extended into the smaller box and licks were recorded by the 
completion of a "drinkometer" circuit which connected the tube and the grid floor. Each 
subject was placed in the apparatus 30 min after drug administration and, upon finding 
the drinking tube, was allowed 20 licks before a shock was administered. The shock was 
terminated when the subject withdrew from the tube and a 3 min timer was activated at 
the end of the first shock. During the subsequent 3 min period, shocks were delivered 
after every 20 licks. This paradigm did not require training of the subjects, which 
removed any potential effects of repeated drug administration. Chlordiazepoxide 
pretreatment resulted in a dose-related increase in the number of shocks accepted during 
a 3 min test. Diazepam, oxazepam, meprobamate and pentobarbital all had similar 
effects, subjects showing a marked increase in punished responding in each case. These 
results were therefore in agreement with those of Geller et al. (1962), observed in the 
Geller-Seifter conflict paradigm (Vogel et al., 1971). 
Kennett et al. (1998; 2000) tested a group of rats which had been water-deprived for 20 
h. Rats were subsequently placed in an operant conditioning chamber, with access to a 
water bottle spout, and allowed to freely explore and drink for 3 min, timed from the 
first lick of the bottle spout. Upon being returned to their home cage, rats were given 4 h 
free access to water, then deprived for a further 20 h. On the following day, subjects 
were placed in the test chamber and, after 30 s of continuous drinking from the bottle 
spout, subsequent 5 s drinking periods were punished by an electric shock (0.25 rnA for 
200 ms) delivered through the spout. The latency to begin licking again following each 
shock, and the total number of shocks administered, were recorded during a 3 min test. 
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Administration of the benzodiazepine, chlordiazepoxide (Kennett et al., 1998; 2000), or 
the 5-HT2B receptor agonist, BW 723C86 (Kennett et a!., 1998), significantly increased 
punished responding, whereas the 5-HT2c receptor agonist, Ro 60 0175, had no effect 
(Kennett et al., 2000). 
3.1.1.2 Unconditioned tests 
Unconditioned tests measure spontaneous, primarily exploratory, behaviour and include 
the light/dark test box, social interaction tests, elevated plus-maze and open-field (see 
Chaouloff et a!., 1997; Rodgers, 1997). The elevated plus-maze and open-field have 
been employed in the current investigation and therefore are described in greater detail 
in sections 3.1.2 and 3.1.3. 
Unconditioned behaviour tests involve exploration of novel environments and are 
frequently used in the investigation of the behavioural effects of pharmacological 
agents. However, attention must be paid to locomotor activity, as this variable can 
impinge on the behavioural effects of drugs under investigation. Factor, or principal 
component, analysis is often used in an attempt to separate locomotion-dependent from 
locomotion-independent behaviours (Chaouloff et ai., 1997). Factor analysis describes 
the relationships between variables, aiding interpretation of several behavioural 
parameters within a single test or between a battery of tests (File, 1992). For example, 
on the elevated plus-maze, Factor 1 may refer to locomotor activity (closed and total 
arm entries, rearing) and Factor 2 may refer to approach/avoidance conflict (anxiety-
related) behaviour (% open arm entries and % time spent on the open arms) (Chaouloff 
et a!., 1997; File, 1992). Additional factors may take into account exploratory 
behaviours, such as head-dipping (File, 1992). 
(1) Light-dark test box 
The light-dark (or black and white) test box is used to examine the conflict between 
exploratory behaviour and aversion to a brightly illuminated environment (see File, 
1992). Costall et a!. (1989) employed this paradigm to investigate the effects of a 
number of putative anxiolytic and anxiogenic compounds, administered 40 - 45 min 
prior to testing, in several strains of mice (albino BKW, black C571BLl6, brown DBA2 
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and albino Tuck). The apparatus comprised a two-compartment metal box (45 x 27 x 27 
cm), the base of which was divided into 9 cm squares. The smaller compartment (two-
fifths of the box) was painted black and always illuminated by a 60 W red light bulb, 
while the adjoining, larger compartment was painted white and illuminated by a white 
light bulb of varying intensity (15, 25, 40, 60, 100 W) or by a 60 W red light bulb. 
Following acclimatisation to the test room for 1 h, subjects were placed in the centre of 
either the white or the black compartment and observed for: (1) the number of 
exploratory rearings and line crossings within each compartment, (2) the number of 
transitions between the 2 compartments, (3) the time spent in the different 
compartments, and (4) the latency of the initial movement into the opposite 
compartment. Control data was obtained by placing mice in a test box illuminated solely 
by red light bulbs; these subjects demonstrated random activity between the two 
compartments which reflected the relative sizes of the sections, mice spending 60 - 70 
% of the time in the larger section. There was no effect of changed illumination on the 
number of transitions performed by mice initially placed in either the white or the black 
arena. Increased illumination (60 and 100 W) significantly decreased the latency of 
movement from white to black and the % time spent in the white compartment, in mice 
initially placed in the white arena. Mice initially placed in the black compartment 
demonstrated a significantly greater latency to enter the white arena and spent 
significantly more time in the black section. Both rearing behaviour and the numbers of 
line crossings in the white section were significantly decreased in mice initially placed 
in either compartment, where there were high levels of illumination (60 and 100 W) in 
the white arena. Line crossings were significantly increased in the black compartment in 
mice initially placed in either section, while rearing behaviour in the black section was 
significantly increased in mice initially placed in this arena. Thus, the authors concluded 
that a brightly illuminated white arena was aversive and inhibited the exploratory 
behaviour of the mice (Costall et al., 1989). 
Aversion to a brightly illuminated environment, shown by reduced rearing behaviour, 
line crossings and time spent in the white arena, can be reversed by anxiolytic 
compounds (Chaouloff et aI., 1997; Costall et aI., 1989; Sanchez, 1995) so that the 
behaviour of drug-treated mice is the same as that of control mice (Costall et aI., 1989). 
101 
Chapter 3 Behavioural Testing J 
For example, the benzodiazepines diazepam, chlordiazepoxide and triazolam, the 
substituted benzamides sulpiride and tiapride, the 5-HT3 receptor antagonists GR 
38032F, ICS-205-930, MDL 72222, zacopride and BRL 43694, buspirone, alcohol, 
nicotine and the dopamine receptor antagonist SCH 23390 were shown to antagonise 
the aversion of the subjects to the brightly illuminated compartment. In contrast, 
FG7142, a benzodiazepine receptor inverse agonist, demonstrated anxiogenic properties 
shown by a reduced latency of movement into the black section and increased time 
spent, increased rearing behaviour and line crossings in the black compartment (Costall 
et al., 1989). 
(2) Social interaction 
Social interaction tests examine the anxiety that is generated by placing rats in an 
unfamiliar and/or brightly illuminated environment (see File, 1992). Rats are housed 
individually for several days before the testing period. Under either low or high 
illumination, the subjects are then: (1) familiarised with the test box, by being placed 
individually in the box for 10 min on the two days immediately before the test day, or 
(2) given no prior acquaintance with the box. On the test day, randomly selected pairs of 
rats with the same previous familiarisation experience are placed in the test box for 1 0 
min and monitored for interaction behaviours, such as sniffing, grooming, following, 
mounting and crawling over or under the other rat. Social interaction is maximal when 
rats are placed in a familiar environment under low levels of illumination. Increasing 
levels of illumination or unfamiliarity with the test box reduces levels of social 
interaction, this behaviour thus being minimal when rats are placed in a brightly lit, 
unfamiliar environment. Social interaction behaviour is sensitive to the effects of 
chlordiazepoxide; chronic pretreatment with the benzodiazepine has been shown to 
significantly reduce the unfamiliarity- and high illumination-induced decrease in this 
behaviour (File & Hyde, 1978; File, 1980). 
(3) Activity meter 
A simple measure of general locomotor activity, which is also measured as part of the 
plus-maze and open-field paradigms, is the activity meter. This model may comprise a 
clear plastic box with infrared beams, housed within a sound-attenuated cupboard, 
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Horizontal and vertical locomotor activity is measured by the number of beams crossed 
during a given period (see Griebel et al., 1997b). 
3.1.2 The elevated plus-maze 
The elevated plus-maze is a widely used rodent model of anxiety-related behaviour, 
being employed in the development of anxiolytic drugs and as a method for attempting 
to understand the psychological and neurochemical bases of anxiety (see Dawson & 
Tricklebank, 1995). It is an approach/avoidance conflict model, as the natural 
exploratory behaviour of rodents in a novel environment ("approach", "curiosity") is in 
conflict with the animal's instinct to avoid aversive environments ("fear", "caution"), 
such as open spaces (see Figure 3.1; Handley & McBlane, 1993 a; Handley et at., 1993; 
Holmes, 200 1 ). 
The model was developed from an elevated Y -maze, which consisted of a total of three 
open and enclosed arms present in different ratios (0:3, 1 :2, 2: 1 or 3 :0) (Montgomery, 
1955). Female Wistar rats were tested in randomised order, each being placed 
individually in the centre of the Y -maze and allowed 10 min for free exploration, during 
which the sequence of maze arms entered was recorded. This process was repeated on 
successive days during a three or five day period (Montgomery, 1952; 1955; 
Montgomery & Monkman, 1955). It was demonstrated that: (1) exploratory behaviour 
decreased during each trial but recovered within 24 h (Montgomery, 1952), (2) that a 
novel environment could evoke both exploratory behaviour and "fear" (approach-
avoidance conflict behaviour), and (3) that open arms evoked greater avoidance 
behaviour, indicative of greater "fear", than enclosed arms (Montgomery, 1955). In a 
further experiment, Montgomery & Monkman (1955) subjected the rats to an auditory 
stimulus to evoke a "fear" response. Evocation of a "fear" response immediately prior to 
testing on the Y -maze had no effect on the exploratory behaviour of the rats, while 
evocation of a "fear" response during the test reduced the amount of exploratory 
behaviour, demonstrating that exploratory behaviour is not motivated by "fear" 
(Montgomery & Monkman, 1955). 
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"CURIOSITY" - the ~ AMOUNT c:::::::> tendency to approach I TOTAL I novel stimuli ~ 
~ G)~ 
I Open ~ ~ Enclosed I let AROUSAL STATUS CHOICE D n 8 
"CAUTION' - the ~l 
IOPEN I propensity to avoid 
TOTAL potential danger Malaise or motor 
Figure 3.1 
! impairment 
[ FEAR or ANXIETY ) 
A schematic diagram of the theoretical basis of the elevated plus-
maze (after Handley & McBlane, 1993a). 
Novel stimuli induce both "curiosity" (approach), which results in open arm entries, and 
"caution" (avoidance), which results in enclosed arm entries. The level of fear or 
anxiety will impact on the degree of caution expressed. The open/total arm entries ratio 
expresses the outcome of the approach/avoidance conflict. Arousal status will differ 
with the administration of drugs, resulting in greater or lesser total movement, while 
motor impairment will reduce total activity. 
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Handley & Mithani (1984) constructed a plus-maze which was elevated 70 cm above 
the floor and consisted of two open and two enclosed arms (each 10 x 45 em) positioned 
opposite to each other, the enclosed arms having 10 cm high walls. Male hooded Lister 
(HL) rats were tested for a 10 min period and the number of open and enclosed arm 
entries recorded. Rats behaved in a similar manner to that demonstrated in the Y -maze 
(Montgomery, 1955), demonstrating a clear preference for the enclosed arms of the 
maze. In particular the number of open arm entries, by being calculated as a ratio to 
total arm entries, was deemed to account for overall exploratory activity and provided a 
realistic measure of "fear"-motivated behaviour (Handley & Mithani, 1984). Open arm 
entries are usually expressed as a proportion of total arm entries, in an effort to remove 
any drug effects which affect both arm types equally (Handley & McBlane, 1993a). 
Pellow et al. (1985) further validated the elevated plus-maze as an animal model of 
anxiety, feeling the need for a short, simple test which relied on spontaneous activity, 
rather than requiring training procedures, noxious stimuli or food or water deprivation, 
such as the conditioned tests described above (see Brett & Pratt, 1990; Pellow et aI., 
1985). Pellow and colleagues (I985) thus confirmed the results of Handley & Mithani 
(1984), in addition to identifying an increase in anxiety-related behaviours, such as 
freezing and defecation, on the open arms. 
It has been assumed that avoidance of the open arms is due to fear of the height of the 
maze andlor high light intensity (see Dawson & Tricklebank, 1995), but fear of open 
space or lack of thigmotactic cues, where rats remain close to vertical surfaces, may be 
the primary anxiogenic factor (see Treit et aI., 1993). This has been demonstrated by 
varying the height of the maze (6, 25 and 50 cm above the floor), which was expected to 
alter open arm activity, but in fact there was no difference in the % number of open arm 
entries or % time spent on the open arms, between the different maze heights (Treit et 
al., 1993). Furthermore, Handley & McBlane (1993a) tested Wistar rats on the elevated 
plus-maze in complete darkness (0 lux), observed via an infrared camera, and reported 
no difference in the open:total arm entries ratio compared to animals tested under 
normal lighting (170 lux). 
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Measurement of ethological variables can provide further indications of anxiety-like and 
exploratory behaviour and are important when assessing the effects of pharmacological 
manipulation on behaviour measured on the elevated plus-maze (see Setem et aI., 
1999). For example, "scanning" or "head-dips", whereby the rodent extends its head 
over the edge of an open arm; "risk assessment", which involves extending the head and 
forepaws on to an open arm and may be accompanied by a "stretched attend posture" 
(i.e. full body stretch); "self-grooming", whereby the rodent cleans itself with the 
tongue, teeth and/or forepaws; "end-exploring", which is described as the number of 
times the rodent reaches the end of an open arm (Cruz et al., 1994; Dawson & 
Tricklebank, 1995; Rodgers & Dalvi, 1997). 
The elevated plus-maze test has been shown to be sensitive to the effects of anxiolytic 
and anxiogenic drugs. In particular, consistent and reproducible data has been reported 
on the behavioural profiles of compounds acting at the GABAA-benzodiazepine 
receptor complex (see Hogg, 1996). Pretreatment with both the clinically effective 
anxiolytics chlordiazepoxide and diazepam (pellow et al., 1985) and the novel putative 
anxiolytics CL 218,872 and tracazolate (pellow & File, 1986) resulted in increased 
exploration of the open arms, shown by an increased % number of open arm entries and 
% time spent on the open arms. Pretreatment with the known anxiogenic drug 
yohimbine (Pellow et aI., 1985) and the putative anxiogenic compounds FG 7142 and 
Ro 5-4864 (pellow & File, 1986) led to reduced open arm exploration. Ethological 
variables further enable the detection of anxiolytic or anxiogenic properties of 
compounds, sometimes providing information which measures of locomotor activity, 
such as numbers of open arm entries, do not uncover (Setem et al., 1999; Weiss et aI., 
1998). For example, chlordiazepoxide significantly increased the % time spent on the 
open arms and numbers of head-dips, and decreased the numbers of stretched-attend 
postures (Weiss et al., 1998), while the 5-HT1A partial agonist ipsapirone was 
demonstrated to have anxiolytic properties by decreasing risk assessment and increasing 
scanning behaviour, without altering the % number of open arm entries or % time spent 
on the open arms (Setem et aI., 1999). 
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The plus-maze has also been demonstrated to be a suitable experimental paradigm for 
testing anxiety-related behaviours and the effects of anxiolytic and anxiogenic drugs in 
mice (see Lister, 1987). Lister (1987) tested male NIH Swiss mice on apparatus 
comprising two open (5 x 30 cm) and two enclosed (5 x 30 x 15 cm) arms, elevated 38.5 
cm above the floor. Mice were placed in the centre of the maze, facing an open arm, and 
observed for 5 min. The total number of arm entries, % time spent on the open arms and 
% number of open arm entries were recorded. As seen in rats, mice were shown to have 
a consistent preference for the closed arms of the plus-maze. FG 7142 and caffeine 
treatment led to a reduced % time spent on the open arms, indicating an anxiogenic 
action. Chlordiazepoxide, ethanol and sodium pentobarbital increased both the % time 
spent on the open arms and the total number of arm entries, indicating anxiolytic actions 
(Lister, 1987). 
Use of the elevated plus-maze as an effective model for investigating the 
neurotransmitter systems involved in anxiety-like behaviour is described in section 
3.1.6. 
Although the elevated plus-maze is extremely widely used, the results obtained are not 
always consistent, particularly concerning the use of serotonergic compounds (Graeff ef 
aI., 1996; Handley & McBlane, 1993b). A possible explanation for such inconsistencies 
was described by Schwarting et al. (1998), whereby male Wistar rats were tested on the 
elevated plus-maze on two occasions, 24 h apart and then grouped according to "high-" 
or "low-anxiety" levels, as demonstrated by the amount of time spent on the open arms. 
Subsequent post-mortem analysis of 5-HT, dopamine and their metabolites showed 
reduced levels of 5-HT in the ventral striatum in the "high-anxiety" group, following the 
second plus-maze exposure. The ventral striatum includes the nucleus accumbens, an 
area associated with motivation~ based on their data the authors suggested that this brain 
region may also be involved in emotional behaviour, and individual differences in 
serotonergic activity within the ventral striatum may help to explain the observed 
differences in animals' behavioural responses to pharmacological manipulation 
(Schwarting et al., 1998). 
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The plus-maze has substantial construct validity as a model of anxiety, in that there is a 
high degree of similarity between its theoretical background and "anxiety" as a 
physiological state (see Handley & McBlane, 1993a) and the anxiolytic effects of a 
broad range of compounds, proven to be clinically effective, have been successfully 
demonstrated using this model. However, although the elevated plus-maze is commonly 
used as a screening method for compounds with anxiolytic potential (see Hogg, 1996; 
Treit, 1985), its predictive validity, or its ability to predict whether novel compounds 
will prove to be clinically effective, is still being proven (see Handley & McBlane, 
1993a). In addition to its use as a model for studying the effects of specific compounds, 
the elevated plus-maze is useful for investigation of the neural mechanisms involved in 
the "anxiety" state itself (see File, 1992; Handley & McBlane, 1993a; Treit, 1985). 
3.1.3 The open-field 
A second, commonly used test of anxiety-related behaviour is the open-field, which has 
been used to examine "emotionality" or, " the state of being emotional ... consists of a 
group of organic, experiential and expressive reactions and denotes a general upset or 
excited condition of the animal" (Hall, 1934b). Hall (1934a) used a circular open-field, 
which was 8 feet in diameter with a sheet tin wall 18 inches high. The base of the open 
field was linoleum and marked out in a number of zones and sections to enable tracking 
of the rat's movements. Rats were tested for 2 min, and defecation and urination were 
used as measures of "emotionality". "Emotional", rather than "normal", defecation and 
urination were defined as responses which ceased upon repeated exposure to the 
environment which originally evoked them, as rats placed in a novel environment 
demonstrated reductions in defecation and urination with successive trials (Hall, 1934a). 
An additional measure of "emotionality" was the presentation of a food receptacle 
containing wet mash, placed in the centre of the open-field. The subjects had been food-
deprived for 23 h and the number of trials (14 in total) required before each subject ate 
the food was seen as an indicator of the animal's level of "emotionality", the emotional 
response being a barrier to the satisfaction of the animal's need for food (Hall, 1934a; 
1934b). Hall later investigated the relationship between "emotionality" and ambulatory 
activity. He tested rats in the open-field for 2 min every day for 28 successive days, 
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which varied with respect to food deprivation and presentation of food in the open-field. 
"Emotionality" was shown to correlate negatively with ambulatory activity; the more 
emotional the animals were (shown by increased defecation) the less active they were 
(Hall, 1936; Whimbey & Denenberg, 1967). 
The open-field test also involves the conflict between the animal's exploratory drive and 
avoidance of open, brightly lit spaces (see Schmitt & Hiemke, 1998a); "anxiety" may 
override the animal's tendency to explore (see Zimmermann et aI., 200]). The apparatus 
tends to be highly illuminated (see Schmitt & Hiemke, ] 998a; Zimmermann et al., 
2001) and may be either square (see Kohler & Lorens, 1978; Schmitt & Hiemke, 
1998b), or circular (see Zimmermann et aI., 2001) and the base is divided into sections. 
Rats are placed in the open-field arena and observed for a set time period, ranging from 
5 (see Escorihuela et a/., 1999) or 10 min (see Schmitt & Hiemke, 1998a~ Zimmermann 
et aI., 2001) to 50 min (see Kohler & Lorens, 1978), and a number of behaviours are 
noted, including: numbers of squares entered, time spent in the inner and outer zones, 
rearing, grooming and defecation (see Escorihuela et al., 1999; Kohler & Lorens, 1978; 
Schmitt & Hiemke, 1998b; Schwarting et aI., 1998; Zimmermann et aI., 2001). 
Furthermore, "enriched" environments may be employed as an additional measure of 
exploratory activity, whereby novel objects, such as plastic toys, are placed in the arena 
and approaches towards the objects and time spent sniffing the objects are recorded (see 
Schmitt & Hiemke, 1998b; Zimmermann et aI., 2001). 
Similar to the elevated plus-maze, the open-field can be used for testing the anxiolytic 
or anxiogenic properties of different compounds (see Schmitt & Hiemke, 1998b), in 
addition to the effects of central serotonergic lesions. For example, electrolytic lesioning 
of the median raphe nuclei, approximately three weeks prior to behavioural testing, 
resulted in a 55 % reduction in forebrain 5-HT levels and increased locomotor activity 
within the open-field (Kohler & Lorens, 1978). 
3.1.4 Effects of repeated testing and handling and duration of test 
There is some evidence that repeated testing and/or handling alter rats' behavioural 
responses to pharmacological manipulation when tested on the elevated plus-maze. In 
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addition, different studies report different effects of repeated testing on control animals. 
For example, Bertoglio & Carobrez (2000) tested male Wistar rats on a series of 
modified plus-maze apparatus on two occasions, 48 h apart. They demonstrated a 
significant reduction in the % number of open arm entries and % time spent on the open 
arms of the standard elevated plus-maze in Trial 2, while enclosed arm entries 
(locomotor behaviour), % time spent in the centre of the maze and risk assessment 
behaviour were unaffected. The results in the elevated T -maze (two open arms, one 
enclosed arm) and L-maze (one open arm, one enclosed arm), whereby Trial I 
experience of these apparatus still resulted in reduced open arm behaviour in Trial 2, led 
the authors to suggest that the presence of at least two different aversive environments 
was the critical factor in the avoidance learning process. This was further confirmed by 
the lack of effect of open arm confinement in Trial 1 on the % number of open arm 
entries and % time spent on the open arms in Trial 2 (Bertoglio & Carobrez, 2000). 
However, other authors have reported a lack of habituation with repeated testing. For 
example, Pellow et al. (1985) tested a group of male HL rats on the plus-maze on three 
consecutive days, examining the numbers of open and enclosed arm entries and the time 
spent on open and enclosed arms. Habituation did not occur, as there was no significant 
difference in the % number of open arm entries, the % time spent on the open arms, or 
the total number of arm entries, across the three test days, demonstrating that novelty 
was not a critical factor in the rats' behaviour (Pellow et aI., 1985). Lister (I 987) 
demonstrated no change in anxiety-related behaviours (% open arm entries and % time 
spent on the open arms) in mice tested on the elevated plus-maze on four occasions, 48 
h apart. Treit et al. (1993) reported findings consistent with those of Pellow et al. 
(1985), where male SD rats were tested on the elevated plus-maze on 18 consecutive 
days and demonstrated no significant change in the % time spent on the open arms, 
indicating a lack of habituation. However, there was a marginal decrease in the % 
number of open arm entries between the first and last trials, which may have indicated 
an increase in "fear" of the open arms after the first trial (Treit et aI., 1993). These 
results were further explored by confining the subjects to an open arm of the plus-maze 
for 30 min on three consecutive days, followed by free exploration of the apparatus for 
5 min on each of the following three days. It was expected that forced exposure to the 
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open arms would lead to reduced avoidance of these areas, but instead resulted in 
decreased % time spent on the open arms and % number of open arm entries, compared 
to control animals, during the first of the subsequent free exploration trials. Thus, it 
appeared that rats' "fear" of open spaces was resistant to modification (Treit et aI., 
1993). Handley & McBlane (1993a) investigated whether lack of habituation was due to 
rats having insufficient time, during a 10 min plus-maze exposure, to fully evaluate their 
environment. Thus, they tested Wistar rats on the elevated plus-maze for 1 h, then on 
the following day examined behaviour during a 10 min exposure. Total ann entries were 
marginally decreased on Day 2 compared with the first 10 min on Day 1, while open 
arm entries decreased by 74 % and open/total arm entries ratio decreased by 58 % on 
Day 2, indicating that prolonged exposure to the plus-maze led to an increase in open 
arm aversion (Handley & McBlane, 1993a). 
File et al. (1990) also demonstrated that control animals do not differ in their responses 
on the elevated plus-maze over repeated tests, while a single previous trial ranging from 
24 h (File, 1990) to two weeks earlier (File et al., 1990), renders the animal insensitive 
to the anxiolytic effects of chlordiazepoxide and is termed "one-trial tolerance". This 
phenomenon is believed to involve an interaction between the animal's experience on 
the elevated plus-maze during the first trial and an action of chlordiazepoxide with 
benzodiazepine receptors during the second trial. Chronic treatment is usually required 
to induce tolerance to chlordiazepoxide-induced anxiolysis on the elevated plus-maze, 
but a single 5 min prior exposure to the maze has the same behavioural effect (File, 
1990; File et aI., 1992). The animal's experience of the open arms of the elevated plus-
maze during Trial 1 was thought to be the crucial factor in this phenomenon (File et aI., 
1990). 
In a later study, File et al. (1992) demonstrated an additional effect of handling on the 
responses of chlordiazepoxide-treated rats. Male HL rats were tested on the elevated 
plus-maze; one group were handled and injected with saline daily for three weeks and a 
second group were not handled until the experimental day. Within each group, animals 
were administered either chlordiazepoxide or vehicle 30 min prior to being tested on the 
plus-maze and all groups were further divided into those which were tested on a single 
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occasion and those which were tested on two successive days. In unhandled animals, 
chlordiazepoxide significantly increased the % time spent on the open arms both in 
animals with no prior maze experience and in animals which had been tested on the 
elevated plus-maze on the previous day. In handled animals, however, chlordiazepoxide 
still induced a significant increase in the % time spent in the open arms in maze-naIve 
animals, but this effect was abolished in the group which had previously been exposed 
to the plus-maze. The authors concluded that the effects of handling and prior 
experience of the plus-maze had a combined effect of reducing the anxiolytic effect of 
chlordiazepoxide (File et aI., 1992). 
Andrews & File (1993) demonstrated effects of chronic handling in vehicle-treated male 
HL rats. Handling-habituated rats were subjected to daily handling for seven days, 
which consisted of weighing each rat and administering an i.p. injection of water. The 
unhandled rats were undisturbed until the test day. Vehicle-treated unhand led rats spent 
significantly less % time on the open arms and performed a significantly lower % 
number of open arm entries, compared to handled rats. However, the authors do state 
that these differences were not consistently reproducible and may be due to differences 
in handling history by the animal supplying company (Andrews & File, 1993). Brett & 
Pratt (1990) demonstrated no differences between handled and unhandled control 
animals, in their sub-acute study on male Long-Evans hooded rats, where the handling 
procedure involved being handled daily for two days, then being injected with diazepam 
or vehicle daily for three days. They demonstrated a significant increase in the ratio of 
open/total entries and time in the diazepam-treated rats, compared to the vehicle-treated 
rats. However, in a chronic experiment, where rats were handled daily for two days, 
then: (1) injected daily with vehicle for 27 days, or (2) injected with vehicle for 24 days 
then diazepam for three days, or (3) injected with diazepam for 27 days, there were no 
significant differences between treatment groups with respect to the ratio of open/total 
entries or time. The authors concluded that the lack of anxiolytic effect of diazepam in 
the chronic study was due to the chronic handling and injection regimen (Brett & Pratt, 
1990). 
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The length of the plus-maze trials has also been demonstrated to affect the behavioural 
response of rats to diazepam. File et al. (1993a) tested male HL rats on the elevated 
plus-maze on two occasions, 24 h apart. Rats were administered diazepam or vehicle 
and tested for either 5 or 10 min on each occasion. Diazepam had an anxiolytic effect in 
the first trial, whether 5 or 10 min, shown by increasing the % number of open ann 
entries. The anxiolytic effect of diazepam was abolished in rats which were tested for 5 
min in both Trial 1 and Trial 2; there was no difference in the % number of open arm 
entries between control and diazepam-treated animals. However, rats which were tested 
for 10 min in both trials still demonstrated an anxiolytic response to diazepam (File et 
ai., 1993a). 
These data have led to the suggestion that different forms of "fear" may be expressed 
under different conditions. It may be that Trial 1 "anxiety" involves the unfamiliarity of 
the environment and "fear" of the open arms, while Trial 2 primarily involves "fear" of 
heights (File et ai., 1993a). However, the latter is now believed to be more likely the 
lack ofthigmotactic cues, rather than the degree of elevation (Treit et ai., 1993). 
Untreated mice have been reported to differ in their behavioural responses on the 
elevated plus-maze in successive trials. Male Swiss-Webster mice were tested on the 
plus-maze for 5 min, on three successive days (Trials 1 - 3) and Trial 4 was conducted 
ten days after the third trial. Mice demonstrated significant reductions in total arm 
entries, % number of open arm entries, % time spent on the open arms, head-dipping 
and stretched attend postures, in Trial 2 compared to Trial 1. These changes were 
maintained or further enhanced in Trial 3 and in Trial 4 (Holmes & Rodgers, 1998). 
Although mice which were not subject to any pharmacological manipulation differed in 
their responses in successive trials on the elevated plus-maze, the same responses to 
chlordiazepoxide were observed as those seen in rats. Chlordiazepoxide induced an 
anxiolytic response in maze-naIve mice, shown by an increase in % time spent on the 
open arms. This response was abolished in a second 5 min exposure to the plus-maze 24 
h later, regardless of whether the first trial was of 5 min or 10 min duration. The latter 
effect was reversed in a 10 min trial, demonstrating that prior maze experience does not 
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affect responses to chlordiazepoxide when both trials are of 10 min duration (Holmes & 
Rodgers, 1999). 
3.1.5 Behavioural testing in different strains 
There is a lack of consistency in the results obtained in animal behavioural testing, due 
to differences in specific experimental conditions and laboratories (Handley & 
McBlane, 1993b; Hogg, 1996). Genetic (Ramos & Mormede, 1998) and gender 
(palanza, 2001; Ramos & Monnede, 1998) differences can also induce different 
behavioural responses to environmental challenges. 
The physiological mechanisms involved in "emotion" may be further clarified by 
characterising different strains with respect to a variety of behavioural measures (Ramos 
& Mormede, 1998). For example, male and female Lewis (LEW) and spontaneously 
hypertensive rats (SHR) were tested in the open-field, elevated plus-maze, activity 
meter and black and white box. With regard to locomotion, shown by total activity in 
the open-field, closed ann entries on the plus-maze and beam breaks in the activity 
meter, there were no differences between the two strains or between genders. However, 
with regard to anxiety-related behaviour, shown by reduced locomotor activity in the 
central zone of the open-field, % number of open arm entries and % time spent on the 
open arms of the plus-maze and time spent in the white compartment of the black and 
white box, the LEW rats were demonstrated to be more "anxious". In addition, male rats 
within both strains tended to demonstrate greater anxiety-related behaviours (Ramos & 
Mormerle, 1998; Ramos et al., 1998). The authors concluded that these two strains 
could prove a useful genetic tool in the study of anxiety (Ramos et aI., 1998). 
Rex et al. (1999) compared the behaviour of male Fischer 344 and Harlan-Wistar rats 
on the elevated plus-maze, black and white test box, social interaction test and a 
modified (food reward) open-field test. The Fischer 344 rats showed increased anxiety-
related behaviour compared to the Harlan-Wi star rats, which was consistent across all 
tests. The Fischer rats did not seek food in the modified open-field test, had a greater 
latency of contact and spent less time in social contact in the social interaction test, 
spent less time on the open arms and entered the open anns less frequently on the 
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elevated plus-maze, and spent less time in the:white compartment of the black and white 
test box (Rex et al., 1999). King (1999) compared the behaviour of three strains of rat -
SD, Dark Agouti (DA) and HL - on the standard elevated plus-maze and on an unstable 
elevated plus-maze, which comprised four open arms and was oscillated in the 
horizontal plane. The DA rats displayed greater anxiety-related behaviour than the other 
two strains, spending less time on the open arms, performing fewer open arm entries 
and having lower overall locomotor activity (total distance travelled). The HL rats were 
shown to be least "anxious" with regard to these parameters. The Ill., rats were again 
less "anxious" on the unstable plus-maze, as they performed significantly fewer escape 
attempts than the other two strains (King, 1999). Pellow et al. (1985) compared the 
behaviour of two strains of rat, HL and Wi star, on the elevated plus-maze and 
demonstrated no significant differences. Both strains performed significantly fewer 
open arm entries and spent less time on the open arms compared to the enclosed arms, 
indicating that either strain would be suitable for testing on the elevated plus-maze. 
However, during their pilot studies the authors observed that black hooded PVG rats did 
not show a consistent aversion to the open arms. Therefore, they advocated care when 
choosing a suitable strain for this model (pellow et al., 1985). 
In addition, genetic manipulations in mice provide models for the neural mechanisms of 
"anxiety" (Holmes, 2001). For example, Heisler et al. (1998) bred 5-HT1A receptor null-
mutant mice through truncation of the 5-HT lA receptor protein. Therefore, the 
homozygous mutant mice lacked functional 5-HT lA receptors, as indicated by receptor 
autoradiography and a lack of hypothermic response to 8-0H-DPAT administration. 
Mutant mice demonstrated increased "anxiety" levels, shown by significantly reduced 
locomotor activity and crossings within the central zone of the open-field, and 
significantly increased latency to respond to a novel object within the home cage 
(familiar environment), compared to both heterozygous and wild-type mice (Heisler et 
al., 1998). 
3.1.6 5-HT and anxiety 
The role of 5-HT in anxiety-related behaviour has been investigated by disrupting 
central serotonergic activity or by administering 5-HT receptor-selective ligands, and 
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analysing su.bsequent behavioural responses in both cases. In addition, in vitro stud-ies 
have aimed to elucidate whether pre- or post-synaptic mechanisms are involved. 
However, it is important to note that responses to 5-HT ligands in animal behavioural 
paradigms differ depending on the model, specific experimental conditions and the 
laboratory (Dawson & Tricklebank, 1995; Handley & McBlane, 1993b; Handley et aI., 
1993; Schwarting et al., 1998). Such differences in responses to pharmacological 
manipulation may indicate multiple mechanisms of anxiety (Graeff et al., 1996; 
Handley et aI., 1993). 
3.1.6.1 Disruption of central serotonergic activity 
The selective serotonergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) has been 
used in several behavioural paradigms to determine the effects of central 5-HT lesions 
on animal behaviour. For example, Briley et al. (1990) administered 5,7-DHT (250 Ilg) 
via an intracerebroventricular (i.c.v.) injection and measured 5-HT levels and 
CH]paroxetine binding 14 days later. A significant decrease in cortical (81 %) and 
hippocampal (99 %) 5-HT levels, in addition to reduced cortical eH] paroxetine binding 
(53 %), was observed. Anxiety-like behaviour was significantly reduced in the lesioned 
animals, as demonstrated by the increase in % number of open arm entries on the 
elevated plus-maze, while locomotor activity was unchanged (Briley et aI., 1990). 
Hall et al. (1999) administered 5,7-DHT i.c.v. to male SD rats and subsequently 
measured 5-HT levels via an in vivo microdialysis probe implanted in the left striatum. 
Two weeks post-Iesioning rats were tested on the elevated plus-maze and open-field. 
Rats were grouped according to the extent of 5-HT depletion (low: 0 - 50 %; moderate: 
51 - 75 %; high: 76 - 100 %) and their behavioural responses analysed. Increased levels 
of anxiety were observed in animals with low or moderate 5-HT depletion, as shown by 
reduced numbers of crossings in the central zone of the open-field and reduced numbers 
of open arm entries and increased defecation in the plus-maze. However, high levels of 
5-HT depletion significantly reduced crossings within the outer zone of the open field, 
had no effect on crossings within the central zone and no effect on behaviour in the 
elevated plus-maze. The authors suggested that serotonergic lesions may have a 
biphasic effect on anxiety, whereby increasingly severe lesions reversed the anxiogenic 
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effects of smaller lesions. Another possible explanation for this result was that 
compensatory changes were occurring after partial lesions and were abolished following 
complete lesions (Hall et aI., 1999). 
In addition to altering responses in the elevated plus-maze and open-field, 5,7-DHT 
administration has been shown to increase punished responding (Tye et al., 1977). Rats 
were trained to press a reinforcement lever to receive a food reward and, in subsequent 
tests, the reinforcement was paired with an electric foot-shock. Lesioned animals 
continued to press the reinforcement lever when shocks were administered, whereas 
control animals learned to avoid the foot-shocks. Thus 5-HT depletion appeared to have 
a "punishment-releasing effect", reversing the suppressive effects of punishment (Tye et 
al., 1977). 
Another compound employed to disrupt serotonergic activity is p-chlorophenylalanine 
(PCP A), which is an irreversible tryptophan hydroxylase inhibitor, and administration 
thus results in depletion of 5-HT (see Koe & Weissman, 1968). File & Hyde (1977) 
administered a single dose of PCPA (400 mg/kg i.p.) to male hooded rats three days 
prior to a social interaction test (see section 3.1.1). Brain 5-HT concentrations were 
depleted by 74 % while social interaction, which declines with increased illumination 
and levels of unfamiliarity (File & Hyde, 1978), was consistent over all test situations 
(low/high illumination and/or familiar/unfamiliar environment) (File & Hyde, 1977). 
PCP A has also been shown to increase punished responding in animals where a 5 1 % 
reduction in whole brain 5-HT concentration was recorded (Tye et aI., 1979). Such data 
indicated a role for 5-HT in the mediation of conflict behaviour (File & Hyde, 1977; 
Tye et al., 1977; 1979). 
3.1.6.2 5-HT receptor-selective ligands 
5-HT-related compounds have been extensively studied on the elevated plus-maze. 5-
HT2 and 5-HT3 receptor antagonists and 5-HTIA partial agonists have anxiolytic actions, 
while 5-HT2 and 5-HTlC agonists have been demonstrated to be anxiogenic. However, 
different studies have reported different drug actions, effects also varying between 
anxiety models (see Handley & McBlane, 1993b). Griebel et al. (1997a) tested the 
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effects of several 5-HT receptor-specific antagonists on the behaviour of male SD rats 
in the elevated plus-maze. The non-selective 5-HT 2 antagonist mianserin and the 
selective 5-HT2B12C antagonist SB 206553 were both demonstrated to have anxiolytic 
actions, as shown by increasing both the % number of open arm entries and the % time 
spent on the open arms, compared to control animals. The magnitude of response in 
both cases was similar to that following pretreatment with the benzodiazepine 
diazepam. The selective 5-HT2A receptor antagonist MDL 100,907 had no effect on 
these parameters, indicating that blockade of this receptor does not have an anxiolytic-
like effect in rats tested on the elevated plus-maze model of anxiety (Griebel et aI., 
1997a). The 5-HT lA receptor partial agonist buspirone was demonstrated to increase 
both the % time spent in the open arms and risk assessment (head-dipping) behaviour 
(Griebel et aI., 1997b). Similarly, buspirone and ipsapirone have been demonstrated to 
increase exploratory behaviour of mice in the white compartment of a light-dark test 
box (Sanchez, 1995). 
3.1.6.3 In vitro studies 
File et al. (1993b) investigated the effects of a social interaction test and elevated plus-
maze test on the subsequent release and uptake of GABA and 5-HT in hippocampal and 
frontal cortical slices. Male HL rats were subjected to one of a series of test conditions: 
(1) remaining in the home cage, (2) a single 5 min plus-maze test, (3) two 10 min plus-
maze tests separated by 24 h, or (4) a social interaction test with varying light and 
familiarity conditions. Brain tissue was obtained immediately after the test and 200 Ilm 
hippocampal and cortical slices prepared. Potassium-evoked release of eH]5-HT was 
significantly increased in hippocampal slices prepared from animals exposed to the 5 
min elevated plus-maze test or the social interaction test (high illumination, familiar 
condition). These results provided some indication of rapid changes in presynaptic 
function, as a response to anxiety-testing (File et aI., 1993b). 
3.1. 7 Aims of the investigation 
The longer-term behavioural consequences of MDMA administration in rats have been 
little studied and were therefore examined as part of this thesis (see Chapter 4). In 
addition, there is very little published data on the behaviour of the DA strain (apart from 
118 
Chapter 3 Behavioural Testing I 
King, 1999), which has been used in several earlier studies on the neurotoxic 
consequences of MDMA administration (see Colado et aI., 1995; O'Shea et aI., 1998) 
and was to be used for most studies reported in this thesis. Therefore, as a prelude to 
investigating the longer-term behavioural effects of MDMA administration in the DA 
strain, it was important to establish a baseline. This was achieved by comparing the 
locomotor and anxiety-related behaviour of DA rats with that of SD rats, a more 
commonly used strain (e.g. Briley et ai., 1990; Griebel et aI., 1997a; 1997b; King, 1999; 
Schmitt & Hiemke, 1998a; 1998b). Two widely used behavioural paradigms, the 
elevated plus-maze and open-field, were thus employed, in addition to the activity meter 
which provided further information concerning locomotor behaviour in the two strains. 
Following the determination of baseline behaviours in both strains, the effects of acute 
diazepam administration were investigated. Diazepam is a clinically-effective anxiolytic 
compound which has been used in the characterisation of the elevated plus-maze as a 
suitable model of "anxiety" (see Handley & Mithani, 1984; Pellow et aI., 1985) and is 
frequently employed when testing animals on the plus-maze (e.g. Brett & Pratt, 1990; 
File et aI., 1993a; Treit et aI., 1993). Diazepam treatment induces a clear anxiolytic 
response, shown by increased open arm exploration (see Pellow et aI., 1985), 
Anxiolysis has also been demonstrated, in response to diazepam administration, in other 
behavioural models, such as the Vogel conflict test (Vogel et aI., 1971) and the light-
dark test box (Costall et ai., 1989). This drug was employed in the current study as an 
additional measure for assessing the suitability of DA rats for future behavioural 
investigation. 
3.2 METHODS 
3.2.1 Animals and drug administration 
Adult male DA and SD rats were housed as detailed in section 2.1(2). Diazepam was 
dissolved in 0.9 % NaCI w/v with 15 % Tween 20 and injected at a dose of 1 or 1.5 
mg/kg s.c., 30 min prior to rats being tested on the plus-maze. 
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3.2.2 Behavioural assessment 
DA and SD rats (n = 9, in each group) were tested on the elevated plus-maze in 
randomised order on two occasions: Day 1 and Day 26. The test days were deemed to 
be separated by a suitable time period to prevent the development of habituation. 
Animals were monitored for numbers of arm entries, time spent on open and closed 
arms and a number of simple behaviours, as detailed in section 2.6.1. All animals were 
also tested in the open-field, on the three consecutive days subsequent to the first plus-
maze test day, being monitored for numbers of zone crossings and several anxiety-
related behaviours (see section 2.6.2). Days 1 and 2 were performed under white-light 
illumination, to test any possible effects of habituation, and Day 3 was performed under 
red-light illumination. 
A second group of DA and SD rats (n = 8, in each group) were tested in automated 
activity meters and monitored for overall locomotor activity (total numbers of infrared 
beam-breaks) and rearing activity (numbers of upper level beam-breaks). A further 
group of DA and SD rats were administered diazepam (1 mglkg) or vehicle (n = 8, in 
each group) 30 min prior to being tested on the elevated plus-maze. Locomotor and 
ethological variables were monitored and recorded as before. This experiment was 
repeated two weeks later, when diazepam was again administered, but at the higher dose 
of 1.5 mglkg. 
3.2.3 Statistics 
The elevated plus-maze and open-field data were analysed by two-way analysis of 
variance (ANOVA), with repeated measures, with STRAIN (DA or SD) x DAY (day of 
testing) as factors, followed by a Bonferroni post-hoc test. Activity meter data was 
analysed by two-way ANOV A, with repeated measures, with STRAIN (DA or SD) x 
TIME (of data collection) as factors, followed by a Bonferroni post-hoc test. The effects 
of diazepam were analysed by two-way ANOV A, with STRAIN (DA or SD) x 
TREATMENT (diazepam or vehicle) as factors, followed by a Bonferroni post-hoc test. 
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3.3 RESULTS 
3.3.1 Behaviour of DA and SD rats on the elevated plus-maze 
Naive DA and SD rats demonstrated pronounced differences in their behaviour on the 
elevated plus-maze. With regard to anxiety-related behaviour, DA rats performed a 
significantly lower % number of open arm entries (Figure 3.2a) and spent significantly 
less % time on the open arms (Figure 3.2b) on both test days compared to SD rats, 
resulting in main effects of STRAIN. The % number of open arm entries and % time 
spent on the open arms did not differ between the two test days in either strain, thus no 
main effects of DAY or interactions were observed. 
With regard to locomotor behaviour, DA rats were significantly less active than the SD 
strain on both test days, shown by lower numbers of total and closed arm entries. DA 
rats performed an approximately three-fold lower number of total arm entries on Day 1 
and approximately two-fold lower number of total arm entries on Day 26 compared to 
SD rats, resulting in a main effect of STRAIN (Figure 3.2c). Similarly, DA rats 
performed approximately half the number of closed arm entries than SD rats on both 
test days, resulting in a main effect of STRAIN (Figure 3.2d). There were no differences 
in the numbers of total or closed arm entries between the two test days in either strain, 
therefore neither main effects of DAY nor interactions were observed. 
With regard to the ethological variables measured on the elevated plus-maze (Table 
3.1), DA rats performed significantly greater defecation and grooming behaviour 
compared to the SD strain. This resulted in main effects of STRAIN and, with respect to 
grooming behaviour, post-hoc analysis showed a statistically significant difference 
between strains on both Day 1 (p < 0.05) and Day 26 (p < 0.001). However, there were 
no differences within either strain when comparing both the defecation and grooming 
behaviour on the two test days, thus neither main effects of DAY nor interactions were 
observed in either case. DA rats performed significantly fewer numbers of head dips 
compared to SD rats, resulting in a main effect of STRAIN and post-hoc analysis 
showed a statistically significant difference on Day 1 (p < 0.01). 
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Figure 3.2 The behaviour of DA and SD rats on the elevated plus-maze. 
Results shown as mean ± s.e.m., n = 9 in each group. (a) Open arm entries, calculated 
as a % oj total arm entries. DA rats were different from SD rats (F (1, 16) = 6.4, p < 
0.05). There was no difference between days within either strain. (b) Time spent on the 
open arms, calculated as a % of time spent on all arms. DA rats were different from SD 
rats (F (1, 16) = 10.8, < 0.01) with post-hoc analysis showing a significant difference 
between strains on Day 1 (*p < 0.05). There was no difference between days within 
either strain. (e) Total arm entries. DA rats were different from SD rats (F (1, 16) := 
29.0, p < 0.0001) and post-hoc analysis demonstrated a significant difference between 
strains on both Day 1 (***p < 0.001) and Day 26 (*p < 0.05). There was no difference 
between days within either strain. (d) Closed arm entries. DA rats were different from 
SD rats (F (1, 16) = 21.8, p < 0.001) and post-hoc analysis demonstrated a significant 
difference between strains on both Day 1 (**p < 0.01) and Day 26 (*p < 0.05). There 
was no difference between days within either strain. 
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Day 1 Day 26 Two-way ANOVA 
SD DA SD DA STRAIN DAY Interaction 
Defecation 0.0 ± 0.0 1.9 ± 0.7 0.2±0.2 2.7 ± 1.1 F (1, 16) = 9.3** F (1, 16) = 0.7 F (1, 16) = 0.2 
Grooming 1.1 ± 0.3 2.4 ± 0.4* 0.8 ±0.5 3.2 ± 0.4*** F (1, 16) = 33.3*** F (1, 16) = 0.3 F (1, 16) = 1.7 
Head dips 13.4 ± 2.5 1.7± 1.1** 13.7 ± 3.7 5.3±1.4 F (1, 16) = 15.5** F (1, 16) = 0.7 F (1, 16) = 0.6 
Rearing 2l.7±1.5 24.9 ± 2.2 16.3 ± 3.0 27.9 ± 2.8** F (1, 16) = 10.2** F (1,16)=0.2 F(l, 16)=2.6 
SAP 6.4 ± 1.0 8.2 ± 1.2 7.0 ± l.3 8.9 ± 1.6 F (1, 16) = 1.5 F (1, 16) = 0.4 F (1, 16) = 0.0 
Sniffing (directed) 21.3 ± 2.3 21.0±l.7 24.0 ± 2.0 25.9 ± 3.8 F (1, 16) = 0.1 F (1,16)=2.1 F (1, 16) = 0.2 
Sniffing 13.4 ± l.2 20.2 ± 1.8 13.1 ± 1.8 17.1 ± 2.5 F(I,16)=6.1* F (1, 16) = 1.2 F (1, 16) = 0.8 (non-directed) 
Table 3.1 Ethological variables measured in DA and SD rats on the elevated plus-maze. 
Results shown as mean ± s.e.m., n = 9 in each group. DA rats were significantly different from SD rats, where *p < 0.05, **p < 0.01 and 
***p < 0.001. 
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However, there was no difference between the number of head dips performed on Day 1 
and Day 26 within either the DA or the SD group, therefore there was no main effect of 
DAY and no interaction. The DA rats performed significantly greater rearing behaviour 
which resulted in a main effect of STRAIN, and post-hoc analysis revealed a 
statistically significant difference between the two strains on Day 26 (p < 0.0 I ). There 
was neither a main effect of DAY nor an interaction. SAP and directed sniffing 
behaviour did not differ between the DA and SD groups on either test day, while non-
directed sniffing was significantly greater in DA rats, resulting in a main effect of 
STRAIN, but no main effect of DAY or interaction. 
3.3.2 Behaviour of DA and SD rats in the open-field 
The behaviour of naiVe DA and SD rats was markedly different in the open-field. The 
number of Zone 2 crossings was significantly lower in the DA group compared to the 
SD rats (Figure 3.3a), resulting in a main effect of STRAIN and, although the number of 
Zone 2 crossings performed by the SD rats increased on consecutive days, there was no 
main effect of DAY and no interaction. 
DA rats demonstrated significantly lower overall locomotor activity, compared to the 
SD group, as shown by an approximately three-fold lower number of total zone 
crossings on all three test days (Figure 3.3b), resulting in a main effect of STRAIN. 
However, when comparing responses on each of the three test days, there was no 
difference between the total number of zone crossings performed by either DA or SD 
rats, thus there was no main effect ofDA Y and no interaction. 
With regard to the ethological variables measured in the open-field (Table 3.2), DA rats 
performed significantly greater defecation and grooming behaviour compared to SD 
rats. This resulted in main effects of STRAIN in both cases, and post-hoc analysis 
showed statistically significant differences on Days 2 and 3 (p < 0.001), with respect to 
defecation behaviour, and on Day 1 (p < 0.05) with respect to grooming. There were no 
differences within either strain when comparing defecation behaviour on the three test 
days, therefore there was neither a main effect of DA Y nor an interaction. 
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Figure 3.3 The behaviour of DA and SD rats in the open-field. 
Days 1 and 2 were performed under white-light illumination and Day 3 was perfonned under red-light illumination. Results shown as mean 
± s.e.m., n = 9 in each group. (a) Zone 2 crossings. DA rats were different from SD rats (F (1, 24) = 8.1, P < 0.01), while post-hoc analysis 
showed a statistically significant difference on Day 3 (*p < 0.05). There was no difference between days within either strain. (b) Total 
number a/zone crossings. DA rats were different from SD rats (F (1,24) = 43.4, P < 0.0001), while post-hoc analysis showed statistically 
significant differences on Day 1 (*p < 0.05), Day 2 (***p < 0.001) and Day 3 (Up < 0.01). There was no difference between days within 
either strain. 
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Day 1 Day 2 Day 3 Two-wa): ANOVA 
SD DA SD DA SD DA STRAIN DAY Interaction 
Defecation 0.1 ± 0.1 1.6 ± 0.6 0.l±0.1 3.7 ± 1.0*** 0.2 ± 0.2 3.3 ± 0.7*** F (1, 24) = 40.7*** F (2, 24) = 1.8 F (2,24) = 1.7 
Freezing 4.2 ±0.7 3.7 ± 0.5 2.9± 0.9 3.1 ± 0.6 4.6± 0.7 4.0± 0.6 F (1, 24) = (lJ F (2,24) == 1.7 F (2, 24) = 0.2 
Grooming 0.4±0.2 3.4 ± 0.7* 0.7 ± 0.3 2.4 ± 0.7 1.1±0.4 3.6 ± 0.6 F (1, 24) = 18.5*** F (2, 24) == 3.5~ F (2, 24) == 2.2 
Rearing 7.0 ± 1.7 1l.0 ± l.8 1O.9±2.2 6.0 ± l.8 13.4 ± l.5 16.3 ± 3.6 F (1, 24) = O.l F (2, 24) == 5.5~ F (2, 24) = 2.6 
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Table 3.2 Ethological variables measured in DA and SD rats in the open-field. 
Results shown as mean ± s.e.m., n = 9 in each group. DA rats were significantly different from SD rats, where *p < 0.05 and ***p < 0.001; 
responses were significantly different between test days, where ~p < 0.05. 
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However, grooming behaviour in the SD rats increased on consecutive test days, 
resulting in a main effect of DAY, but no interaction. Freezing behaviour did not differ 
either between the two strains or on different days. Rearing behaviour also did not differ 
between the two strains, but increased in SD rats over the three test days and, in the DA 
group, decreased on Day 2 compared to Day 1, then increased on Day 3 compared to 
both previous days. This resulted in a main effect ofDA Y, but no interaction. 
3.3.3 Behaviour of DA and SD rats in automated activity meters 
Behaviour of the two strains in the automated activity meter illustrated clear differences 
between DA and SD rats. DA rats demonstrated significantly lower overall locomotor 
activity (Figure 3 Aa), shown by reduced total numbers of infrared beam-breaks, 
resulting in a main effect of STRAIN. In addition, both DA and SD groups 
demonstrated a decrease in total activity over time, resulting in a main effect of TIME. 
However, there was no interaction between the effects of STRAIN and TIME. Rearing 
activity was also significantly lower in the DA rats and decreased over time in both 
strains (Figure 3.4b) resulting in main effects of both STRAIN and TIME but no 
interaction. 
3.3.4 Effects of diazepam on the behaviour of DA and SD rats on the 
elevated plus-maze 
In the next series of experiments, the effect of diazepam treatment on the behaviour of 
DA and SD rats was examined on the elevated plus-maze. With regard to anxiety-
related behaviour observed in SD rats, diazepam treatment (1 mg/kg s.c.) led to an 
increased % number of open arm entries (Figure 3.Sa) and increased % time spent on 
the open arms (Figure 3.Sb). Diazepam treatment did not alter the % number of open 
arm entries performed by DA rats (Figure 3.Sa), but did result in a greater % time being 
spent on the open arms by this strain (Figure 3. 5b). Thus main effects of TREA TMENT 
were observed with respect to both of these behavioural measures. However, there were 
no differences between strains with respect to open arm behaviour, either in diazepam-
treated or vehicle-treated groups, thus neither main effects of STRAIN nor interactions 
were observed. 
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Figure 3.4 The behaviour of DA and SD rats in automated activity meters. 
Results are shown as mean ± s.e.m., n = 8 in each group. (a) Total activity. DA rats were different from SD rats (F (1, 84) = 78.8, p < 
0.0001), post-hoc analysis demonstrating statistical significance during the first 25 minutes (*p < 0.05; up < 0.01; ***p < 0.001). There 
was a decrease in activity over time (F (11, 84) = 21.6, P < 0.0001). (b) Rearing activity. DA rats were different from SD rats (F (1, 84) = 
7.5, P < 0.01) and there was a decrease in activity over time (F (11, 84) = 12.0, P < 0.0001). 
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The etTect of diazepam (1 mg/kg) on the behaviour of DA and SD 
rats on the elevated plus-maze. 
Results shown as mean ± s.e.m., n = 8 in each group. (a) Open arm entries, calculated 
as a % of total arm entries. DA rats were not different from SD rats. Diazepam-treated 
rats were different from vehicle-treated rats (F (1, 28) = 4.7, P < 0.05). (b) Time spent 
on open arms, calculated as a % of time spent on all arms. DA rats were not different 
from SD rats. Diazepam-treated rats were different from vehicle-treated rats (F (1, 28) = 
6.7, P < 0.05). (c) Total arm entries. DA rats were different from SD rats (F (1,28) = 
21.3, P < 0.0001) with post-hoc analysis showing a significant difference between 
strains in both diazepam-treated and vehicle-treated animals (*p < 0.05). There was no 
difference between diazepam-treated and vehicle-treated rats. (d) Closed arm entries. 
DA rats were different from SD rats (F (1, 28) = 20.0, P < 0.001) with post-hoc analysis 
showing a significant difference between strains in both diazepam-treated (**p < 0.0]) 
and vehicle-treated (*p < 0.05) animals. There was no difference between diazepam-
treated and vehicle-treated animals. 
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Vehicle Diazepam Two-way ANOVA 
SD DA SD DA STRAIN TREATMENT Interaction 
Defecation o.o± 0.0 1.8 ± 0.9 O.O± 0.0 3.4 ± 0.9** F (1, 28) = 16.8*** F (1, 28) = l.7 F (1, 28) = 1.7 
Grooming 0.4 ± 0.3 4.5 ± 0.7*** 0.6 ± 0.2 l.8 ± 0.6 F (1, 28) = 3l.3*** F (1,28) = 7.1~ F (1, 28) = 1O.2§§ 
Head dips 21 ± 4.3 4.3 ± 0.9** 26.9 ± 4.1 5.3 ± 0.9*** F (1, 28) = 36.7*** F (1, 28) = 1.3 F (1, 28) = 0.6 
Rearing 17.3 ± l.7 24.8 ± l.7 15 ± 3.3 18 ± 2.8 F (1, 28) = 4.5* F (1, 28) = 3.3 F (1,28) = 0.8 
SAP 6.3 ± 1.2 4.1 ± 0.6 2.8 ±0.9 3 ±0.8 F (1, 28) = 1.1* F (1, 28) = 6.5~ F (1, 28) = l.7 ! 
I 
Sniffing (directed) 38.4 ± 2.7 27.3 ± 4.9 44.1 ±4.7 26.9 ± 2.3** F (1, 28) = 13.9*** F (1, 28) = 0.5 F (1, 28) = 0.7 
Sniffing 12.9 ± 2.6 14.8 ± 2 10 ± 2.3 11 ± 2.2 F (1,28) = 0.4 F (1, 28) = 2. 1 F (1, 28) = 0.0 (non-directed) 
~-----
Table 3.3 Ethological variables measured in DA and SD rats, pretreated with diazepam (1 mglkg) or vehicle 30 min prior to 
being tested on the elevated plus-maze. 
Results shown as mean ± s.e.ffi., n = 8 in each group. DA rats significantly different from SD rats, where **p < 0.01 and ***p < 0.001; 
diazepam-treated rats significantly different from vehicle-treated rats, where ~p < 0.05; significant interaction between STRAIN and 
TREATMENT effects, where §§p < 0.01. 
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Diazepam treatment had no effect on locomotor activity, within either strain, as both 
total (Figure 3.Sc) and closed (Figure 3.Sd) arm entries were unaltered compared to 
vehicle-treated groups. Thus main effects of TREATMENT were not observed. 
Diazepam- and vehicle-treated DA rats demonstrated significantly lower overall 
locomotor activity than both SD treatment groups, shown by fewer numbers of total 
(Figure 3.Sc) and closed (Figure 3.Sd) arm entries. This resulted in main effects of 
STRAIN with respect to both measures, while there were no interactions between the 
effects of TREATMENT and STRAIN in either behaviour. 
With regard to the ethological variables measured in the elevated plus-maze (Table 3.3), 
diazepam treatment resulted in a significant decrease in grooming behaviour performed 
by DA rats and a significant decrease in stretched attend postures performed by SD rats, 
resulting in main effects of TREATMENT in both cases. DA rats demonstrated greater 
defecation, grooming and rearing behaviour compared to the SD strain, resulting in 
main effects of STRAIN in each case. Post-hoc analysis showed statistically significant 
differences in defecation in diazepam-treated rats (p < 0.01) and in grooming behaviour 
in vehicle-treated rats (p < 0.001). An interaction between STRAIN and TREATMENT 
effects was also observed with regard to grooming behaviour. DA rats performed 
significantly fewer head dips and significantly less directed sniffing than SD rats, 
resulting in main effects of STRAIN in both cases. Post-hoc analysis demonstrated 
statistically significant differences between strains with regard to head dips, in both 
diazepam-treated (p < 0.001) and vehicle-treated (p < 0.01) groups. With regard to 
directed sniffing, post-hoc analysis demonstrated statistical significance in diazepam-
treated rats (p < 0.01). There was no difference within either strain with regard to either 
of these measures, therefore no main effects of TREATMENT or interactions were 
observed. There was no difference between strains or treatment groups with respect to 
non-directed sniffing. 
Two weeks later, all animals which had previously been treated with diazepam were 
administered a second, higher dose of diazepam (1. S mglkg), while all animals which 
had previously been administered vehicle were again injected with vehicle, 30 min prior 
to being tested on the elevated plus-maze. 
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Figure 3.6 
Treatment Treatment 
The effect of diazepam (1.5 mg/kg) on the behaviour of DA and SD 
rats on the elevated plus-maze. 
Results shown as mean ± s.e.m., n = 8 in each group. (a) Open arm entries, calculated 
as a % of total arm entries. There were no significant differences either between strains 
or between treatment groups. (b) Time spent on open arms, calculated as a % of time 
spent on all arms. There were no significant differences either between strains or 
between treatment groups. (c) Total arm entries. DA rats were different from SO rats (F 
(1, 27) = 14.2, P < 0.001), with post-hoc analysis showing a significant difference 
between strains in diazepam-treated animals (**p < 0.01). There was no difference 
between diazepam-treated and vehicle-treated rats. (d) Closed arm entries. DA rats were 
different from SD rats (F (1, 27) = 10.3, P < 0.01), with post-hoc analysis showing a 
significant difference between strains in diazepam-treated animals (**p < 0.01). There 
was no difference between diazepam-treated and vehicle-treated rats. 
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Vehicle Diazepam Two-way ANaVA 
SD DA SD DA STRAIN TREATMENT Interaction 
Defecation 0.1 ± 0.1 2.8 ± 0.9** O.O± 0.0 2.1 ± 0.5* F (1,28) = 2l.3*** F (1,28) = 0.5 F (1, 28) = 0.2 
Grooming 1.I±O.4 5.6 ± 0.8*** 1.3 ± 0.2 2.6 ± 0.7 F (1, 28) = 25.4*** F (1, 28) = 6.I~ F (1, 28) = 7.2§ 
Head dips 7.9 ± 2.6 1.5 ± 0.7 20.4 ± 4.1 3.5 ± 1.5*** F (1, 28) = 20.3*** F (1,28) = 7.9M F (1, 28) = 4.1 
Rearing 11.0 ± 3.2 23.1 ± 2.9* 16.4 ± 3.0 18.8 ± 3.7 F (1, 28) = 5.1* F (1, 28) = 0.0 F (1, 28) = 2.3 
SAP 3.1±0.9 3.3 ± 1.2 3.9 ± 1.0 2.5 ± 0.5 F (1, 28) = 0.4 F (1, 28) = 0.0 F (1, 28) = 0.6 
Sniffing (directed) 29.6± 3.3 25.9 ± 3.0 40.0 ± 3.7 21.6 ± 2.1 *** F (1, 28) = 12.7** F (1, 28) = 1.0 F (1, 28) = 5.5§ 
Sniffing 14.6 ± 3.2 18.6 ± 2.9 11.4 ± 2.8 16.3 ± 2.4 F (1, 28) = 2.5 F (1,28) = 1.0 F (1, 28) = 0.0 (non-directed) 
-------------
Table 3.4 Ethological variables measured in DA and SD rats, pretreated with diazepam (1.5 mglkg) or vehicle 30 min prior to 
being tested on the elevated plus-maze. 
Results shown as mean ± s.e.m., n = 8 in each group. DA rats significantly different from SD rats, where *p < 0.05, **p < 0.01 and ***p < 
0.001; diazepam-treated rats significantly different from vehicle-treated rats, where ~p < 0.05 and Mp < 0.01; significant interaction 
between STRAIN and TREATMENT effects, where §p < 0.05. 
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With regard to anxiety-related behaviour, there were no differences between strains or 
between treatment groups in either the % number of open arm entries (Figure 3.6a) or 
the % time spent on the open arms (Figure 3.6b), thus no main effects of STRAIN, 
TREATMENT or interaction were observed. With regard to locomotor activity, 
diazepam treatment had no effect on the number of total (Figure 3.6c) or closed (Figure 
3.6d) arm entries, thus there was no main effect of TREATMENT. Diazepam-treated 
DA rats performed fewer total (Figure 3.6c) and closed (Figure 3.6d) arm entries than 
diazepam-treated SD rats, resulting in main effects of STRAIN in both cases. There 
were no differences in either of these measures between vehicle-treated DA and SD rats. 
With regard to the ethological variables measured (Table 3.4), the differences between 
strains were similar to those seen in the previous experiment (compare with Table 3.3). 
Diazepam treatment resulted in a significant decrease in grooming behaviour performed 
by DA rats and a significant increase in head dips performed by SD rats, resulting in 
main effects of TREATMENT in both cases. DA rats demonstrated greater defecation, 
groommg and rearing behaviour, compared to SD rats, resulting in main effects of 
STRAIN. Post-hoc analysis showed statistically significant differences in defecation 
between strains in both diazepam-treated (p < 0.05) and vehicle-treated (p < 0.01) 
groups. Post-hoc statistical significance was also demonstrated in the grooming (p < 
0.001) and rearing (p < 0.05) behaviour of vehicle-treated groups and an interaction 
between STRAIN and TREATMENT was observed with regard to grooming behaviour. 
DA rats performed fewer head dips and less directed sniffing than SD rats, resulting in 
main effects of STRAIN in both cases. Post-hoc analysis demonstrated statistically 
significant differences between strains in diazepam-treated rats, with regard to both of 
these behaviours (p < 0.001). SAP and non-directed sniffing behaviours did not differ 
either between strains or between treatment groups. 
3.4 DISCUSSION 
This study revealed pronounced differences in the behaviour of naIve DA and SD rats. 
DA rats showed a higher level of anxiety-related behaviour and lower locomotor 
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activity than the SD strain. Furthermore, these differences were seen to be consistent 
across the three different behavioural paradigms employed. 
On the elevated plus maze DA rats demonstrated higher anxiety-related behaviour, 
clearly illustrated by performing a lower % number of open arm entries and by spending 
less % time on the open arms, compared to SD rats. In addition, the DA rats displayed 
lower locomotor activity, as shown by fewer total and closed arm entries. It should be 
noted that measurement of closed arm entries provides a better indication of locomotor 
activity, as it is unaffected by anxiety-related measures such as open arm entries (Cruz 
et al., 1994). These differences in behaviour between the two strains were apparent both 
on Day 1 and again when the animals were tested 25 days later. These data are also 
consistent with the observations of King (1999) who found that DA rats performed 
fewer open arm entries, spent less time on the open arms and demonstrated lower 
overall locomotor activity than both SD and HL rats. 
There were no statistically significant differences in the anxiety-related and locomotor 
behaviour of either strain between the two test days. As discussed in section 3. 1.4, 
repeated exposure of rats to the elevated plus-maze has been reported to alter the type of 
"anxiety" which is being measured and, in particular, alters the response to 
benzodiazepines in later trials (File et al., 1990). Where "one-trial tolerance" has been 
demonstrated, there tends to be a far shorter interval between trials than that employed 
in the current study. For example, tolerance to the anxiolytic effect of chlordiazepoxide, 
as demonstrated by File et al. (1990), involved an inter-trial interval of 24 h or a 
maximum of two weeks. In addition, habituation effects are generally not reported in 
control animals (pellow et al., 1985; File et al., 1990), therefore a 25 day inter-trial 
interval was deemed sufficient for the current study. Furthermore, by increasing the 
elevated plus-maze trial from 5 min to 10 min, "one-trial tolerance" to the anxiolytic 
effects of chlordiazepoxide can be reversed (File et al. 1990). Therefore, the 10 min 
plus-maze trial employed here should have further served to minimise any potential 
effects of re-testing. 
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Similar differences in anxiety-like behaviour were observed in the open-field, where 
DA rats performed far fewer Zone 2 crossings, perhaps indicating less "risk-taking" 
behaviour. By remaining in Zone 1, close to the high surrounding wall of the open-field, 
the DA rats avoided the open space of the centre of the arena, which signified the 
conflict between an exploratory drive and avoidance of open, brightly I it spaces (see 
Schmitt & Hiemke, 1998a). Locomotor behaviour was also lower in the DA rats, shown 
by fewer total numbers of crossings compared to the SD rats. The first two days of 
testing in the open-field were performed under white light illumination in order to test 
the effects of habituation, while the third day was performed under red light 
illumination, which it was hoped would provide a less anxiogenic environment. 
Although the number of Zone 2 crossings performed by SD rats increased over the three 
test days, there was no significant difference between days. There was also no 
difference between days within either strain with respect to the total number of 
crossmgs. Therefore, there was no apparent habituation effect and no effect of 
illumination. 
The differences in behaviour between the two strains were further exemplified in the 
automated activity meter. DA rats demonstrated lower locomotor activity, compared to 
SD rats, as shown by significantly fewer total numbers of infrared beam breaks. 
Several of the ethological variables measured also served to reinforce the differences 
between the two strains. Defecation was significantly higher in DA rats, on both the 
elevated plus-maze and in the open field, a response which is consistent with increased 
"anxiety" or "emotionality" (Hall, 1934b). Grooming behaviour was also significantly 
higher in the DA rats, being termed a "displacement behaviour" in conflict situations 
(see Cruz et al., 1994 and Pellow et al., 1985), and could therefore be expected to 
increase in more "anxious" animals. On the elevated plus-maze, DA rats performed 
significantly fewer head dips than SD rats. This behaviour is an indicator of low levels 
of anxiety-related behaviour, being increased by anxiolytic drugs (Cruz et al., 1994; 
Griebel et aI., 1997b), and thus serves as further proof of greater anxiety-related 
behaviour in DA rats. 
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DA rats performed greater rearing behaviour on the elevated plus-maze (particularly on 
Day 26), but less rearing behaviour in the automated activity meter, compared to SD 
rats. This behaviour is believed to reflect locomotor activity, being a variable which 
loads heavily and exclusively on the activity factor during ethopharmacological 
behavioural analysis (Cruz et ai., 1994; File, 1992; Rodgers & Dalvi, 1997). However, 
although increased rearing on the plus-maze may not be consistent with the other 
measures of locomotor activity in this study, rearing may also be an indicator of 
anxiety-related behaviour. Rodgers & Dalvi (1997) reported a decrease in rearing 
behaviour of mice tested on the elevated plus-maze in response to muscimol, a GABAA 
receptor agonist. Muscimol did not alter locomotor activity, shown by total and closed 
arm entries, but did significantly increase % time spent on the open arms, in addition to 
significantly decreasing rearing behaviour. The authors suggested that rnuscimol had 
anti-anxiety effects which are behaviourally selective and that the reduction in rearing 
was a "consequence of anxiolysis" (Rodgers & Dalvi, 1997). 
There was no significant difference between the two strains with regard to stretched 
attend posture, which is considered to be an anxiety-related (risk assessment) behaviour 
(Cruz et ai., 1994; Griebel et ai., 1997b; Rodgers & Dalvi, 1997). Risk assessment is 
reported to decrease in response to anxiolytic drugs (Griebel et al. 1997b) and may 
therefore be expected to be higher in more "anxious" animals. Although there was no 
difference between the two strains with respect to directed sniffing, DA rats performed 
significantly greater non-directed sniffing, which may also be considered to be a risk 
assessment behaviour (see Rodgers & Dalvi, 1997) and is, therefore, consistent with the 
majority of other ethological measures reported here. 
The pronounced differences in behaviour between the two strains led to the suggestion 
that they may also differ in their responses to pharmacological manipulation. Thus, a 
separate group of animals were administered diazepam, an anxiolytic compound which 
has frequently been used when testing animals on the elevated plus-maze (e.g. Brett & 
Pratt, 1990; File et ai., 1993a; Handley & Mithani, 1984; Pellow et ai., 1985; Treit et 
ai., 1993) and has been shown to increase both open arm exploration (e.g. Handley & 
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Mithani, 1984; Pellow et at., 1985; Treit et al., 1993; Wright et al., 1992) and the time 
spent on the ends of the open arms (Wright et al., 1992). 
Following administration of the lower dose of diazepam (l mg!kg) , a clear anxiolytic 
response was observed in SD rats, shown by a significant increase in the % number of 
open arm entries and the % time spent on the open arms, and a non-significant increase 
in locomotor activity. The behavioural effects of diazepam in DA rats were less clear-
cut. There was no difference in the % number of open arm entries between diazepam-
and vehicle-treated DA rats, although diazepam treatment did result in an increased % 
time spent on the open arms indicating an anxiolytic effect. However, neither DA 
treatment group was significantly different from the SD rats with regard to open arm 
behaviour. Thus, the marked differences observed in naIve animals were not seen where 
animals were injected with vehicle, with respect to anxiety-related measures. It appears 
that brief handling, whilst injecting vehicle, abolishes the high levels of "anxiety" seen 
in naive DA rats. In fact the % number of open arm entries and the % time spent on the 
open arms by vehicle-treated DA rats were approximately three-fold higher than the 
values recorded in naive DA rats (compare Figures 3.5a and 3.5b with Figures 3.2a and 
3.2b). However, such differences did not extend to locomotor behaviour or ethological 
variables, the marked differences between strains being similar to those seen in naiVe 
rats; significant differences in locomotor behaviour between strains were still observed, 
shown by fewer total and closed arm entries in the DA rats. Locomotor activity was not 
significantly changed by diazepam in either strain, indicating that this dose of diazepam 
did not produce sedation. Both diazepam- and vehicle-treated DA rats performed greater 
defecation and grooming behaviour than SD rats, as seen in nalve animals. Diazepam 
administration had no effect on defecation behaviour but did reduce grooming 
behaviour in DA rats, which is consistent with an anxiolytic effect. 
As discussed in section 3.1.4, anxiety-like behaviour can be attenuated by handling 
and/or repeated testing on the elevated plus-maze. For example, Andrews & File (1993) 
demonstrated a significant reduction in open arm behaviour in lll., rats which had not 
been handled, compared to those which had been handled daily for seven days. This is 
consistent with the effects seen in vehicle-treated DA rats in this study, which 
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demonstrated an increase in open arm behaviour compared to naive rats. Brett & Pratt 
(1990) demonstrated that a chronic handling and injecting regimen abolished the 
anxiolytic effects of diazepam. This result is consistent with the % number of open arm 
entries in the current study which did not differ between vehicle- and diazepam-treated 
DA rats, although the % time spent on the open arms was significantly increased in 
diazepam-treated DA rats, compared to control animals. The differences between naive 
and vehicle-treated OA rats are made more remarkable by the fact that the handling 
procedure was acute, being only during the injection procedure. Previous studies have 
not compared naive with treated animals, as even unhandled animals have been injected 
with vehicle. However, handling, to whatever extent, has still been shown to alter 
subsequent behavioural responses on the elevated plus-maze (Andrews & File, 1993; 
Brett & Pratt, 1990). 
During the second diazepam experiment, where a higher dose (1.5 mg/kg) was 
administered two weeks after the first dose, open arm behaviour and locomotor 
behaviour were modestly reduced in all groups, compared to the first diazepam 
experiment (compare Figure 3.6 with Figure 3.5). This may have been due to 
habituation, although this seems unlikely based on the results seen in naive animals, and 
the effects of diazepam (in addition to any differences between strains) were still 
apparent at the higher dose. 
In conclusion, naive DA rats display significantly higher anxiety-like behaviour than SD 
rats, which was seen to be consistent across the different behavioural paradigms 
employed in the current study. These differences were attenuated by acute handling and 
vehicle injection, which made it difficult to accurately assess any anxiolytic effect of 
diazepam in OA rats on the elevated plus-maze. This indicates that OA rats may be 
unsuitable for testing the effects of putative anxiolytic or anxiogenic compounds. 
However, although the magnitude of responses of naive DA rats were markedly 
different from SO rats, anxiety-related and locomotor behaviours were qualitatively 
similar, indicating that DA rats are suitable for investigating the longer-term effects of 
MDMA administration using these behavioural paradigms. 
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BERA VIOURAL TESTING II: 
A study of the effects of MDMA administration on the 
long-term behaviour of Dark Agouti rats in the elevated 
plus-maze and open field 
4.1 INTRODUCTION 
Alterations in serotonergic activity induced by neurotoxins such as 5,7-DHT or PCPA 
result in reduced anxiety-like behaviour in the elevated plus-maze (Briley et ai., 1990; 
Hall et al., 1999), punished responding tests (Tye et aI., 1977; 1979) and social 
interaction tests (File & Hyde, 1977) (see section 3.1.6). Therefore, the depletion of 5-
HT which results from MDMA administration to rats (e.g. Colado et aI., 1993; 
Commins et aI., 1987; O'Hearn et al., 1988; Schmidt, 1987a) might be expected to have 
a similar effect. 
The majority of animal studies investigating the behavioural effects of MDMA have 
focused on the acute phase of action of the drug, which involves both increased 
locomotor behaviour, characteristic of dopaminergic stimulation (see Callaway el at., 
1990; Dafters, 1994; Kehne et al., 1996a; McCreary et aI., 1999; McNamara et aI., 
1995; O'Loinsigh et aI., 2001), and a behavioural syndrome, characteristic of 
serotonergic activation (see Colado et al., 1993; De Souza et al., 1997; Marston et aI., 
1999; Shankaran & Gudelsky, 1999; Slikker Jr. et al., 1989; Spanos & Yamamoto, 
1989). The current chapter is concerned with the longer-term effects of a single dose of 
MDMA on behaviour, as measured in two commonly used animal models of "anxiety": 
the elevated plus-maze and open-field. The effects of MDMA and other amphetamine-
derived compounds on the acute and long-term responses of rats and mice in both 
behavioural paradigms are discussed in the current chapter, while utilisation of the plus-
maze and open-field as behavioural models has been discussed in Chapter 3. 
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Behavioural Testing II 
Effects of amphetamine derivatives on behaviour on the elevated 
plus-maze 
Acute effects 
Lin et ai. (1999) compared the responses of male Quackenbush Swiss mice on the 
elevated plus-maze following acute MDMA and D-amphetamine administration (30 min 
prior to testing). MDMA induced dose-dependent effects on anxiety-related behaviour, 
being anxiogenic at lower doses and anxiolytic at higher doses. At a dose of 1 mg/kg, 
there was no effect on the % time spent on the open arms, % number of open arm 
entries or enclosed arm entries; at 4 mg/kg, the % number of open arm entries was 
significantly decreased while numbers of enclosed arm entries increased, the latter 
indicating a hyperactive effect; at 12 mg/kg, no significant differences were seen in any 
of the behavioural measures; at 20 mg/kg, a significant increase in the % time spent on 
the open arms was observed. These responses were in contrast to the effects of 
amphetamine, which induced a dose-dependent anxiogenic effect, shown by a decrease 
in the % time spent on the open arms (Lin et aI., 1999). 
Morley & McGregor (2000) tested male Wistar rats on the elevated plus-maze 25 min 
after administration of MDMA (1.25, 2.5 or 5 mg/kg) and demonstrated a dose-related 
decrease in the time spent on the open arms and the total number of arm entries. 
Although these results indicated an anxiogenic effect, the authors suggested that 
changes in locomotor behaviour could have some bearing on the changes seen in 
anxiety-like behaviour (Morley & McGregor, 2000). Furthermore, subjects were tested 
on the elevated plus-maze immediately after an emergence test (rats were placed in a 
black box in the corner of an open field and the latency to emerge and open field 
activity were measured), which may have affected anxiety-related behaviour on the 
plus-maze. 
4.1.1.2 Longer-term effects 
Olausson et al. (2000) administered amphetamine (1 mglkg s. c.) to male SO rats, daily 
for 15 days. One group of rats were also chronically administered citalopram (5 mg/kg 
s.c., 60 min prior to each amphetamine dose, daily for 15 days). Behaviour on the 
elevated plus-maze was monitored for a 5 min test period on Day 17. Chronic 
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amphetamine treatment resulted in a significant increase in the % time spent on the open 
arms of the plus-maze compared to both control rats and acutely treated animals (those 
which were tested 35 - 40 min after a single 1 mglkg dose of amphetamine). While the 
% number of open arm entries and total number of arm entries were also significantly 
increased in chronically-treated animals compared to control animals, there was no 
difference between chronic and acute amphetamine treatment with regard to these 
measures. Chronic citalopram pretreatment significantly attenuated the amphetamine-
induced increase in % time spent on the open arms, but had no effect on the % number 
of open arm entries. Acute administration of 5-hydroxytryptophan + benserazide 
( decarboxylase inhibitor) to chronic amphetamine-treated animals abolished the 
amphetamine-induced increases in % time spent on the open arms, % number of open 
arm entries and total arm entries on the plus-maze. The authors concluded that repeated 
amphetamine treatment had a disinhibitory effect on elevated plus-maze behaviour 
(shown by increasing the % time spent on the open arms). The attenuating effects of 
citalopram and 5-hydroxytryptophan were thought likely to involve increased 
serotonergic neurotransmission, which indicated 5-HT -, rather than dopamine-, 
mediated effects of amphetamine with regard to this behavioural model (Olausson el aI., 
2000). 
In contrast, Cancela et al. (2001) demonstrated an anxiogenic effect of chronic 
amphetamine treatment. Male Wistar rats were tested on the elevated plus-maze four 
days after the cessation of treatment, which comprised daily injections (2 mg/kg) for 
nine consecutive days. Amphetamine-treated rats spent a significantly smaller % time 
on the open arms, an effect which was abolished by pretreatment with either the non-
selective dopamine antagonist haloperidol, or the selective dopamine D\ receptor 
antagonist SCH 23390. These results indicated that dopamine D\ receptors play an 
important role in the chronic amphetamine-induced changes in behaviour, measured on 
the elevated plus-maze (Cancela et ai., 2001). However, since neither Olausson et al. 
(2000) nor Cancela et al. (2001) reported analysis of brain monoamine concentrations, 
it cannot be determined whether the observed behavioural changes were due to 
neurotoxic effects of chronic amphetamine treatment, or simply effects of chronic 
dosing. 
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4.1.2 Effects of amphetamine derivatives on behaviour in the open field 
4.1.2.1 Acute effects 
McCreary et al. (1999) investigated the behaviour of male SD rats in an open-
field/activity meter apparatus, comprising a 40 cm3 arena with two rows of infrared 
beams located 4 and 16 cm above the base of the apparatus. General locomotor activity, 
central activity (movement within the inner 16 cm2 area) and rearing activity, were 
assessed by monitoring the numbers of lower and upper level infra-red beam breaks 
during each test period. MDMA (3 mglkg s.c.) was administered immediately prior to 
testing which consisted of 5 min test periods for a total of 90 min. MDMA induced a 
hyperactivity response, shown by increased activity in both the peripheral and central 
areas of the apparatus, while rearing activity was not consistently altered. Pretreatment 
with the 5-HTIB/lD receptor antagonist GR 127935 blocked the MDMA-induced 
hyperactivity, while the 5-HT lA antagonist WAY 100635 had no effect on the 
hyperactivity response (McCreary et aI., 1999). GR 127935 has been shown to block 5-
HT -mediated dopamine efflux in the rat prefrontal cortex (Iyer & Bradberry, 1996), and 
therefore may have blocked MDMA-induced hyperactivity by preventing 5-HTIIJ/1D 
mediation of dopamine efflux (McCreary et aI., 1999). 
O'Loinsigh et al. (2001) tested the acute behavioural effects of MDMA, MDEA and 
MDBA on male Wistar rats, which had been acclimatised to the open field apparatus for 
two days (5 min exposure per day) prior to drug treatment. Rats were administered the 
amphetamine twice daily for four consecutive days (20 mg/kg dose) and tested 30 min 
after the first injection on each day. MDMA administration resulted in a pronounced 
increase in locomotor activity on each of the four treatment days, compared to all other 
treatment groups. MDEA also induced a significant increase in locomotor activity, 
compared to control and MDBA groups, while MDBA had no effect on locomotion. 
MDMA and MDEA significantly reduced rearing behaviour and induced stereotypy, 
Straub tail and head weaving, while MDBA had no effect on any of these behaviours 
(O'Loinsigh et al., 2001). Morley & McGregor (2000) tested male Wistar rats in an 
open field (emergence) apparatus 20 min after administration of MDMA (1.25, 2.5 or 5 
mg!kg), and demonstrated a significant increase in the latency to emerge from the black 
box, a significant decrease in the amount of time spent in the open field and an increase 
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in defecation behaviour. These results indicated an anxiogenic effect of acute MDMA 
treatment and were consistent with the results seen in the elevated plus-maze (Morley & 
McGregor, 2000). 
4.1.2.2 Longer-term effects 
McCreary et ai. (1999) investigated the effect of chronic MDMA treatment (3 mglkg 
s.c. once per day for five consecutive days) on behaviour in the open-field/activity 
meter apparatus. A significant increase in central activity was observed in MDMA-
treated animals on Day 5 compared to Day 1, indicating a sensitisation of this type of 
behaviour, while there was little difference in peripheral activity between the two days. 
Although GR 127935 blocked both peripheral and central activity on Day 1, it had no 
effect on MDMA-induced hyperactivity within either region on Day 5. The authors 
suggested that either the 5-HT 18/lD receptor subtypes have a minimal role in the 
development of behavioural sensitisation to MDMA or, with repeated administration of 
MDMA, the balance between 5-HTl8/lD and dopaminergic systems shifts towards the 
latter (McCreary et ai., 1999). 
McNamara et al. (1995) investigated the behaviour of MDMA-treated male SO rats in 
the open-field and monitored their home-cage locomotor activity. The latter was 
monitored constantly for a total of eight days: (1) 24 h before drug treatment 
commenced; (2) four drug treatment days where rats were administered MDMA twice 
daily (5, 10 or 20 mglkg in each case); and (3) three drug-free days. Animals were 
tested in the open-field on the final day of the experimental period, being monitored for 
the total number of crossings performed within 3 min. Administration of the two higher 
doses of MDMA resulted in a significant increase in total locomotor activity during the 
dl ug-treatment period, while levels had returned to control values 24 hatter the last 
MDMA injection. There were no significant differences between MDMA-pretreated 
and control animals with regard to their behaviour in the open-field, three days after the 
last dose of "MDMA. These results indicate that MDMA-induced changes in locomotor 
activity are dose- and time-dependent, while any behavioural effects are not apparent 
after cessation of drug treatment (McNamara et a/., 1995). 
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4.1.3 Aims of the investigation 
There is little data available concerning the longer-term behavioural consequences of a 
neurotoxic dose of MDMA in rats, thus two simple models of anxiety-related behaviour 
were used for this purpose. The DA strain of rat has been used during the investigation 
of the effects of MDMA on rat body temperature and brain biochemistry (see Chapters 
5 and 6), thus the suitability of this strain for behavioural testing was first assessed by 
comparing the anxiety-related and locomotor behaviour of DA rats with the responses 
of SD rats (see Chapter 3). 
Once a behavioural baseline had been determined in DA rats, it was then possible to 
investigate the longer-term effects of MDMA administration on anxiety-related 
behaviour in this strain. Rats were administered a single neurotoxic dose of MDMA 
(12.5 mg/kg i.p.) or saline and their responses on the elevated plus-maze and in the 
open-field were assessed at three different time-points over a period of 80 days: (I) 
Days 8 - 11, one week after MDMA administration, at which time 5-HT content in rat 
brain is already markedly decreased (see Colado et al., 1995; O'Shea et aI., 1998), and 
therefore any behavioural consequences may be expected to begin to appear; (2) Days 
29 - 32, approximately one month after MDMA administration, which was believed to 
enable a suitable time period to elapse to prevent any habituation effects (see Chapter 
3); and (3) Days 71 - 73 (open-field) and Day 80 (plus-maze), approximately 11 weeks 
after MDMA administration, at which time neurodegenerative effects should still be 
present prior to the onset of serotonergic recovery, which has been demonstrated ] 6 
weeks after drug administration (Scanzello et aI., 1993). 
4.2 METHODS 
4.2.1 Animals and drug administration 
Adult male DA rats were housed as detailed in section 2.1 (2). MDMA was dissolved in 
0.9 % NaCI w/v and injected at a dose of 12.5 mg/kg i.p. on a single occasion. Rectal 
temperature was monitored for 3.5 h following drug administration to provide an 
indication of in vivo efficacy of the dose ofMDMA administered. 
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4.2.2 Behavioural assessment 
DA rats were administered MDMA (12.5 mg/kg i.p.) or saline (n = 8 in each group) and 
tested on the elevated plus-maze in randomised order on three separate occasions: Day 
8, Day 29 and Day 80. Animals were monitored for numbers of arm entries, time spent 
on open arms and several simple behaviours, as detailed in section 2.6.1. 
All rats were also tested in the open-field on three separate occasions, on three 
consecutive days in each case: Days 9 - 11, Days 30 - 32 and Days 71 - 73. The first 
two days of each testing period were performed under white-light illumination and the 
third day under red-light illumination. Animals were monitored for numbers of zone 
crossings and anxiety-related behaviours (see section 2.6.2). 
4.2.3 Statistics 
Data was analysed by two-way ANOV A with repeated measures, with TREATMENT 
(MDMA or saline) as the between subject factor and DAY (day of testing) as the 
repeated measure, followed by Bonferroni post-hoc tests where appropriate. 
4.3 RESULTS 
4.3.1 Acute rectal temperature response to MDMA administration 
MDMA administration resulted in an acute hyperthermic response, constituting a rapid 
rise in rectal temperature of l.5 - 2°C, which reached a peak 40 - 60 min post-injection 
and was sustained for over 3.5 h (see Figure 5.1, Chapter 5). 
4.3.2 Long-term effects of MDMA on the behaviour of DA rats on the 
elevated plus-maze 
MDMA-pretreated rats demonstrated differences in their behaviour on the elevated 
plus-maze compared to saline-treated control rats, which became apparent at the later 
time-points. One week after a single MDMA or saline injection (Day 8), the treatment 
groups did not differ with respect to anxiety-related behaviours, shown by % number of 
open arm entries (Figure 4.1a) and % time spent on the open arms (Figure 4.1b). Three 
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weeks later (Day 29), there were still no statistically significant differences between 
treatment groups with respect to either of the anxiety-related behaviours, although 
MDMA-pretreated animals demonstrated a marginal increase in both measures 
compared to control animals. On Day 80, MDMA-pretreated animals performed a 48 % 
greater % number of open arm entries compared to control animals, although this did 
not reach statistical significance (Figure 4.1a). In addition, MDMA-pretreated rats spent 
a significantly greater % time on the open arms on Day 80 compared to saline-
pretreated rats (Figure 4.1 b), resulting in a main effect of TREATMENT, with post -hoc 
analysis highlighting the difference between treatment groups on Day 80 (p < 0.05). 
Both treatment groups performed a lower % number of open arm entries and spent a 
lower % time on the open arms on Day 29 compared to Days 8 and 80, resulting in a 
main effect of DAY with respect to % time spent on the open arms. No interaction 
effect was observed in either of the anxiety-related behaviours measured. 
With respect to locomotor activity, MDMA-pretreated rats performed greater numbers 
of both total (Figure 4 .1 c) and closed (Figure 4.1 d) arm entries, resulting in significant 
main effects of TREATMENT in both cases. In particular, post-hoc analysis 
demonstrated a statistically significant difference in the number of total arm entries 
between treatment groups on Day 80 (p < 0.05). Both treatment groups performed fewer 
total and closed arm entries on Day 29 compared to the other two test days, resulting in 
significant main effects of DAY, but no significant interactions. With regard to the 
ethological variables measured in the elevated plus-maze (Table 4.1), there were no 
differences between MDMA-pretreated and control animals, thus no main effects of 
TREATMENT were observed. However, several of the behaviours measured were 
performed to a greater or lesser extent on different test days, resulting in main effects of 
DAY. For example, both treatment groups defecated more on Day 29 compared to Days 
8 and 80 (p < 0.05), and both treatment groups performed greater numbers of head dips 
on Day 80 compared to the previous two test days (p < 0.001). Both groups performed 
greater numbers of stretched attend postures (p < 0.0001) and greater directed sniffing 
on Day 8 compared to the latter test days (p < 0.0001), while there were no differences 
between days with respect to both rearing behaviour and non-directed sniffing. 
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Figure 4.1 The behaviour of MDMA- and saline-pretreated DA rats on the 
elevated plus-maze. 
Rats were administered a single dose of MDMA (12.5 mg/kg i.p.) or saline on Day 1. 
Results shown as mean ± s.e.m., n = 8 in each group. (a) Open arm entries, calculated 
as a % of total arm entries. There was no difference between treatment groups or 
between days. (b) Time spent on the open arms, calculated as a % of time spent on all 
arms. MDMA-pretreated rats were different from control rats (F (1, 21) = 7.2, P < 0.05), 
with post-hoc analysis demonstrating a statistical difference on Day 80 (*p< 0.05). 
Responses differed across the test days (F (2, 21) = 5.3, P < 0.05). (c) Total arm entries. 
MDMA-pretreated rats were different from control rats (F (1, 21) = 9.2, P < 0.01) and 
post-hoc analysis demonstrated a significant difference between treatment groups on 
Day 80 (*p < 0.05). Responses differed across the test days (F (2, 21) = 15.2, P < 
0.0001). (d) Closed arm entries. MDMA-pretreated rats were different from control rats 
(F (1, 21) = 8.4, P < 0.01). Responses differed across the test days (F (2, 21) = 13.2, P < 
0.001). 
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Day 29 Day SO Two-way ANOVA 
Saline MDMA Saline MDMA Saline MDMA TREATMENT DAY Interaction 
Defecation 3.0 ± l.0 3.5 ±0.8 4.4 ± 0.8 5.6±0.9 2.6 ± l.2 2.4 ± l.1 F (1, 21) = 0.4 F (2, 21) = 3.8* F (2, 21) = 0.3 
Grooming 4.4 ± 0.8 2.6± 0.2 3.3 ± 0.5 4.3 ± 0.4 4.6 ± 0.6 4.8 ± 0.5 F (1, 21) = 0.3 F (2, 21) = 2.4 F (2, 21) = 3.91'1 
Head dips 3.1±0.7 4.5 ± l.4 2.9 ± 1.1 4.5 ± 1.5 6.6± 0.9 10.0 ± 1.7 F (1,21) = 3.3 F (2, 21) = 13.1*** F (2, 21) = 0.6 
Rearing 26.3 ± 1.6 29.1 ± 3.5 22.9±3.2 29.6±5.7 27.9±2.7 35.1±1.5 F (1, 21) = 4.0 F (2, 21) = 1.4 F (2, 21) = 0.3 
SAP 8.5 ± 0.9 10.0 ± 0.9 3.1 ± 0.9 3.4 ± l.0 3.4 ± 0.6 5.0 ± 0.5 F (1, 21) = 2.7 F (2, 21) = 33.2*** F (2, 21) = 0.5 
Sniffing 27.S ± 2.1 33.4 ± 2.5 16.9 ± 2.2 IS.6 ± 3.0 IS.5 ± 1.4 20.6 ± 1.3 F (I, 21) = 2.9 F (2, 21) = 23.4*** F (2, 21) = 0.6 (directed) 
Sniffmg 17.9±1.3 IS.4±0.S 19.5±2.5 17.9±2.S 19.3±l.S 2l.3±1.6 F (1, 21) = 0.0 F (2, 21) = 0.6 F (2, 21) = 0.4 (non-directed) 
Table 4.1 Ethological variables measured in MDMA- and saline-pretreated DA rats on the elevated plus-maze. 
Rats were administered a single dose ofMDMA (12.5 mglkg i.p.) or saline on Day 1. Results shown as mean ± s.e.m., n = S in each group. 
Responses were different on different days, where *p < 0.05 and ***p < 0.001; significant interaction between TREATMENT and DAY 
effects, where Ap < 0.05. 
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4.3.3 
Behal1ioural Testing lJ 
Long-term effects of MDMA on the behaviour of DA rats in the 
open-field 
Under white-light illumination (the first two days within each testing period), there were 
no differences between the behaviour of MDMA-pretreated and control animals with 
respect to anxiety-related behaviour (Zone 2 crossings, Figure 4.2a), locomotor 
behaviour (total zone crossings, Figure 4.2b), or ethological variables (Figure 4.3), thus 
no main effects of TREATMENT were observed. There were also no differences 
between days with respect to either Zone 2 or total numbers of crossings, thus no main 
effects of DAY were observed. Although the treatment groups did not differ with 
respect to ethological variables, there were observable differences between the test days 
in some of the behaviours monitored, resulting in main effects of DAY (Figure 4.3). For 
example, freezing behaviour increased in both treatment groups with each successive 
testing period, being approximately three times greater on Days 71 - 72 than on Days 9 
- 10 (p < 0.0001), while both groups performed less rearing behaviour on Day 71 
compared to all other white-light test days (p < 0.01). 
Under red-light illumination (the third day of each testing period), differences between 
treatment groups became more apparent at the latest time-point (Day 73). MDMA-
pretreated rats performed more Zone 2 crossings than control rats on both Day 32 and 
Day 73, although this effect was not statistically significant. Thus no main effect of 
TREATMENT was observed. MDMA-pretreated animals performed greater numbers of 
Zone 2 crossings on each successive test day compared to the previous test day, while 
there was very little difference in the response of control animals between test days 
(Figure 4.2c). However, this effect did not reach statistical significance, thus no main 
effect of DAY was seen. With respect to overall locomotor activity, indicated by total 
zone crossings (Figure 4.2d), MDMA-pretreated rats performed more crossings than 
control animals on each day, resulting in a main effect of TREATMENT, with post-hoc 
analysis highlighting the difference between groups on Day 73 (p < 0.05). MDMA-
pretreated animals also performed more total crossings on each successive test day 
compared to the previous test day, but this effect was non-significant, thus neither an 
effect ofDA Y nor an interaction were observed. 
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The behaviour of MDMA- and saline-pretreated DA rats in the 
open-field. 
Rats were administered a single dose of MDMA (12.5 mg/kg i.p.) or saline on Day 1. 
Results shown as mean ± s.e.m., n = 8 in each group. (a) Zone 2 crossings under white-
light illumination. There were no differences between treatment groups or between 
days. (b) Total number of zone crossings under white-light illumination. There were no 
differences between treatment groups or between days. (c) Zone 2 crossings under red-
light illumination. There were no differences between treatment groups or between 
days. (d) Total number of zone crossings under red-light illumination. MDMA-
pretreated rats were different from control rats (F (1, 21) = 11.1, P < 0.01) and post-hoc 
analysis demonstrated statistical significance on Day 73 (*p < 0.05). There was no 
difference between days. 
152 
72 
• 
Chapter 4 Behavioural Testing II 
c:::J saline 
6 (a) Defecation _MDMA 11 (b) Freezing 
10 
15 
"c::I 
~ 9 ... 8 
.£ .g 
... 
8- 8- 7 
til II> 
Q) Q) 6 .~ 3 .~ 5 
.... .... 
0 0 
... 
... 4 l! 2 l! 
~ ~ 3 Z 1 2 
1 
0 0 
9 10 30 31 71 72 9 10 30 31 71 
Day Day 
6 (c) Grooming 25 (d) Rearing 
] 5 "c::I 
S S 20 
... 
... 
.£ .g 
... 4 ~ 15 8-til 
S Q) .~ 3 .~ 
.... 
.... 
0 ~ 10 
.... l! 2 l! 
~ ~ 5 Zl 
0 0 
9 10 30 31 71 72 9 10 30 31 71 
Day Day 
Figure 4.3 Ethological variables measured in MDMA- and saline-pretreated 
DA rats in the open-field, under white-light illumination. 
Rats were administered a single dose ofMDMA (12.5 mg/kg i.p.) or saline on Day 1. 
Results shown as mean ± s.e.m., n = 8 in each group. (a) Defecation. There were no 
differences between treatment groups or between days. (b) Freezing. There were no 
differences between treatment groups. Responses differed across the test days (F (5, 42) 
= 17.9, P < 0.0001). (c) Grooming. There were no differences between treatment groups 
or between days. (d) Rearing. There were no differences between treatment groups. 
Responses differed across the test days (F (5,42) = 4.2, P < 0.01). 
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Da~ 11 Da~32 Da~73 Two-wa~ ANOVA 
Saline MDMA Saline MDMA Saline MDMA TREATMENT DAY Interaction 
Defecation 3.8 ±0.7 5.3 ±0.6 4.4 ± 1.0 5.1 ± 1. 7 4.0±0.7 1.9 ± 1.0 F (1, 21) = 0.0 F (2, 21) = 1.7 F (2,21) = 1.6 
Freezing 2.8 ±0.5 2.6 ± 0.5 7.0 ± 0.9 7.6 ± 1.0 6.8 ± 1.4 6.0 ±0.9 F(1,21)=0.1 F (2,21) = 12.4MA F (2, 21) = 0.3 
Grooming 3.8 ± 1.1 4.3 ± 0.5 4.6± 0.7 3.6± 0.5 4.6 ± 0.7 4.1±1.3 F (I, 21) = 0.2 F (2, 21) = 0.1 F (2, 21) = 0.5 
Rearing 9.6 ± 3.3 13.4 ± 3.5 14.0 ± 2.0 18.6 ± 3.7 12.9 ± 2.4 21.0 ± 1.9 F (1,21) = 5.7* F (2, 21) = 2.0 F (2, 21) = 0.3 
- --- --- -----
Table 4.2 Ethological variables measured in MDMA- and saline-pretreated DA rats in the open-field, under red-light 
illumination. 
Rats were administered a single dose ofMDMA (12.5 mglkg i.p.) or saline on Day 1. Results shown as mean ± s.e.m., n = 8 in each group. 
MDMA-pretreated group different from saline-pretreated group, where *p < 0.05~ responses were different on different days, where MAp < 
0.001. 
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Under red-light illumination, the majority of ethological variables did not differ 
between treatment groups on any of the test days (Table 4.2). The single exception was 
rearing behaviour, which was consistently greater in MDMA-pretreated rats compared 
to control animals and increased on each successive test day in the MDMA-pretreated 
group, resulting in a main effect of TREATMENT, but neither an effect of DA Y nor an 
interaction. Freezing behaviour differed across the test days; both treatment groups 
performed more freezing behaviour on Days 32 and 73 compared to Day 11 (p < 0.001). 
which resulted in a main effect of DAY. Defecation behaviour remained consistent 
between the three red-light test days in saline-pretreated rats, while MDMA-pretreated 
rats defecated less on Day 73 compared to Days 11 and 32, although this effect was not 
significant. There were no differences in grooming behaviour within either treatment 
group between the three red-light test days. 
4.4 DISCUSSION 
This study demonstrated that a single neurotoxic dose of MDMA (which results in an 
approximately 20 - 40 % regional brain depletion of 5-HT and 5-HlAA - see section 
5.3.3) has a long-term effect on anxiety-related and locomotor behaviour, as measured 
in the elevated plus-maze and open field. 
On Day 8, one week after administration of MDMA or saline, there was no difference 
between treatment groups with regard to anxiety-related behaviours (% number of open 
arm entries and % time spent on the open arms). On Day 29, four weeks post-
administration, there was no statistically significant difference between the treatment 
groups with regard to either of these measures. On Day 80, approximately 11 weeks 
after drug administration, MDMA-pretreated rats performed a greater, although non-
statistically significant, % number of open arm entries compared to control animals. At 
this time-point, MDMA-pretreated rats spent a significantly greater % time on the open 
arms compared to control animals, the mean value being 177 % greater. Since the open 
arms of the elevated plus-maze are believed to evoke a "fear" response (see 
Montgomery, 1955; Handley & Mithani, 1984), the increase in open arm activity 
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expressed by MDMA-pretreated rats strongly indicates that these animals were less 
"anxious" . 
On all three test days, the MDMA-pretreated group displayed higher locomotor activity, 
as shown by greater numbers of total and closed ann entries. These differences became 
most apparent on Day 80, with MDMA-pretreated animals performing a statistically 
significant 75 % greater number of total arm entries and a 53 % greater number of 
closed arm entries, compared to control animals. 
Both treatment groups demonstrated a decline in anxiety-related and locomotor 
behaviour on Day 29, compared to Days 8 and 80 which, with the exception of % 
number of open arm entries, resulted in statistically significant differences in responses 
between the different test days. Although the strain comparison study (see Chapter 3) 
did not demonstrate a significant habituation effect in naIve animals between their 
responses on Trial 2 and Trial 1, which were separated by 25 days, it seems likely that 
some habituation occurred in the current study. Here, both treatment groups differed in 
their behaviour in Trial 2 compared to Trial 1, which were separated by 21 days. There 
are two possible explanations for these observed differences: (1) the interval between 
trials is critical in determining whether or not habituation occurs, or (2) the single 
injection of saline seven days before Trial 1 has some bearing on the control group's 
behaviour. The first point seems an unlikely explanation for this result, as control 
animals tend not to demonstrate any differences in behaviour between trials (Pellow et 
aI., 1985; File et al., 1990). 
However, the second point requires further discussion. There were no clear differences 
between the responses of naive animals (Figure 3.2) and the saline-pretreated rats in the 
current study (Figure 4.1), with the exception of the % number of open arm entries _ 
saline-pretreated rats performed a greater % number of open arm entries on Day 8 (Trial 
1) compared to naive rats on Day 1 (23.8 ± 2.6 vs. 14.91 ± 4.5). However, there was no 
difference between naIve and saline-pretreated animals in Trial 1 with regard to the % 
time spent on the open arms or the numbers of total and closed arm entries. The effects 
of handling have been predominantly demonstrated in chronic studies, whereby rats are 
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handled and injected with water or saline daily for one or two weeks prior to being 
tested on the elevated plus-maze (Andrews & File, 1993; File et al., 1992). However, a 
single handling/injecting experience is sufficient to alter the response of DA rats, as 
reported in Chapter 3, where an i.p. saline injection 30 min prior to exposure to the 
elevated plus-maze abolished the significantly greater anxiety-like behaviour of naiVe 
DA rats, compared to naive SD rats. In the current study, all animals were injected one 
week prior to Trial 1, where little difference was seen between naive and saline-injected 
animals; differences only became apparent during Trial 2. Thus, in this case, perhaps 
there is some interaction between repeated testing and handling. Whatever the 
explanation for this phenomenon, control animals are obviously tested in parallel to 
drug-treated animals to enable a direct determination of the effects of the particular drug 
in question and any additional effects of repeated testing or handling should be 
consistent across the treatment groups. 
With regard to the ethological variables measured on the elevated plus-maze, there were 
no significant differences between treatment groups. There were, however, some 
differences between the responses observed on different test days. For example, both 
treatment groups defecated most during Trial 2 (Day 29) and least on Day 80. 
Defecation is reported to signify increased "anxiety" or "emotionality" (Hall, 1934b), 
thus the reduction in this behaviour on Day 80 demonstrates a reduction in "anxiety" at 
this time-point. Although this is consistent with the reduction in other anxiety-related 
behaviours shown by MDMA-pretreated animals, such as the % time spent on the open 
arms, it does not explain the lack of difference between treatment groups. With regard 
to this measure, there was little difference between the responses of naive DA rats (see 
Table 3.1) and either group in the current study (see Table 4.1). However, the numerical 
values involved were very low in all cases, which therefore makes significant effects of 
treatment difficult to detect. Both treatment groups performed increased numbers of 
head dips on Day 80, compared to Days 8 and 29. This behaviour is increased by 
anxiolytic drugs (Cruz et aI., 1994; Griebel et aI., 1997b), and therefore indicates 
reduced anxiety-like behaviour at the latest time-point. Both groups performed greater 
numbers of stretched attend postures and greater directed sniffing behaviour on Day 8 
compared to the latter two trials, again indicating reduced anxiety-related behaviour at 
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the later time-points, these behaviours being indicative of risk assessment (Cruz et aI., 
1994; Griebel et aI., 1997; Rodgers & Dalvi, 1997), which decreases in response to 
anxiolytic drugs (Griebel et al. 1997). 
In the open-field under white-light illumination, there were no significant differences 
between the responses of MDMA- and saline-pretreated DA rats, with regard to 
anxiety-related or locomotor behaviour. This may have been because a brightly lit 
environment tends to induce approach-avoidance conflict behaviour, whereby animals 
avoid open, brightly illuminated spaces (Schmitt & Hiernke, 1998a), resulting in high 
levels of "anxiety" in both treatment groups. Red-light illumination, however, 
uncovered some differences between the behaviour of MDMA- and saline-pretreated 
rats in the open-field. There was little difference between the numbers of Zone 2 or total 
crossings performed by saline-pretreated rats on the different red-light test days, while 
MDMA-pretreated animals performed successively greater numbers of Zone 2 and total 
crossings on each test day. This resulted in behavioural differences between the two 
treatment groups, the total number of crossings reaching statistical significance on Day 
73. It may be that red-light illumination provided a less anxiogenic environment, 
enabling some of the differences between the treatment groups to be unmasked, and is 
consistent with the results of Escorihuela et al. (1999) who demonstrated increased 
locomotor activity under "dark" (red-light illumination), compared to "light" 
(fluorescent lighting), conditions. 
However, there was little difference between the two treatment groups with regard to 
the ethological variables measured, with the exception of rearing behaviour, which 
increased with successive test days in the MDMA-pretreated group and was consistently 
higher than that of the control group. Rearing is reflective oflocomotor activity (Cruz et 
al., 1994; File, 1992; Rodgers & Dalvi, 1997), and therefore the significantly higher 
levels seen in MDMA-pretreated animals (particularly at the later time-points) are 
consistent with the increased numbers of crossings performed by this group. 
The majority of behavioural studies in MDMA-treated animals have been performed 
during the acute phase of action of the drug, which includes hyperactivity (Lin et aI., 
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1999; Marston et al., 1999; McCreary et al~, 1999) and a stereotyped behavioural 
syndrome (Marston et aI., 1999). However, the reduction in anxiety-related behaviour 
seen in the current study is generally consistent with reported data where, for example: 
(1) acute MDMA administration (at higher doses, at least) has an anxiolytic effect on 
the behaviour of mice on the elevated plus-maze (Lin et al., 1999); (2) chronic MDMA 
administration has an anxiolytic effect on the behaviour of rats in the open-field 
(McCreary et al., 1999); and (3) acute and chronic amphetamine treatment have 
anxiolytic effects on the behaviour of rats on the elevated plus-maze (Olausson et aI., 
2000). There are some exceptions, as McNamara et al. (1995) demonstrated no 
differences between the open-field behaviour of MDMA- and saline-treated rats three 
days after cessation of drug treatment. 
The importance of the current findings should be put into context with regard to the 
effects of MDMA administration on brain 5-HT and the possible functional 
consequences of these effects in experimental animals and human recreational MDMA 
users. MDMA has been demonstrated to induce significant, long-lasting damage to 
central serotonergic systems in the brains of a number of different species (see Chapter 
1). In rats, this damage is characterised by a selective degeneration of forebrain axon 
tenninals (e.g. Commins et al., 1987; O'Hearn et aI., 1988) and a decrease in 5-HT 
content (e.g. Colado et al., 1995; Schmidt, 1987a) and eH]paroxetine binding (e.g. 
Colado et aI., 1995). Since disruptions in serotonergic activity induced by 5,7-DHT 
(e.g. Briley et aI., 1990; Hall et aI., 1999; Tye et al., 1977) or PCPA (e.g. File & Hyde, 
1977; Tye et aI., 1979) result in a reduction in anxiety-related behaviour, it might be 
expected that MDMA-induced serotonergic damage would have similar anxiolytic 
effects. 
There is also evidence to suggest that human recreational users of MDMA exhibit 
serotonergic neurotoxicity, shown by a reduction in CSF 5-HIAA levels (McCann et aI., 
1994) and a decrease in brain 5-HT transporter binding activity (McCann et aI., 1998). 
Psychological problems associated with 'Ecstasy' use have also been reported. For 
example, Parrott et al. (2000) noted an increase in anxiety, hostility and obsessional and 
impulsive behaviour in heavy 'Ecstasy' users (individuals who had taken 'Ecstasy' on 
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more than 20 occasions). However, as is often the case with human studies concerning 
illicit drug use, it is difficult to separate the effects of MDMA from either the potential 
effects of other drugs being used concurrently, such as alcohol, tobacco, cannabis and 
other amphetamines, or from pre-existing psychological conditions (P arrott et aI., 
2000). McCann et al. (1999) subjected MDMA users (individuals who had taken 
'Ecstasy' on at least 25 occasions) to an m-CPP challenge whereby the mixed 5-HT 
agonist and 5-HT -releasing compound, which has been demonstrated to increase 
anxiety in healthy individuals, was administered on Day 4 of a five day in-patient 
programme. MDMA users were significantly less sensitive to the anxiogenic effects of 
m-CPP than control subjects, shown by a greatly reduced occurrence of an m-CPP-
induced panic attack. The authors suggested that this response was indicative of 
downregulation of postsynaptic 5-HT 2C receptors and that it may be a functional 
consequence of brain serotonergic neurotoxicity (McCann et al., 1999). Therefore, 
although the anxiogenic or anxiolytic effects of MDMA use in humans have not yet 
been clarified, alterations in 5-HT activity are likely to have functional, possibly 
behavioural, consequences. 
In conclusion, the effect of a single dose of MDMA (l2.S mg/kg i.p.), as used in the 
current study, has been demonstrated to induce a 20 - 40 % loss of 5-HT in all brain 
regions examined one week post-treatment (see section 5.3.3). Furthermore, this degree 
of serotonergic depletion has been shown to result in pronounced reductions in anxiety-
related behaviour. The fact that such behavioural changes did not become apparent until 
over two months after a single dose of MDMA, while significant serotonergic 
depletions have been observed one week post-treatment, indicates that the behavioural 
changes observed are not solely due to serotonergic neurotoxicity, but that adaptive 
changes are occurring within the brain. In addition, these data highlight the potential 
damage incurred by human recreational users of MDMA - with recent evidence of 
serotonergic depletion (Kish et aI., 2000) and reduced densities of 5-HT transporters 
(McCann et al., 1998; Ricaurte et al., 2000) in the brains of chronic MDMA users, the 
fact that a relatively modest loss has long-term behavioural consequences in animals, 
suggests that high and/or frequent use may not be necessary to have long-lasting 
behavioural consequences in humans. 
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CHAPTER 5 
TEMPERATURE I: 
A STUDY OF THE LONG-TERM EFFECTS OF MDMA 
ADMINISTRA TION ON THERMOREGULATION 
IN DARK AGOUTI RATS 
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TEMPERA TURE I: 
A study of the long-term effects of MDMA administration 
on thermoregulation in Dark Agouti rats 
5.1 INTRODUCTION 
The acute effects of MDMA administration on temperature in rodents have been 
described in Chapter 1. The current chapter is concerned with the longer-term effects of 
MDMA on thermoregulation in DA rats. In particular, the effects of thermoregulatory 
"challenges" have been investigated in addition to a study of potential MDMA-induced 
changes in 5-HT receptor function. 
5.1.1 Effects of MDMA administration on temperature: involvement of 
5-HT 
Long-term neurotoxic damage to brain serotonergic systems has been demonstrated to 
occur following administration of MDMA to rats (see Battaglia et al., 1987; 1988; 
1991; Colado et aI., 1995; 1997a; 1999a; Commins et al., 1987; Molliver et al, 1990; 
O'Hearn et al., 1988; O'Shea et aI., 1998; Schmidt, 1987a; Schmidt et al., 1987; Stone 
et al., 1986), and following recreational use by humans (see Kish et aI., 2000; McCann 
et aI., 1994; 1998; Semple et aI., 1999). In addition, acute hyperthermia results from 
MDMA administration to rats (e.g. Broening et aI., 1995; Colado et aI., 1993; Dafters, 
1994; 1995; Nash et al., 1988; O'Shea et al., 1998) and has been reported in human 
recreational users of MDMA, where temperatures of over 43°C have been documented 
(e.g. Chadwick et aI., 1991; Randall, 1992; Screaton et al., 1992). However, it should be 
noted that, in rats, ambient temperature plays an important role in MDMA-induced 
changes in body temperature - low ambient temperatures tend to induce hypothermic 
responses, while higher ambient temperatures induce hyperthermic responses (see 
Broening et al., 1995; Dafters, 1994; 1995; Dafters & Lynch, 1998; Gordon et aI., 1991; 
Schmidt et aI., 1990a). 
Since 5-HT is believed to be involved in temperature regulation (see Kruk & Pycock, 
1991; Lucki, 1998; Milton, 1977; Myers, 1981; Rang et aI., 1995), MDMA-induced 
damage to serotonergic nerve endings might be expected to alter thermoregulatory 
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responses. Such changes could be potentially hannful to human recreational users of 
MDMA, particularly since MDMA is usually ingested in hot, crowded environments 
(see Green et aI., 1995; Henry et aI., 1992), which may further potentiate a 
hyperthermic response (see Henry et ai., 1992). 
Salmi & Ahlenius (1998) investigated the involvement of 5-HT lA and 5-HT 2N2C 
receptors in thermoregulation in male SD rats. Administration of 1-(2,5-dimethoxY-4-
iodophenyl)-2-aminopropane (DOl; 0.025 - 1.6 mglkg s.c.) resulted in a dose-dependent 
hyperthermic response 20 min after injection, the maximal increase in rectal 
temperature being l.1 °C following a dose of 0.4 mglkg. Pretreatment with either 8-
hydroxy-2-(di-n-propylamino)tetralin (8-0H-DPAT; 0.05 mg/kg s.c.) or ritanserin (1 
mglkg s.c.) abolished the DOl-induced hyperthermia. Pretreatment with either of the 5-
HT lA receptor antagonists pindolol (0.5 - 1 mglkg s.c.) or N-[2-[ 4-(2-methoxyphenyl)-
1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide 3HCI (WAY 100,635; 
0.1 - 0.4 mglkg s.c.), potentiated DOl-induced hyperthermia. This effect was abolished 
by pretreatment with the 5-HT2A12C receptor antagonist ritanserin. The authors suggested 
that the potentiation of DOl-induced hyperthermia by WAY 100,635 could be due to 
the 5-HT lA antagonist enhancing the response induced by DOl at 5-HT 2N2C 
postsynaptic receptors. Furthermore, the DOIIW AY 100,635-induced hyperthermic 
response was fully blocked by the selective 5-HT 2A antagonist amperozide, indicating 
an important role for 5-HT2A receptors in rat thermoregulation (Salmi & Ahlenius, 
1998). 
Mazzola-Pomietto et al. (1995) demonstrated that DOl administration (1 mg/kg i.p.) to 
male Wistar rats resulted in a hyperthermic response (approximately 1.5 °C), which 
peaked within 1 h of drug administration. Pretreatment with the 5-HT antagonists 
metergoline, mesulergine, mianserin, ketanserin, LY53857, ritanserin or spiperone 
significantly attenuated the DOl-induced hyperthermic response. Mesulergine, 
mianserin, ketanserin, L Y53857 and ritanserin are reported to have higher affinity for 5-
HT 2A and 5-HT 2C receptors than other receptor subtypes. Spiperone is reported to have a 
higher affinity for 5-HT 2A receptors, compared to 5-HT 2C receptors, thus its blockade of 
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DOl-induced hyperthermia indicated the importance of 5-HT2A receptors in mediation 
of this hyperthermic response (Mazzola-Pomietto et aI., 1995). 
Mazzola-Pomietto et al. (1996) administered 1-(3-chlorophenyl)piperazine (m-CPP; 2.5 
mglkg i.p.) to male Wistar rats and demonstrated a hyperthermic response 
(approximately 1°C), which peaked within 30 min of injection. Pretreatment with 
metergoline, mesulergine, mianserin, ketanserin, LY53857 or ritanserin significantly 
attenuated the m-CPP-induced hyperthermic response (Mazzola-Pomietto et al., 1996). 
While rats did not become sensitised to the hyperthermic effects of 001, within 17 
consecutive days of drug administration (Mazzola-Pomietto et al., 1995), tolerance to 
the hyperthermic effects ofm-CPP developed within five days (Mazzola-Pomietto et aI., 
1996). In addition, m-CPP-treated rats were not cross-tolerant to DOl; after five 
consecutive days of m-CPP treatment hyperthermia no longer occurred, yet a single 
challenge dose of DOl induced a hyperthermic response. These results indicated that m-
CPP and DOl-induced hyperthermia are mediated by different 5-HT receptors and, 
since both compounds have antagonistic actions at 5-HT 2A and 5-HT 2C receptors, while 
DOl-induced hyperthermia is believed to be mediated by 5-HT 2A receptors, the authors 
suggested that m-CPP-induced hyperthermia is mediated by 5-HT 2C receptors (Mazzola-
Pomietto et al., 1996). 
5.1.2 Aims of the investigation 
Several reported studies have suggested that administration of neurotoxic doses of 
.MDMA results in long-term functional changes in thermoregulation and 5-HT receptor 
activity (see below). Thus, the current study was undertaken as a further investigation 
into both of these areas. In each case, .MDMA was administered to male DA rats at a 
neurotoxic dose of 12.5 mglkg i.p. 
5.1.2.1 "Thermoregulatory challenges" 
Dafters & Lynch (1998) investigated the effects of a "thermoregulatory challenge" on 
the body temperature of rats administered .MDMA (10 mglkg s.c., daily for four 
consecutive days), under ambient temperature (Ta) conditions of 22 or 28°C. Animals 
were exposed to a high T a environment (30°C) for 1 h ("thermoregulatory challenge") 
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on three separate occasions: (1) one week prior to MDMA treatment, (2) four weeks 
post-treatment, and (3) 14 weeks post-treatment. On the pre-drug test day, body 
temperature increased by approximately 2 °e, reaching a maximum within 60 min after 
commencement of the "thermoregulatory challenge", and returning to pre-challenge 
values 50 min later (110 min after the start of the challenge). Four weeks after drug 
administration, body temperature increased by approximately 1.5 °e, being maximal 
within 40 min after the start of the challenge, and returning to pre-challenge values a 
further 120 min later. Fourteen weeks post-treatment, body temperature increased by 
approximately 1.6 oe, within 30 min of the beginning of the challenge, and returned to 
pre-challenge values 180 min later. Thus, the hyperthermic response induced by 
exposure to a high Ta was prolonged after administration of MDMA; 14 weeks post-
treatment, this response lasted for over 1.5 h after the end of the 60 min challenge. The 
authors concluded that such a response to an environmental challenge indicated 
relatively permanent changes in the neural mechanisms involved in thermoregulation, 
and that these changes might be indicative of serotonergic neurotoxicity (Dafters & 
Lynch, 1998). 
There were some difficulties in interpreting the data of Dafters & Lynch (1998), in 
particular: (1) a parallel vehicle-treated control group was not used; the same animals 
were used in the "thermoregulatory challenge" prior to and following MDMA 
administration. This meant that, instead of being able to directly compare the 
temperature responses of MDMA-treated with control animals during each test, the 
responses were compared to those recorded at the same time during the previous test, 
which resulted in a somewhat confusing presentation of data; (2) although MDMA was 
administered at 14:00 h on each treatment day (a time which was chosen to minimise 
any effects of the diurnal temperature cycle - see Dafters, 1994), the thermoregulatory 
challenges were performed at different times of the day on each occasion; the pre-drug 
challenge commenced at 13 :00 h, the four week post-drug challenge commenced at 
10:00 h, and the 14 week post-drug challenge commenced at 09:30 h. Thus any 
potential effects of diurnal rhythms on thermoregulatory mechanisms were not 
accounted for in this part of the study; (3) the authors suggested that the observed 
impairments in thermoregulation were a manifestation of serotonergic neurotoxicity, yet 
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did not assess brain concentration of 5-HT in the animals. Therefore, any relationship 
between the extent of serotonergic damage and the long-term effects of MDMA 
administration on thermoregulation could not be determined. 
The current study repeated the work of Dafters & Lynch (1998), to some extent, and 
comprised: (1) administration of a single dose of MDMA, (2) two "thermoregulatory 
challenges", involving exposure of the animals to a high (30 ± 0.5 °C) or a low (10 ± 
0.5 °C) Ta environment for 60 min, five to six weeks post-treatment, and (3) h.p.I.c. 
analysis of regional brain concentrations of 5-HT and 5-IDAA. In addition, 
conventional rectal temperature measurement was performed, rather than the 
biotelemetric temperature measuring devices used by Dafters & Lynch (1998). 
5.1.2.2 Effects of MDMA pretreatment on MDMA-induced hyperthermia 
Shankaran & Gudelsky (1999) treated male SD rats with a neurotoxic regimen of 
MDMA (10 mglkg i.p., four times at 2 h intervals), and injected a further single dose of 
MDMA (7.5, 10 or 20 mglkg) one week later. A dose-dependent hyperthennic response 
was observed in both MDMA- and vehicle-pretreated animals; the increase in body 
temperature following a single dose of MDMA to vehicle-pretreated rats ranged from 
1.2 °C (7.5 mglkg) to 2.2 °C (20 mg/kg). Following injection of all three doses of 
MDMA, the hyperthermic response seen in MDMA-pretreated animals was less than 
that seen in vehicle-pretreated rats. This effect was statistically significant following 
MDMA doses of 7.5 and 10 mg/kg, where the :MDMA-induced hyperthermic responses 
in MDMA-pretreated rats were approximately 58 % and 35 %, respectively, less than 
the responses seen in vehicle-pretreated rats. The authors suggested that the attenuated 
hyperthermic responses to low doses of MDMA in rats previously treated with a 
neurotoxic regimen of:MDMA, might indicate attenuation of stimulated 5-HT release. 
Administration of a higher dose of :MDMA (20 mglkg) , however, might evoke the 
release of 5-HT to stimulate sufficient 5-HT2 receptors, and thus produce a maximal 
hyperthermia. The authors also suggested that the diminished MDMA-induced 
hyperthermic response to a subsequent dose of MDMA, might reflect an up-regulation 
of 5-HT1A receptors (stimulation of which can induce hypothermia), thus antagonising a 
5-HT2 receptor-mediated hyperthermic response. Furthermore, it was suggested that 
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. MDMA-induced depletion of 5-HT might result in functional deficits in serotonergic 
neurotransmission (Shankaran & Gudelsky, 1999). 
The current study involved administration of a single neurotoxic dose of MDMA or 
saline, followed by second and third doses ofMDMA (12.5 mg/kg i.p.) administered to 
all rats, approximately three weeks and five weeks after the first dose, respectively. 
5.1.2.3 5-HT lA receptor function 
Aguirre et al. (1998) demonstrated a significant Increase In postsynaptic 5-HT I A 
receptor density in the frontal cortex and hypothalamus, and a significant decrease in 
regional brain 5-HT content, of male Wistar rats one week after administration of 
MDMA (30 mg/kg i.p.). As shown by Goodwin et al. (1987), administration of 8-
hydroxy-2-(di-n-propylamino)tetralin (8-0H-DPAT; 1 mglkg s.c.) resulted in a 
hypothermic response of approximately 1.75 °C in control animals. This effect was 
potentiated in animals which had received MDMA (30 mg/kg i.p., twice each day for 
four consecutive days) seven days earlier; MDMA-treated animals demonstrated a drop 
in temperature of approximately 2.75 0c. Pretreatment with fluoxetine, ketanserin or 
haloperidol prevented MDMA-induced loss of 5-HT content, and fluoxetine and 
ketanserin prevented MDMA-induced increases in 5-HT lA receptor density. None of the 
three pretreatment compounds modified 8-0H-DPAT-induced hypothermia. These 
results indicated that MDMA administration induced adaptive changes in postsynaptic 
5-HT lA receptors (Aguirre et aI., 1998). 
In contrast, McNamara et al. (1995) did not demonstrate any effect of MDMA 
pretreatment on 8-0H-DPAT-induced hypothermia. MDMA was administered to male 
SD rats (5, 10 or 20 mg/kg i.p., twice daily for four consecutive days) and, four days 
after the last MDMA injection, there was no significant difference in the rectal 
temperature of the treatment groups. On Day 8, administration of 8-0H-DPAT (0.15 
mg/kg s.c.) resulted in a hypothermic response, which comprised a drop in rectal 
temperature of approximately 3 °e, 30 min post-injection. None of the doses of 
MOMA had any significant effect on the magnitude of the 8-0H-DP AT-induced 
hypothermic response (McNamara et aI., 1995). 
167 
Chapter 5 Temperature I 
As conflicting results have previously been reported, the current study was performed 
and involved: (1) administration of a single dose of MDMA or saline, and (2) three to 
four weeks later, 8-0H-DPAT was administered (0.057, 0.09 and 0.11 mglkg s.c.) to all 
animals and their temperature response monitored. 
5.1.2.4 5-HTlA and 5-HTl c receptor function 
Administration of DOl (Mazzola-Pomietto et al., 1995; Salmi & Ahlenius, 1998) and 
m-CPP (Mazzola-Pomietto et al. 1996) have been demonstrated to induce acute 
hyperthermic responses, which were believed to be mediated by the 5-HT2A receptor 
and the 5-HT 2C receptor, respectively (Mazzola-Pomietto et al., 1995; 1996). Thus the 
current study comprised administration of both of these compounds to MDMA-nalve 
DA rats and monitoring of rectal temperature. It was planned that a subsequent study 
would involve investigation of DOI- and m-CPP-induced changes in rectal temperature, 
in MDMA-pretreated animals. 
5.2 METHODS 
5.2.1 Animals and drug administration 
Male DA rats were housed as detailed in section 2.1(1). MDMA was administered at a 
dose of 12.5 mglkg i.p. and 8-0H-DPAT was administered at doses of 0.057, 0.09 and 
0.11 mglkg s.c. 
5.2.2 Temperature and weight measurement 
Rectal temperature was measured, as detailed in section 2.7, at regular intervals during 
all experiments. In one group of rats, rectal temperature was also monitored every one 
or two days (at 10:00 - 11 :00 h) preceding and succeeding MDMA administration, in 
order to determine whether MDMA had any long-lasting effect on rectal temperature 
under 'normal' (20 ± 2°C) ambient temperature conditions. Weight was also monitored 
in the latter group of rats every one or two days, to determine whether MDMA had any 
effect on normal weight gain. 
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5.2.3 Acute temperature response to MDMA administration 
MDMA (12.5 mg/kg i.p.) or saline (n = 12 in each group) was administered to a group 
of rats at 10:00 - 11 :00 h. Rectal temperature was measured prior to injection and at 
regular intervals thereafter, for a total of3.5 h. 
5.2.4 Measurement of 5-HT and 5-HIAA in regional brain tissue 
A separate group of rats, administered MDMA (12.5 mglkg i.p.) or saline (n = 7 - 10 in 
each group) one week previously, were sacrificed and their brains dissected to provide 
cortical, hippocampal, striatal and hypothalamic tissue samples (see section 2.8 for 
details). 5-HT and 5-HIAA levels in these brain regions were subsequently measured 
using h.p.I.c. with electrochemical detection (see section 2.9 for details). 
5.2.5 Thermoregulatory challenges 
5.2.5.1 High ambient temperature 
Five to six weeks following administration of MDMA (12.5 mglkg i.p.) or saline, all 
animals (n = 12 in each treatment group) were subjected to a thermoregulatory 
challenge. Rectal temperature was recorded in a 'normal' ambient temperature 
environment (20 ± 2°C), 10 min and immediately prior to commencement of the 
challenge. The rats were then placed in a high ambient temperature environment (30 ± 
0.5 °C) for 60 min. Rectal temperature was monitored at regular intervals during the 
challenge and for a further 2.5 h when the animals had been returned to the 'normal' 
environment. 
5.2.5.2 Low ambient temperature 
MDMA-pretreated (12.5 mglkg i.p.) and control animals were also subjected to a low 
ambient temperature challenge (n = 6 in each group). Rectal temperature was again 
measured prior to, during, and after the challenge, which consisted of a 60 min exposure 
to a low ambient temperature environment (10 ± 0.5 °C). 
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5.2.6 
Temperature I 
Effect of pretreatment with MDMA on the hyperthermic response of 
rats to subsequent doses of MDMA 
A separate group of rats were administered MDMA (12.5 mg/kg i.p) or saline (n = 5 - 6 
in each group) and their acute temperature response monitored. Approximately three 
weeks later, both groups were administered MDMA (12.5 mglkg i.p.) and their acute 
temperature response again measured. Approximately two weeks after the second dose, 
both groups were administered :MDMA (12.5 mg/kg i.p.) and their temperature 
monitored as before. 
5.2.7 Long-term effects of acute MDMA administration: 5-HTtA receptor 
function 
Three to four weeks following :MDMA administration (12.5 mg/kg i.p.), MDMA-
pretreated and control rats (n = 6 in each group) were administered the 5-HT lA receptor 
agonist 8-0H-DPAT (0.11 mglkg s.c.). Rectal temperature was recorded at regular 
intervals throughout the experiment. Two further doses of 8-0H-DPAT (0.057 and 
0.090 mg/kg s.c.) were administered to MDMA- and saline-pretreated rats (n = 6 in 
each group) and temperature was monitored. 
5.2.8 Acute temperature response to administration of 5-HTzA and 5-HTzc 
receptor agonists 
The 5-HT2A agonist (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOl; I - 2 
mg/kg Lp.) and the 5-HT2c agonist 1-(3-chlorophenyl)piperazine (m-CPP~ 1.5 - 10 
mglkg i.p.) were administered to a group of rats (n = 4) and rectal temperature was 
monitored prior to and following injection, for a total of 90 min. 
5.2.9 Statistics 
Two-way ANOV A with repeated measures was performed on all temperature data, with 
TREATMENT (MDMA or saline) as the between subjects factor and TIME (or DAY, 
for analysis of day-to-day temperature and weight data, or DOSE for analysis of 8-0H-
DPAT data) as the repeated measure. Indole concentrations were analysed by student's 
unpaired I-tests. 
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5.3 RESULTS 
5.3.1 Acute temperature response to MDMA administration 
Following administration of a single dose of MDMA (12.5 mglkg i.p.) rectal 
temperature was increased by approximately 1.5 - 2 °C compared to control animals, 
peaking at 60 min (Figure 5.1) and being sustained for over 3.5 h. This resulted in main 
effects of both TREATMENT and TIME and a significant interaction between these 
effects (F (7, 88) = 4.4, P < 0.001). 
5.3.2 Effects of MDMA administration on rectal temperature and body 
weight 
MDMA administration had no effect on day-to-day rectal temperature, as measured at 
the same time (10:00 - 11 :00 h) and same ambient temperature (20 ± 2°C) on each 
occasion (Figure 5.2a), therefore there was no main effect of TREATMENT. However, 
there were differences in temperature between days prior to treatment, within both 
treatment groups, thus a main effect of DAY was observed but no interaction. 
The two treatment groups did differ in their day-to-day weight gain (Figure S.2b), the 
saline treatment group being of greater weight both prior to and following the injection 
day. Both groups gained weight over the whole measurement period resulting in a main 
effect of DAY. Although the MDMA treatment group demonstrated a small drop in 
weight on the day after injection and both groups demonstrated a drop in weight on Day 
26 (Figures 5.2b and 5 .2c), there was no difference between the two treatment groups 
where weight was calculated as a % of pretreatment values (Figure 5.2c). 
5.3.3 Effects of MDMA administration on 5-HT and 5-HIAA levels in 
regional brain tissue 
MDMA administration resulted in a loss of both 5-HT and 5-IDAA in all brain regions 
examined one week post-treatment (Table 5.1). In particular, there were statistically 
significant reductions in 5-HT concentration of 41 % in the hypothalamus and 21 % in 
the striatum (p < 0.05). 
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Figure 5.1 Acute effect of MDMA administration on rectal temperature. 
Rats were administered MDMA (12.5 mglkg i.p.) or saline at t = 0 (denoted by arrow). 
Results shown as mean ± s.e.m., n = 12 in each group. MDMA-treated rats were 
different from control rats (F (1, 88) = 187, P < 0.0001) with post-hoc analysis showing 
statistical significance during the period t 20 - 210 (***p < 0.001). Rectal temperature 
changed over time (F (7, 88) = 24.7, P < 0.0001). 
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Figure 5.2 Rectal temperature and body weight of a group of rats, measured every 1 - 2 days preceding and succeeding MDMA 
administration. 
Results shown as mean ± s.e.m., n = 6 in each group. MDMA (12.5 mg/kg i.p.) or saline was administered on Day 17 (denoted by arrows). 
(a) Rectal temperature. There was no difference between treatment groups, prior to or following MDMNsaIine administration. There was 
a difference in temperature between days prior to injection (Days 1 - 17: F (4, 25) = 5.6, P < 0.01) (b) Body weight MDMA-treatment 
group was different from the control group both prior to (Days I -- 17: F (1, 35) = 6.9, *p < 0.05) and following (Days 18 -- 32: F (1,30) = 
23.2, ***p < 0.0001) injection. Body weight increased over the measurement period (Days 1 - 17: F (6,35) = 130.4, P < 0.0001; Days 18-
32: F (5,30) = 73.5, P < 0.0001). (c) Body weight 0/ animals on days/ollowing treatment, calculated as a % o/weight immediately prior 
to injection. There was no difference between treatment groups. 
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Indole concentration 
(ngLg tissue) 
Indole Saline MDMA % loss t p 
Hypothalamus 5-HT 310 ± 24 184 ± 33 41 2.9 0.01 * 
5-HIAA 348 ± 42 227 ± 44 35 1.9 0.08 
Hippocampus 5-HT 197 ± 29 133 ± 18 32 1.9 0.07 
5-HIAA 265 ± 27 219 ± 24 18 1.3 0.21 
Cortex 5-HT 242 ± 27 191 ± 32 21 1.2 0.26 
5-HIAA 215 ± 12 170 ± 18 21 2.0 0.06 
Striatum 5-HT 316 ± 20 250 ± 22 21 2.2 0.04* 
5-HIAA 407 ± 20 343 ± 24 16 2.0 0.06 
Table 5.1 Regional brain 5-HT and 5-HIAA levels measured 1 week after 
administration of MDMA. 
Rats were administered MDMA (12.5 mg/kg i.p.) or saline and were sacrificed I week 
later for measurement of 5-HT and 5-HIAA. Results shown as mean ± s.e.m., n = 7 -10 
in each group. MDMA-treated rats demonstrated a significant loss of 5-HT where *p < 
0.05. 
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5.3.4 Thermoregulatory challenges 
5.3.4.1 High ambient temperature 
Five to six weeks after MDMA administration, there was no difference between the 
rectal temperature of the MDMA-pretreated and control animals. When both groups 
were subjected to a high ambient temperature environment (30 ± 0.5 °C) for 60 min, the 
MDMA-pretreated group demonstrated a faster rise in rectal temperature than the 
control group (Figure 5.3), resulting in a main effect of TREATMENT. 
The rectal temperature of both MDMA- and saline-pretreated animals increased during 
the high ambient temperature challenge. A maximal change in temperature, compared to 
that at t = 0, was reached at t = 40 in the MDMA-pretreated animals (AT = 0.69 °C) and 
at t = 60 in the control group (AT = 0.77 °C). Thus there was a main effect of TIME but 
no interaction between TREATMENT and TIME. 
When the rats were returned to a 'normal' (20 ± 2°C) environment, the MDMA-
pretreated animals demonstrated a prolonged hyperthermic response compared to the 
control group, resulting in a main effect of TREATMENT. The rectal temperature of 
both groups decreased over time, thus a main effect of TIME was observed in addition 
to an interaction between the effects of TREATMENT and TIME (F (6,77) = 3.3, P < 
0.01). 
5.3.4.2 Low ambient temperature 
Prior to commencement of the low ambient temperature challenge (10 ± 0.5 °c for 60 
min) both MDMA- and saline-pretreated groups demonstrated an initial temperature 
rise of approximately 1 °c (Figure 5.4). 
Subsequently, both during and after the challenge, the rectal temperature of both groups 
steadily declined towards pre-challenge values, resulting in a main effect of TIME. The 
temperature of MDMA-pretreated animals remained higher than that of the control 
animals throughout the period to - 180, resulting in main effects of TREATMENT (Figure 
5.4). There was no interaction between the effects of TREATMENT and TIME. 
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Figure 5.3 Rectal temperature of a group of rats subjected to a high ambient 
temperature thermoregulatory challenge, 5 - 6 weeks following 
administration of MDMA. 
Rats were subjected to a high ambient temperature environment (30 ± 0.5 °C) for 60 
min, 5 - 6 weeks after administration of a single dose of MDMA (12.5 mg/kg i.p.) or 
saline. Results shown as mean ± s.e.m., n = 12 in each group. MDMA-pretreated rats 
were different from control rats both during the challenge (to-60: F (1, 44) = 8.8, P < 
0.01) and when the rats had been returned to a 'normal' (20 ± 2°C) environment (160-210: 
F (1, 77) = 72.2, P < 0.0001). Post-hoc analysis demonstrated a significant difference 
between treatment groups, where *p < 0.05 and ***p < 0.001. Rectal temperature 
changed over time (to - 60: F (3, 44) = 15.9, P < 0.0001; t60 _ 210: F (6, 77) = 7.8, P < 
0.0001). 
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Figure 5.4 Rectal temperature of a group of rats subjected to a low ambient 
temperature thermoregulatory challenge, 5 - 6 weeks following 
administration of MDMA. 
Rats were subjected to a low ambient temperature environment (10 ± 0.5 °C) for 60 
min, 5 - 6 weeks after administration of a single dose of MDMA (12.5 mglkg i.p.) or 
saline. Results shown as mean ± s.e.m., n = 6 in each group. MDMA-pretreated rats 
were different from control rats both during the challenge (to-60: F (1, 20) = 10.3, P < 
0.01) and when the rats had been returned to a 'normal' (20 ± 2 °C) environment (t60.180: 
F (1, 35) = 29.2, P < 0.0001). Post-hoc analysis demonstrated a significant difference 
between treatment groups, where *p < 0.05 and **p < 0.01. Rectal temperature changed 
overtime (t60-180: F (6,35) = 6.5, P < 0.001). 
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5.3.5 
Temperature I 
Effect of pretreatment with MDMA on the hyperthermic response of 
rats to subsequent doses of MDMA 
A group of rats that had been pretreated 23 days earlier with either MDMA (12.5 mg/kg 
i.p.) or saline were both injected with MDMA (12.5 mglkg i.p.). The resulting 
hyperthermic response was similar in both groups (Figure 5.5). Twelve days later, all 
rats were again challenged with MDMA (12.5 mg/kg i.p.), the resulting hyperthermic 
response being similar to that seen after the previous doses (Figure 5.5). There was no 
difference in the hyperthermic responses seen between the three different MDMA-
treated groups. 
5.3.6 Long-term effects of acute MDMA administration: 5-HT1A receptor 
function 
Administration of 8-0H-DPAT (0.11 mg/kg s.c.) induced an acute hypothermic 
response in both MDMA- and saline-pretreated animals, reaching a nadir at 25 min 
post-injection (Figure 5.6a) and resulting in a main effect of TIME. The rectal 
temperature of MDMA-pretreated animals remained marginally higher than that of the 
saline-pretreated animals throughout the experiment, resulting in a main effect of 
TREATMENT. There was no interaction between the effects of TREATMENT and 
TIME. 
A similar response was apparent at all three doses of 8-0H-DPAT investigated (Figure 
5.6b); there was no difference in the change in temperature at the nadir (.1T at 25 min) 
between MDMA- and saline-pretreated rats, thus no main effect of TREA TMENT was 
observed at this time-point. 
5.3.7 Acute temperature response to administration of 5-HT1A and 5-HTu ' 
receptor agonists 
Neither the 5-HT2A agonist DOr, nor the 5-HT2C agonist m-CPP had any significant 
hyperthermic effect on rectal temperature (Table 5.2). 
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Figure 5.5 Acute effect of MDMA administration (1, 2 or 3 doses) on rectal 
temperature. 
Rats were administered MDMA (12.5 mglkg i.p.) or saline (denoted by arrow) on 3 
separate occasions: Day 1, Day 24 and Day 36. Results shown as mean ± s.e.m., n = 5 -
6 in each group. There was no difference in the basal temperature of the groups. The 
first injection of MDMA produced a significant rise in rectal temperature compared to 
saline-treated control animals (F (1, 10) = 100.4, P < 0.001). A hyperthermic response 
was also evident after the second (F (1, 10) = 104.3, P < 0.001) and third (F (1, 9) == 
115.5, P < 0.001) MDMA injection. There was no difference in hyperthermic response 
between the 3 MDMA treatment groups. 
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Figure 5.6 Effect of 8-0H-DPAT on the rectal temperature of rats 3 - 4 weeks following administration of MDMA. 
Rats were administered 8-0H-DPAT (denoted by arrow) 3 - 4 weeks after administration of a single dose ofMDMA (12.5 mglkg i.p.) or 
saline. Results shown as mean ± s.e.m., n = 6 in each group. (a) Rectal temperature response following administration of 8-0H-DPAT 
(0.11 mglkg s.c.). MDMA-pretreated animals were different from control animals (F (1, 25) = 17.0, p < 0.001) and post-hoc analysis 
demonstrated a statistically significant difference at t = 0 min. Rectal temperature differed over time (F (4, 25) = 30.8, P < 0.0001). (b) 
Rectal temperature response follmving administration of 8-0H-DPAT (0.057, 0.090, 0.110 mg/kg s.c.). Results shown as change in 
temperature, 25 min post-injeclion. MDMA-pretreated animals were not different from control animals at any of the 3 doses of 8-0H-
DPAT. 
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Rectal teml2erature (OC) 
Drug Dose (mg/kg) t=Omin t = 60 min 
.1T 
DOl 1.0 39.4±0.1 38.4 ± 0.3 -1.0 
2.0 39.2 ± 0.1 38.7 ± 0.2 -0.5 
m-CPP 1.5 39.3 ± 0.2 39.2 ± 0.1 -0.1 
2.5 39.2 ± 0.1 38.9 ± 0.1 -0.3 
5.0 38.5 ± 0.5 3S.6 ± 0.1 +0.1 
10.0 39.3 ± 0.1 38.2 ± 0.2 -l.1 
Table 5.2 Acute effect of administration of DOl and m-CPP on rectal 
temperature. 
Rats were administered DOl (1 or 2 mg/kg i.p.) or m-CPP (1.5, 2.5, 5.0 or 10.0 mglkg 
i.p.). Results shown as mean ± s.e.m., n = 4 in each group. Change in temperature (AT) 
was calculated as the difference in rectal temperature between t = 0 and t = 60 min. 
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5.4 DISCUSSION 
This study has demonstrated that a single neurotoxic dose ofMDMA (12.5 mg/kg) can 
have longer-term effects on thermoregulation in rats, when exposed to a high ambient 
temperature "thermoregulatory challenge". In addition, three doses of MDMA 
administered several weeks apart resulted in a pronounced acute hyperthermic response 
on each occasion, even though regional brain concentrations of 5-HT were depleted by 
20 - 40 % one week after a single dose (12.5 mg/kg). 
In concurrence with previous studies (e.g. Breening et al., 1995~ Colado et al., 1993; 
Dafters, 1994~ 1995; Nash et al., 1988; O'Shea et al., 1998), an acute hyperthermic 
response was seen following MDMA administration. A single dose of MDMA (12.5 
mglkg i.p.) resulted in a rectal temperature rise of approximately 1.5 - 2°C, which 
peaked within 60 min of drug administration and was sustained for over 3.5 h. Rectal 
temperature had returned to control values within 24 h and there was no difference 
between MDMA- and saline-treated animals, with respect to this measure, over the 
subsequent two weeks. Overall, MDMA treatment did not have any significant effect on 
weight gain - although the MDMA treatment group was of lower weight than the 
control group throughout the measurement period, when post-treatment weight was 
calculated as a % of pretreatment values there was no difference between the treatment 
groups. However, a transient decrease in weight was observed in the MDMA treatment 
group on the day following drug administration, indicative of an anorexic effect, which 
is consistent with previous studies (see Colado et aI., 1997b). 
One week after administration of MDMA (12.5 mglkg i.p.), cortical, hippocampal, 
hypothalamic and striatal concentrations of 5-HT and 5-IDAA were analysed using 
h.p.1.c. The extent of 5-HT depletion ranged from 21 % in the cortex and striatum, to 32 
% and 41 % in the hippocampus and hypothalamus, respectively. 5-HIAA was also 
depleted in all four brain regions (16 - 35 %). The extent of damage to serotonergic 
systems seen in the current study, as indicated by depletion of 5-HT and its metabolite, 
is also in agreement with previous studies in rats (e.g. Aguirre et aI., 1998; Broening et 
ai., 1995; Colado et aI., 1993; 1995; 1997a~ 1998; Farfel & Seiden, 1995a; Malberg et 
aI., 1996; McNamara et aI., 1995; 0' Shea et al., 1998; Shankaran & Gudelsky, 1999) 
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and with reported serotonergic neurotoxicity in humans (e.g. Kish et aI., 2000; McCann 
et a/., 1998; Semple et a!., 1999). 
Five to six weeks after administration of a single dose of MDMA, there was no 
difference in the rectal temperature of MDMA- and saline-pretreated rats. However, 
when all animals were exposed to a high T a environment (30 ± 0.5 °C) for 60 min, the 
rectal temperature response of MDMA-pretreated rats was markedly different to that of 
saline-pretreated animals. Rats which had been administered MDMA several weeks 
earlier demonstrated a faster rise in rectal temperature during the "thennoreb'Ulatory 
challenge"; this group reached a peak hyperthermic response of approximately 0.7 °C, 
40 min after commencement of the challenge, which was significantly greater than the 
response of the saline-pretreated control group at this time-point. The rectal temperature 
of the control group increased steadily during the challenge, reached a maximal 
hyperthermic response of approximately 0.8 °C by the end of the challenge, and then 
declined steadily towards pre-challenge values. However, when MDMA-pretreated 
animals were returned to a 'normal' Ta environment (20 ± 0.5 °C), rectal temperature 
initially dropped by approximately 0.3 °C, being parallel to the saline-pretreated group 
during the period t60 _ 100. Subsequently, the rectal temperature of the MDMA-pretreated 
group rose again and remained approximately 0.5 °C above that of the control group for 
the remainder of the experiment. 
Thus, although MDMA administration had no effect on rectal temperature measured 
under 'normal' Ta conditions, when MDMA-pretreated animals were subjected to a high 
T a "thermoregulatory challenge" an apparent long-term defect in thermoregulation was 
observed; the hyperthermic response induced by exposure to a high T a environment was 
sustained for a significantly longer period of time, compared to control animals. These 
data are in agreement with those reported by Dafters & Lynch (1998), where MDMA 
administration resulted in sustained hyperthermic responses to "thermoregulatory 
challenges" four and 14 weeks post-treatment. It should be noted that rats were group-
housed in the current study, which might be expected to affect their thermoregulatory 
responses. The sustained hyperthermia observed in MDMA-treated rats could involve a 
behavioural response, whereby group-housed rats huddle together, rather than a 
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physiological response resulting from MDMA administration. However, animals were 
housed individually in the study performed by Dafters & Lynch (1998), indicating that 
the sustained hyperthermia was a genuine physiological response. Furthermore, the 
current study has demonstrated that such changes in thermoregulatory mechanisms have 
resulted from a 20 - 40 % depletion of regional brain 5-HT levels. 
In addition to the high Ta challenge, as reported above and by Dafters & Lynch (1998), 
a second "thermoregulatory challenge" was undertaken: animals were exposed to a low 
Ta environment (10 ± 0.5 °C) for 60 min. Prior to commencement of the challenge, 
there was no difference in the rectal temperatures of the MDMA- and saline-pretreated 
groups. However, between the first and second temperature measurements (t = -10 and t 
= 0 min, respectively), both groups demonstrated a temperature rise of approximately 1 
°C, which is likely to be a response to handling of the animals (see Eikelboom, 1986). 
Subsequently, both during and after the challenge, both groups demonstrated a steady 
decline in rectal temperature towards pre-challenge values. The temperature of the 
MDMA-pretreated group remained higher than that of the control group throughout the 
challenge (to _ 60) and post-challenge (t60 - 180) periods, reaching statistical significance at 
two time-points (t = 100 and t = 140 min). However, unlike the sustained hyperthermia 
seen after a high T a challenge, the pattern of response in this experiment was the same 
in both MDMA- and saline-pretreated animals. 
Therefore, in animals where a long-term defect in thermoregulation is indicated (as seen 
in the high Ta challenge experiment) perhaps heat-dissipating mechanisms, such as 
sweating and increasing blood flow to the tail, are compromised. In contrast, the 
response seen during the low T a challenge experiment indicates that heat-retaining 
mechanisms, such as piloerection, are unaffected. However, the lack of difference in 
temperature response between treatment groups when exposed to low T a could be due to 
the fact that animals were group-housed (three per cage). By huddling together, any heat 
loss would be minimised thus different results might be seen if animals were housed 
individually. Gordon et al. (1991) demonstrated that, during the acute hyperthermic 
response to MDMA, piloerection occurred and blood flow to the tail (as indicated by 
measurement of tail skin temperature) was not increased. These responses have been 
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observed during the work undertaken for this thesis and the lack of significant change in 
tail temperature following MDMA administration (see Chapter 6) is consistent with 
Gordon et al. (1991). Both piloerection and the lack of increase in blood flow to the tail 
would be likely to exacerbate hyperthermia by attenuating heat dissipation (Gordon et 
ai., 1991). Thus, it may be that MDMA administration compromises thermoregulatory 
mechanisms both acutely and when animals are exposed to an environment which 
"challenges" such mechanisms. 
When rats were administered three doses of MDMA, separated by two or three weeks, 
the acute hyperthermic response to each dose was the same as that seen following 
previous doses. Thus, it appears that up to 40 % depletion of 5-HT has no long-lasting 
effect on MDMA-induced acute hyperthermia. Shankaran & Gudelsky (1999) 
performed a similar study, whereby a neurotoxic MDMA treatment regimen (10 mglkg 
i.p., four times at 2 h intervals) resulted in a 45 % reduction of striatal 5-HT, one week 
later. These authors also demonstrated that, apart from after the highest dose employed 
(20 mg/kg), MDMA-induced hyperthermia was significantly attenuated in rats which 
had previously been administered MDMA. However, it is difficult to draw direct 
comparisons between the current study and the results of Shankaran & Gudelsky 
(1999), as the latter involved: (1) a different strain of rat (SD), (2) a multiple dose 
treatment regimen (10 mg/kg, four times at 2 h intervals), and (3) a one week interval 
between the initial administration of MDMA and a subsequent, single, "challenge" 
dose. As the extent of 5-HT depletion (one week post-treatment) was similar between 
the two studies, the differences in strain and treatment regimen appear to have no 
bearing on the observed differences in results. Also, the striatal depletion of 5-HT 
reported by Shankaran & Gudelsky (1999) one week post-treatment was similar to that 
reported by Scanzello et al. (1993) two- and eight- weeks post-treatment, where the 
strain and treatment regimen were identical. Therefore, there is no reason to suppose 
that the different interval between the first and second doses of MDMA in the current 
study (three weeks), compared to the Shankaran & Gudelsky (1999) study (one week), 
had any influence on the differences seen in acute hyperthermic responses to the second 
dose of MDMA. Since the highest "challenge" dose of MDMA (20 mglkg) used by 
Shankaran & Gudelsky (1999) did not significantly attenuate the MDMA-induced acute 
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hyperthermic response, while the two lower doses did, perhaps there is some threshold 
dose above which depletion of 5-HT does not affect the temperature response. The 20 _ 
40 % reduction in regional brain 5-HT concentrations observed in the current study, 
following a single dose of MDMA (12.5 mg/kg), may have been insufficient to 
significantly alter MDMA-induced hyperthermia; perhaps only a far more severe loss of 
5-HT (70 - 80 %) would have long-lasting functional consequences. 
Administration of 8-0H-DPAT three or four weeks after a single neurotoxic dose of 
MDMA (12.5 mg/kg) resulted in a hypothermic response, which paralleled that of 
saline-pretreated animals. Although the rectal temperature of the MDMA-pretreated rats 
was higher than that of saline-pretreated animals throughout the experiment, this 
difference only reached statistical significance at t = 0 (immediately prior to 8-0H-
DPAT administration). There was no difference in the maximal decrease in temperature 
(at t = 25 min) between MDMA- and saline-pretreated animals, following 
administration of any of the three doses of 8-0H-DPAT (0.057, 0.09 and 0.11 mglkg). 
These results are in agreement with McNamara et al. (I995) and indicate that MDMA 
administration has no long-lasting effect on 5-HT lA receptor function. 
However, both the current data and that of McNamara et al. (1995) are in contrast to 
Aguirre et al. (1998), who reported that MDMA pretreatment led to a potentiation of 8-
OH-DPAT-induced hypothermia. However, Aguirre et al. (1998) demonstrated no 
difference in the 8-0H-DP AT -induced hypothermic response between animals which 
had received eight doses of MDMA (30 mglkg i.p., twice daily on four consecutive 
days), and those which had been administered a single dose (30 mglkg i.p.). The extent 
of 5-HT depletion following a mUltiple dose treatment regimen (Aguirre et aI., 1998) 
was similar to that seen in the current study after a single dose of MDMA. Therefore it 
would be expected that, if the modification of the 8-0H-DPAT -induced hypothermia 
was due to 5-HT depletion, then the response in animals which had received a single 
dose would be different from that in animals administered multiple doses. One possible 
reason for the discrepancy in results, may be that the 8-0H-DPAT-induced hypothermic 
response of control animals (approximately -1.8 °C) reported by Aguirre et al. (1998) 
was actually smaller than that seen in other studies (-2.1 to -3°C: see Goodwin et a/., 
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1987; McNamara et af., 1995; current study). Thus, if 8-0H-DPAT administration had 
resulted in an acute hypothermia of at least -2°C, the effect of MDMA pretreatment 
reported by Aguirre et al. (1998) might not have been significant. 
Neither DOl nor m-CPP had any effect on rectal temperature at the range of doses used 
in the current study. This is in contrast to the acute hyperthennic responses reported by 
Mazzola-Pomietto et af. (1995; 1996) and Salmi & Ahlenius (1998). Therefore the 
proposed experiment, whereby MDMA-pretreated animals would have been 
"challenged" with DOl and m-CPP, was not performed. It may be that DA rats are more 
resistant to any effects of DO I and m-CPP, although this seems unlikely since the range 
of doses used far exceeded those employed by Mazzola-Pomietto et al. (1995; 1996) 
and Salmi & Ahlenius (1998). Since Kennett (personal communication) was also unable 
to demonstrate consistent temperature changes following administration of DOlor m-
CPP to SD or Wistar rats, it is possible that acute hyperthermic responses to DOlor m-
CPP are weak and require particular environmental conditions for their manifestation. 
In conclusion, the current study has clearly demonstrated that a single dose of MDMA 
can result in a 20 - 40 % depletion of regional brain 5-HT and 5-HlAA, one week post-
treatment. Since 5-HT is believed to play an important role in temperature regulation 
(see Kruk & Pycock, 1991; Lucki, 1998; Milton, 1977; Myers, 1981; Rang et aI., 1995), 
it seems that this degree of 5-HT depletion has long-term functional consequences; 
when rats were exposed to a "thermoregulatory challenge" a sustained hyperthermia 
was seen, indicating that heat-dissipating mechanisms might be compromised under 
high T a conditions. However, a 20 - 40 % loss of 5-HT was not sufficient to modiry 
acute hyperthermic responses to subsequent doses of MDMA. Since heat-dissipating 
mechanisms also appear to be compromised during an acute hyperthermic response to 
MDMA (see Gordon et aI., 1991; Mechan et al., 2001a), perhaps a far greater 5-HT 
depletion (70 - 80 %) would be required to have any significant effect on the different 
mechanisms involved in MDMA-induced acute hyperthermia. 
Serotonergic neurotoxicity has also been reported in human recreational users of 
MDMA, including significant reductions in brain 5-HT content and 5-HT transporter 
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activity (e.g. Kish et al., 2000; McCann et al., 1998; Semple et al., 1999). One of the 
major consequences of MDMA ingestion by humans is hyperthermia, with temperatures 
of over 43°C being reported (e.g. Chadwick et al., 1991; Randall, 1992; Screaton et aI., 
1992). This hyperthermic response is believed to be associated with the major adverse 
clinical effects of MDMA (see Green et al., 1995), such as disseminated intravascular 
coagulation and rhabdomyolysis (see Chadwick et al., 1991; Henry et aI., 1992; 
Screaton et aI., 1992). MDMA administration to rats under high Ta conditions tends to 
induce hyperthermia, while low Ta conditions tend to induce hypothermia (see Broening 
et al., 1995; Dafters, 1994; 1995; Dafters & Lynch, 1998; Gordon et aI., 1991). 
Therefore, hyperthermia is likely to occur in human MDMA users, since ingestion 
usually occurs in hot, crowded environments (see Green et ai., 1995; Henry et aI., 
1992), which may further potentiate the hyperthermic response (Henry et aI., 1992). 
If brain levels of 5-HT in human recreational users of MDMA are depleted by a similar 
extent to that seen in rats in the current study, there may be serious functional 
consequences. Continued use of MDMA under high T a conditions may significantly 
compromise thermoregulatory mechanisms, resulting in sustained hyperthermia and 
additional potentially life-threatening complications. 
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CHAPTER 6 
TEMPERATURE II: 
A STUDY OF THE ACUTE HYPERTHERMIC 
RESPONSE FOLLOWING MDMA ADMINISTRATION 
TO DARK AGOUTI RATS 
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TEMPERATURE II: 
A study of the acute hyperthermic response following 
MDMA administration to Dark Agouti rats 
6.1 INTRODUCTION 
MDMA administration to rodents and humans results in an acute hyperthermic response 
which has been well-documented (see Chapter 1~ Broening et al., 1995; Chadwick el 
al., 1991~ Colado et aI., 1993; Dafters, 1994~ 1995~ Nash et aI., 1988; O'Shea et aI., 
1998~ Randall, 1992~ Schmidt et al., 1990a; Screaton et al., 1992). However, the 
specific pharmacology of this response has not been clarified, thus the current chapter 
comprises an investigation of MDMA-induced acute hyperthermia in rats, through the 
use of a series of drugs which affect serotonergic or dopaminergic function. 
6.1.1 Acute hyperthermic response following MDMA administration: 
involvement of 5-HT 
Grahame-Smith (1971) demonstrated that administration of a monoamine oxidase 
(MAO) inhibitor (tranylcypromine (TCP)~ 20 mg/kg i.p.) 30 min prior to L-tryptophan 
(30 - 200 mglkg i.p.), resulted in a dose-dependent increase in 5-HT synthesis within the 
brain. Acute hyperactivity and hyperthermia were observed and peaked within 30 min 
and 60 min after L-tryptophan injection, respectively, and these responses were seen to 
positively correlate with the accumulation of brain 5-HT (Grahame-Smith, 1971). 
MDMA administration results in a substantial, acute release of 5-HT from serotonergic 
nerve endings (see Colado & Green, 1994; Crespi et al, 1997~ Johnson et aI., 1986; 
Koch & Galloway, 1997~ Meehan et aI., 2000~ Sabol & Seiden, 1998; Schmidt et aI., 
1987; Schmidt & Taylor, 1988; Shankaran & Gudelsky, 1999; Stene et aI., 1986; 
1987b), while the acute hyperthermic response, which also results from MDMA 
treatment, has been postulated to be a consequence of 5-HT release and the subsequent 
stimulation of 5-HT2 receptors (see Shankaran & Gudelsky, 1999). This suggestion is 
further supported by the fact that: (1) other 5-HT releasing drugs, such as p_ 
chloroamphetamine (PCA) and fenfluramine (see Berger et al., 1992; Crespi et aI., 
1997; Martin & Artigas, 1992), also produce hyperthermia (Colado et al., 1993; 
Pawlowski, 1981; Sugrue, 1984), and (2) 5-HT 2 receptor antagonists, such as ketanserin 
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; and MDL 11,939, block the MDMA-induced acute hyperthermic response (Malberg et 
aI., 1996; Nash et aI., 1988; Schmidt et aI., 1990a). 
6.1.2 Aims of the investigation: the use of drugs affecting 5-HT or 
dopamine function 
The current study was undertaken in an attempt to elucidate the mechanisms involved in 
MDMA-induced acute hyperthermia in rats, and a series of drugs which affect 5-HT or 
dopamine function were employed for this purpose (see below). Rectal temperature was 
closely monitored during each experiment, as it was important that each pretreatment 
compound under investigation did not induce hypothermia in control animals. (If 
hypothermia was seen in control rats, any effect on MDMA-induced hyperthermia 
could not then be easily attributed to MDMA-mediated events, but could be due to 
effects of the pretreatment compound alone). 
6.1.2.1 5-HT l /2 and 5-HT2 receptor antagonists 
• Methysergide, a non-selective 5-HT 112 receptor antagonist, which has been 
demonstrated to block fenfluramine-induced acute hyperthermia (Sugrue, 1984). 
• MDL 11,939, a 5-HT2 antagonist, which has previously been reported to 
competitively antagonise MDMA-induced hyperthermia in male SD rats: Schmidt e( 
al. (1990a) co-administered MDL 11,939 (5 mglkg s.c.) with MDMA (I 0, 20 and 30 
mglkg s.c.), and demonstrated a complete blockade of MDMA-induced 
hyperthermia at the lowest dose and significant attenuation at the two higher doses. 
MDL 11,939 also attenuated MDMA-induced reductions in brain 5-HT 
concentration, measured one week later (Schmidt et al., 1990a; 1990b; 1990c). 
• Ritanserin, a 5-HT 2 antagonist, which has been demonstrated to prevent the acute 
hyperthermia induced by co-administration of an MAO inhibitor (clorgyline) and 5-
hydroxy-L-tryptophan (5-HTP) (Nisijima et al., 2001), and to attenuate MDMA-
induced 5-HT depletion (Schmidt et al., 1990b). 
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6.1.2.2 5-HT2A and 5-HT2C receptor antagonists 
• MDL 100,907, a selective 5-HT2A antagonist, which has been shown to prevent 
MDMA-induced reductions in regional brain 5-HT concentrations and MDMA-
induced stimulation of striatal dopamine synthesis (Schmidt et ai., 1992) 
• SB 242084, a selective 5-HT 2C antagonist, which potently inhibits m-CPP-induced 
hypolocomotion, an in vivo model of central 5-HT2c receptor function (Kennett et 
aI., 1997). 
6.1.2.3 Serotonin reuptake inhibiton 
• Zimeldine, which has been reported to have no effect on fenfluramine-induced acute 
hyperthermia (Sugrue, 1984). 
• Fluoxetine, which has been demonstrated to significantly attenuate the 
synaptosomal release of eH]5-HT induced by MDMA, peA, fenfluramine and 
methamphetamine (Berger et aI., 1992) and to attenuate fenfluramine-induced 
hyperthermia (Sugrue, 1984). 
6.1.2.4 Dopamine Dl and D2 receptor antagonists 
• Remoxipride, a dopamine D2 receptor antagonist. 
• SCH 23390, a dopamine D1 antagonist, which has been reported to attenuate both 
methamphetamine-induced hyperthermia and synaptosomal eH]dopamine uptake 
(Metzger et aI., 2000). 
6.1.2.5 Dopamine reuptake inhibitors 
• GBR 12909, which has been demonstrated to significantly attenuate MDMA-
induced deficits in striatal 5-HT and 5-IDAA content and tryptophan hydroxylase 
(TPH) activity (Stone et aI., 1988), in addition to attenuating MDMA-induced 
increases in extracellular dopamine concentrations, as measured via in vivo 
micro dialysis (Nash & Brodkin, 1991). 
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6.2 METHODS 
6.2.1 Animals, drug administration and temperature measurement 
Male DA rats were housed as detailed in sections 2.1(1) and 2.1(3). All pretreatment 
compounds were injected 20 min prior to injection of MDMA (12.5 mglkg i.p.) or 
vehicle, with the exception of the fluoxetine experiment where fluoxetine was 
administered 5 min before and 55 min after administration ofMDMA (15 mg/kg i.p.) or 
vehicle. (Note that the latter experiment was undertaken by the research group of Dr 
M.I. Colado and, as such, the protocol employed was that in common use in their 
laboratory). 
All drugs were dissolved in normal saline and injected i.p. unless otherwise stated and 
doses are quoted as the base weight. Methysergide was dissolved in 20 % DMSD in 
normal saline. Ritanserin, MDL 100,907 and MDL 11,939 were dissolved in 2 % glacial 
acetic acid in deionised water. SB 242084 was dissolved in normal saline and citric acid 
(25 mM) containing a saturated solution of J3-cyclodextrin and 30 % polyethylene 
glycol. GBR 12909 was dissolved in peanut oil and administered s.c. in a volume of 2 
ml/kg. 
Rectal temperature was measured, as detailed in section 2.7, at regular intervals during 
all experiments. During one experiment, tail skin temperature was also measured by 
binding the temperature probe to the upper tail region with plastic tape. 
6.2.2 Statistics 
Statistical analysi8 of acute rectal and tail skin temperature data were performed using 
GraphPad Prism. Data were analysed by two-way ANDV A with repeated measures, 
with TREATMENT (MDMA or vehicle) as the between subjects factor and TIME as 
the repeated measure. 
Statistical analyses of the antagonist/uptake inhibitor pretreatment studies and 
micro dialysis experiments were performed using BMDP/386 Dynamic. Data were 
analysed by two-way ANOV A with repeated measures (programme 2V) or, where 
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missing values occurred, an unbalanced repeated measures model (programme 5V) was 
used. Both used TREATMENT as the between-subjects factor and TIME as the 
repeated measure. ANDV A was performed on both pre-treatment and post-treatment 
(starting immediately after MDMAlsaline injection) data. 
6.3 RESULTS 
6.3.1 Effect of MDMA administration on rectal and tail skin temperature 
MDMA administration (12.5 mg/kg i.p.) resulted in a rectal temperature rise of 
approximately + 1.2 °C compared to the control group, which reached a peak 40 min 
after injection and was sustained for over 3 h (Figure 6.1a). This resulted in a main 
effect of TREATMENT. Following the initial temperature rise, rectal temperature 
subsequently declined towards pretreatment values resulting in a main effect of TIME, 
but no interaction effect. 
Tail skin temperature was also measured immediately prior to, and at regular intervals 
after, administration of MDMA or saline (Figure 6.1b). The initial tail temperatures 
were: MDMA-treated group, 27.2 ± 1°C; control group: 25.5 ± 0.5 dc. Although the tail 
temperature of the MDMA-treated group was lower than that of the control group 
during the period t40 - 80 and at t = 180 min, overall there was no statistically significant 
difference between the two treatment groups. 
6.3.2 Effect of methysergide, MDL 11,939 and ritanserin on MDMA-
induced hyperthermia 
The non-~elective 5-HT1I2 receptor antagonist methysergide (10 mg/kg i.p.). did not 
modify the MDMA-induced hyperthermic response and had no effect on the rectal 
temperature of control animals (Figure 6.2). The 5-HT2 antagonist MDL 11,939 (5 
mg/kg i.p.) abolished the MDMA-induced hyperthermia (Figure 6.3) without altering 
the rectal temperature of control animals. However, the 5-HT2 antagonist ritanserin (1 
mg/kg i.p.) had no effect on the MDMA-induced acute hyperthermic response (Figure 
6.4) and did not alter the rectal temperature of control animals. 
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Figure 6.1 Acute effect of MDMA administration on rectal and tail skin temperature. 
Rats were administered MDMA (12.5 mglkg i.p.) or saline (denoted by arrows). Results shown as mean ± s.e.m., n = 3 - 4 in each group. 
(a) Rectal temperature. MDMA induced a significant rise in rectal temperature compared to saline-treated control animals (F (1, 21) = 
246.5, P < 0.0001) and post-hoc analysis demonstrated statistically significant differences throughout the period tzo _ 180 (***p < 0.001). 
Rectal temperature changed over time (F (6, 21) = 3.27, P < 0.05). (b) Tail skin temperature. There was no statistically significant 
difference between treatment groups. 
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Figure 6.2 Effect of methysergide on MDMA-induced acute hyperthermia. 
Rats were administered methysergide (10 mglkg i. p.) or vehicle (denoted by broken 
arrow) 20 min prior to injection with :MDMA (12.5 mg/kg i.p.) or saline (denoted by 
full arrow). Results shown as mean ± s.e.m., n = 4 - 5 in each group. There was no 
difference in the basal temperatures of the groups. :MDMA produced a significant rise in 
rectal temperature (F (1, 6) = 76.4, P < 0.001) compared to the vehicle-treated control 
group. Methysergide did not modify the :MDMA-induced hyperthermic response and 
had no effect on the temperature of control animals. 
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Figure 6.3 Effect ofMDL 11,939 on MDMA-induced acute hyperthermia. 
Rats were administered MDL 11,939 (5 mglkg i.p.) or vehicle (denoted by broken 
arrow) 20 min before administration ofMDMA (12.5 mg/kg i.p.) or saline (denoted by 
full arrow). Results shown as mean ± s.e.m., n = 4 - 5 in each group. There was no 
difference in the basal temperature of the groups. MDMA produced a significant rise in 
rectal temperature (F (1, 7) = 36.3, P < 0.001) compared to the vehicle-treated control 
group. 1\.1DL 11,939 abolished the MDMA-induced hyperthermia (F (1, 8) = 73.5, P < 
0.001) without altering the temperature of control rats. 
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Figure 6.4 Effect of ritanserin on MDMA-induced acute hyperthermia. 
Rats were administered ritanserin (1 mglkg i.p.) or vehicle (denoted by broken arrow) 
20 min before administration of MDMA (12.5 mglkg i.p.) or saline (denoted by full 
arrow). Results shown as mean ± s.e.m., n = 4 - 5 in each group. There was no 
difference in the basal temperature of the groups. MDMA produced a significant rise in 
rectal temperature (F (1, 7) = 21.0, p < 0.01) compared to the vehicle-treated control 
group. Ritanserin did not modify the MDMA-induced hyperthermia and had no effect 
on the rectal temperature of control animals. 
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6.3.3 
Temperature II 
Effect of selective 5-HT1A and 5-HTlC receptor antagonists on 
MDMA-induced hyperthermia 
The potent and selective 5-HT2A antagonist MDL 100,907 (0.1 mg/kg i.p.) had no effect 
on MDMA-induced hyperthermia and did not alter the basal temperature of control 
animals (Figure 6.5a). Modest attenuation of .MDMA-induced hyperthennia was 
observed at a dose of 0.3 mg/kg i.p., without altering the rectal temperature of control 
animals (Figure 6.5b). The 5-HT2c antagonist SB 242084 (3 mg/kg i.p.) did not alter 
MDMA-induced hyperthermia and had no effect on the rectal temperature of control 
rats (Figure 6.6). 
6.3.4 Effect of 5-HT uptake inhibitors on MDMA-induced hyperthermia 
The 5-HT uptake inhibitor zimeldine was administered at a dose of 10 mg/kg i.p. 
(Figure 6.7a), and did not alter MDMA-induced hyperthermia or have any effect on the 
rectal temperature of control rats. The 5-HT uptake inhibitor fluoxetine (10 mg/kg i. p.) 
also had no effect on the MDMA-induced hyperthermic response or on the temperature 
of control rats (Figure 6. 7b). 
6.3.5 Effect of remoxipride and SeD 23390 on MDMA-induced 
hyperthermia 
The dopamine D2 receptor-selective antagonist remoxipride (10 mg/kg i.p.) had no 
effect on the MDMA-induced hyperthennic response (Figure 6.8). However, in 
contrast, the dopamine Dl receptor-selective antagonist SCH 23390 (1 and 2 mglkg i.p.) 
attenuated the MDMA-induced hyperthermic response, without altering the rectal 
temperature of control rats (Figure 6.9a and b). This effect was dose-dependent; the 
difference in rectal temperature between MDMA and SCH 23390 + MDMA treatment 
groups (as measured at the time of the maximal MDMA-induced hyperthermic 
response; 90 min) increased with increasing dose of SCH 23390 (0.3, 1 and 2 mg/kg; 
Figure 6.9c). At the highest dose ofSCH 23390 (2.0 mg/kg i.p.), the temperature of the 
MDMA + SCH 23390 group was significantly lower than that of the control group 
during t20-170 post-MDMA injection (Figure 6.9b). 
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Figure 6.5 Effect of MDL 100,907 on MDMA-induced acute hyperthermia. 
Rats were administered MDL 100, 907 (0.1 or 0.3 mglkg i.p.) or vehicle (denoted by broken arrows) 20 min before administration of 
MDMA (12.5 mglkg i.p.) or saline (denoted by full arrows). Results shown as mean ± s.e.m., n = 4 - 5 in each group. (a) MDL 100,907 
(0.1 mglkg). MDMA produced a significant rise in rectal temperature (F (1, 8) = 86.0, p < 0.001) compared to the vehicle-treated control 
group. MDL 100,907 did not modify the MDMA-induced hyperthermia and had no effect on the rectal temperature of control animals. (b) 
MDL 100,907 (0.3 mglkg). MDMA produced a significant rise in rectal temperature (F (1, 6) = 307.0, P < 0.001) compared to the control 
group. MDL 100,907 attenuated the MDMA-induced hyperthermia (F (1, 6) = 22.4, P < O.OI) without altering the rectal temperature of 
control animals. 
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Figure 6.6 Effect of SB 242084 on MDMA-induced acute hyperthermia. 
Rats were administered SB 242084 (3 mglkg i.p.) or vehicle (denoted by broken arrow) 
20 min before administration of MDMA (12.5 mg/kg i.p.) or saline (denoted by full 
arrow). Results shown as mean ± s.e.m., n = 3 - 4 in each group. There was no 
difference in the basal temperature of the groups. MDMA produced a significant rise in 
rectal temperature (F (1, 6) = 70.4, P < 0.001) compared with the vehicle-treated control 
group. SB 242084 did not modify the MDMA-induced hyperthermic response and had 
no effect on the rectal temperature of control rats. 
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Figure 6.7 Effect of5-HT uptake inhibitors on MDMA-induced acute hyperthermia. 
(a) Zime/dine. Rats were administered zimeldine (10 mg/kg i.p.) or vehicle (denoted by broken arrow) 20 min before administration of MDMA (12.5 
mg/kg i.p.) or saline (denoted by full arrow). Results sho\W as mean ± s.e.m., n = 4 in each group. There was no difference in the basal temperature of 
the groups. MDMA produced a significant rise in rectal temperature (F (1, 6) = 65.6, P < 0.001) compared with the vehicle-treated control group. 
Zimeldine did not modifY the MDMA-induced hyperthermic response and had no effect on the rectal temperature of control rats. (b) Fluoxetine. Rats 
were administered fluoxetine (10 mg/kg i.p.) or vehicle (denoted by broken arrows) 5 min before and 55 min after administration ofMDMA (15 mglkg 
i.p.) or saline (denoted by full arrow). Results sh<mn as mean ± s.e.m., n = 4 - 6 in each group. There was no difference in the basal temperature of the 
groups. MDMA produced a significant rise in rectal temperature (F (I, 9) = 74.3, P < 0.001) compared with the vehicle-treated control group. 
Fluoxetine did not modifY the MDMA-induced hyperthermic response and had no effect on the rectal temperature of control rats. 
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Figure 6.8 Effect of remoxipride on MDMA-induced acute hyperthermia. 
Rats were administered remoxipride (10 mglkg i.p.) or vehicle (denoted by broken 
arrow) 20 min before administration ofMDMA (12.5 mglkg i.p.) or saline (denoted by 
full arrow). Results shown as mean ± s.e.m., n = 3 - 4 in each group. MDMA produced 
a significant rise in rectal temperature, over 40 min after injection (F (1, 6) = 15.3, P < 
0.01) compared with the vehicle-treated control group. Remoxipride did not modifY the 
MDMA-induced hyperthermic response and had no effect on the rectal temperature of 
control rats. 
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hyperthennic response (F (1, 6) = 8.8, P < 0.05) during f(,o-170 without altering the rectal temperature of control rats. (b) SeB 23390 (2 mglkg). MDMA 
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Figure 6.10 Effect of GBR 12909 on MDMA-induced acute hyperthermia. 
Rats were administered GBR 12909 (10 mglkg s.c.) or vehicle (denoted by broken 
arrow) 20 min before administration of MDMA (12.5 mg/kg i.p.) or saline (denoted by 
full arrow). Results shown as mean ± s.e.m., n = 3 - 4 in each group. There was no 
difference in the basal temperature of the groups. MDMA produced a significant rise in 
rectal temperature (F (1, 8) = 86.0, P < 0.001) compared with the control group. GBR 
12909 did not modify the MDMA-induced hyperthermic response and had no effect on 
the rectal temperature of control rats. 
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6.3.6 Effect of GBR 12909 on MDMA-induced hyperthermia 
The selective dopamine uptake inhibitor GBR 12909 (10 mglkg s.c.) did not alter the 
MDMA-induced hyperthermia and had no effect on the rectal temperature of control 
animals (Figure 6.10). 
6.4 DISCUSSION 
This study has demonstrated that the acute hyperthermic response which follows 
administration of MDMA to rats does not appear to be solely mediated by 5-HT 
receptors, and that dopamine Dl receptors playa major role in the response. 
As reported in previous studies (e.g. Broening et al., 1995; Colado et al., 1993; Dafters, 
1994; 1995; Nash et aI., 1988; O'Shea et al., 1998), and as demonstrated in Chapter 5, 
administration of MDMA (12.5 mglkg Lp.) resulted in an acute hyperthennic response 
of approximately + 1.2 DC. However, the rise in rectal temperature was not accompanied 
by an overall change in tail skin temperature; while the maximal increase in rectal 
temperature occurred 40 min post-injection, the tail temperatures of the MDMA-treated 
group were lower than those of the control group during the period t40 . 80 and at t = 180 
min, although this difference was not statistically significant. Tail skin temperature can 
be used to provide an estimation of tail blood flow (Gordon et al., 1991; Mohaghegh et 
al., 1997), and has previously been demonstrated not to increase following 
administration of MDMA (Gordon et al., 1991) or methamphetamine (Mohaghegh el 
al., 1997). For example, Gordon et al. (1991) demonstrated that, while rectal 
temperature was still significantly higher in MDMA-treated animals 3 h post-injection 
(approximately 4 DC above control values), tail skin temperature was approximately 2 
°C lower than in saline-treated rats. These authors also exposed a drug-naive group to a 
high T a environment (37°C) for 60 min, and observed a significant increase in both 
rectal (+3 DC) and tail (+8 DC) temperature, compared to saline-treated rats. The authors 
concluded that MDMA treatment resulted in a failure to increase blood flow to the tail, 
a common thennoregulatory response to an increase in body temperature (see Grant. 
1963) which was demonstrated in the group exposed to a high Ta (Gordon et aI., 1991), 
Although it is difficult to make a direct comparison between the current study and that 
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of Gordon et al. (1991), as the latter did not report the pattern of change in rectal and 
tail temperature but only the values measured 3 h post-injection, the results are 
nevertheless similar. Therefore, based on the results of the current study and those of 
Gordon et al. (1991), MDMA treatment appears to interfere with normal heat 
dissipation mechanisms. 
It has previously been suggested (see Shankaran & Gudelsky, 1999) that the acute 
release of 5-HT which occurs following MDMA administration to rats (see Colado & 
Gree~ 1994; Meehan et aI., 2000; Sabol & Seiden, 1998; Schmidt et al., 1987; Schmidt 
& Taylor, 1988; Stone et al., 1986; 1987b) is involved in mediation of the acute 
hyperthermic response. Thus, a number of 5-HT receptor antagonists were administered 
in an attempt to identify the receptor sUbtype(s) involved. Administration of the non-
selective 5-HT 112 receptor antagonist, methysergide (10 mglkg) , had no effect on the 
MDMA-induced acute hyperthermic response, neither did pretreatment with the 5-HT 2 
antagonist ritanserin (1 mglkg). The lack of effect. of ritanserin is in contrast to the 
reported effects of ketanserin, a 5-HT 2 receptor antagonist with structural similarities. 
For example, (1) Nash et al. (1988) administered ketanserin (3 mg/kg i.p.) to male SD 
rats 1 h prior to MDMA (3 or 10 mg/kg i.p.), and demonstrated a complete blockade of 
the MDMA-induced acute hyperthermic response, and (2) Malberg et al. (1996) 
administered ketanserin (6 mglkg i.p.) to male Holtzman rats 1 h prior to administration 
of MDMA (40 mg/kg s.c.), and observed a hypothermic response in the ketanserin + 
MDMA treatment group, while ketanserin alone did not alter rectal temperature. There 
is some question as to the selectivity of ketanserin, however, which has also been 
demonstrated to have an antagonistic action at central ul-adrenoceptors (see Dudley et 
aI., 1988; McCall & Schuette, 1984). 
Administration of another 5-HT2 antagonist, MDL 11,939 (5 mg/kg), resulted in a 
complete blockade of the hyperthermic response of MDMA-treated animals, without 
affecting the rectal temperature of control animals. This result is in agreement with the 
data of Schmidt et al. (1990a), where the same dose of MDL 11,939 blocked or 
significantly attenuated hyperthermia induced by MDMA (10, 20 and 30 mg/kg) in SD 
rats, and prevented MDMA-induced regional brain depletions of 5-HT measured one 
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week later. However, in addition to its high selectivity and affinity for the 5-HT 2 
receptor binding site, MDL 11,939 does have moderate affinity for the a.-I adrenergic 
receptor, although it is 35 and 80 times less potent than cyproheptadine and ketanserin, 
respectively (see Dudley et aI., 1988). 
In the current study, pretreatment with the selective 5-HT 2C receptor antagonist, sa 
242084 (3 mg/kg), had no effect on MDMA-induced acute hyperthermia. At the lower 
dose administered (0.1 mglkg) the 5-HT2A antagonist, MDL 100,907, also had no effect 
on the hyperthermic response. However, a modest attenuation was observed following 
the higher dose (0.3 mglkg). 
Administration of two serotonin reuptake inhibitors, zimeldine ( I 0 mg/kg) and 
fluoxetine (10 mglkg), had no effect on MDMA-induced acute hyperthermia. However, 
fluoxetine has been demonstrated to almost completely abolish the MDMA-induced 
release of 5-HT within the hippocampus, as measured via in vivo microdialysis (Meehan 
et aI., 2001b). The results of the current study are in agreement with Malberg et al. 
(1996), who demonstrated that fluoxetine prevented MDMA-induced regional brain 
depletion of 5-HT and 5-HIAA measured 14 days post-treatment, without altering the 
acute hyperthermic response. In addition, Berger et al. (1992) demonstrated that 
fluoxetine pretreatment significantly attenuated the synaptosomal release of CH]5-HT, 
as induced by MDMA, peA, methamphetamine and fenfluramine. The current results 
are also in agreement with a study performed in humans using another serotonin uptake 
inhibitor, citalopram: Liechti & Vollenweider (2000) demonstrated that citalopram 
pretreatment (40 mg in 500 ml saline solution), 90 min prior to oral administration of 
MDMA (1.5 mg/kg), attenuated MDMA-induced increases in blood pressure and heat1 
rate, while having no effect on MDMA-induced increases in body temperature. 
In addition to 5-HT, dopamine is acutely released following MDMA administration to 
rats (see Colado et aI., 1999a; Crespi et al., 1997; Gudelsky et aI., 1994; Koch & 
Galloway, 1997; Johnson et aI., 1986; Nash, 1990; Nash & Brodkin, 1991; Sabol & 
Seiden, 1998; Schmidt et al., 1992; Shankaran & Gudelsky, 1999; Yamamoto & 
Spanos, 1988). Furthermore, it has been postulated that stimulation of 5-HT2 receptors 
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following MDMA-induced 5-HT release might serve to enhance dopamine release, at 
least in the striatum (see Gudelsky et al., 1994; Nash, 1990; Schmidt et al., 1990b). 
Thus a series of compounds which affect dopaminergic function were administered in 
an attempt to determine whether dopamine receptors are involved in the mediation of 
the MDMA-induced hyperthermic response in rats. 
Pretreatment with the dopamine O2 receptor antagonist, remoxipride (10 mglkg), did not 
affect the MDMA-induced acute hyperthermia. However, the 0 1 antagonist, SCH 23390 
(0.3, 1 and 2 mg/kg), dose-dependently attenuated the hyperthermic response. In fact, at 
the highest dose, hypothermia occurred in the SCH 23390 + MDMA treatment group, 
while the temperature of control animals was unaltered. These results are consistent 
with the observations of Metzger et al. (2000), who reported that SCH 23390 
pretreatment attenuated methamphetamine-induced hyperthermia in SO rats. In 
addition, Bronstein & Hong (1995) demonstrated a delayed hypothermic response in SD 
rats administered SCH 23390 (0.5 mg/kg s.c.) and methamphetamine (10 mglkg s.c.); 
although the peak hyperthermic response was not attenuated, hypothermia was observed 
in the SCH 23390 + methamphetamine treatment group 5 h post-injection. The authors 
suggested that the protective effects of SCH 23390 pretreatment against 
methamphetamine-induced lethality could be due to this delayed hypothermic action 
(Bronstein & Hong, 1995). There is also some evidence for an interaction of SCH 
23390 with central 5-HT2 receptors: Bischoff et al. (1986) reported partial inhibition of 
in vivo eH]spiperone binding in the rat frontal cortex. However, such an effect was not 
observed in the striatum or hippocampus, and 45 - 50 % inhibition in the frontal cortex 
was only observed following administration of 3 and 10 mg/kg SCH 23390 - no 
significant effect was seen at the doses used in the current study (Bischoff et at., 1986). 
There is additional support for the hypothermic effects of SCH 23390 in previous work 
demonstrating the involvement of D2 receptors in temperature responses in rats. For 
example, Faunt & Crocker (1987) showed that administration of the primarily O2-
selective agonist, apomorphine (0.25 - 1 fJ.Mol/kg), resulted in a dose-dependent 
hypothermia. Following administration of apomorphine (1 fJ.Mollkg), a maximal 
decrease in temperature of"1.2 °C was observed 30 min post-injection, an effect which 
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was potentiated by pretreatment with SCH 23390 (0.35 and 1.74 ~MoVkg) (Faunt & 
Crocker, 1987). Thus, if hypothermia can be induced through dopamine D2 receptor 
stimulation, it could be postulated that the hypothermic response observed in the 
MDMA + SCH 22390 treatment group, following the highest dose of SCH 23390 (2 
mglkg) in the current study, is due to complete blockade of DI receptors by the 
antagonist, enabling expression of D2 receptor stimulation by MDMA-released 
dopamine. 
Pretreatment with the dopamine uptake inhibitor, GBR 12909 (10 mglkg) did not 
modify the MDMA-induced acute hyperthermic response, and has also been shown not 
to alter the MDMA-induced increase in extracellular dopamine, or decrease in 
extracellular HV A, in the striatum (Mechan et aI., 2001 b). These results are not 
consistent with the reports of Koch & Galloway (1997), who demonstrated that GBR 
12909 (1 ~Mol) completely blocked in vitro MDMA-induced dopamine release in rat 
striatal slices, and had no effect on MDMA-induced 5-HT release, or Nash & Brodkin 
(1991), who demonstrated that striatal dopamine release following central 
administration of MDMA (1 0 ~Mol) was significantly inhibited by systemic 
administration of the dopamine uptake inhibitors GBR 12909 (10 mg/kg i.p.) and 
mazindol (5 mg/kg i.p.). In addition, Marek et al. (1990) demonstrated that 
methamphetamine-induced neostriatal dopamine release was prevented by pretreatment 
with a high dose of mazindol (40 mglkg i.p.), while a 20 mglkg dose had no effect. 
However, differences in methodology might explain the different results obtained in the 
current study, compared to those previously reported: in particular, comparisons 
between in vivo and in vitro results (Koch & Galloway, 1997), and the fact that both 
MDMA and GBR 12909 were administered peripherally in the current study, in contrast 
to central administration ofMDMA by Nash & Brodkin (1991). The current results are 
consistent with those observed in mice, where GBR 12909 also failed to protect against 
acute MDMA-induced dopamine depletion (O'Shea et aI., 2001). While it could be 
argued that the dose ofGBR 12909 used in the current study (10 mglkg) was too low to 
alter MDMA-induced effects, nevertheless it is comparable to doses used in some 
previous studies (e.g. Nash & Brodkin, 1991; Rothman et al., 1991). 
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The majority of work described in this chapter strongly indicated the lack of direct 
involvement of 5-HT receptors in the MDMA-induced acute hyperthermic response - a 
non-selective 5-HT1I2 antagonist (methysergide), a 5-HT2 antagonist (ritanserin) and 
two serotonin uptake inhibitors (zimeldine and fluoxetine) had no effect on this 
response. However, a second 5-HT2 antagonist (MOL 11,939) and a selective 5-HT2A 
antagonist (MDL 100, 907) did modify the response, thus indicating some involvement 
of the 5-HT2A receptor. Although MDL 100,907 has been reported to have a lack of 
affinity for dopamine D2 receptors (see Kehne et a/., 1996a; 1996b), it has been 
demonstrated to attenuate dopamine synthesis and release. For example, Schmidt et al. 
(1992) reported that pretreatment with MDL 100,907 (0.01 - 1 mglkg s.c.) 30 min prior 
to administration ofMDMA (20 mg/kg s.c) to SD rats, completely prevented MDMA-
induced stimulation of striatal dopamine synthesis, and striatal dopamine release was 
significantly attenuated. In addition, Pehek et al. (2001) demonstrated that MDL 
100,907 (10 and 100 JlMol) significantly attenuated in vivo potassium-stimulated 
dopamine release within the medial prefrontal cortex (mPFC) of SD rats. 
Therefore, it could be postulated that the hyperthermic response which results from 
MDMA administration is mediated through a combination of 5-HT 2A and dopamine D\ 
receptors: (1) 5-HT released by MDMA acts directly at 5-HT2A receptors, in addition to 
indirectly enhancing the actions ofMDMA-released dopamine at Dl receptors, (2) MDL 
100,907 directly antagonises serotonergic stimulation of 5-HT2A receptors, and 
attenuates MDMA-induced dopamine release, and (3) SCH 23390 directly antagonises 
dopaminergic stimulation ofDl receptors. In combination, these postulated events could 
explain modification of the acute hyperthermia by both 5-HT 2/5-HT 2A receptor 
antagonists and a Dl antagonist. This hypothesis does not, however, explain the lack of 
effect of another 5-HT2 antagonist (ritanserin) and a 5-HTlI2 antagonist (methysergide)-
perhaps MDL 11,939 has additional actions at receptors other than the 5-HT2 receptor 
(such as the a-I receptor) and perhaps the modification of the hyperthermic response 
seen at the higher dose ofMDL 100,907 was due to its attenuation of dopamine release. 
In conclusion, the current study demonstrated that the acute hyperthermia which follows 
MDMA administration to rats is not solely mediated by 5-HT receptors, but that 
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dopamine Dl receptors playa major role in the hyperthermic response. Recreational 
MDMA use by humans can be followed by an extreme hyperthermia (see Chadwick et 
aI., 1991; Henry et al., 1992; Mallick & Bodenham, 1997; Randall, 1992; Screaton el 
al., 1992), which might lead to disseminated intravascular coagulation and 
rhabdomyolysis (see Chadwick et al., 1991; Henry et al., 1992; Screaton et aI., 1992). 
Current treatment tends to involve cooling the body with ice (see Brown & Osterloh, 
1987; Mallick & Bodenham, 1997; Screaton et al., 1992), or administration of the 
peripherally-acting muscle relaxant dantrolene (see Mallick & Bodenham, 1997; Tehan, 
1993), which might act by reducing thermogenesis (see Barrett, 1992). Thus it is 
plausible that a dopamine Dl antagonist could be administered as a more specific 
preventative measure against the life-threatening consequences of the hyperthermic 
response. 
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A STUDY OF THE MECHANISMS INVOLVED 
IN MDMA-INDUCED STRIATAL DOPAMINE LOSS 
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NEUROPROTECTION: 
A study of the mechanisms involved in MDMA-induced 
striatal dopamine loss in NIHIS mice 
INTRODUCTION 
The acute and longer-term neurochemical changes which occur following MDMA 
administration to rats and mice have been described in Chapter 1. The current chapter is 
concerned with the mechanisms involved in the longer-term neurotoxic action of 
MDMA on dopaminergic systems in the mouse brain. Therefore, literature concerning 
the longer-term effects ofMDMA administration to mice, and comparison to the effects 
seen in rats, will be highlighted here. In addition, the use of drugs with putative 
neuroprotective abilities and the neuroprotective effects of preventing MDMA-induced 
hyperthermia, as reported in rats and mice, will be reviewed. 
7.1.1 Longer-term neurotoxic effects of MDMA administration: 
comparisons between mice and rats 
Administration of MDMA to rats results in long-term neurotoxic damage to regional 
brain serotonergic systems, as evidenced by selective degeneration of forebrain axon 
terminals and decreases in 5-HT and 5-HIAA content, tryptophan hydroxylase activity 
and eH]paroxetine binding (see Battaglia et aJ., 1987; 1988; 1991; Colado el aI., 1995; 
1997a; 1999a; Commins et al., 1987; O'Hearn et ai., 1988; Schmidt, 1987a; Schmidt et 
aI., 1987; Stone et a/., 1986). However, long-term neurotoxic changes in brain 
dopaminergic systems have been reported not to occur following MDMA 
administration to rats (Battaglia et a/., 1987; 1991; Colado et a/., 1997a; Schmidt et al., 
1987; Stone et aI., 1986). In contrast, MDMA selectively damages dopaminergic 
systems in mice, while having little effect on brain 5-HT content (Laverty & Logan, 
1990; Logan et aI., 1988; Miller & O'Callaghan, 1993; 1994; 1995; O'CaUaghan & 
Miller, 1994). 
Stone et al. (1987a) demonstrated potential differences in MDMA pharmacokinetics 
between species, longer-term deficits in serotonergic activity only being seen in mice 
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where multiple doses of MDMA were administered, compared to rats where a single 
dose had a long-lasting effect. For example, administration of MDMA (10 mg/kg s. c.) 
to rats resulted in decreases in tryptophan hydroxylase activity and 5-HT and S-HIAA 
concentrations, which were still 20 - 40 % below control values one week later. In mice, 
an acute decrease in S-HT and S-HIAA concentrations was observed 3 h post-treatment, 
but values returned to control levels within 24 h. However, administration of mUltiple 
doses of MDMA to mice (15 mg/kg s.c., six times, at 4 h intervals) resulted in 
reductions in hippocampal tryptophan hydroxylase activity and 5-HT and 5-HIAA 
concentrations, which were still 25 - 30 % below control values one week later (Stone el 
ai., 1987a). 
Logan et al. (1988) demonstrated marked differences in the longer-term neurotoxic 
effects of MDMA between rats and mice. Administration of multiple doses of MDMA 
(25 mg/kg i.p., three times, at 12 h intervals) to rats resulted in an approximately SO % 
decrease in cortical 5-HT and 5-HIAA,. which was still apparent seven days post-
treatment, while there was no effect on striatal dopamine and nop AC concentrations. 
In mice, however, only small decreases were seen in cortical 5-HIAA and striatal 
nop AC concentrations. Administration of a higher dose of MDMA to mice (50 mg/kg 
i.p., three times, at 12 h intervals) resulted in a prolonged decrease in cortical 5-HIAA 
concentration, levels being approximately 80 % of control values two weeks post-
treatment, while both dopamine and DOP AC concentrations were diminished by 
approximately 50 %, an effect which persisted for at least two weeks following 
administration ofMDMA (Logan et aI., 1988). 
Laverty & Logan (1990) extended their earlier work (Logan et aI., 1988) by 
investigating the effects of several pretreatment compounds on MDMA-induced 
neurotoxicity in rats and mice. MK-801 (1 mg/kg i.p.) was administered 30 min before 
MDMA (50 mg/kg i.p.) for a total of three times in 24 h. Seven days later the 
neurotoxic effects of MDMA, as indicated by reductions in striatal and cortical 
concentrations of 5-HT and 5-HIAA in rats and by reductions in striatal dopamine and 
its metabolites in mice, were shown to be significantly attenuated in MK-801-pretreated 
animals. Furthermore, in mice, pretreatment with haloperidol (S mglkg i.p.) or ex-
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methyl-p-tyrosine (200 mglkg ester i.p.) also prevented the MDMA-induced reduction 
in striatal dopamine, OOP AC and HV A concentrations, whereas pretreatment with 
fluoxetine (10 mglkg i.p.) had no effect (Laverty & Logan, 1990). 
Miller & O'Callaghan (1993) investigated the biochemical effects of MDMA., in 
addition to methamphetamine and fenfluramine, in female C57BU6 mice, by measuring 
the levels of glial fibrillary acidic protein (GF AP) in the cortex, hippocampus and 
striatum. Central nervous system injury results in astrocytic hypertrophy and, therefore, 
enhanced expression of the astrocyte-localised GFAP (see Miller & O'Callaghan, 
1993). MDMA (25 mglkg s.c.) was administered a total of four times, at 2 h intervals, 
and regional levels of GF AP were shown to be significantly increased 48 h later. The 
authors also investigated the involvement of glutamate in MDMA-induced 
neurotoxicity, by pretreating animals with the NMDA antagonist, MK-80 1 (1 mg/kg 
s.c., 30 min prior to the first and third doses ofMDMA). The increases in striatal GFAP 
were completely prevented by MK-801 in MDMA-treated animals, thus indicating a 
potential role for excitatory amino acids in the MDMA-induced neurotoxic injury 
(Miller & O'Callaghan, 1993). 
O'Callaghan & Miller (1994) further extended their earlier work (Miller & 
O'Callaghan, 1993) by investigating additional measures of neurotoxicity. Female 
C57BL/6J mice were administered multiple doses ofMDMA (20 mg/kg s.c., four times, 
at 2 h intervals) which resulted in: (1) significant increases in GF AP concentration in 
the striatum and, to a lesser extent, in the cortex, (2) rapid decreases in striatal tyrosine 
hydroxylase and dopamine concentrations and smaller decrements in cortical 5-HT 
concentration, and (3) argyrophilic axons and fine debris in the striatum, particularly the 
lostral, dorsal and lateral aspects. These results indicated that MDMA administration 
resulted in striatal and cortical damage and, in particular, that dopaminergic projections 
to the striatum were the primary targets of degeneration (O'Callaghan & Miller, 1994). 
In addition to the protective effects of MK-801 pretreatment against the MDMA-
induced increase in striatal GFAP (Miller & O'Callaghan, 1993; O'Callaghan & Miller, 
1994), the decreases in striatal tyrosine hydroxylase and dopamine concentrations, as 
measured three days post-treatment, were also prevented by MK-801 (O'Callaghan & 
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Miller, 1994). However, it was later shown that the neuroprotective action of MK-801 
was likely to be due to its ability to reduce core temperature (Miller & 0 'Callaghan, 
1994). 
Miller & O'Callaghan (1994) investigated the effects of altering core temperature on the 
neurotoxic effects of MDMA, in addition to methamphetamine and MDA. Female 
C57BL/6J mice were administered MDMA (20 mg/kg s.c.) a total of four times, at 2 h 
intervals, and biochemical measurements were made three days later. MDMA-induced 
acute hyperthermia, decrease in striatal dopamine concentration and increase in GF AP 
were all prevented both by lowering ambient temperature (from 22°C to 15 "'C) and by 
pretreatment with MK-801 (Miller & O'Callaghan, 1994; 1995). The hypothermic and 
neuroprotective effects ofMK-801 were also observed both in male C57BL/6J mice and 
in female B6C3Fl mice, indicating that the effects seen were not gender- or strain-
specific (Miller & O'Callaghan, 1995). By increasing ambient temperature to 27°C, the 
effects of lowering ambient temperature and MK-80 1 were completely reversed and 
significantly attenuated, respectively. Additional compounds reported to cause 
hypothermia (ethanol, pentobarbital, diethyldithiocarbamate (DDC), fenfluramine or 
cocaine) were administered prior to MDMA, to investigate whether their temperature-
altering effects also affected MDMA-induced neurotoxicity. In general. compounds 
which induced greater reductions in core temperature provided greater neuroprotection. 
For example, ethanol and pentobarbital, which had similar hypothermic effects to MK-
801, significantly blocked the MDMA-induced decrease in striatal dopamine 
concentration and increase in GF AP. Thus it was clearly demonstrated that, by 
preventing MDMA-induced hyperthermia, neurotoxicity was also prevented or 
significantly attenuated (Miller & O'Callaghan, 1994). 
O'Shea et al. (2001) investigated the effects of pretreatment with GBR 12909 and 
fluoxetine on the neurochemical effects of MDMA administration to male Swiss 
Webster mice, in an attempt to assess the involvement of 5-HT and dopamine 
transporters in MDMA-induced neurotoxicity. MDMA (l0, 20 or 30 mglkg i.p.) was 
administered for a total of three doses at 3 h intervals and, seven days later, significant 
reductions in striatal dopamine, DOP AC and HV A were observed in animals 
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administered the two higher doses of MDMA. In contrast, no effects on regional brain 
concentrations of 5-HT or 5-HIAA were observed. Pretreatment with GBR 12909 (10 
mglkg i.p. 30 min before each 30 mglkg MDMA injection) prevented the MDMA-
induced reduction in striatal dopamine, DOP AC and HV A concentrations, measured 
seven days post-treatment. However, pretreatment with fluoxetine (10 mglkg i.p. 30 min 
before each MDMA injection) did not significandy attenuate the MDMA-induced 
reduction in striatal concentrations of dopamine and its metabolites. While the selective 
dopamine uptake inhibitor GBR 12909 protected against longer-term striatal dopamine 
loss, it had no effect on MDMA-induced acute hyperthermia. Thus the neuroprotective 
effect of GBR 12909 did not result from any effect on temperature (O'Shea et al., 
2001). 
A number of studies have investigated the effects of restraint on MDMA-induced 
hyperthermia and reductions in striatal dopamine concentration, restraint being 
employed to characterise the physiological consequences of "stress" (see Johnson et al.. 
2000; Miller & o 'Callaghan, 1994; 1995). For example, Johnson et al. (2000) 
administered MDMA (20 mglkg s.c., four times, at 2 h intervals) to female C57BLl6 
mice 30 min after restraint commenced. The restraint procedure comprised placing each 
mouse in a 35 mI centrifuge tube (25 mm diameter, 89 mm length), with perforations in 
the closed end to provide airflow and a clip secured across the open end to prevent the 
mouse backing out of the tube. The apparatus enabled movement from supine to prone 
position. Rectal temperature was measured prior to the animal being placed in the 
restraint apparatus, each time the animal was removed from the apparatus for an 
injection, and at the end of the experiment (2 h after the last injection). H.p.l.c. analysis 
of dopamine, 5-HT, noradrenaline and their metabolites was performed three days later. 
Restraint prevented the MDMA-induced acute hyperthermic response, mducing 
hypothermia in both MDMA- and saline-treated mice. MDMA-treated, unrestrained 
mice demonstrated an 82 % reduction in striatal dopamine, DOP AC and HV A. 
Restraint substantially blocked MDMA-induced reductions in striatal dopamine, while 
having no effect on dopamine levels in saline-treated mice; MDMA-treated, restrained 
mice demonstrated a 32 % decrement in striatal dopamine concentration. Thus, the 
induction of "stress" in mice, in producing hypothermia, served to protect against the 
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neurotoxic effects of MDMA shown by preventing MDMA-induced reductions in 
striatal dopamine concentration (Johnson et aI., 2000; Miller & o 'Callaghan, 1994; 
1995) and increases in striatal GFAP (Miller & O'Callaghan, 1994; 1995). 
7.1.2 Aims of the investigation: the use of putative neuroprotective 
compounds 
The current study was undertaken in an attempt to elucidate the mechanisms involved in 
the neurotoxic action of MDMA in mice, there being few reports on the effects of 
MDMA in mice, in contrast to the substantial number of studies on rats. Following the 
study of O'Shea et al. (2001) where the selective dopamine uptake inhibitor GBR 
12909 was demonstrated to have neuroprotective effects on longer-term MDMA-
induced reductions in striatal dopamine, a range of putative neuroprotective agents were 
chosen to investigate different aspects of the neurotoxic pathway. In addition, as 
temperature has been demonstrated to play an important role in the neuroprotective 
abilities of certain compounds (e.g. Ali et aI., 1994; Buchan & Pulsinelli, ) 990; 
Callahan & Ricaurte, 1998; Colado et aI., 1993; 1995; 1998; 1999b; 1999c; Farfel & 
Seiden, 1995a; 1995b; Hewitt & Green, 1994; Kita et al., 2000; Miller & 0' Callaghan, 
1994; 1995; Murray et aI., 1996), rectal temperature was monitored regularly 
throughout each experiment. 
Three or four doses of MDMA (see Colado et aI., 1999c; Laverty & Logan, 1990; 
Logan et aI., 1988; Miller & O'Callaghan, 1993; 1994; 1995; O'Callaghan & Miller, 
1994; O'Shea et aI., 2001; Stone et aI., 1987a) or methamphetamine (see Miller & 
0' Callaghan, 1993; Sonsalla et aI., 1989; 1991) have generally been reported as 
necessary to produce neurotoxic damage in mice. Therefore, a preliminary study was 
conducted to confirm the necessity for multiple doses to induce dopaminergic 
neurotoxicity, whereby mice were administered one, two or three doses of MDMA and 
striatal levels of dopamine and its metabolites were analysed one week later. All other 
experiments involved the administration of three doses ofMDMA (25 mg/kg i.p.) at 3 h 
intervals. 
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Tbe compounds studied were: 
(1) The low affinity non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist AR-RI5896AR, which has previously been shown to be neuroprotective in 
animal models of focal and global ischaemia (Cregan et al., 1997), but did not protect 
against MDMA-induced neurodegenerative loss of 5-HT or 5-IDAA in the 
hippocampus, striatum or cortex ofthe rat (Colado et al., 1998). 
(2) The non-competitive NMDA antagonist MK-801, which is neuroprotective in 
animal models of ischaemia (e.g. Buchan & Pulsinelli, 1990) and against MDMA-
(Colado et ai., 1993; Colado & Green, 1994; Farfel & Seiden, 1995a; Hewitt & Green, 
1994), methamphetamine- (Baldwin et al., 1993; Bowyer et aI., 1994; Farfel & Seiden, 
1995b; Green et ai., 1992; Johnson et aI., 1989) and p-chloroamphetamine- (Farfel & 
Seiden, 1995b) induced neurotoxicity in rats and MDMA-, MDA- (Miller & 
O'Callaghan, 1993; 1995; O'Callaghan & Miller, 1994) and methamphetamine- (Albers 
& Sonsalla, 1995; Ali et aI., 1994; Boireau et ai., 1995; Miller & O'Callaghan, 1993; 
1995; O'Callaghan & Miller, 1994, Sonsalla et al., 1989; 1991) induced neurotoxicity 
in mice. However, MK-80 1 has been demonstrated to induce hypothermia, and 
therefore its neuroprotective effects have been attributed to its ability to lower core 
temperature (Albers & Sonsalla, 1995; Ali et aI., 1994; Bowyer et aI., 1994; Buchan & 
Pulsinelli, 1990; Farfel & Seiden, 1995a; 1995b; Miller & Q'Callaghan, 1994; 1995). 
(3) The GABAmimetic clomethiazole, which is neuroprotective in animal models of 
ischaemia (Baldwin et aI., 1994; Cross et al., 1991; Green, 1998) and against MDMA-
(Colado et aI., 1993; 1998; 1999b; Colado & Green, 1994; Hewitt & Green, 1994) and 
methamphetamine- (Baldwin et al., 1993; Green et aI., 1992) induced neurotoxicity in 
rats and methamphetamine-induced neurotoxicity in mice (Green et aI., 1992), 
Although clomethiazole has been demonstrated to attenuate the MDMA-induct:u 
hyperthermic response (Colado et aI., 1993; 1998; 1999b; Hewitt & Green, 1994), it 
appears that some additional neuroprotective mechanism is involved, Colado et al. 
(1998) maintained the rectal temperature of rats pretreated with clomethiazole near that 
ofMDMA-treated animals and demonstrated that, although the degree of protection was 
diminished, it was still present. 
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(4) The novel, and relatively selective, nitric oxide synthase (NOS) inhibitor AR-
R17477 AR, which has been shown to be protective in animal models of global and 
focal ischaemia (O'Neill et aI., 2000). 
(5) The NOS inhibitor S-methyl-L-thiocitrulline (S-MTC), which has heen 
demonstrated to protect against methamphetamine-induced dopaminergic neurotoxicity 
in mice (Itzhak et aI., 2000). 
(6) The NOS inhibitor 7-nitroindazole (7-NI), which protects against 
methamphetamine- (Ali & Itzhak, 1998; Callahan & Ricaurte, 1998; Di Monte et aI., 
1996; Itzhak & Ali, 1996; Itzhak et al., 2000) and MDMA- (Colado et al., 1999c) 
induced neurotoxicity in mice. However, some studies have shown that the 
neuroprotective effects of 7 -NI are likely to be due to its ability to prevent 
methamphetamine- (Callahan & Ricaurte, 1998) or MDMA- (Colado et aI., 1999c) 
induced hyperthermia. 
(7) The spin trap reagent a-phenyl-N-tert-butyl nitrone (PBN), which significantly 
attenuates MDMA- (Colado & Green, 1995; Colado et al., 1997a; Yeh et ai., 1999) and 
PCA- (Murray et ai., 1996) induced neurotoxicity in rats and MPTP- (Ferger el aI., 
2000) and methamphetamine- (Kita et al., 2000) induced neurotoxicity in mice. 
However, some studies have shown that PBN prevents MDMA- (Colado & Green, 
1995), PCA- (Murray et al., 1996) and methamphetamine- (Kita et al., 2000) induced 
hyperthermia, while others have shown modest neuroprotection without altering 
MDMA-induced acute hyperthermia (Colado et aI., 1997a). 
7.2 METHODS 
7.2.1 Animals, drug administration and temperature measurement 
Adult male NllI/S mice were used for all experiments, except in the 7-NI treatment 
experiment where Swiss Webster mice were employed, and were housed as detailed in 
sections 2.1(1) and 2.1(3). 
Pretreatment compounds were administered 30 min prior to each dose of MDMA (25 
mg/kg i.p.) or saline. This regimen was repeated for a total of three times, at 3 h 
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intervals, the same dose of pretreatment compound being employed on each occasion. 
unless otherwise stated. In the S-MTC and 7-NI experiments, a lower dose of MDMA 
(20 mg/kg i.p.) was used, as the higher dose caused some mortality. However. 
reductions in striatal dopamine and hyperthermic responses were of similar magnitude 
to those seen in all other experiments, indicating that the main effects of MDMA were 
similar to those seen in other parts of the study. Drugs were administered i.p. unless 
otherwise specified. All drugs were administered in normal saline unless otherwise 
stated and doses are quoted as the base weight. 
Rectal temperature was measured, as detailed in section 2.7, at regular intervals during 
all experiments. For the experiment where the effect of different doses of MDMA was 
examined, an M5003 digital thermometer was employed which resulted in the recording 
of lower actual temperature values. However, the changes in rectal temperature were 
similar to those seen in all other experiments. 
7.2.2 Effect of different doses of MDMA on striatal monoamine 
concentrations 
In order to assess the effect of different total doses of MDMA on striatal monoamine 
concentration, the protocol employed for all other experiments was modified. In this 
experiment, groups of mice (n = 6 in each case) were administered either MDMA (25 
mg/kg i.p.) or saline three times at 3 h intervals (0 h, 3 h, 6 h), as follows: (1) MDMA 
was administered at each time-point; (2) MDMA was administered at 0 hand 3 hand 
saline was injected at 6 h; (3) MDMA was administered at 0 h and saline was injected at 
3 hand 6 h; (4) saline was administered at each time-point. 
7.2.3 Measurement of monoamines and their metabolites in cerebral 
tissue 
One week following treatment, rruce were sacrificed and regional brain tissue was 
processed as described in section 2.8. 5-HT, dopamine and their metabolites were 
subsequently measured by h.p.l.c. with electrochemical detection, as described in 
section 2.9.6. 
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7.2.4 Statistics 
Striatal concentrations of dopamine and its metabolites were analysed using one-way 
ANOV A, followed by the Tukey multiple comparison post-hoc test, and regional brain 
concentrations of 5-HT and 5-HIAA were analysed using an unpaired I-test (GraphPad 
Prism). Statistical analyses of temperature data involved ANOV A with repeated 
measures (programme 2V) or, where missing values occurred, an unbalanced repeated 
measures model (programme 5V) was used. TREATMENT was the between subjects 
factor and TIME was the repeated measure. ANOV A was performed on both pre-
treatment and post-treatment data (BMDP/386 Dynamic). 
7.3 RESULTS 
7.3.1 Effect of different doses of MDMA on striatal monoamine 
concentrations and rectal temperature 
Mice administered a single dose of MDMA (25 mg/kg i.p. at 0 h) demonstrated a mean 
3 % decline in striatal dopamine levels, which was not statistically significant. 
Administration of two doses ofMDMA (25 mg/kg i.p. at 0 and 3 h) resulted in a 57 % 
decrease in striatal dopamine concentration compared to control animals, while mice 
administered three doses ofMDMA (25 mg/kg i.p. at 0, 3 and 6 h) demonstrated a 71 % 
decrease in striatal dopamine concentration compared to saline-treated control mice 
(Figures 7.Ia and 7.Ic). There was no statistically significant difference in the loss of 
striatal dopamine between mice administered two or three doses of MDMA. Similar 
reductions were seen in the striatal concentrations of OOP AC and HV A (Figure 7. 1 b), 
while no changes in striatal concentrations of 5-HT or 5-HIAA were observed following 
any of the doses ofMDMA (Table 7.1). 
A single dose of MDMA produced a rise in rectal temperature which lasted for over 3 h, 
while temperature had returned to control values 4 h after administration (Figure 7.2a). 
Mice administered two doses of MDMA (at 0 hand 3 h) demonstrated a similar rise in 
temperature to the first group, this rise being sustained until after the second dose and 
then declined after 5 h, reaching control values 6.5 h after the first dose (Figure 7.2b). 
Mice administered three doses of MDMA demonstrated a rise in temperature following 
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the first dose which was further increased after the second dose. Rectal temperature 
declined towards control values prior to the third dose, after which a rapid increase was 
again observed (Figure 7.2c). 
7.3.2 Effect of MDMA on regional brain 5-HT and 5-HIAA 
concentrations 
Administration of three doses of MDMA did not significantly alter concentrations of 5-
HT or 5-IDAA in the striatum, hypothalamus, hippocampus or cortex as measured 
seven days post-treatment, in any of the experiments performed (for example see Table 
7.2). In addition, this lack of effect was not altered by any of the pretreatment 
compounds investigated (for example see Figure 7.3). 
7.3.3 Effect of NMDA antagonists on MDMA-induced striatal dopamine 
loss and hyperthermia 
The low affinity non-competitive NMDA antagonist AR-R15896AR (20 mg/kg i.p. 
before the first MDMA dose and 5 mglkg i.p. before the second and third doses) did not 
protect against MDMA-induced striatal dopamine loss, there being no difference in 
dopamine concentration between MDMA and AR-R15896AR + MDMA treatment 
groups (Figure 7.4a). MDMA-induced reductions in striatal concentrations of DOPAC 
and HVA were also not modified by AR-R15896AR pretreatment (Table 7.3). AR-
R15896AR had no effect on the acute hyperthermic response following the first two 
injections ofMDMA but abolished the rise seen following the third dose (Figure 7.4b). 
The high affinity non-competitive NMDA antagonist, MK-801 (0.5 mglkg i.p.) also 
afforded no protection against MDMA-induced reductions in striatal dopamine 
concentration (Figure 7.5a). This compound had no overall statistically significant 
effect on MDMA-induced hyperthermia, although the MDMA-induced temperature rise 
following the third dose was prevented by MK-801 pretreatment (Figure 7.5b). There 
were no statistically significant differences between MDMA- and saline-treatment 
groups with respect to striatal concentrations of DOPAC or HV A (Table 7.4). 
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Figure 7.1 Effect of different doses of MDMA on striatal concentrations of dopamine and its metabolites. 
3 
MDMA (25 mglkg i.p ., 1,2 or 3 doses) or saline was administered 3 times at 3 h intervals and striatal concentrations of dopamine, DOPAC and HVA 
were measured 1 week post-treatment. Results shown as mean ± s.e.m., n = 5 - 6 in each group. (a) Dopamine. There was a significant difference 
between treatment groups (F (3, 20) = 21.2, P < 0.0001) and Tukey's multiple comparison test demonstrated a significant reduction in dopamine levels 
in MDMA (x 2) and MDMA (x 3) treatment groups compared to saline-treated control mice (***p < 0.001) and compared to the MDMA (x 1) 
treatment group (M1p < 0.001). (b) DOPAC and HVA. There was a significant difference between treatment groups in the concentrations of DOPAC (F 
(3, 20) = 10.0, P < 0.00l) and HVA (F (3 , 20) = 4.8, P < 0.05). Tukey's multiple comparison test demonstrated a significant reduction in: (1) DOPAC 
levels in MDMA (x 2) and MDMA (x 3) treatment groups compared to saline-treated control mice (**p < 0.01) and compared to the MDMA (x 1) 
treatment group (6p < 0.05 ; Mp < 0.0 I), and (2) HV A levels in the MDMA (x 2) treatment group compared to saline-treated control mice (*p < 0.05). 
(c) Loss of striatal dopamine following 1, 2 or 3 doses ofllfl)l~, calculated as a % of control values. 
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Indole concentration (nsLs ti~~y~) 
Treatment 5-HT 5-HIAA 
Saline 220 ± 10 (6) 208 ± 21 (6) 
MDMA(x 1) 230 ± 23 (6) 219±34(5) 
MDMA(x2) 193 ± 25 (6) 199 ± 41 (6) 
MDMA(x3) 210 ± 14 (5) 241 ± 13 (5) 
One-way ANOV A F (3,20) = 0.7 F (3, 20) = 0.4 
Table 7.1 Effect of different doses of MDMA on striatal concentrations of 5-
HT and 5-HIAA. 
MDMA (25 mg/kg i.p., 1, 2 or 3 doses) or saline was administered 3 times at 3 h 
intervals and striatal concentrations of 5-HT and 5-HIAA were measured 1 week post-
treatment. Results shown as mean ± s.e.m. There were no statistically significant 
reductions in the concentrations of 5-HT or 5-HIAA following any of the doses of 
MDMA. 
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MDMA (25 mg/kg i.p .• 1. 2 or 3 doses) or saline was administered 3 times at 3 h intervals (denoted by arrows). Results shown as mean ± s.e.m., n = 5 -
6 in each group. (a) Effect of 1 dose of MDMA. MDMA was administered at 0 h and saline was administered at 3 and 6 h. MDMA-treated animals 
demonstrated a significant rise in rectal temperature compared to control mice. during to. 35 (F (1, 10) = 12.2, P < 0.01). (b) Effect of2 doses of MDMA 
MDMA was administered at 0 and 3 h and saline was administered at 6 h. MDMA-treated animals demonstrated a significant rise in rectal temperature 
compared to control mice (F (I, 10) = 14.4, p < 0.01). (c) Effect of 3 doses of MDMA. MDMA was administered at all 3 time-points (0, 3 and 6 h). 
MDMA-treated animals demonstrated a significant rise in rectal temperature compared to control mice (F (1.9) = 32.5, P < 0.01). 
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Indole concentration 
(ngLg tissue) 
Indole Saline MDMA % loss t p 
Striatum 5-HT 314±18 275 ± 34 12 1.1 0.3 
5-HIAA 257 ±24 267 ± 21 
- 0.3 0.8 
Hypothalamus 5-HT 494 ± 52 422 ± 56 15 1.0 0.4 
5-HIAA 387 ± 56 345 ± 60 11 0.5 0.6 
Hippocampus 5-HT 357 ± 40 344 ± 19 4 0.3 0.8 
5-HJAA 312 ± 22 345 ± 23 
- 1.0 0.3 
Cortex 5-HT 425 ± 56 350 ± 18 18 1.2 0.3 
5-HIAA 165 ± 22 144 ± 8 13 0.8 0.4 
Table 7.2 Effect of MDMA on regional brain concentrations of 5-HT and 5-
HIAA. 
Mice were administered MDMA (25 mglkg Lp.) or saline, 3 times at 3 h intervals, and 
regional brain concentrations of 5-HT and 5-IDAA were measured 1 week post-
treatment. Results shown as mean ± s.e.m. There were no statistically significant 
reductions in the concentrations of 5-HT or 5-IDAA in any of the brain regions 
examined. 
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Figure 7.3 Effect of c1omethiazole (CMZ) pretreatment on regional brain 5-RT 
and 5-HIAA concentrations following MDMA administa·ation. 
Mice were administered CMZ (50 mg/kg i. p.) or saline 30 min before 'MDMA (25 
mg/kg i.p.) or saline, 3 times at 3 h intervals, and regional brain concentrations of 5-HT 
and 5-IDAA were measured 1 week post-treatment. Results shown as mean ± s.e.m. n 
= 3 - 6 in each group . There were no differences between treatment groups with respect 
to concentrations of 5-HT or 5-IDAA in all brain regions examined (striatum, 
hypothalamus, hippocampus, cortex) . 
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Figure 7.4 Effect of AR-R15896AR on MDMA-induced striatal dopamine loss and acute hyperthermia. 
Mice were administered AR-R15896AR (dose I, 20 mglkg i.p.; doses 2 and 3, 5 mglkg i.p.) or saline 30 min before MDMA (25 mg/kg i.p.) or saline, 3 
times at 3 h intervals. Results shown as mean ± s.e.m., n = 3 - 6 in each group. (a) Striatal dopamine concentration measured I week after treatment. 
There was a significant difference between treatment groups (F (3, 20) = 58 .6, P < 0.0001) and Tukey's multiple comparison test demonstrated a 
significant reduction in dopamine levels compared to saline-treated control animals, in both MDMA and AR-R 15896AR + MDMA treatment groups 
(***p < 0.001). (b) MDMA-induced acute hyperthermia. Broken arrows denote times of AR-R15896AR1saline injections, full arrows denote 
MDMAlsaline injections. There was no difference in the basal temperature of the groups . MDMA produced a significant rise in rectal temperature (F (1 
8) = 196.8, P < 0.001) compared to saline-treated mice. MDMA-induced hyperthermia was attenuated after the third dose of AR-R15896AR (F (1 , 10) = 
18.2, p < 0.0 1). AR-R15896AR had no effect on the rectal temperature of control mice. 
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DOJ2amine metabolite conc~ntriltion (ngig ti~~y~) 
Treatment DOPAC HVA 
Saline 2364 ± 538 931±125 
MDMA 1077 ± 195 645 ± 103 
AR-R15896AR 1248 ± 88 754 ± 42 
+MDMA 
AR-R15896AR 2588 ± 638 1049± 141 
One-way ANOY A F (3, 20) = 4.5* F (3,20) = 3.5'" 
Table 7.3 Effect of AR-R15896AR on MDMA-induced loss of DOPAC and 
HV A in the striatum. 
Mice were administered AR-R15896AR (dose 1, 20 mg/kg i.p.; doses 2 and 3, 5 mglkg 
i.p.) or saline 30 min before MDMA (25 mg/kg i.p.) or saline, 3 times at 3 h intervals, 
and striatal DOPAC and HV A concentrations were measured 1 week post-treatment. 
Results shown as mean ± s.e.m., n = 3 - 6 in each group. There was a significant 
difference between treatment groups with respect to the concentrations of both DOP AC 
and HV A (*p < 0.05), but Tukey's multiple comparison test did not reveal any 
differences between specific pairs of treatment groups. 
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Effect ofMK-801 on MDMA-induced striatal dopamine loss aDd acute hyperthermia. 
7 8 
Mice were administered MK-801 (0.5 mglkg i.p.) or saline 30 min before MDMA (25 mglkg i.p.) or saline, 3 times at 3 h intervals. Results shown as 
mean ± s.e.m. , n = 3 - 6 in each group. (a) Striatal dopamine concentration measured 1 week after treatmellt. There was a significant difference 
between treatment groups (F (3, 20) = 14.9, p < 0.000 1) and Tukey's multiple comparison test demonstrated a significant reduction in dopamine levels 
compared to saline-treated control animals, in the MK-80 1 + MDMA treatment group (*p < 0.05) . (b) MDMA-induced acute hyperthermia. Broken 
arrows denote times of MK-80l/saline injections, full arrows denote MDMAlsaline injections. There was no difference in the basal temperature of the 
groups . MDMA produced a significant rise in rectal temperature (F (1 , 8) = 8.8, P < 0.05) compared to saline-treated mice. MK-801 did not modify 
MDMA-induced hyperthermia and bad no effect aD the rectal temperature of control mice. . 
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DOQamine metabolite concentration (ngLg tis~y~) 
Treatment DOPAC HVA 
Saline 1923 ± 235 884 ± 101 
MDMA 1404 ± 193 755 ± 92 
MK-801 +MDMA 1406 ± 298 757 ± 111 
MK-801 2172 ± 91 977 ± 67 
One-way ANDV A F (3, 20) = 3.8* F (3, 20) = 1.6 
Table 7.4 Effect of MK-801 on MDMA-induced loss of DOPAC and HVA in 
the striatum. 
Mice were administered MK-801 (0.5 mglkg i.p.) or saline 30 min before MDMA (25 
mglkg i.p.) or saline, 3 times at 3 h intervals, and striatal DOPAC and HVA 
concentrations were measured 1 week post-treatment. Results shown as mean ± s.e.m., 
n = 3 - 6 in each group. There was a significant difference between treatment groups 
with respect to DOPAC concentration (*p < 0.05), but Tukey's mUltiple comparison test 
did not reveal any significant differences between specific pairs of treatment groups. 
There was no difference between treatment groups with respect to HV A concentration. 
Chapter 7 
7.3.4 
Neuroprotection 
Effect of c1omethiazole on MDMA-induced striatal dopamine loss 
and hyperthermia 
The GABAmimetic compound clomethiazole (CMZ; 50 mg/kg i.p.) did not protect 
against MDMA-induced striatal dopamine loss (Figure 7.6a) and there were no 
statistically significant differences between treatment groups with respect to striatal 
levels of DOPAC or HV A (Table 7.5). Following each dose of c]omethiazole. a 
hypothermic response was observed in both MDMA- and saline-treated mice (Figure 
7.6b). However, apart from after the third dose of clomethiazole where hypothennia 
was sustained for over 1 h, CMZ + MDMA-treated mice still demonstrated peak 
hyperthermic responses similar to those ofMDMA-treated mice (Figure 7.6b). 
7.3.5 Effect of NOS inhibitors on MDMA-induced striatal dopamine loss 
and hyperthermia 
The novel, and relatively selective, nNOS inhibitor AR-R17477AR (5 mglkg s.c.) 
provided complete protection against MDMA-induced striatal dopamine loss (Figure 
7.7a). There were no statistically significant differences between treatment groups with 
respect to DOP AC or HV A concentrations, although both metabolites were reduced in 
MDMA-treated mice (Table 7.6). Following each dose of AR-R17477AR, a 
hypothermic response was observed in MDMA- treated mice (Figure 7.7b). However, 
apart from after the third dose of AR-RI7477AR, AR-R17477AR + MDMA-treated 
mice still demonstrated peak hyperthermic responses which corresponded to the 
temperature response ofMDMA-treated mice (Figure 7.7b). 
The NOS inhibitor S-methyl-L-thiocitrulline (S-MTC; 10 mg/kg i.p.) also provided 
significant neuroprotection against striatal dopamine loss (Figure 7.8a), without altering 
the MDMA-induced hyperthermic response (Figure 7.8b). 
Pretreatment with the NOS inhibitor 7-nitroindazole (7-NI; 50 mg/kg i.p.) produced 
substantial protection against MDMA-induced striatal dopamine loss (Figure 7.9a) 
However, in contrast to the other two NOS inhibitors used, 7-NI also induced a marked 
hypothermic response in both MDMA- and saline-treated animals (Figure 7.9b). 
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Effect of c1omethiazole (CMZ) on MDMA-induced striatal dopamine loss and acute hyperthermia. 
8 
Mice were administered CMZ (50 mg/kg i.p .) or saline 30 min before MDMA (25 mg/kg i.p .) or saline, 3 times at 3 h intervals . Results shown as mean 
± S.e.ffi., n = 3 - 6 in each group. (a) Striatal dopamine concentration measured 1 week after treatment. There was a significant difference between 
treatment groups (F (3, 20) = 26.1, p < 0.0001) and Tukey's multiple comparison test demonstrated a significant reduction in dopamine levels compared 
to saline-treated control mice, in both MDMA and CMZ + MDM1\Jireatment groups (***p < 0.001) . (b) MDMA-illduced acute hyperthermia. Broken 
arrows denote times of CMZ/saline injections, full arrows denote MDIvWsaline injections. There \\'as no difference in the basal temperature of the 
groups. MDMA produced a significant rise in rectal temperature (F (1, 9) = 20.9, p < 0.0 1) compared to saline-treated mice. CMZ induced a 
hypothermic response in both MDMA-treated (F (I , 9) = 7.5, P < 0.05) and saJine-treated mice (F (1, 10) = 12.7, p < 0.01). 
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Chapter 7 Neuroprotection 
DOQamine metabolite concentration (niLg ti~sy~) 
Treatment DOPAC HVA 
Saline 1230 ± 155 654 ± 67 
MDMA 1107 ± 123 562 ± 51 
CMZ+MDMA 777 ± 85 512 ± 50 
CMZ 1196 ± 124 584 ± 39 
One-way ANOV A F (3, 19) = 2.9 F (3,19) = 1.3 
Table 7.5 Effect of clomethiazole (CMZ) on MDMA-induced loss of DOPAC 
and BV A in the striatum. 
Mice were administered CMZ (50 mglkg Lp.) or saline 30 min before MDMA (25 
mglkg Lp.) or saline, 3 times at 3 h intervals, and striatal DOPAC and HVA 
concentrations were measured 1 week post-treatment. Results shown as mean ± s.e.m., 
n = 3 - 6 in each group. There were no statistically significant differences between 
treatment groups with respect to OOP AC or HV A concentrations. 
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Effect of AR-R17477AR on MDMA-induced striatal dopamine loss and acute hyperthermia. 
Mice were administered AR-RI7477AR (5 mglkg s .c.) or saline 30 min before MDMA (25 mglkg i.p.) or saline, 3 times at 3 h intervals. Results shown 
as mean ± s .e.m., n = 3 - 6 in each group . (a) Striatal dopamine concentration measured 1 week after treatment. There was a significant difference 
between treatment groups (F (3, 20) = 9.7, P < 0.001) and Tukey' s multiple comparison test demonstrated a significant reduction in dopamine levels 
compared to saline-treated control mice, in MDMA-treated animals (***p < 0.001). AR-RI7477AR protected against this reduction (AR-RI7477AR + 
MDMA different from MDMA, Mp < 0.01). (b) MDMA-induced acute hyperthermia. Broken arrows denote times of AR-RI7477AR1saline injections, 
full arrows denote MDMNsaline injections. There was no difference in the basal temperature of the groups. MDMA produced a significant rise in 
rectal temperature (F (1 , 8) = 18 .0, P < 0 .01) compared to saline-treated mice. AR-R I7477AR induced a hypothermic response in MDMA-treated mice, 
after the third dose (F (1, 7) = 68 .6, P < 0.00l). 
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Chapter 7 Neuroprotection 
DOl2amine metabolite concentration (ngl8 tis~y~) 
Treatment DOPAC HVA 
Saline 1406 ± 81 914 ± 40 
MDMA 1021 ± 116 731 ± 59 
AR-R17477AR 1143±108 855 ± 76 
+MDMA 
AR-R17477AR 1241 ± 151 903 ± 59 
One-way ANOV A F (3, 15) = 2.0 F (3, 15) = 2.2 
Table 7.6 Effect of AR-R17477AR 00 MDMA-ioduced loss of DOPAC and 
BV A in the striatum. 
Mice were administered AR-R17477 AR (5 mglkg s.c.) or saline 30 min before MDMA 
(25 mglkg i.p.) or saline, 3 times at 3 h intervals, and striatal DOPAC and HV A 
concentrations were measured 1 week post-treatment. Results shown as mean ± s.e.m., 
n = 3 - 6 in each group. There were no significant differences between treatment groups 
with respect to DOP AC or HV A concentrations. 
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Effect of S-methyl-L-thiocitrulline (S-MTC) on MDMA-induced striatal dopamine loss and acute hyperthermia. 
Mice were administered S-MTC (10 mg/kg i.p .) or saline 30 min before MDMA (20 mg/kg i.p.) or saline, 3 times at 3 h intervals. Results shown as 
mean ± s.e.m., n = 6 - l Oin each group. (a) Striatal dopamine concentration measured 1 week after treatment. There was a significant difference 
between treatment groups (F (3 , 24) = 9.7, P < 0.0001) and Tukey's multiple comparison test demonstrated a significant reduction in dopamine levels 
compared to saline-treated control mice, in both MDMA and S-MTC + MDMA treatment groups (***p < 0.00 I). S-MTC provided significant 
protection against this reduction (S-MTC + MDMA different from MDMA, Mp < 0.01) . (b) tvmMA-induced acute hyperthermia. Broken arrows 
denote times of S-MTC/saline injections, full arrows denote MDMAlsaline injections . There was no difference in the basal temperature of the groups. 
MDMA produced a significant rise in rectal temperature (F (1 , 16) = 17.2, p < 0.00 1) compared to saline-treated mice. S-MTC did not modify the 
MDMA-induce hyperthermic response and had no effect on the rectal temperature of control mjce. 
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Figure 7.9 Effect of 7-nitroindazole (7-NI) on MDMA-induced striatal dopamine loss and acute hyperthermia. 
Mice were administered 7-NI (50 mg/kg i.p .) or saline 30 min before MDMA (20 mg/kg i.p.) or saline, 3 times at 3 h intervals. Results shown as mean 
± s.e.m., n = 6 - 10 in each group. (a) Striatal dopamine concentration measured 1 week after treatment. There was a significant difference between 
treatment groups (F (3, 40) = 17.9" P < 0.0001) and Tukey's mUltiple comparison test demonstrated a significant reduction in dopamine levels compared 
to saline-treated control mice, in both MDMA (***p < 0.00l) and 7-NI + MDMA (*p < 0.05) treatment groups. 7-NI provided significant protection 
against this reduction (7-NI + MDMA different from MDMA, 6Mp < 0.001). (b) MDMA-induced acute hyperthermia. Broken arrows denote times of 
7-N1fsaline injections, futi arrows denote MDMNsaline injections. MDMA produced a significant rise in rectal temperature (F (1 , 22) = 7.6, P < 0.01) 
compared to saline-treated mice. 7-NI abolished the MDMA-induced hyperthermic response (F (1 , 25) = 24.3, P < 0.001) and induced a frank 
hypothennia in saline-treated mice (F (1 , 16) = 169.0, P < 0.001) . 
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Chapter 7 
7.3.6 
Neuroprotection 
Effect of PBN on MDMA-induced striatal dopamine loss and 
hyperthermia 
The nitrone free radical trapping agent a-phenyl-N-tert-butyl nitrone (pBN; 120 mg/kg 
i.p.) did not protect against MDMA-induced striatal dopamine loss (Figure 7. lOa) or 
against loss of striatal DOPAC and HVA (Table 7.7). This dose also did not modify 
MDMA-induced hyperthermia, even though a hypothermic response was observed in 
saline-injected control animals (Figure 7.1 Ob). 
At a dose of 150 mg/kg i.p. however, there was no difference in striatal dopamine 
concentration (Figure 7. 11 a), or DOPAC and HV A concentrations (Table 7.8), between 
the PBN + ~MA treatment group and saline-treated control animals. However, this 
effect was accompanied by a hypothermic response in both ~MA- and saline-treated 
mice (Figure 7.11b). 
A third protocol was undertaken in an attempt to attain neuroprotection without 
modification of the MDMA-induced hyperthermic response. PBN was administered at a 
dose of 120 mglkg i.p. on the first two occasions and at a dose of 150 mslkg i.p. on the 
third occasion. Following each dose of PBN a hypothermic response was observed in 
MDMA- treated mice, but, apart from after the third dose of PBN, PBN + MDMA-
treated mice still demonstrated peak hyperthermic responses which corresponded to the 
temperature responses ofMDMA-treated mice (Figure 7.l2b). However, this treatment 
regime did not prevent the ~MA-induced striatal dopamine loss~ dopamine 
concentrations in PBN + MDMA-treated mice were the same as those recorded in 
MDMA-treated animals (Figure 7.12a). There were no statistically significant 
reductions in DOP AC or HV A concentrations in MDMA-treated animals compared to 
saline-treated control animals (Table 7.9). 
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Figure 7.10 Effect of a-phenyl-N-tert-butyl nitrone (PBN, 120 mg/kg x 3) on MDMA-induced striatal dopamine loss and acute 
hyperthermia. 
Mice were administered PBN (120 mg/kg i.p.) or saline 30 min before MDMA (25 mg/kg i.p .) or saline, 3 times at 3 h intervals. Results shown as mean 
± s.e.m., n = 3 - 6 in each group. (a) Striatal dopamine concentration measured 1 week after treatment. There was a significant difference between 
treatment groups (F (3 , 20) = 33.5, P < 0.0001) and Tukey's multiple comparison test demonstrated a significant reduction in dopamine levels in 
MDMA-treated animals, compared to saline-treated control mice, in both MDMA and PBN + MDMA treatment groups (***p < 0.001) . (b) MDMA-
induced acute hyperthermia. Broken arrows denote times of PBN/saJine injections, full arrows denote MDMAlsaline injections. There was no 
difference in the basal temperature of the groups. MDMA produced a significant rise in rectal temperature (F (l , 8) = 208.4, p < 0.001) compared to 
saline-treated mice. PBN induced a hypothermic response in MDMA-treated mice, folJowing the fi rst dose (F (I , 9) = 15.3, P < 0.01) and in saline-
treated mice after each dose (F (I , 7) = 77.4, P < 0.001). 
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Chapter 7 Neuroprotection 
Do~amine metabolite concentrlltiQn (n~g ti~~y~) 
Treatment DOPAC HVA 
Saline 2364 ± 538 930 ± 125 
MDMA 1077 ± 195* 645 ± 103 
PBN (120) + MDMA 1302 ±486 657 ± 187 
PBN (120) 2301 ± 338 1004 ± 95 
One-way ANOY A F (3, 20) = 4.3~ F (3,20) = 2.9 
Table 7.7 Effect of a-phenyl-N-tert-butyl nitrone (PBN, 120 mg/kg x 3) on 
MDMA-induced loss of DOPAC and HVA in the striatum. 
Mice were administered PBN (120 mglkg i.p.) or saline 30 min before MDMA (25 
mg/kg i.p.) or saline, 3 times at 3 h intervals, and striatal DOPAC and HV A 
concentrations were measured 1 week post-treatment. Results shown as mean ± s.e.m., 
n = 3 - 6 in each group. There was a significant difference between treatment groups 
with respect to DOPAC concentration ep < 0.05) and Tukey's multiple comparison test 
demonstrated a significant loss in striatal DOPAC in MDMA-treated mice (*p < 0.05) 
compared to saline-treated mice. PBN did not protect against this loss. There were no 
differences between treatment groups with respect to HV A concentration. 
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Figure 7.11 Effect of a-phenyl-N-tert-butyl nitrone (PBN, 150 mg/kg x 3) on MDMA-induced striatal dopamine loss and acute 
hyperthermia. 
Mice were administered PBN (1 50 mg/kg i.p.) or saline 30 min before MDMA (25 mg/kg i.p .) or saline, 3 times at 3 h intervals. Results shown as mean 
± s.e.m. , n = 3 - 6 in each group. (a) StriataL dopamine concentration measured I week after treatment. There was a significant difference between 
treatment groups (F (3, 20) = 6.4, P < 0.01) . (b) MDMA-induced acute hyperthermia. Broken arrows denote t~es of PBN/saline injections, full arrows 
denote MDMAlsaline injections . MDMA produced a significant rise in rectal temperature (F (1 , 8) = 8.8, P < 0.05) compared to saline-treated mice. 
PBN induced a hypothemuc response in both MDMA-treated (F (1 , 9) = 34.2, P < 0.001) and saline-treated mice (F (I, 6) = 14.7, P < 0.01). 
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Chapter 7 Neuroprotection 
DOQamine metabolite concentration (ngLg tissue) 
Treatment DOPAC HVA 
Saline 1923 ± 235 884 ± 101 
MDMA 1404 ± 193 755 ± 92 
PBN (150) + MDMA 1797± 188 976 ± 91 
PBN (150) 2360 ± 317 1045 ± 63 
One-way ANOV A F (3,20) = 4.0* F (3, 20) = 2.6 
Table 7.8 Effect of a-phenyl-N-tert-butyl nitrone (PBN, 150 mg/kg x 3) on 
MDMA-induced loss of DOPAC and HVA in the striatum. 
Mice were administered PBN (150 mglkg i.p.) or saline 30 min before MDMA (25 
mg/kg i.p.) or saline, 3 times at 3 h intervals, and striatal DOPAC and HV A 
concentrations were measured 1 week post-treatment. Results shown as mean ± s.e.m., 
n = 3 - 6 in each group. There was a significant difference between treatment groups 
with respect to DOPAC concentration (*p < 0.05) and no differences between treatment 
groups with respect to HV A concentration. 
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Figure 7.12 Effect of a-phenyl-N-tert-butyl nitrone (PBN, 120 + 120 + 150 mg/kg) on MDMA-induced striatal dopamine loss and 
acute hyperthermia. 
Mice were administered PBN (first 2 doses, 120 mglkg i.p., third dose, 150 mglkg i.p .) or saline 30 min before MDMA (25 mg/kg i.p .) or saline, 3 
times at 3 h intervals . Results shown as mean ± s.e.m., n = 3 - 6 in each group . (a) Striatal dopamine concentration measured 1 week after treatment 
There were no statistically significant differences between treatment groups. (b) MDMA-illduced acute hyperthermia. Broken arrows denote times of 
PBN/saline injections, full arrows denote MDMAlsaline injections . There was no difference in the basal temperature of the groups . MDMA produced a 
significant rise in rectal temperature (F (1 , 10) = 9.0, p < 0.05) compared to saline-treated mice. PBN induced a hypothermic response in both MDMA-
treated (F (1 , 8) = 10.8, P < 0.05) and saline-treated mice (F (1 , 10) = 27.6, P < 0.001) . 
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Chapter 7 Neuroprotection 
Dopamine metabQlit~ concentratiQn (ngLg tiI2I2Y~) 
Treatment DOPAC HVA 
Saline 961 ± 68 574 ± 34 
MDMA 678 ± 90 411 ± 39 
PBN (120 + 120 + 150) + MDMA 632 ± 169 405 ± 76 
PBN (120 + 120 + 150) 753 ± 114 468 ± 47 
One-way ANOV A F (3, 20) = 1.9 F (3,20) = 2.9 
Table 7.9 Effect of PBN (120 + 120 + 150 mg/kg) on MDMA-induced loss of 
DOPAC and HV A in the striatum. 
Mice were administered PBN (first 2 doses, 120 mg/kg i.p., third dose, 150 mglkg i.p.) 
or saline 30 min before MDMA (25 mglkg Lp.) or saline, 3 times at 3 h intervals. and 
striatal DOP AC and HV A concentrations were measured 1 week post-treatment. Results 
shown as mean ± s.e.m., n = 3 - 6 in each group. There were no statistically significant 
differences between treatment groups with respect to DOP AC or HV A concentrations. 
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7.4 DISCUSSION 
This study has highlighted some of the differences in MDMA-induced neurotoxicity 
between rats and mice and has demonstrated that putative neuroprotective compounds 
differ in their ability to prevent long-lasting damage to monoaminergic systems in the 
two species. In concurrence with previous studies (Laverty & Logan, 1990; Logan et 
al., 1988; Miller & O'Callaghan, 1994; 1995; O'Callaghan & Miller, 1994; O'Shea et 
al., 2001), MDMA administration produced a selective neurotoxic loss of striatal 
dopamine and its metabolites, while regional brain concentrations of 5-HT and 5-HIAA 
were unaffected. In addition, none of the pretreatment compounds employed had any 
effect on 5-HT or 5-HlAA concentrations. 
Previous studies on the effects of both methamphetamine and MDMA in mice have 
demonstrated that several doses (three or four doses administered within 24 h) are 
required to produce neurotoxic damage (e.g. Colado et ai., 1999c; Laverty & Logan, 
1990; Logan et al., 1988; Miller & O'Callaghan, 1993; 1994; 1995; O'Callaghan & 
Miller, 1994; O'Shea et ai., 2001; Sonsalla et al., 1989; 1991; Stone et al., 1987a). The 
effects of one, two or three doses of MDMA on striatal monoamine concentrations were 
thus investigated in the current study. 5-HT and 5-HIAA concentrations were unaltered, 
whereas dose-dependent reductions in dopamine, DOPAC and HVA were observed: 
three doses of MDMA administered at 3 h intervals resulted in a 71 % reduction in 
striatal dopamine concentration compared to control animals, two doses induced a 57 % 
reduction, and one dose had no significant effect on striatal dopamine concentration. All 
subsequent experiments therefore utilised the administration of three doses of MDMA 
at 3 h intervals and resulted in 40 - 60 % reductions in striatal dopamine concentration 
in MDMA-treated mice. 
In the preliminary experiment, the temperature responses after one, two and three doses 
of MDMA were also monitored. A single dose produced a rise in rectal temperature of 
approximately + 1. 5 °C, which was sustained for over 3 h; two doses resulted in a 
temperature rise after the first dose, which was sustained for over 5 h; three doses 
resulted in a hyperthermic response after the first dose, which was sustained for over 5 
h, temperature then declined towards control values prior to the third dose, after which 
248 
Chapter 7 Neuroprotection 
an increase in temperature was observed. In all other experiments, an increase in rectal 
temperature of approximately +2 °C was observed following the first dose of MDMA 
and rectal temperature declined towards pretreatment values prior to the second dose, 
after which a second rise in temperature was observed. The same pattern of decline 
towards control values and subsequent hyperthermic response were seen prior to and 
following the third dose of'MDMA, respectively. The likely reason for the different 
temperature responses seen in the preliminary experiment, compared to all other 
experiments, is the different thermometer used - a digital thermometer was used in the 
preliminary experiment, which gave lower value readings than the rectal probes used in 
all other experiments. 
The two NMDA antagonists used in the current study - AR-R15896AR and MK-80\ _ 
have previously been demonstrated to be neuroprotective in animal models of ischaemia 
(see Buchan & Pulsinelli, 1990; Cregan et ai., 1997). MK-801 has also been shown to 
protect against MDMA-, methamphetamine- and p-chloroamphetamine-induced 
neurotoxicity in rats and against MDMA-, MDA- and methamphetamine-induced 
neurotoxicity in mice (as reviewed in the introduction; see section 7.1.2). However, 
MK-801 has also been shown to induce hypothermia, which itself is likely to produce 
neuroprotection (Albers & Sonsalla, 1995; Ali et ai., 1994; Farfel & Seiden, 1995a; 
1995b; Miller & o 'Callaghan, 1994; 1995). In the current study, neither AR-
R15896AR nor MK-801 protected against MDMA-induced dopaminergic neurotoxicity 
in mice; the lack of protective effect of AR-R15896AR concurred with results seen in 
rats, where it did not protect against 'MDMA-induced serotonergic damage (Colado et 
aI., 1998). In addition, neither of the NMDA antagonists had any effect on MDMA-
induced hyperthermia, with the exception of the third dose in each case; both AR-
R15896AR and MK-801 attenuated the hyperthermic response to MDMA treatment 
following the third dose of pretreatment compound. However, since neither of the 
NMDA antagonists prevented 'MDMA-induced neurotoxicity, it seems likely that the 
degree of hypothermia produced following the third dose of antagonist in each 
experiment was insufficient to provide neuroprotection. Thus it appears that activation 
ofNMDA receptors is not directly involved in MDMA-induced neurotoxicity in mice. 
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The GABAmimetic compound clomethiazole has been demonstrated to provide 
neuroprotection in animal models of ischaemia and against MDMA-induced 
neurotoxicity in rats and methamphetamine-induced neurotoxicity in rats and mice (see 
section 7.1.2)' However, c1omethiazole did not alter MDMA-induced striatal dopamine 
loss in mice and, with the exception of the third dose, c1omethiazole also did not modify 
MDMA-induced hyperthermia. Therefore, the fact that clomethiazole is neuroprotective 
against MDMA-induced serotonergic neurotoxicity in rats (although the mechanism 
involved is yet to be clarified), the lack of neuroprotection in mice indicates some 
different mechanism of action between the two species. 
Each of the three NOS inhibitors used in the current study (AR-RI7477AR, S-MTC and 
7-NI) provided significant neuroprotection against MDMA-induced dopamine loss in 
the mouse striatum. These results are, in general, in agreement with previous studies 
where all three compounds have been demonstrated to provide neuroprotection in 
different rodent models of neurodegeneration. For example, AR-R17477 AR provides 
protection in animal models of global and focal ischaemia, S-MTC and 7-NI protect 
against methamphetamine-induced neurotoxicity in mice, and 7-NI protects against 
MDMA-induced neurotoxicity in mice (see section 7.1.2). However, there is some 
controversy as to whether 7-NI is neuroprotective through effects on amphetamine-
induced hyperthermia; Callahan & Ricaurte (1998) reported that 7 -NI prevented 
methamphetamine-induced hyperthermia, and Colado et al. (1999c) demonstrated 
similar effects following MDMA administration to mice. In contrast, Di Monte et al. 
(1996), Itzhak & Ali (1996) and Itzhak et aJ. (2000) did not demonstrate any effects of 
7-NI on methamphetamine-induced hyperthermia, except at a high dose (50 mg/kg 
administered 30 min before methamphetamine, three times at 3 h intervals; Itzhak el (d., 
2000). In the current study, AR-R17477 AR only attenuated MDMA-induced 
hyperthermia after the third dose. Based on the NMDA antagonist experiments, where 
hyperthermia was also only attenuated after the third dose of pretreatment compound 
(see section 7.3.2), this should not, in itself, have provided neuroprotection. S-MTC did 
not modify the MDMA-induced hyperthermic response, but did provide significant 
neuroprotection, while 7-NI did prevent MDMA-induced hyperthermia. Therefore, in 
mice, NOS inhibitors have been demonstrated to play an important role in protection 
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against MDMA-induced striatal dopamine loss, which, in the case of AR-R17477 AR 
and S-MTC, is not dependent on modification of the hyperthermic response. 
In the current study, PBN only provided neuroprotection against MDMA-induced 
striatal dopamine loss where the acute hyperthermic response was significantly 
attenuated or completely prevented: (1) the lowest dose administered (120 mg/kg) did 
not modify MDMA-induced reductions in striatal dopamine measured one week post-
treatment and had no effect on MDMA-induced hyperthermia; (2) administration of the 
highest dose (150 mg/kg) resulted in striatal dopamine concentrations in PBN + 
. MDMA-treated mice being the same as those in saline-treated mice, but a hypothermic 
response was observed in PBN-treated mice; (3) the intermediate dose of PBN (120 + 
120 + 150 mg/kg) did not prevent MDMA-induced striatal dopamine loss and did not 
alter the peak hyperthermic responses of MDMA-treated mice. These results are 
consistent with preVIOUS studies, which have demonstrated PBN-induced 
neuroprotection against MDMA- and PCA-induced neurotoxicity in rats and against 
MPTP- and methamphetamine-induced neurotoxicity in mice, while there is some 
evidence for prevention of amphetamine-induced hyperthermia (as reviewed in the 
introduction; see section 7.1.2). The lack of protective effect of PBN against MDMA-
induced neurotoxicity in mice indicates that the free radical species scavenged by PBN 
are not directly involved. 
It should be noted here that rectal temperature was measured in all experiments, thus 
hyperthermic and hypothermic responses are described with reference to rectal 
temperature rather than brain temperature. Neuroprotection can be attained in animal 
models of ischaemia by reducing brain temperature (e.g. Barone et ai., 1997), while 
rectal temperature has been reported to unreliably reflect brain temperature in such 
models (see Busto et al., 1987) . .19-tetrahydrocannabinol (THe) has also been reported 
to provide neuroprotection against focal and global ischaemia, possibly via the 
induction of hypothermia. However, chronic administration of THC has recently been 
demonstrated to induce an increase in brain temperature, while rectal temperature was 
not significantly altered (perron et al., 2001). The question therefore arises as to 
whether compounds which have been shown to be neuroprotective, such as AR-
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R17477AR, provide such protection via a reduction in brain temperature (while rectal 
temperature is unaltered) or some other mechanism. Further examination of the 
mechanisms involved in mediation of brain and rectal temperature are clearly required 
and, ideally, measurement of both should be performed during investigation of putative 
neuroprotective compounds. 
The current study has demonstrated that NOS is involved m MDMA-induced 
dopaminergic neurotoxicity in mice, but the exact mechanistic pathway is, as yet, 
unclear. There is believed to be an excitotoxic cascade of events which occurs following 
glutamatergic stimulation of NMDA receptors, resulting in the production of nitric 
oxide (NO) and free radicals (see Figure 7.13; Rang et al., 1995). NMDA receptor 
activation results in increased calcium ion (Ca2+) movement inwards through the 
NMDA receptor channel. Subsequently, calcium-calmodulin activates NOS, leading to 
the formation of NO + L-citrulline from L-arginine + oxygen (02). Depending on the 
redox state of the cell, NO may be formed as either: (1) NO·, which reacts with 
superoxide anions (02) to form peroxynitrite radicals (ONOO") or, (2) NO", which 
nitrosylates a sulphydryl group on the NMDA receptor causing its downregulation thus 
preventing further Ca2+ entry. ONOO" radicals can, in tum, cause lipid peroxidation or 
react with macromolecules, resulting in intracellular calcium overload and cell death. 
Superoxide dismutase (SOD) can prevent the formation of ONOO" radicals by causing 
the reduction of 02" to O2 + hydrogen peroxide (H202), which is further degraded to O2 
+ water (H20) via the action of catalase. NO· also activates guanylate cyclase, which 
leads to the production of cyclic guanosine monophosphate (cGMP), having subsequent 
actions on protein kinases and ion channels (see Garthwaite et al., 1989; Moncada et aI., 
1991; Rang et ai., 1995; Wiesinger, 2001). 
The formation of NO· and, subsequently, ONOO", is believed to be involved in 
methamphetamine-induced dopaminergic neurotoxicity in mice. For example, Di Monte 
et al. (1996) proposed a pathway whereby oxygen free radicals (e.g. O2") are produced 
following methamphetamine-induced dopamine release, and interact with NO· 
(produced via a glutamate-activated NOS pathway) to produce ONOO" radicals (Di 
Monte et aI., 1996). Further evidence for the production of ONOO" following 
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methamphetamine administration involves the formation of 3-nitrotyrosine (3-NT), 
which is an in vivo marker of ONOO· generation (Imam & Ali, 2000; Imam et aI., 1999; 
2001). Peroxynitrite production and methamphetamine-induced dopaminergic 
neurotoxicity can be prevented by pretreatment with a selective ONOO· decomposition 
catalyst (5,10, 15,20-tetrakis(N-methyl-4' -pyridyl)porphyrinato iron III; F eTMPyP), 
however this compound also prevents methamphetamine-induced hyperthermia (Imam 
et al., 1999). Selenium, an antioxidant compound, has also been demonstrated to 
attenuate methamphetamine-induced ONOO· production in both in vivo and in vitro 
systems (Imam & Ali, 2000). 
Nitric oxide has similarly been demonstrated to be involved in the long-term effects of 
MDMA in rats, as shown by the protective effects of NOS inhibitors. For example. 
Taraska & Finnegan (1997) administered MDMA or methamphetamine to SD rats (10 
mg/kg, four times at 2 h intervals) and demonstrated significant attenuation of MDMA-
induced serotonergic loss and methamphetamine-induced dopaminergic loss, where 
animals were pretreated with the NOS inhibitor JII3 -nitro-L-arginine methyl ester (L-
NAME). However, the protective effects of L-NAME against methamphetamine-
induced dopamine loss, at least, were accompanied by the prevention of 
methamphetamine-induced hyperthermia (Taraska & Finnegan, 1997). Zheng & 
Laverty (1998) demonstrated partial neuroprotection by the NOS inhibitor J? -nitro-L-
arginine (L-NOARG) against MDMA-induced serotonin depletion in rat frontal and 
parietal cortex seven days post-treatment, while acute hyperthermia was unaltered. 
The involvement of NO in amphetamine-induced neurotoxicity has also been 
demonstrated in vitro. For example, Cerruti et al., (1995) demonstrated that 
methamphetamine and MDMA were toxic to embryonic rat brain dopaminergic and 
serotonergic cells, respectively, and that NOS inhibitors (L-Jlf-nitro-arginine (N-Arg). 
L-nitro-methylarginine (L-NMA) and aminoguanidine) protected against this toxicity. 
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Figure 7.13 Postulated mechanism for the induction of cytotoxicity or 
cytoprotection through the formation of nitric oxide (NO) (after Rang et ai., 1995). 
Glutamatergic stimulation of N1\1DA receptors results in increased ca.lcium (Ca2+) entry 
through the receptor channel. Calcium-calmodulin activates nitric oxide syntha 
(NOS), leading to the formation of NO, as either: (1) NO·, which reacts with superoxide 
anions (02") to form peroxynifrite radicals (ONOO"), leading to lipid peroxidation, 
intracellular calcium overload and cell death, or (2) NO+, which nitrosylates a 
sulphydryl group on the NMDA receptor causing its downregulation and prevention of 
further Ca2+ entry. Superoxide dismutase (SOD) can prevent the formation of ON 0 " 
by causing the reduction of O2" to oxygen (02) + hydrogen peroxide (H202) whi h i 
further degraded to O2 + water (H20) via the action of catalase. NO· also activate 
guanylate cyclase, leading to the production of cyclic guanosine monophosphat 
(cGMP). 
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The neuronal isoform of NOS (nNOS) is believed to be involved in methamphetamine-
induced dopaminergic toxicity (Imam et al., 2001; Itzhak et al., 1998) and in animal 
models of cerebral ischaemia (Huang et al., 1994). Itzhak et al. (1998) administered 
methamphetamine (5 mg/kg i.p., three times at 3 h intervals) to homozygote nNOS 
knockout mice (-1-) and striatal concentrations of dopamine, nop AC and HV A were 
measured three days later. There was no difference in striatal catecholamine 
concentrations between methamphetamine- and saline-treated nNOS (-1-) mice, while 
wild-type methamphetamine-treated mice demonstrated striatal dopamine losses of at 
least 35 %. The nNOS (-1-) mice also did not demonstrate methamphetamine-induced 
hyperthermia (Itzhak et al., 1998). Imam et al. (2001) demonstrated that nNOS (-1-) 
mice, when administered methamphetamine, did not produce peroxynitrite as evidenced 
by the lack of production of3-NT. 
The results of the current study do not support direct involvement of increased 
glutamatergic activity at NMDA receptors in MDMA-induced striatal dopamine loss, as 
the administration of neither of the NMDA receptor antagonists (AR-RI5896AR and 
MK-80 1) provided any neuroprotection. However, as two of the NOS inhibitors used 
(AR-RI7477AR and S-MTC) did provide substantial neuroprotection, it may be that 
some mechanism other than NMDA receptor stimulation triggers NOS activation. 
Although PBN was only neuroprotective where hyperthermia was prevented. there is 
evidence to support the involvement of free radicals in MDMA-induced neurotoxicity in 
mice (Cadet et al., 1994; 1995; 2001; Colado et al., 2001; Jayanthi et al., 1999). Colado 
et al. (2001) used an in vivo free radical-generating system to measure MDMA-induced 
free radical formation. The interaction of salicylic acid with hydroxyl radicals (OW) (or 
peroxynitrite; Narayan et al., 1997) generates 2,3- and 2,5-dihydroxybenzoic acid (2.3-
and 2,5-DHBA), a reaction which is used both in vivo and in vitro as an assay for 
measuring OIr and ONOO· formation (see Chiueh et al., 1992; 1993; Colado et al.. 
1997a; 1999a; 2001; Giovanni et al., 1995; Halliwell & Kaur, 1997; Narayan et aI., 
1997). For in vivo measurement, a microdialysis probe is implanted in the brain and 
perfused with salicylic acid, the resulting dialysate is analysed via h.p.l.c. and the 
concentration of 2,3- and 2,5-DHBA present thus provides a measure of OW 
production (see Chiueh et al., 1992; 1993; Colado et aI., 1997a; 2001). Colado et al. 
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(2001) demonstrated that MDMA administration to mice (20 mg/kg, three times at 3 h 
intervals) resulted in a significant increase in the conversion of salicylic acid to 2,3-
DHBA in the striatal dialysate, indicating MDMA-induced free radical formation. This 
result is in agreement with studies performed in rats, where MDMA administration 
leads to increased conversion of salicylate to 2,3-DHBA (Colado et aI., 1997a; 1999a). 
Free radical involvement in MDMA-induced neurotoxicity has also been demonstrated 
in both in vivo and in vitro copper/zinc superoxide dismutase (CulZnSOD) systems: (1) 
homozygous and heterozygous transgenic mice carrying the human Cu/ZnSOD gene 
have shown significant attenuation of MDMA-induced reductions in striatal dopamine 
concentration, indicating a role for oxygen-based free radicals in MDMA-induced 
neurotoxicity (Cadet et aI., 1994; 1995; 2001; Jayanthi, 1999); (2) embryonic rat brain 
cell cultures carrying the human CulZnSOD enzyme are resistant to both 
methamphetamine- and MDMA- induced toxicity (Cerruti et ai., 1995). MDMA 
administration has also been shown to cause significant decreases in SOD, catalase and 
glutathione peroxidase activity, and significant increases in lipid peroxidation, in the 
brains of non-transgenic mice. Homozygous Cu/ZnSOD mice, however, are unaffected 
by MDMA with regard to SOD and catalase activity and lipid peroxidation, while 
glutathione peroxidase activity is increased (Cadet et ai., 2001). 
In addition to glutamate-activated production of free radicals, dopamine released by 
MDMA may be auto-oxidised, resulting in the production of 011 and quinones (see 
Chiueh et ai., 1993; Graham et ai., 1978), the latter also being formed as a product of 
MDMA metabolism (Hiramatsu et aI., 1990). Cytotoxicity may be induced by 
disruption of mitochondrial electron transport systems, through the actions of oxygen-
based free radicals and dopamine itself (Ben-Shachar et al., 1995; Zhang et al., 1990). 
Using the in vivo micro dialysis system for measurement of 011 formation (see above), 
Colado et al. (2001) demonstrated that AR-R17477AR prevented MDMA-induced free 
radical production. The NOS inhibitor (5 mglkg) was administered 30 min prior to each 
dose of MDMA (20 mg/kg, three times at 3 h intervals) and abolished MDMA-induced 
increases in 2,3-DHBA formation, thus indicating prevention of free radical production. 
Furthermore, the inhibitory actions of AR-R17477 AR were demonstrated not to involve 
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trapping of free radicals, through its lack of effect on in vitro lipid peroxidation. 
Incubation of rat cortical synaptosomes with ferrous chloride (FeCh) and ascorbic acid 
results in production of malondialdehyde (a thiobarbituric acid-reacting substance 
(TBARS), derived from the breakdown of polyunsaturated fatty acids), which is 
quantified by a 2-thiobarbituric acid colour reaction (see Colado et al., 2001; Das & 
Ratty, 1987). In contrast to the free radical scavenger butylated hydroxytoluene (BHT), 
AR-R17477 AR had no effect on malondialdehyde formation measured in this manner, 
indicating that it does not act as a free radical scavenger (Colado et a/., 2001). 
Since the neuronal isoform of NOS is believed to be involved in methamphetamine-
induced neurotoxicity, the selectivity of the NOS inhibitors which protected against 
MDMA-induced striatal dopamine loss in the current study, is also likely to be 
important. S-MTC has been demonstrated to be a potent, reversible, slow-binding 
inhibitor of all of the human NOS isoforms - nNOS, inducible NOS (iNOS) and 
endothelial NOS (eNOS) - its effects on nNOS being the most potent (Furfine el aI., 
1994). In addition, S-MTC has been shown to inhibit rat nNOS and iNOS (Narayanan 
& Griffith, 1994). AR-R17477 AR has also been shown to be a potent inhibitor of 
human nNOS, being 17-fold selective for nNOS versus eNOS (O'Neill el al., 2000). 
Although further studies need to be performed, to assess the selectivity of these 
compounds for nNOS versus the other NOS isoforms in rodents, it does appear that 
nNOS is involved in MDMA-induced neurotoxicity. 
In conclusion, this study has confirmed that MDMA administration to mice results in 
selective dopaminergic toxicity, as shown by striatal loss of dopamine and its 
metabolites. Furthermore, the neuroprotective effects of preventing MDMA-induced 
hyperthermia have been demonstrated - in particular, neuroprotection afforded by 7-NI 
and PBN could not be separated from modification of the acute hyperthermic response. 
In the case of the GABAmimetic compound clomethiazole, it appears that some 
different mechanism of action may exist between rats and mice~ clomethiazole is 
neuroprotective against MDMA-induced serotonergic damage in rats, but did not have 
any effect on the striatal dopamine loss in mice. The two compounds which 
significantly attenuated MDMA-induced reductions in striatal dopamine concentration 
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without modifying the acute hyperthermic response - AR-R17477AR and S-MTC - are 
believed to be relatively selective nNOS inhibitors, thus indicating the involvement of 
nNOS in the neurotoxic pathway. Although PBN did not provide neuroprotection, there 
is evidence that free radicals are being fonned and their production is inhibited by AR-
R17477AR. As neither of the NMDA antagonists (AR-R15896AR and MK-801) were 
neuroprotective, free radicals are presumably not being formed as a result of excessive 
glutamatergic activity at NMDA receptors, but by some other route - probably via the 
auto-oxidation ofMDMA metabolites (see Figure 7.14). 
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8 GENERAL DISCUSSION 
The aims of this study were to examine some of the acute and long-term functional 
consequences of MDMA administration to rats. Studies of the long-term behavioural 
and thermoregulatory responses were conducted, and a pharmacological investigation 
was made of the acute MDMA-induced hyperthermic response. In addition, the 
mechanisms involved in the neurotoxic effects of MDMA administration to mice were 
investigated. 
8.1 BASELINE ANXIETY-RELATED AND LOCOMOTOR BEHAVIOUR OF DARK 
AGOUTI RATS 
Prior to investigation of the long-term behavioural consequences of a single neurotoxic 
dose of MDMA in Dark Agouti (DA) rats, a pilot study was performed to enable 
determination of the baseline anxiety-related and locomotor behaviour of this strain. 
Thus the behaviour ofDA rats was compared with that of a more commonly used strain, 
the Sprague-Dawley (SD), on the elevated plus-maze and in the open-field. DA rats 
showed significantly higher levels of anxiety-related behaviour, as evidenced by lower 
open arm behaviour (% open arm entries and % time spent on the open arms) on the 
plus-maze and fewer crossings towards the centre of the open-field, compared to the SD 
strain. In addition, DA rats demonstrated significantly lower levels of locomotor 
activity, as indicated by lower numbers of total and closed arm entries on the plus-maze 
and total zone crossings in the open-field. Ethological variables, such as defecation and 
grooming (which were markedly greater in DA rats), provided further evidence of 
increased "anxiety" in this strain. 
Subsequently, the responses of both strains to acute diazepam administration were 
assessed on the elevated plus-maze. However, the differences between the two strains 
were abolished following acute handling whilst injecting vehicle. While both strains 
demonstrated an anxiolytic response to diazepam, shown by increased % time spent on 
the open arms, vehicle-treated DA rats were no longer different in their responses 
compared to vehicle-treated SD rats. For example, the % number of open arm entries 
and % time spent on the open arms by vehicle-treated DA rats were approximately 
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three-fold higher than the values recorded in naive DA rats, which resulted in similar % 
open arm entries and % time spent on the open arms in both vehicle-treated strains. 
Although the magnitude of anxiety-related responses was greater in naiVe DA rats 
compared to the SD strain, responses were still qualitatively similar. Thus DA rats were 
deemed suitable for measurement of "anxiety" - and locomotor- behaviour in MDMA-
treated animals. 
8.2 LONG-TERM BEHAVIOURAL CONSEQUENCES OF MDMA 
ADMINISTRATION 
The long-term behavioural consequences of a single neurotoxic dose of MDMA (12.5 
mglkg i.p.), shown to produce a 20 - 40 % depletion of 5-HT, were investigated in DA 
rats. Subjects were tested on the elevated plus-maze and in the open-field at three time-
points: (1) one week post-treatment (Days 8 - 11), (2) one month post-treatment (Days 
29 - 32), and (3) ten to eleven weeks post-treatment (open-field: Days 71 - 73; plus-
maze: Day 80). Significant differences in anxiety-related- and locomotor- behaviour 
were observed in both "anxiety" models. For example, on Day 80 MDMA-pretreated 
rats spent a greater % time on the open arms of the plus-maze, and on Day 73 performed 
a greater, although not statistically significant, number of Zone 2 crossings in the open-
field. The open arms of the plus-maze are believed to evoke a "fear" response (see 
Montgomery, 1955; Handley & Mithani, 1984), while crossings towards the centre of 
the open-field involves the conflict between exploratory drive and avoidance of open, 
brightly lit spaces (see Schmitt & Hiernke, 1998a). Thus these data strongly indicated 
that a single dose of MDMA, ten to eleven weeks earlier, produced a marked reduction 
in "anxiety". In addition, MDMA-pretreated rats demonstrated higher levels of 
locomotor activity on the plus-maze, shown by greater numbers of total and closed arm 
entries on all three test days compared to control animals, total arm entries reaching 
statistical significance on Day 80. Similar results were observed in the open-field, at 
least under red-light illumination, where MDMA-pretreated rats performed greater 
numbers of total crossings on each test day which again reached statistical significance 
at the latest time-point. 
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Disruption of serotonergic activity induced by 5,7-DHT (see Briley et aI., 1990; Hall et 
aI., 1999; Tye et aI., 1977) or PCPA (see File & Hyde, 1977; Tye et al., 1979) results in 
reduced anxiety-like behaviour, thus it could be expected that MDMA-induced 
serotonergic neurotoxicity would have similar consequences. While there is some 
evidence of increased anxiety in human recreational users of MDMA, it is difficult to 
separate the effects of MDMA from those of other illicit drugs or from any pre-existing 
psychological conditions (see Parrott et aI., 2000). However, McCann et al., (1999) 
demonstrated that chronic users of MDMA were less susceptible to an m-CPP-induced 
panic attack than non-MDMA users, which was suggested to indicate a downregulation 
of postsynaptic 5-HT 2C receptors and could be indicative of functional consequences of 
MDMA ingestion. In addition, the reduction in "anxiety" seen in rats in the current 
study could be interpreted as an increase in "impulsivity", which has been reported to 
occur in human recreational users ofMDMA (Morgan, 1998). 
The fact that marked reductions in anxiety-related behaviour did not become apparent 
until over two months after a single dose of MDMA, while significant serotonergic 
depletions have been observed one week post-treatment (see Colado et al., 1995; 
O'Shea et aI., 1998), indicates that the behavioural changes observed are not solely due 
to serotonergic neurotoxicity, but that adaptive changes are occurring within the brain. 
8.3 LONG-TERM CONSEQUENCES OF MDMA ADMINISTRATION ON 
THERMOREGULATORY BEHAVIOUR 
Previously reported studies have shown that: (1) a prior neurotoxic dose regimen of 
MDMA results in an attenuation of the acute hyperthermic response to a single dose of 
MDMA several weeks later (Shankaran & Gudelsky, 1999), and (2) prior multiple 
doses of MDMA resulted in prolonged hyperthermia when animals were subjected to a 
"thermoregulatory challenge" over three months later (Dafters & Lynch, 1998). In 
addition, conflicting results have been reported concerning the effects of prior MDMA 
administration on 8-0H-DPAT -induced hypothermia. Aguirre et al. (1998) 
demonstrated a potentiation of the hypothermic response in MDMA-pretreated animals, 
whereas McNamara et al. (1995) demonstrated no effect ofMDMA-pretreatment. 
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Thus the current study was performed in an attempt to further elucidate the long-term 
consequences ofMDMA pretreatment on thermoregulatory responses: 
(1) Five to six weeks after a single neurotoxic dose of MDMA (12.5 mglkg i. p.), 
DA rats were subjected to a high ambient temperature (Ta) "thermoregulatory 
challenge", which consisted of a 60 min exposure to a T a of 30 ± 0.5 °C. Rectal 
temperature was monitored prior to, during, and after exposure to the high or low T 1\ 
environment. Prior to the challenge, there was no difference in rectal temperature values 
between MDMA- and saline-pretreated animals. However, rats which had been 
administered MDMA five to six weeks earlier demonstrated a faster rise in rectal 
temperature during the challenge and a sustained hyperthermic response upon being 
returned to a 'normal' environment (20 ± 2°C). These data indicated a long-term defect 
in thermoregulation, were consistent with the findings of Dafters & Lynch (1998), and 
were accompanied by 20 - 40 % depletions in regional brain concentrations of 5-HT and 
5-HIAA, as measured one week after MDMA administration. 
(2) A second challenge was performed where animals were subjected to a low Til 
(10 ± 0.5 °C) for 1 h, five to six weeks after administration ofMDMA (12.5 mg/kg i.p.). 
In this experiment the rectal temperature ofMDMA-pretreated rats remained marginally 
higher than control values during and after the challenge, which could indicate a lack of 
effect of MDMA on heat-retaining mechanisms. However, since animals were group-
housed (three per cage), heat retention could have been achieved by the rats huddling 
together, and perhaps greater differences between treatment groups would have been 
observed if the animals had been housed separately. 
(3) Another group of rats were administered one, two or three doses of MDMA 
(12.5 mglkg i.p.) two or three weeks apart and the temperature response to each dose 
was monitored. There was no difference in the acute hyperthermic response between 
animals which had been administered one or two previous doses of MDMA and those 
animals which had only received a single dose. These data showed that a 20 - 40 % 
depletion of 5-HT had no long-lasting effect on the acute hyperthermic response, which 
was in contrast to the results of Shankaran & Gudelsky (1999) who reported that a 
neurotoxic dose regimen of MDMA attenuated the acute hyperthermia induced by a 
single dose one week later. However, the differences in experimental methodology 
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between the current study and that of Shankaran & Gudelsky (1999) make a direct 
comparison of results unfeasible. It is possible that only a more severe loss of 5-HT 
content (e.g. 70 - 80 %) would have significant, long-lasting effects on the MDMA-
induced acute hyperthermic response. 
(4) Rats which had been injected with MDMA (12.5 mglkg i.p.) three or four weeks 
previously were administered 8-0H-DPAT (0.057, 0.09, 0.11 mglkg s.c.) and their 
temperature response monitored. There was no significant difference in the acute 
hypothermic response to 8-0H-DPAT, at any of the doses administered, between 
MDMA- and saline-pretreated animals. These results were consistent with those of 
McNamara et al. (1995), indicating that MDMA administration has no lasting effect on 
5-HT IA receptor function. 
Thus the current study indicated long-term functional consequences of MDMA 
administration, and a 20 - 40 % depletion of regional brain 5-HT, on thermoregulatory 
responses to a high Ta challenge. However, this degree of loss of 5-HT content was 
insufficient to alter subsequent hyperthermic responses to acute MDMA administration 
and did not alter 5-HT IA receptor function. 
8.4 AN INVESTIGATION OF THE ACUTE HYPERTHERMIC RESPONSE TO 
MDMA ADMINISTRATION 
During the course of the studies on the longer-term thermoregulatory responses to 
MDMA administration, it was decided that the acute hyperthermic response required 
further investigation. MDMA administration results in an acute release of 5-HT (see 
Colado & Green, 1994~ Crespi et al., 1997; Johnson et al., 1986; Schmidt et al., 1987; 
Stone et aI., 1986), and the acute hyperthermic response which also follows MDMA 
(see Dafters, 1994; Malberg et aI., 1996; O'Shea et al., 1998) has been assumed to be 5-
HT -mediated (see Shankaran & Gudelsky, 1999). Dopamine is also acutely released 
following MDMA administration to rats (see Colado et al., 1999a; Gudelsky et aI., 
1994~ Yamamoto & Spanos, 1988), and stimulation of 5-HT2 receptors following 
MDMA-induced 5-HT release has been suggested to further enhance dopamine release, 
at least in the striatum (see Gudelsky et aI., 1994; Nash, 1990; Schmidt et aI., 1999b). 
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Thus a series of 5-HT and dopamine receptor antagonists and uptake inhibitors were 
employed in an attempt to determine the receptor subtype(s) involved in this response. 
Administration of the non-selective 5-HT 112 receptor antagonist, methysergide, the 5-
HT 2 antagonist, ritanserin, or the 5-HT 2C antagonist, SB 242084, had no effect on the 
MDMA-induced hyperthermic response. The selective 5-HT 2A antagonist, MDL 
100,907, modestly attenuated the response following the highest dose, while the 
selective 5-HT2 antagonist, MDL 11,939, completely blocked the MDMA-induced 
acute hyperthermia. Neither of the selective serotonin uptake inhibitors, zimeldine or 
fluoxetine, had any effect on the hyperthermic response, even though fluoxetine almost 
completely abolished the MDMA-induced acute hippocampal release of 5-HT. The 
dopamine D2 receptor antagonist, remoxipride, and the dopamine uptake inhibitor, GBR 
12909, also had no effect on the MDMA-induced acute hyperthermic response, while 
the selective Dl antagonist, SCH 23390, dose-dependently inhibited the response. 
Therefore, with the exception ofMDL 11,939 and the highest dose ofMDL 100,907, 
these data strongly indicated that 5-HT is not directly involved in mediation of the acute 
hyperthermia which follows MDMA administration, and that dopamine D, receptors 
play some role in the response. 
8.5 AN INVESTIGATION OF MDMA-INDUCED NEUROTOXICITY IN MICE 
While MDMA administration to rats (see Aguirre et al., 1998; Colado et al., 1993; 
Farfel & Seiden, 1995a; Scanzello et al., 1993), guinea-pigs (see Battaglia et aI., 
1988a), non-human primates (see Ricaurte et at., 1988c) and humans (see McCann et 
aI., 1994; 1998) results in long-term serotonergic neurotoxicity, dopaminergic depletion 
occurs following MDMA administration to mice (see Battaglia et aI., 1988a; Logan et 
al., 1988). However, the mechanisms involved in dopaminergic neurotoxicity in mice 
have been little studied, thus a series of putative neuroprotective compounds were 
administered prior to MDMA and striatal levels of dopamine and its metabolites were 
analysed one week later. In addition, since a number of compounds are believed to 
provide neuroprotection via attenuation of the acute hyperthermic response (see Ali et 
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aI., 1994; Callahan & Ricaurte, 1998, Miller & O'Callaghan, 1994), rectal temperature 
was closely monitored throughout each experiment. 
Neither of the NMDA antagonists, AR-R15896AR and MK-801, provided any 
protection against MDMA-induced dopamine depletion. The lack of effect of AR-
R15896AR is consistent with the lack of protection against MDMA-induced 
serotonergic neurotoxicity in rats (see Colado et aI., 1998), and, while MK.-801 has been 
shown to be neuroprotective, it has also been shown to attenuate amphetamine 
derivative-induced hyperthermia (see Albers & Sonsalla, 1995; Miller & O'Callaghan, 
1994). The GABAmimetic compound, clomethiazole, also did not afford any protection 
against MDMA-induced dopamine depletion, which is in contrast to its neuroprotective 
effects against MDMA-induced 5-HT depletion in rats (see Colado et aI., 1993; Colado 
& Green, 1994; Hewitt & Green, 1994). The free radical scavenger, PBN, only provided 
protection against dopaminergic neurotoxicity where the acute hyperthermic response 
was attenuated. This result is consistent with the effects seen in rats, where PBN 
provides protection against serotonergic depletion, but also attenuates hyperthermia (see 
Colado & Green, 1995). All three NOS inhibitors used in the current study, AR-
R174 77 AR, S-MTC and 7 -NI, provided significant protection against MDMA-induced 
dopamine depletion, and have all been demonstrated to be neuroprotective in different 
animals models of neurodegeneration (see Colado et al., 1999c; Itzhak et aI., 2000; 
O'Neill et al., 2000). While AR-R17477AR and S-MTC had no significant effect on the 
acute hyperthermic response, 7-NI completely prevented the response, which is 
consistent with previously reported results (Callahan & Ricaurte, 1998; Colado el aI., 
1999c). 
The protective effects of AR-R17477AR and S-MTC, which are both relatively 
selective nNOS inhibitors, thus indicates the involvement of nNOS in the neurotoxic 
pathway. While PBN did not protect against dopamine loss, there is evidence that free 
radicals are produced in mice following MDMA administration (see Colado el aI., 
2001). However, since neither NMDA antagonist provided neuroprotection, it appears 
that free radicals are not being formed as a result of increased glutamatergic activity at 
NMDA receptors, but could involve the auto-oxidation ofMDMA metabolites. 
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8.6 CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
The studies which have been reported in this thesis have demonstrated that 
administration of a single dose ofMDMA (12.5 mglkg i.p.) to rats resulted in a 20 - 40 
% regional brain depletion of 5-HT and 5-IDAA, which was shown to have long-term 
functional consequences: (1) reductions in anxiety-related behaviour over two months 
after a single neurotoxic dose, and (2) long-lasting alterations in thermoregulatory 
responses to a high Ta challenge five to six weeks post-drug administration. 
Furthermore, the selective dopaminergic depletion following MDMA administration to 
mice was suggested to involve nNOS, and it appeared that the free radicals which are 
acutely generated are not as a result of excessive glutamatergic activity at NMDA 
receptors, but probably involve auto-oxidation ofMDMA metabolites. 
Suggestions for future work include: 
(1) Extending the time period for testing "anxiety" on the plus-maze and in the 
open-field - animals could be tested up to six or 12 months post-treatment, and regional 
brain 5-HT levels could be analysed in a parallel treatment group at each time-point to 
enable evaluation of changes in behaviour with reference to serotonergic depletion and 
recovery. 
(2) Additional behavioural tests (such as delayed non-match to place and prepulse 
inhibition) could be performed at the same time-points employed in the current study 
and up to six or 12 months after drug administration, to further explore the behavioural 
consequences of a single neurotoxic dose. 
(3) The acute hyperthermic response to MDMA could be investigated in primates in 
the same manner as that employed in rats, whereby a series of drugs whi('.h affect 5-HT 
or dopamine function are administered prior to MDMA. If, for example, the DI 
antagonist SCH 23390 attenuated the hyperthermic response in primates, it could also 
be administered after MDMA in an attempt to lower body temperature. This could 
provide a better understanding of the acute hyperthermic response in humans (which 
can have potentially fatal consequences). 
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(4) A simple method of investigating whether long-term changes 10 
thermoregulatory behaviour also occur in human recreational users of MDMA, could be 
to place subjects in a high ambient temperature environment (e.g. 30°C) for a limited 
time period (e.g. 1 - 2 h) and monitor body temperature. 
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